USPatent applicationPatented

Methods of using interleukin-3 (IL-3) mutant polypeptides for ex-vivo expansion of hematopoietic stem cells

Granted 12 Nov 2002 · 2 office actions

Current assignee: Pharmacia Corporation · originally Pfizer

Law firm: Law firm · Log in to unlock

Attorney: Attorney · Log in to unlock

Inventors: Joseph Polazzi, Maire Helena Caparon, Kumnan Paik, John Patrick McKearn +7 · Examiner: Gary L. Kunz · AU 1647 · TC 1600

Application· this page
8559390
filed 15 Nov 1995
Publication
Not published
not published
Patent
US 6,479,261
granted 12 Nov 2002

Life of the application

11 dated events
⤢ drag to zoom19961998200020022004200620082010201220142016ProsecutionTerm & fees
ProsecutionTerm & feeshover for detail · click to open

Abstract

The present invention relates to recombinant human interleukin-3 (hIL-3) variant or mutant proteins (muteins). These hIL-3 muteins contain amino acid substitutions and may also have amino acid deletions at both the N- and C-termini. The invention also relates to pharmaceutical compositions containing the hIL-3 muteins and methods for using them. Additionally, the present invention relates to recombinant expression vectors comprising nucleotide sequences encoding the hIL-3 muteins, related microbial expression systems, and processes for making the hIL-3 muteins using the microbial expression systems. Included in the present invention are deletion mutants of hIL-3 in which from 1 to 14 amino acids have been deleted from the N-terminus, and from 1 to 15 amino acids (a.a.119 to 133) have been deleted from the C-terminus, and which also contain amino acid substitutions in the polypeptide. These hIL-3 multiple mutation polypeptides may have biological activities similar to or better than hIL-3 and, in some cases, may also have an improved side effect profile.

Description

100 parts
›This application is a continuation of U.S. application…

This application is a continuation of U.S. application Ser. No. 08/411,796, filed Apr. 6, 1995, now U.S. Pat. No. 5,677,149; which entered the U.S. national stage under 35 USC §371 from PCT/US93/11198, filed Nov. 22, 1993; which is a continuation-in-part of U.S. application Ser. No. 07/981,044, filed Nov. 24, 1992, now abandoned.

This is a continuation-in-part of U.S. application Ser. No. 07/981,044 filed Nov. 24, 1992 which is incorporated herein by reference.

›FIELD OF THE INVENTION

The present invention relates to mutants or variants of human interleukin-3 (hIL-3) which contain one or more amino acid substitutions and which may have portions of the native hIL-3 molecule deleted. These hIL-3 single and multiple mutation polypeptides retain one or more activities of native hIL-3 and may also show improved hematopoietic cell-stimulating activity and/or an improved activity profile which may include reduction of undesirable biological activities associated with native hIL-3.

›BACKGROUND OF THE INVENTION · 1 of 2

Colony stimulating factors (CSFs) which stimulate the differentiation and/or proliferation of bone marrow cells have generated much interest because of their therapeutic potential for restoring depressed levels of hematopoietic stem cell-derived cells. CSFs in both human and murine systems have been identified and distinguished according to their activities. For example, granulocyte-CSF (G-CSF) and macrophage-CSF (M-CSF) stimulate the in vitro formation of neutrophilic granulocyte and macrophage colonies, respectively while GM-CSF and interleukin-3 (IL-3) have broader activities and stimulate the formation of both macrophage, neutrophilic and eosinophilic granulocyte colonies. IL-3 also stimulates the formation of mast, megakaryocyte and pure and mixed erythroid colonies.

Because of its ability to stimulate the proliferation of a number of different cell types and to support the growth and proliferation of progenitor cells, IL-3 has potential for therapeutic use in restoring hematopoietic cells to normal amounts in those cases where the number of cells has been reduced due to diseases or to therapeutic treatments such as radiation and chemotherapy.

Interleukin-3 (IL-3) is a hematopoietic growth factor which has the property of being able to promote the survival, growth and differentiation of hematopoietic cells. Among the biological properties of IL-3 are the ability (a) to support the growth and differentiation of progenitor cells committed to all, or virtually all, blood cell lineages; (b) to interact with early multipotential stem cells; (c) to sustain the growth of pluripotent precursor cells; (d) to stimulate proliferation of chronic myelogenous leukemia (CML) cells; (e) to stimulate proliferation of mast cells, eosinophils and basophils; (f) to stimulate DNA synthesis by human acute myelogenous leukemia (AML) cells; (g) to prime cells for production of leukotrienes and histamines; (h) to induce leukocyte chemotaxis; and (i) to induce cell surface molecules needed for leukocyte adhesion.

Mature human interleukin-3 (hIL-3) consists of 133 amino acids. It has one disulfide bridge and two potential glycosylation sites (Yang, et al., CELL 47:3 (1986)).

Murine IL-3 (mIL-3) was first identified by Ihle, et al., J. IMMUNOL. 126:2184 (1981) as a factor which induced expression of a T cell associated enzyme, 20-hydroxysteroid dehydrogenase. The factor was purified to homogeneity and shown to regulate the growth and differentiation of numerous subclasses of early hematopoietic and lymphoid progenitor cells.

In 1984, cDNA clones coding for murine IL-3 were isolated (Fung, et al., NATURE 307:233 (1984) and Yokota, et al., PROC. NATL. ACAD. SCI. USA 81:1070 (1984)). The murine DNA sequence coded for a polypeptide of 166 amino acids including a putative signal peptide.

The gibbon IL-3 sequence was obtained using a gibbon cDNA expression library. The gibbon IL-3 sequence was then used as a probe against a human genomic library to obtain a human IL-3 sequence.

Gibbon and human genomic DNA homologues of the murine IL-3 sequence were disclosed by Yang, et al., CELL 47:3 (1986). The human sequence reported by Yang, et al. included a serine residue at position 8 of the mature protein sequence. Following this finding, others reported isolation of Pro 8 hIL-3 cDNAs having proline at position 8 of the protein sequence. Thus it appears that there may be two allelic forms of hIL-3.

Dorssers, et al., GENE 55:115 (1987), found a clone from a human cDNA library which hybridized with mIL-3. This hybridization was the result of the high degree of homology between the 3′ noncoding regions of mIL-3 and hIL-3. This cDNA coded for an hIL-3 (Pro 8 ) sequence.

U.S. Pat. Nos. 4,877,729 and 4,959,455 disclose human IL-3 and gibbon IL-3 cDNAs and the protein sequences for which they code. The hIL-3 disclosed has serine rather than proline at position 8 in the protein sequence.

Clark-Lewis, et al., SCIENCE 231:134 (1986) performed a functional analysis of murine IL-3 analogues synthesized with an automated peptide synthesizer. The authors concluded that the stable tertiary structure of the complete molecule was required for full activity. A study on the role of the disulfide bridges showed that replacement of all four cysteines by alanine gave a molecule with {fraction (1/5000)}th the activity as the native molecule. Replacement of two of the four Cys residues by Ala(Cys 79 , Cys 140 →Ala 79 , Ala 140 ) resulted in an increased activity. The authors concluded that in murine IL-3 a single disulfide bridge is required between cysteines 17 and 80 to get biological activity that approximates physiological levels and that this structure probably stabilizes the tertiary structure of the protein to give a conformation that is optimal for function. (Clark-Lewis, et al., PROC. NATL. ACAD. SCI. USA 85:7897 (1988)).

International Patent Application (PCT) WO 89/00598 discloses gibbon- and human-like IL-3. The hIL-3 contains a Ser 8 →Pro 8 replacement. Suggestions are made to replace Cys by Ser, thereby breaking the disulfide bridge, and to replace one or more amino acids at the glycosylation sites.

EP-A-0275598 (WO 88/04691) illustrates that Ala 1 can be deleted while retaining biological activity. Some mutant hIL-3 sequences are provided, e.g., two double mutants, Ala 1 →Asp 1 , Trp 13 →Arg 13 (pGB/IL-302) and Ala 1 →Asp 1 , Met 3 →Thr 3 (pGB/IL-304) and one triple mutant Ala 1 →Asp 1 , Leu 9 →Pro 9 , Trp 13 →Arg 13 (pGB/IL-303).

WO 88/05469 describes how deglycosylation mutants can be obtained and suggests mutants of Arg 54 Arg 55 and Arg 108 Arg 109 Lys 10 might avoid proteolysis upon expression in Saccharomyces cerevisiae by KEX2 protease. No mutated proteins are disclosed. Glycosylation and the KEX2 protease activity are only important, in this context, upon expression in yeast.

WO 88/06161 mentions various mutants which theoretically may be conformationally and antigenically neutral. The only actually performed mutations are Met 2 →Ile 2 and Ile 131 →Leu 131 . It is not disclosed whether the contemplated neutralities were obtained for these two mutations.

›BACKGROUND OF THE INVENTION · 2 of 2

WO 91/00350 discloses nonglycosylated hIL-3 analog proteins, for example, hIL-3 (Pro 8 Asp 15 Asp 70 ), Met 3 rhul-3 (Pro 8 Asp 15 Asp 70 ); Thr 4 rhuL-3 (Pro 8 Asp 15 Asp 70 ) and Thr 6 rhuIL-3 (Pro 8 Asp 15 Asp 70 ). It is said that these protein compositions do not exhibit certain adverse side effects associated with native hIL-3 such as urticaria resulting from infiltration of mast cells and lymphocytes into the dermis. The disclosed analog hIL-3 proteins may have N termini at Met 3 , Thr 4 , or Thr 6 .

WO 90/12874 discloses cysteine added variants (CAVs) of IL-3 which have at least one Cys residue substituted for a naturally occurring amino acid residue.

›SUMMARY OF THE INVENTION

The present invention relates to recombinant human interleukin-3 (hIL-3) variant or mutant proteins (muteins). These hIL-3 muteins contain amino acid substitutions and may also have amino acid deletions at either/or both the N- and C-termini. Preferably, these mutant polypeptides of the present invention contain one to three amino acids which differ from the amino acids found at the corresponding positions in the native hIL-3 polypeptide. The invention also relates to pharmaceutical compositions containing the hIL-3 muteins, DNA coding for the muteins, and methods for using the muteins. Additionally, the present invention relates to recombinant expression vectors comprising nucleotide sequences encoding the hIL-3 muteins, related microbial expression systems, and processes for making the hIL-3 muteins using the microbial expression systems.

The present invention includes mutants of hIL-3 in which from 1 to 14 amino acids have been deleted from the N-terminus and/or from 1 to 15 amino acids have been deleted from the C-terminus, and in which from one to three amino acid substitutions have been made. Preferred muteins of the present invention are those in which amino acids 1 to 14 have been deleted from the N-terminus, or amino acids 126 to 133 have been deleted from the C-terminus, and which both also contain from one to three amino acid substitutions in the polypeptide sequence. These hIL-3 multiple mutation polypeptides may have biological activities similar to or better than hIL-3 and, in some cases, may also have an improved side effect profile, i.e., some muteins may have a better therapeutic index than native hIL-3. The present invention also provides muteins which may function as IL-3 antagonists or as discrete antigenic fragments for the production of antibodies useful in immunoassay and immunotherapy protocols. In addition to the use of the hIL-3 mutant polypeptides of the present invention in vivo, it is envisioned that in vitro uses would include the ability to stimulate bone marrow and blood cell activation and growth before infusion into patients.

Antagonists of hIL-3 would be particularly useful in blocking the growth of certain cancer cells like AML, CML and certain types of B lymphoid cancers. Other conditions where antagonists would be useful include those in which certain blood cells are produced at abnormally high numbers or are being activated by endogenous ligands. Antagonists would effectively compete for ligands, presumably naturally occurring hemopoietins including and not limited to IL-3, GM-CSF and IL-5, which might trigger or augment the growth of cancer cells by virtue of their ability to bind to the IL-3 receptor complex while intrinsic activation properties of the ligand are diminished. IL-3, GM-CSF and or IL-5 also play a role in certain asthmatic responses. An antagonist of the IL-3 receptor may have utility in this disease by blocking receptor-mediated activation and recruitment of inflammatory cells.

›BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is the human IL-3 gene for E. coli expression (pMON5873), encoding the polypeptide sequence of natural (wild type) human IL-3 [SEQ ID NO:128], plus an initiator methionine, as expressed in E. coli , with the amino acids numbered from the N-terminus of the natural hIL-3.

FIG. 2 : ClaI to NsiI Replacement Fragment. FIG. 2 shows the nucleotide sequence of the replacement fragment used between the ClaI and NsiI sites of the hIL-3 gene. The codon choice used in the fragment corresponds to that found in highly expressed E. coli genes (Gouy and Gautier, 1982). Three new unique restriction sites, EcoRV, XhoI and PstI were introduced for the purpose of inserting synthetic gene fragments. The portion of the coding sequence shown encodes hIL-3 amino acids 20-70.

FIGS. 3A and 3B shows the nucleotide and amino acid sequence of the gene in pMON5873 with the sequence extending from NcoI through HindIII. The codon choices used to encode amino acids 1-14 and 107-133 correspond to that found in highly expressed E. coli genes.

FIG. 4 shows the construction of the plasmid vector pMON5846 which encodes [Met-(1-133) hIL-3 (Arg 129 )].

FIG. 5 shows the construction of the plasmid vector pMON5847 (ATCC 68912) which encodes [Met-(1-133) hIL-3 (Arg 129 )].

FIG. 6 shows the construction of plasmid vector pMON5853 which encodes [Met-(15-133) hIL-3 (Arg 129 )].

FIG. 7 shows the construction of the plasmid vector pMON5854 which encodes [Met-(1-133) hIL-3 (Arg 129 )].

FIG. 8 shows the DNA sequence and resulting amino acid sequence of the lamB signal peptide.

FIG. 9 shows the construction of the plasmid vector pMON5978 which encodes Met-Ala-(15-125) hIL-3.

FIG. 10 shows the construction of the plasmid vector pMON5988 which encodes Met-Ala(15-125) hIL-3.

FIG. 11 shows the construction of the plasmid vector pMON5887 which encodes Met-(1-125) hIL-3.

FIG. 12 shows the construction of pMON6457 which encodes (15-125) hIL-3; it contains the araBAD promoter and the lamB signal peptide fused to the variant hIL-3 amino acids 15-125.

FIG. 13 shows the construction of pMON6458; it contains the araBAD promoter and the lamb signal peptide fused to the variant hIL-3 amino acids 15-125.

FIG. 14 shows the construction of pMON6467 in which the bases encoding amino acids 35-40 of hIL-3 were deleted using site-directed PCR mutagenesis methods. pMON6467 was used as the template for the generation of single amino acid variants at positions 35-40 of hIL-3.

FIG. 15 shows the construction of single amino acid substitutions at position 35 of hIL-3 using site-directed PCR mutagenesis methods. The mutagenesis results in 20 different single amino substitutions, which is referred to as a “library”, at position 35 of hIL-3.

›DETAILED DESCRIPTION OF THE INVENTION · 1 of 20

The present invention relates to muteins of human interleukin-3 (hIL-3) in which amino acid substitutions have been made at from one to three positions in the amino acid sequence of the polypeptide and to hIL-3 muteins which have substantially the same structure and substantially the same biological activity. Preferred muteins of the present invention are (15-125) hIL-3 deletion mutants which have deletions of amino acids 1 to 14 at the N-terminus and/or 126 to 133 at the C-terminus and which both also have from one to three amino acid substitutions in the polypeptide and muteins having substantially the same structure and substantially the same biological activity. As used herein human interleukin-3 corresponds to the amino acid sequence (1-133) as depicted in FIG. 1 and (15-125) hIL-3 Corresponds to the 15 to 125 amino acid sequence of the hIL-3 polypeptide. Naturally occurring variants of hIL-3 polypeptide amino acids are also included in the present invention (for example, the allele in which proline rather than serine is at position 8 in the hIL-3 polypeptide sequence) as are variant hIL-3 molecules which are modified post-translationally (e.g. glycosylation).

The present invention also includes the DNA sequences which code for the mutant polypeptides, DNA sequences which are substantially similar and perform substantially the same function, and DNA sequences which differ from the DNAs encoding the muteins of the invention only due to the degeneracy of the genetic code.

Included in the present invention are novel mutant human interleukin-3 polypeptides comprising a polypeptide having the amino acid sequence of native human interleukin-3 wherein amino acids 126 to 133 have been deleted from the C-terminus of the native human interleukin-3 polypeptide and amino acids 1 to 14 have been deleted from the N-terminus of the native human interleukin-3 polypeptide and, in addition, polypeptides of the present invention also have one to three amino acid substitutions in the polypeptide sequence. The muteins of the present invention can have from one to three amino acid substitutions in the hIL-3 polypeptide chain and, in addition, can have deletions of amino acids at the N-terminus and/or the C-terminus.

Also included in the present invention are the DNA sequences coding for the muteins of the present invention; the oligonucleotide intermediates used to construct the mutant DNAs; and the polypeptides coded for by these oligonucleotides. These polypeptides may be useful as antagonists or as antigenic fragments for the production of antibodies useful in immunoassay and immunotherapy protocols.

The mutant hIL-3 polypeptides of the present invention may also have methionine, alanine, or methionine-alanine residues inserted at the N-terminus.

The present invention includes hIL-3 mutant polypeptides of the formula I:

Ala Pro Met Thr Gln Thr Thr Ser Leu Lys Thr Ser Trp Val Asn

[SEQ ID NO:15]

1               5                   10                  15

Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

20                  25                  30

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Xaa Xaa Xaa

35                  40                  45

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

50                  55                  60

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

65                  70                  75

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

80                  85                  90

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

95                 100                 105

Xaa Phe Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

110                 115                 120

Xaa Xaa Xaa Gln Gln Thr Thr Leu Ser Leu Ala Ile Phe

125                 130

wherein

Xaa at position 17 is Ser, Lys, Gly, Asp, Met, Gln, or Arg:

Xaa at position 18 is Asn, His, Leu, Ile, Phe, Arg, or Gln;

Xaa at position 19 is Met, Phe, Ile, Arg, Gly, Ala, or Cys;

Xaa at position 20 is Ile, Cys, Gln, Glu, Arg, Pro, or Ala;

Xaa at position 21 is Asp, Phe, Lys, Arg, Ala, Gly, Glu, Gln, Asn, Thr, Ser or Val;

Xaa at position 22 is Glu, Trp, Pro, Ser, Ala, His, Asp, Asn, Gln, Leu, Val or Gly;

Xaa at position 23 is Ile, Val, Ala, Leu, Gly, Trp, Lys, Phe, Ser, or Arg;

Xaa at position 24 is Ile, Gly, Val, Arg, Ser, Phe, or Leu;

Xaa at position 25 is Thr, His, Gly, Gln, Arg, Pro, or Ala;

Xaa at position 26 is His, Thr, Phe, Gly, Arg, Ala, or Trp;

Xaa at position 27 is Leu, Gly, Arg, Thr, Ser, or Ala;

Xaa at position 28 is Lys, Arg, Leu, Gln, Gly, Pro, Val or Trp;

Xaa at position 29 is Gln, Asn, Leu, Pro, Arg, or Val;

Xaa at position 30 is Pro, His, Thr, Gly, Asp, Gln, Ser, Leu, or Lys;

Xaa at position 31 is Pro, Asp, Gly, Ala, Arg, Leu, or Gln;

Xaa at position 32 is Leu, Val, Arg, Gln, Asn, Gly, Ala, or Glu;

Xaa at position 33 is Pro, Leu, Gln, Ala, Thr, or Glu:

Xaa at position 34 is Leu, Val, Gly, Ser, Lys, Glu, Gln, Thr, Arg, Ala, Phe, Ile or Met;

Xaa at position 35 is Leu, Ala, Gly, Asn, Pro, Gln, or Val;

Xaa at position 36 is Asp, Leu, or Val;

Xaa at position 37 is Phe, Ser, Pro, Trp, or Ile;

Xaa at position 38 is Asn, or Ala;

Xaa at position 40 is Leu, Trp, or Arg;

Xaa at position 41 is Asn, Cys, Arg, Leu, His, Met, or Pro;

Xaa at position 42 is Gly, Asp, Ser, Cys, Asn, Lys, Thr, Leu, Val, Glu, Phe, Tyr, Ile, Met or Ala;

Xaa at position 43 is Glu, Asn, Tyr, Leu, Phe, Asp, Ala, Cys, Gln, Arg, Thr, Gly or Ser;

Xaa at position 44 is Asp, Ser, Leu, Arg, Lys, Thr, Met, Trp, Glu, Asn, Gln, Ala or Pro;

Xaa at position 45 is Gln, Pro, Phe, Val, Met, Leu, Thr, Lys, Trp, Asp, Asn, Arg, Ser, Ala, Ile, Glu or His;

Xaa at position 46 is Asp, Phe, Ser, Thr, Cys, Glu, Asn, Gln, Lys, His, Ala, Tyr, Ile, Val or Gly;

Xaa at position 47 is Ile, Gly, Val, Ser, Arg, Pro, or His;

Xaa at position 48 is Leu, Ser, Cys, Arg, Ile, His, Phe, Glu, Lys, Thr, Ala, Met, Val or Asn;

Xaa at position 49 is Met, Arg, Ala, Gly, Pro, Asn, His, or Asp;

Xaa at position 50 is Glu, Leu, Thr, Asp, Tyr, Lys, Asn, Ser, Ala, Ile, Val, His, Phe, Met or Gln;

›DETAILED DESCRIPTION OF THE INVENTION · 2 of 20

Xaa at position 51 is Asn, Arg, Met, Pro, Ser, Thr, or His;

Xaa at position 52 is Asn, His, Arg, Leu, Gly, Ser, or Thr;

Xaa at position 53 is Leu, Thr, Ala, Gly, Glu, Pro, Lys, Ser, or Met;

Xaa at position 54 is Arg, Asp, Ile, Ser, Val, Thr, Gln, Asn, Lys, His , Ala or Leu;

Xaa at position 55 is Arg, Thr, Val, Ser, Leu, or Gly;

Xaa at position 56 is Pro, Gly, Cys, Ser, Gln, Glu, Arg, His, Thr, Ala, Tyr, Phe, Leu, Val or Lys;

Xaa at position 57 is Asn or Gly;

Xaa at position 58 is Leu, Ser, Asp, Arg, Gln, Val, or Cys;

Xaa at position 59 is Glu Tyr, His, Leu, Pro, or Arg;

Xaa at position 60 is Ala, Ser, Pro, Tyr, Asn, or Thr;

Xaa at position 61 is Phe, Asn, Glu, Pro, Lys, Arg, or Ser;

Xaa at position 62 is Asn His, Val, Arg, Pro, Thr, Asp, or Ile;

Xaa at position 63 is Arg, Tyr, Trp, Lys, Ser, His, Pro, or Val;

Xaa at position 64 is Ala, Asn, Pro, Ser, or Lys;

Xaa at position 65 is Val, Thr, Pro, His, Leu, Phe, or Ser;

Xaa at position 66 is Lys, Ile, Arg, Val, Asn, Glu, or Ser;

Xaa at position 67 is Ser, Ala, Phe, Val, Gly, Asn, Ile, Pro, or His;

Xaa at position 68 is Leu, Val, Trp, Ser, Ile, Phe, Thr, or His;

Xaa at position 69 is Gln, Ala, Pro, Thr, Glu, Arg, Trp, Gly, or Leu;

Xaa at position 70 is Asn, Leu, Val, Trp, Pro, or Ala;

Xaa at position 71 is Ala, Met, Leu, Pro, Arg, Glu, Thr, Gln, Trp, or Asn;

Xaa at position 72 is Ser, Glu, Met, Ala, His, Asn, Arg, or Asp;

Xaa at position 73 is Ala, Glu, Asp, Leu, Ser, Gly, Thr, or Arg;

Xaa at position 74 is Ile, Met, Thr, Pro, Arg, Gly, Ala;

Xaa at position 75 is Glu, Lys, Gly, Asp, Pro, Trp, Arg, Ser, Gln, or Leu:

Xaa at position 76 is Ser, Val, Ala, Asn, Trp, Glu, Pro, Gly, or Asp;

Xaa at position 77 is Ile, Ser, Arg, Thr, or Leu;

Xaa at position 78 is Leu, Ala, Ser, Glu, Phe, Gly, or Arg;

Xaa at position 79 is Lys, Thr, Asn, Met, Arg, Ile, Gly, or Asp;

Xaa at position 80 is Agn, Trp, Val, Gly, Thr, Leu, Glu, or Arg;

Xaa at position 81 is Leu, Gln, Gly, Ala, Trp, Arg, Val, or Lys;

Xaa at position 82 is Leu, Gln, Lys, Trp, Arg, Asp, Glu, Asn, His, Thr, Ser, Ala, Tyr, Phe, Ile, Met or Val;

Xaa at position 83 is Pro, Ala, Thr, Trp, Arg, or Met;

Xaa at position 84 is Cys, Glu, Gly, Arg, Met, or Val;

Xaa at position 85 is Leu, Asn, Val, or Gln;

Xaa at position 86 is Pro, Cys, Arg, Ala, or Lys;

Xaa at position 87 is Leu, Ser, Trp, or Gly;

Xaa at position 88 is Ala, Lys, Arg, Val, or Trp;

Xaa at position 89 is Thr, Asp, Cys, Leu, Val, Glu, His, Asn, or Ser;

Xaa at position 90 is Ala, Pro, Ser, Thr, Gly, Asp, Ile, or Met;

Xaa at position 91 is Ala, Pro, Ser, Thr, Phe, Leu, Asp, or His;

Xaa at position 92 is Pro, Phe, Arg, Ser, Lys, His, Ala, Gly, Ile or Leu;

Xaa at position 93 is Thr, Asp, Ser, Asn, Pro, Ala, Leu, or Arg;

Xaa at position 94 is Arg, Ile, Ser, Glu, Leu, Val, Gln, Lys, His, Ala, or Pro;

Xaa at position 95 is His, Gln, Pro, Arg, Val, Leu, Gly, Thr, Asn, Lys, Ser, Ala, Trp, Phe, Ile, or Tyr;

Xaa at position 96 is Pro, Lys, Tyr, Gly, Ile, or Thr;

Xaa at position 97 is Ile, Val, Lys, Ala, or Asn;

Xaa at position 98 is His, Ile, Asn, Leu, Asp, Ala, Thr, Glu, Gln, Ser, Phe, Met, Val, Lys, Arg, Tyr or Pro;

Xaa at position 99 is Ile, Leu, Arg, Asp, Val, Pro, Gln, Gly, Ser, Phe, or His;

Xaa at position 100 is Lys, Tyr, Leu, His, Arg, Ile, Ser, Gln, or Pro;

Xaa at position 101 is Asp, Pro, Met, Lys, His, Thr, Val, Tyr, Glu, Asn, Ser, Ala, Gly, Ile, Leu, or Gln;

Xaa at position 102 is Gly, Leu, Glu, Lys, Ser, Tyr, or Pro;

Xaa at position 103 is Asp, or Ser;

Xaa at position 104 is Trp, Val, Cys, Tyr, Thr, Met, Pro, Leu, Gln, Lys, Ala, Phe, or Gly;

Xaa at position 105 is Asn, Pro, Ala, Phe, Ser, Trp, Gln, Tyr, Leu, Lys, Ile, Asp, or His;

Xaa at position 106 is Glu, Ser, Ala, Lys, Thr, Ile, Gly, or Pro;

Xaa at position 108 is Arg, Lys, Asp, Leu, Thr, Ile, Gln, His, Ser, Ala or Pro;

Xaa at position 109 is Arg, Thr, Pro, Glu, Tyr, Leu, Ser, or Gly;

Xaa at position 110 is Lys, Ala, Asn, Thr, Leu, Arg, Gln, His, Glu, Ser, or Trp;

Xaa at position 111 is Leu, Ile, Arg, Asp, or Met;

Xaa at position 112 is Thr, Val, Gln, Tyr, Glu, His, Ser, or Phe;

Xaa at position 113 is Phe, Ser, Cys, His, Gly, Trp, Tyr, Asp, Lys, Leu, Ile, Val or Asn;

Xaa at position 114 is Tyr, Cys, His, Ser, Trp, Arg, or Leu;

Xaa at position 115 is Leu, Asn, Val, Pro, Arg, Ala, His, Thr, Trp, or Met;

Xaa at position 116 is Lys, Leu, Pro, Thr, Met, Asp, Val, Glu, Arg, Trp, Ser, Asn, His, Ala, Tyr, Phe, Gln, or Ile;

Xaa at position 117 is Thr, Ser, Asn, Ile, Trp, Lys, or Pro;

Xaa at position 118 is Leu, Ser, Pro, Ala, Glu, Cys, Asp, or Tyr;

Xaa at position 119 is Glu, Ser, Lys, Pro, Leu, Thr, Tyr, or Arg;

Xaa at position 120 is Asn, Ala, Pro, Leu, His, Val, or Gln;

Xaa at position 121 is Ala, Ser, Ile, Asn, Pro, Lys, Asp, or Gly;

Xaa at position 122 is Gln, Ser, Met, Trp, Arg, Phe, Pro, His, Ile, Tyr, or Cys;

Xaa at position 123 is Ala, Met, Glu, His, Ser, Pro, Tyr, or Leu;

and which can additionally have Met- preceding the amino acid in position 1; and wherein from 1 to 14 amino acids can be deleted from the N-terminus and/or from 1 to 15 amino acids can be deleted from the C-terminus; and wherein from one to three of the amino acids designated by Xaa are different from the corresponding amino acids of native (1-133) human interleukin-3 with the proviso that when Xaa at position 22 is Leu, and/or Xaa at position 34 is Gly or Glu, and/or Xaa at position 44 is Ala, and/or Xda at position 46 is Lys or Ala, and/or Xaa at position 50 is Lys, and/or Xaa at position 59 is Pro or Arg, and/or Xaa at position 63 is Lys, and/or Xaa at position 75 is Gly or Arg, and/or Xaa at position 94 is Pro, and/or Xaa at position 98 is Arg, and/or Xaa at position 106 is Lys, and/or Xaa at position 110 is Ala or Glu, and/or Xaa at position 111 is Met, then there must be at least one additional substitution besides the ones indicated.

Included in the present invention are (1-133) hIL-3 mutant polypeptides of the Formula II:

Ala Pro Met Thr Gln Thr Thr Ser Leu Lys Thr Ser Trp Val Asn

(SEQ ID NO:16)

1               5                   10                 15

Cys Xaa Xaa Xaa Xaa Xaa Glu Xaa Xaa Xaa Xaa Leu Xaa Xaa Xaa

›DETAILED DESCRIPTION OF THE INVENTION · 3 of 20

20                   25                 30

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Leu Xaa Xaa Glu Xaa Xaa

35                   40                 45

Xaa Xaa Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Leu Xaa Xaa

50                   55                 60

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

65                   70                 75

Xaa Xaa Leu Xaa kaa Xaa Xaa Xaa Cys Xaa Pro Xaa Xaa Xaa Xaa

80                   85                 90

Xaa Xaa Xaa Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asp Xaa Xaa

95                  100                105

Xaa Phe Xaa Xaa Lys Leu Xaa Phe Xaa Xaa Xaa Xaa Leu Xaa Xaa

110                 115                120

Xaa Xaa Xaa Gln Gln Thr Thr Leu Ser Leu Ala Ile Phe

125                 130

wherein

Xaa at position 17 is Ser, Gly, Asp, Met, or Gln; Xaa at position 18 is Asn, His, Leu, Ile, Phe, Arg, or Gln;

Xaa at position 19 is Met, Phe, Ile, Arg, or Ala;

Xaa at position 20 is Ile or Pro;

Xaa at position 21 is Asp or Glu;

Xaa at position 21 is Ile, Val, Ala, Leu, or Gly;

Xaa at position 24 is Ile, Val, Phe, or Leu;

Xaa at position 25 is Thr, His, Gly, Gln, Arg, Pro, or Ala;

Xaa at position 26 is His, Phe, Gly, Arg, or Ala;

Xaa at position 28 is Lys, Leu, Gln, Gly, Pro, or Val;

Xaa at position 29 is Gln, Asn, Leu, Arg, or Val;

Xaa at position 30 is Pro, His, Thr, Gly, or Gln;

Xaa at position 31 is Pro, Asp, Gly, Ala, Arg, Leu, or Gln;

Xaa at position 32 is Leu, Arg, Gln, Asn, Gly, Ala, or Glu;

Xaa at position 33 is Pro, Leu, Gln, Ala, or Glu;

Xaa at position 34 is Leu, Val, Gly, Ser, Lys, Ala, Arg, Gln, Glu, Ile, Phe, Thr or Met;

Xaa at position 35 is Leu, Ala, Asn, Pro, Gln, or Val;

Xaa at position 36 is Asp or Leu;

Xaa at position 37 is Phe, Ser, Pro, Trp, or Ile;

Xaa at position 38 is Asn or Ala;

Xaa at position 41 is Asn, Cys, Arg, His, Met, or Pro;

Xaa at position 42 is Gly, Asp, Ser, Cys, Ala, Asn, Ile, Leu, Met, Tyr, Val or Arg;

Xaa at position 44 is Asp or Glu;

Xaa at position 45 is Gln, Val, Met, Leu, Thr, Lys, Ala, Asn, Glu, Ser, or Trp;

Xaa at position 46 is Asp, Phe, Ser, Thr, Cys, Ala, Asn, Gln, Glu, His, Ile, Lys, Tyr, Val or Gly;

Xaa at position 47 is Ile, Val, or His;

Xaa at position 49 is Met, Asn, or Asp;

Xaa at position 50 is Glu, Thr, Ala, Asn, Ser or Asp;

Xaa at position 51 is Asn, Arg, Met, Pro, Ser, Thr, or His;

Xaa at position 52 is Asn or Gly;

Xaa at position 53 is Leu, Met, or Phe;

Xaa at position 54 is Arg, Ala, or Ser;

Xaa at position 55 is Arg, Thr, Val, Leu, or Gly;

Xaa at position 56 is Pro, Gly, Cys, Ser, Gln, Ala, Arg, Asn, Glu, His, Leu, Thr, Val or Lys;

Xaa at position 59 is Glu, Tyr, His, Leu, or Arg;

Xaa at position 60 is Ala, Ser, Asn, or Thr;

Xaa at position 61 is Phe or Ser;

Xaa at position 62 is Asn, Val, Pro, Thr, or Ile;

Xaa at position 63 is Arg, Tyr, Lys, Ser, His, or Val;

Xaa at position 64 is Ala or Asn;

Xaa at position 65 is Val, Thr, Leu, or Ser;

Xaa at position 66 is Lys, Ile, Arg, Val, Asn, Glu, or Ser;

Xaa at position 67 is Ser, Phe, Val, Gly, Asn, Ile, or His:

Xaa at position 68 is Leu, Val, Ile, Phe, or His;

Xaa at position 69 is Gln, Ala, Pro, Thr, Glu, Arg, or Gly;

Xaa at position 70 is Asn or Pro;

Xaa at position 71 is Ala, Met, Pro, Arg, Glu, Thr, or Gln;

Xaa at position 72 is Ser, Glu, Met, Ala, His, Asn, Arg, or Asp;

Xaa at position 73 is Ala, Glu, Asp, Leu, Ser, Gly, Thr, Arg, or Pro;

Xaa at position 74 is Ile or Met;

Xaa at position 75 is Glu, Gly, Asp, Ser, or Gln;

Xaa at position 76 is Ser, Val, Ala, Asn, Glu, Pro, Gly, or Asp;

Xaa at position 77 is Ile, Ser, or Leu;

Xaa at position 79 is Lys, Thr, Asn, Met, Arg, Ile, Gly, or Asp;

Xaa at position 80 is Asn, Val, Gly, Thr, Leu, Glu, or Arg;

Xaa at position 81 is Leu, or Val;

Xaa at position 82 is Leu, Gln, Trp, Arg, Asp, Ala, Asn, Glu, His, Met, Phe, Ser, Thr, Tyr or Val;

Xaa at position 83 is Pro, Ala, Thr, Trp, or Met;

Xaa at position 85 is Leu or Val;

Xaa at position 87 is Leu or Ser;

Xaa at position 88 is Ala, Arg, or Trp;

Xaa at position 89 is Thr, Asp, Glu, His, Asn, or Ser;

Xaa at position 90 is Ala, Asp, or Met;

Xaa at position 91 is Ala, Pro, Ser, Thr, Phe, Leu, or Asp;

Xaa at position 92 is Pro or Ser;

Xaa at position 93 is Thr, Asp, Ser, Pro, Ala, Leu, or Arg;

Xaa at position 95 is His, Pro, Arg, Val, Leu, Gly, Asn, Ile, Phe, Ser or Thr;

Xaa at position 96 is Pro or Tyr;

Xaa at position 97 is Ile, Val, or Ala;

Xaa at position 98 is His, Ile, Asn, Asp, Ala, Thr, Leu, Arg, Gln, Glu, lys, Met, Ser, Tyr, Val or Pro;

Xaa at position 99 is Ile, Leu, Val, or Phe;

Xaa at position 100 is Lys, Leu, His, Arg, Ile, Gln, Pro, or Ser;

Xaa at position 101 is Asp, Pro, Met, Lys, His, Thr, Val, Asn, Ile, Leu or Tyr;

Xaa at position 102 is Gly, Glu, Lys, or Ser;

Xaa at position 104 is Trp, Val, Tyr, Met, or Leu;

Xaa at position 105 is Asn, Pro, Ala, Phe, Ser, Trp, Gln, Tyr, Leu, Lys, Ile, Asp, or His;

Xaa at position 106 is Glu, Ser, Ala, or Gly;

Xaa at position 108 is Arg, Ala, Gln, Ser or Lys;

Xaa at position 109 is Arg, Thr, Glu, Leu, Ser, or Gly;

Xaa at position 112 is Thr, Val, Gln, Glu, His, or Ser;

Xaa at position 114 is Tyr or Trp;

Xaa at position 115 is Leu or Ala;

Xaa at position 116 is Lys, Thr, Met, Val, Trp, Ser, Leu, Ala, Asn, Gln, His, Met, Phe, Tyr or Ile;

Xaa at position 117 is Thr, Ser, or Asn;

Xaa at position 119 is Glu, Ser, Pro, Leu, Thr, or Tyr;

Xaa at position 120 is Asn, Pro, Leu, His, Val, or Gln;

Xaa at position 121 is Ala, Ser, Ile, Asn, Pro, Lys, Asp, or Gly;

Xaa at position 122 is Gln, Ser, Met, Trp, Arg, Phe, Pro, His, Ile, Tyr, or Cys;

Xaa at position 123 is Ala, Met, Glu, His, Ser, Pro, Tyr, or Leu;

and which can additionally have Met- preceding the amino acid in position 1; and wherein from 1 to 14 amino acids can be deleted from the N-terminus and/or from 1 to 15 amino acids can be deleted from the C-terminus; and wherein from one to three of the amino acids designated by Xaa are different from the corresponding amino acids of native (1-133) human interleukin-3 with the proviso that when Xaa at position 34 is Gly or/and Xaa or position 46 is Lys or Ala or/and Xaa at position 59 is Arg and/or Xaa at position 63 is Lys and/or Xaa at position 75 is Gly and/or Xaa at position 98 is Arg then there must be at least one additional substitution besides the ones indicated.

›DETAILED DESCRIPTION OF THE INVENTION · 4 of 20

Included in the present invention are (1-133) hIL-3 mutant polypeptides of the Formula III:

Ala Pro Met Thr Gln Thr Thr Ser Leu Lys Thr Ser Trp Val Asn

(SEQ ID NO:17)

1               5                   10                 15

Cys Xaa Xaa Xaa Ile Xaa Glu Xaa Xaa Xaa Xaa Leu Lys Xaa Xaa

20                  25                 30

Xaa Xaa Xaa Xaa Xaa Asp Xaa Xaa Asn Leu Asn Xaa Glu Xaa Xaa

35                  40                 45

Xaa Ile Leu Met Xaa Xaa Asn Leu Xaa Xaa Xaa Asn Leu Glu Xaa

50                  55                 60

Phe Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Ile Glu

65                  70                 75

Xaa Xaa Leu Xaa Xaa Leu Xaa Xaa Cys Xaa Pro Xaa Xaa Thr Ala

80                  85                 90

Xaa Pro Xaa Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Asp Xaa Xaa

95                 100                105

Xaa Phe Xaa Xaa Lys Leu Xaa Phe Xaa Xaa Xaa Xaa Leu Glu Xaa

110                 115                120

Xaa Xaa Xaa Gln Gln Thr Thr Leu Ser Leu Ala Ile Phe

125                 130

wherein

Xaa at position 17 is Ser, Gly, Asp, Met, or Gln;

Xaa at position 18 is Asn, His, or Ile;

Xaa at position 19 is Met or Ile;

Xaa at position 21 is Asp or Glu;

Xaa at position 23 is Ile, Ala, Leu, or Gly;

Xaa at position 24 is Ile, Val, or Leu;

Xaa at position 25 is Thr, His, Gln, or Ala;

Xaa at position 26 is His or Ala;

Xaa at position 29 is Gln, Asn, or Val;

Xaa at position 30 is Pro, Gly, or Gln;

Xaa at position 31 is Pro, Asp, Gly, or Gln;

Xaa at position 32 is Leu, Arg, Gln, Asn, Gly, Ala, or Glu;

Xaa at position 33 is Pro or Glu;

Xaa at position 34 is Leu, Val, Gly, Ser, Lys, Ala, Arg, Gln, Glu, Ile, Phe, Thr or Met;

Xaa at position 35 is Leu, Ala, Asn, Pro, Gln, or Val;

Xaa at position 37 is Phe, Ser, Pro, or Trp;

Xaa at position 38 is Asn or Ala;

Xaa at position 42 is Gly, Asp, Ser, Cys, Ala, Asn, Ile, Leu, Met, Tyr or Arg;

Xaa at position 44 is Asp or Glu;

Xaa at position 45 is Gln, Val, Met, Leu, Thr, Ala, Asn, Glu, Ser or Lys;

Xaa at position 46 is Asp, Phe, Ser, Thr, Ala, Asn Gln, Glu, His, Ile, Lys, Tyr, Val or Cys;

Xaa at position 50 is Glu, Ala, Asn, Ser or Asp;

Xaa at position 51 is Asn, Arg, Met, Pro, Ser, Thr, or His;

Xaa at position 54 is Arg or Ala;

Xaa at position 54 is Arg or Ala;

Xaa at position 55 is Arg, Thr, Val, Leu, or Gly;

Xaa at position 56 is Pro, Gly, Ser, Gln, Ala, Arg, Asn, Glu, Leu, Thr, Val or Lys;

Xaa at position 60 is Ala or Ser;

Xaa at position 62 is Asn, Pro, Thr, or Ile;

Xaa at position 63 is Arg or Lys;

Xaa at position 64 is Ala or Asn;

Xaa at position 65 is Val or Thr;

Xaa at position 66 is Lys or Arg;

Xaa at position 67 is Ser, Phe, or His;

Xaa at position 68 is Leu, Ile, Phe, or His;

Xaa at position 69 is Gln, Ala, Pro, Thr, Glu, Arg, or Gly;

Xaa at position 71 is Ala, Pro, or Arg;

Xaa at position 72 is Ser, Glu, Arg, oz Asp;

Xaa at position 73 is Ala or Leu;

Xaa at position 76 is Ser, Val, Ala, Asn, Glu, Pro, or Gly;

Xaa at position 77 is Ile or Leu;

Xaa at position 79 is Lys, Thr, Asn, Met, Arg, Ile, Gly, or Asp;

Xaa at position 80 is Asn, Gly, Glu, or Arg;

Xaa at position 82 is Leu, Gln, Trp, Arg, Asp, Ala, Asn, Glu, His, Ile, Met, Phe, Ser, Thr, Tyr or Val;

Xaa at position 83 is Pro or Thr;

Xaa at position 85 is Leu or Val;

Xaa at position 87 is Leu or Ser;

Xaa at position 88 is Ala or Trp;

Xaa at position 91 is Ala or Pro;

Xaa at position 93 is Thr, Asp, Ser, Pro, Ala, Leu, or Arg;

Xaa at position 95 is His, Pro, Arg, Val, Leu, Gly, Asn, Phe, Ser or Thr;

Xaa at position 96 is Pro or Tyr;

Xaa at position 97 is Ile or Val;

Xaa at position 98 is His, Ile, Asn, Leu, Ala, Thr, Arg, Gln, Lys, Met, Ser, Tyr, Val or Pro;

Xaa at position 99 is Ile, Leu, or Val;

Xaa at position 100 is Lys, Arg, Ile, Gln, Pro, or Ser;

Xaa at position 101 is Asp, Pro, Met, Lys, His, Thr, Pro, Asn, Ile, Leu or Tyr;

Xaa at position 104 is Trp or Leu;

Xaa at position 105 is Asn, Pro, Ala, Ser, Trp, Gln, Tyr, Leu, Lys, Ile, Asp, or His;

Xaa at position 106 is Glu or Gly;

Xaa at position 108 is Arg, Ala, or Ser;

Xaa at position 109 is Arg, Thr, Glu, Leu, or Ser;

Xaa at position 112 is Thr, Val, or Gln;

Xaa at position 114 is Tyr or Trp;

Xaa at position 115 is Leu or Ala;

Xaa at position 116 is Lys, Thr, Val, Trp, Ser, Ala, His, Met, Phe, Tyr or Ile;

Xaa at position 117 is Thr or Ser;

Xaa at position 120 is Asn, Pro, Leu, His, Val, or Gln;

Xaa at position 121 is Ala, Ser, Ile, Asn, Pro, Asp, or Gly;

Xaa at position 122 is Gln, Ser, Met, Trp, Arg, Phe, Pro, His, Ile, Tyr, or Cys;

Xaa at position 123 is Ala, Met, Glu, His, Ser, Pro, Tyr, or Leu;

and which can additionally have Met- preceding the amino acid in position 1; and wherein from 1 to 14 amino acids can be deleted from the N-terminus and/or from 1 to 15 amino acids can be deleted from the C-terminus; and wherein from one to three of the amino acids designated by Xaa are different from the corresponding amino acids of native (1-133) human interleukin-3 with the proviso that when Xaa at position 22 is Leu, and/or Xaa at position 34 is Gly or Glu, and/or Xaa at position 44 is Ala, and/or Xaa at position 46 is Lys or Ala, and/or Xaa at position 50 is Lys, and/or Xaa at position 59 is Pro or Arg, and/or Xaa at position 63 is Lys, and/or Xaa at position 75 is Gly or Arg, and/or Xaa at position 94 is Pro, and/or Xaa at position 98 is Arg, and/or Xaa at position 106 is Lys, and/or Xaa at position 110 is Ala or Glu, and/or Xaa at position 111 is Met, then there must be at least one additional substitution besides the ones indicated. and which can additionally have Met- preceding the amino acid in position 1; and wherein from 1 to 14 amino acids can be deleted from the N-terminus and/or from 1 to 15 amino acids can be deleted from the C-terminus; and wherein from one to three of the amino acids designated by Xaa are different from the corresponding amino acids of native (1-133) human interleukin-3 with the proviso that when Xaa at position 34 is Gly and/or Xaa at position 46 is Lys or Ala, and/or Xaa at position 63 is Lys, and/or Xaa at position 98 is Arg, then two or three of the amino acid designated by Xaa are different from the corresponding amino acids of the native (1-133) human interleukin-3.

›DETAILED DESCRIPTION OF THE INVENTION · 5 of 20

Included in the present invention are (1-133) hIL-3 mutant polypeptides of the Formula IV:

Ala Pro Met Thr Gln Thr Thr Ser Leu Lys Thr Ser Trp Val Asn

[SEQ ID NO:18]

1               5                   10                 15

Cys Xaa Xaa Met Ile Asp Glu Xaa Ile Xaa Xaa Leu Lys Xaa Xaa

20                  25                 30

Pro Xaa Pro Xaa Xaa Asp Phe Xaa Asn Leu Asn Xaa Glu Asp Xaa

35                  40                 45

Xaa Ile Leu Met Xaa Xaa Asn Leu Arg Xaa Xaa Asn Leu Glu Ala

50                  55                 60

Phe Xaa Arg Xaa Xaa Lys Xaa Xaa Xaa Asn Ala Ser Ala Ile Glu

65                  70                 75

Xaa Xaa Leu Xaa Xaa Leu Xaa Pro Cys Leu Pro Xaa Xaa Thr Ala

80                  85                 90

Xaa Pro Xaa Arg Xaa Pro Ile Xaa Xaa Xaa Xaa Gly Asp Trp Xaa

95                 100                105

Glu Phe Xaa Xaa Lys Leu Xaa Phe Tyr Leu Xaa Xaa Leu Glu Xaa

110                 115                120

Xaa Xaa Xaa Gln Gln Thr Thr Leu Ser Leu Ala Ile Phe

125                 130

wherein

Xaa at position 17 is Ser, Gly, Asp, or Gln;

Xaa at position 18 is Asn, His, or Ile;

Xaa at position 23 is Ile, Ala, Leu, or Gly;

Xaa at position 25 is Thr, His, or Gln;

Xaa at position 26 is His or Ala;

Xaa at position 29 is Gln or Asn;

Xaa at position 30 is Pro or Gly;

Xaa at position 32 is Leu, Arg, Asn, or Ala;

Xaa at position 34 is Leu, Val, Ser, Ala, Arg, Gln, Glu, Ile, Phe, Thr, or Met;

Xaa at position 35 is Leu, Ala, Asn, or Pro;

Xaa at position 29 is Asn or Ala;

Xaa at position 42 is Gly, Asp, Ser, Ala, Asn, Ile, Leu, Met, Tyr or Arg;

Xaa at position 45 is Gln, Val, Met, Leu, Ala, Asn, Glu, or Lys;

Xaa at position 46 is Asp, Phe, Ser, Ala, Gln, Glu, His, Val or Thr;

Xaa at position 50 is Glu Asn, Ser or Asp;

Xaa at position 51 is Asn, Arg, Pro, Thr, or His;

Xaa at position 55 is Arg, Leu, or Gly;

Xaa at position 56 is Pro, Gly, Ser, Ala, Asn, Val, Leu or Gln;

Xaa at position 62 is Asn, Pro, or Thr;

Xaa at position 64 is Ala or Asn;

Xaa at position 65 is Val or Thr;

Xaa at position 67 is Ser or Phe;

Xaa at position 68 is Leu or Phe;

Xaa at position 69 is Gln, Ala, Glu, or Arg;

Xaa at position 76 is Ser, Val, Asn, Pro, or Gly;

Xaa at position 77 is Ile or Leu;

Xaa at position 79 is Lys, Asn, Met, Arg, Ile, or Gly;

Xaa at position 80 is Asn, Gly, Glu, or Arg;

Xaa at position 82 is Leu, Gln, Trp, Arg, Asp, Asn, Glu, His, Met, Phe, Ser, Thr, Tyr or Val;

Xaa at position 87 is Leu or Ser;

Xaa at position 88 is Ala or Trp;

Xaa at position 91 is Ala or Pro;

Xaa at position 93 is Thr, Asp, or Ala;

Xaa at position 95 is His, Pro, Arg, Val, Gly, Asn, Ser or Thr;

Xaa at position 98 is His, Ile, Asn, Ala, Thr, Arg, Gln, Glu, Lys, Met, Ser, Tyr, Val or Leu;

Xaa at position 99 is Ile or Leu;

Xaa at position 100 is Lys or Arg;

Xaa at position 101 is Asp, Pro, Met, Lys, Thr, His, Pro, Asn, Ile, Leu or Tyr;

Xaa at position 105 is Asn, Pro, Ser, Ile or Asp;

Xaa at position 108 is Arg, Ala, or Ser;

Xaa at position 109 is Arg, Thr, Glu, Leu, or Ser;

Xaa at position 112 is Thr or Gln;

Xaa at position 116 is Lys, Val, Trp, Ala, His, Phe, Tyr or Ile;

Xaa at position 117 is Thr or Ser;

Xaa at position 120 is Asn, Pro, Leu, His, Val, or Gln;

Xaa at position 121 is Ala, Ser, Ile, Pro, or Asp;

Xaa at position 122 is Gln, Met, Trp, Phe, Pro, His, Ile, or Tyr;

Xaa at position 123 is Ala, Met, Glu, Ser, or Leu;

and which can additionally have Met- preceding the amino acid in position 1; and wherein from 1 to 14 amino acids can be deleted from the N-terminus and/or from 1 to 15 amino acids can be deleted from the C-terminus; and wherein from one to three of the amino acids designated by Xaa are different from the corresponding amino acids of native (1-133) human interleukin-3.

Preferred polypeptides of the present invention are (15-125) hIL-3 mutant polypeptides of the Formula V:

Asn Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

[SEQ ID NO:19]

1                5                   10                 15

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Xaa Xaa

20                  25                 30

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

35                  40                 45

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

50                  55                 60

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

65                  70                 75

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

80                  85                 90

Xaa Xaa Phe Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

95                 100                105

Xaa Xaa Xaa Xaa Gln Gln

110

wherein

wherein

Xaa at position 3 is Ser, Lys, Gly, Asp, Met, Gln, or Arg;

Xaa at position 4 is Asn, His, Leu, Ile, Phe, Arg, or Gln;

Xaa at position 5 is Met, Phe, Ile, Arg, Gly, Ala, or Cys;

Xaa at position 6 is Ile, Cys, Gln, Glu, Arg, Pro, or Ala;

Xaa at position 7 is Asp, Phe, Lys, Arg, Ala, Gly, Glu, Gln, Asn, Thr, Ser or Val;

Xaa at position 8 is Glu, Trp, Pro, Ser, Ala, His, Asp, Asn, Gln, Leu, Val, or Gly;

Xaa at position 9 is Ile, Val, Ala, Leu, Gly, Trp, Lys, Phe, Ser, or Arg;

Xaa at position 10 is Ile, Gly, Val, Arg, Ser, Phe, or Leu;

Xaa at position 11 is Thr, His, Gly, Gln, Arg, Pro, or Ala;

Xaa at position 12 is His, Thr, Phe, Gly, Arg, Ala, or Trp;

Xaa at position 13 is Leu, Gly, Arg, Thr, Ser, or Ala;

Xaa at position 14 is Lys, Arg, Leu, Gln, Gly, Pro, Val or Trp;

Xaa at position 15 is Gln, Asn, Leu, Pro, Arg, or Val;

Xaa at position 16 is Pro, His, Thr, Gly, Asp, Gln, Ser, Leu, or Lys;

Xaa at position 17 is Pro, Asp, Gly, Ala, Arg, Leu, or Gln;

Xaa at position 18 is Leu, Val, Arg, Gln, Asn, Gly, Ala, or Glu;

Xaa at position 19 is Pro, Leu, Gln, Ala, Thr, or Glu;

Xaa at position 20 is Leu, Val, Gly, Ser, Lys, Glu, Gln, Thr, Arg, Ala, Phe, Ile or Met;

Xaa at position 21 is Leu, Ala, Gly, Asn, Pro, Gln, or Val;

Xaa at position 22 is Asp, Leu, or Val;

Xaa at position 23 is Phe, Ser, Pro, Trp, or Ile;

Xaa at position 24 is Asn, or Ala;

Xaa at position 26 is Leu, Trp, or Arg;

Xaa at position 27 is Asn, Cys, Arg, Leu, His, Met, Pro;

Xaa at position 28 is Gly, Asp, Ser, Cys, Ala, Lys, Asn, Thr, Leu, Val, Glu, Phe, Tyr, Ile or Met;

›DETAILED DESCRIPTION OF THE INVENTION · 6 of 20

Xaa at position 29 is Glu, Asn, Tyr, Leu, Phe, Asp, Ala, Cys, Gln, Arg, Thr, Gly or Ser;

Xaa at position 30 is Asp, Ser, Leu, Arg, Lys, Thr,Met, Trp, Glu, Asn, Gln, Ala or Pro;

Xaa at position 31 is Gln, Pro, Phe, Val, Met, Leu, Thr, Lys, Asp, Asn, Arg, Ser, Ala, Ile, Glu, His or Trp;

Xaa at position 32 is Asp, Phe, Ser, Thr, Cys, Glu, Asn, Gln, Lys, His, Ala, Tyr, Ile, Val or Gly;

Xaa at position 33 is Ile, Gly, Val, Ser, Arg, Pro, or His;

Xaa at position 34 is Leu, Ser, Cys, Arg, Ile, His, Phe, Glu, Lys, Thr, Ala, Met, Val or Asn;

Xaa at position 35 is Met, Arg, Ala, Gly, Pro, Asn, His, or Asp;

Xaa at position 36 is Glu, Leu, Thr, Asp, Tyr, Lys, Asn, Ser, Ala, Ile, Val, His, Phe, Met or Gln;

Xaa at position 37 is Asn, Arg, Met, Pro, Ser, Thr, or His;

Xaa at position 38 is Asn, His, Arg, Leu, Gly, Ser, or Thr;

Xaa at position 39 is Leu, Thr, Ala, Gly, Glu, Pro, Lys, Ser, Met, or;

Xaa at position 40 is Arg, Asp, Ile, Ser, Val, Thr, Gln, Asn, Lys, His, Ala or Leu;

Xaa at position 41 is Arg, Thr, Val, Ser, Leu, or Gly;

Xaa at position 42 is Pro, Gly, Cys, Ser, Gln, Glu, Arg, His, Thr, Ala, Tyr, Phe, Leu, Val or Lys;

Xaa at position 43 is Asn or Gly;

Xaa at position 44 is Leu, Ser, Asp, Arg, Gln, Val, or Cys;

Xaa at position 45 is Glu Tyr, His, Leu, Pro, or Arg;

Xaa at position 46 is Ala, Ser, Pro, Tyr, Asn, or Thr;

Xaa at position 47 is Phe, Asn, Glu, Pro, Lys, Arg, or Ser;

Xaa at position 48 is Asn, His, Val, Arg, Pro, Thr, Asp, or Ile;

Xaa at position 49 is Arg, Tyr, Trp, Lys, Ser, His, Pro, or Val;

Xaa at position 50 is Ala, Asn, Pro, Ser, or Lys;

Xaa at position 51 is Val, Thr, Pro, His, Leu, Phe, or Ser;

Xaa at position 52 is Lys, Ile, Arg, Val, Asn, Glu, or Ser;

Xaa at position 53 is Ser, Ala, Phe, Val, Gly, Asn, Ile, Pro, or His;

Xaa at position 54 is Leu, Val, Trp, Ser, Ile, Phe, Thr, or His;

Xaa at position 55 is Gln, Ala, Pro, Thr, Glu, Arg, Trp, Gly, or Leu;

Xaa at position 56 is Asn, Leu, Val, Trp, Pro, or Ala;

Xaa at position 57 is Ala, Met, Leu, Pro, Arg, Glu, Thr, Gln, Trp, or Asn;

Xaa at position 58 is Ser, Glu, Met, Ala, His, Asn, Arg, or Asp;

Xaa at position 59 is Ala, Glu, Asp, Leu, Ser, Gly, Thr, or Arg;

Xaa at position 60 is Ile, Met, Thr, Pro, Arg, Gly, Ala;

Xaa at position 61 is Glu, Lys, Gly, Asp, Pro, Trp, Arg, Ser, Gln, or Leu;

Xaa at position 62 is Ser, Val, Ala, Asn, Trp, Glu, Pro, Gly, or Asp;

Xaa at position 63 is Ile, Ser, Arg, Thr, or Leu;

Xaa at position 64 is Leu, Ala, Ser, Glu, Phe, Gly, or Arg;

Xaa at position 65 is Lys, Thr, Gly, Asn, Met, Arg, Ile, or Asp;

Xaa at position 66 is Asn, Trp, Val, Gly, Thr, Leu, Glu, or Arg;

Xaa at position 67 is Leu, Gln, Gly, Ala, Trp, Arg, Val, or Lys;

Xaa at position 68 is Leu, Gln, Lys, Trp, Arg, Asp, Glu, Asn, His, Thr, Ser, Ala, Tyr, Phe, Ile, Met or Val;

Xaa at position 69 is Pro, Ala, Thr, Trp, Arg, or Met;

Xaa at position 70 is Cys, Glu, Gly, Arg, Met, or Val;

Xaa at position 71 is Leu, Asn, Val, or Gln;

Xaa at position 72 is Pro, Cys, Arg, Ala, or Lys;

Xaa at position 73 is Leu, Ser, Trp, or Gly;

Xaa at position 74 is Ala, Lys, Arg, Val, or Trp;

Xaa at position 75 is Thr, Asp, Cys, Leu, Val, Glu, His, Asn, or Ser;

Xaa at position 76 is Ala, Pro, Ser, Thr, Gly, Asp, Ile, or Met;

Xaa at position 77 is Ala, Pro, Ser, Thr, Phe, Leu, Asp, or His;

Xaa at position 78 is Pro, Phe, Arg, Ser, Lys, His, Ala, Gly, Ile or Leu;

Xaa at position 79 iS Thr, Asp, Ser, Asn, Pro, Ala, Leu, or Arg;

Xaa at position 80 is Arg, Ile, Ser, Glu, Leu, Val, Gln, Lys, His, Ala or Pro;

Xaa at position 81 is His, Gln, Pro, Arg, Val, Leu, Gly, Thr, Asn, Lys, Ser, Ala, Trp, Phe, Ile or Tyr;

Xaa at position 82 is Pro, Lys, Tyr, Gly, Ile, or Thr:

Xaa at position 83 is Ile, Val, Lys, Ala, or Asn;

Xaa at position 84 is His, Ile, Asn, Leu, Asp, Ala, Thr, Glu, Gln, Ser, Phe, Met, Val, Lys, Arg, Tyr or Pro;

Xaa at position 85 is Ile, Leu, Arg, Asp, Val, Pro, Gln, Gly, Ser, Phe, or His;

Xaa at position 86 is Lys, Tyr, Leu, His, Arg, Ile, Ser, Gln, Pro;

Xaa at position 87 is Asp, Pro, Met, Lys, His, Thr, Val, Tyr, Glu, Asn, Ser, Ala, Gly, Ile, Leu or Gln;

Xaa at position 88 is Gly, Leu, Glu, Lys, Ser, Tyr, or Pro;

Xaa at position 89 is Asp, or Ser;

Xaa at position 90 Is Trp, Val, Cys, Tyr, Thr, Met, Pro, Leu, Gln, Lys, Ala, Phe, or Gly;

Xaa at position 91 is Asn, Pro, Ala, Phe, Ser, Trp, Gln, Tyr, Leu, Lys, Ile, Asp, or His;

Xaa at position 92 is Glu, Ser, Ala, Lys, Thr, Ile, Gly, or Pro;

Xaa at position 94 is Arg, Lys, Asp, Leu, Thr, Ile, Gln, His, Ser, Ala, or Pro;

Xaa at position 95 is Arg, Thr, Pro, Glu, Tyr, Leu, Ser, or Gly;

Xaa at position 96 is Lys, Asn, Thr, Leu, Gln, Arg, His, Glu, Ser, Ala or Trp;

Xaa at position 97 is Leu, Ile, Arg, Asp, or Met;

Xaa at position 98 is Thr, Val, Gln, Tyr, Glu, His, Ser, or Phe;

Xaa at position 99 is Phe, Ser, Cys, His, Gly, Trp, Tyr, Asp, Lsy, Leu, Ile, Val or Asn;

Xaa at position 100 is Tyr, Cys, His, Ser, Trp, Arg, or Leu;

Xaa at position 101 is Leu, Asn, Val, Pro, Arg, Ala, His, Thr, Trp, or Met;

Xaa at position 102 is Lys, Leu, Pro, Thr, Met, Asp, Val, Glu, Arg, Trp, Ser, Asn, His, Ala, Tyr, Phe, Gln, or Ile;

Xaa at position 103 is Thr, Ser, Asn, Ile, Trp, Lys, or Pro;

Xaa at position 104 is Leu, Ser, Pro, Ala, Glu, Cys, Asp, or Tyr;

Xaa at position 105 is Glu, Ser, Lys, Pro, Leu, Thr, Tyr, or Arg;

Xaa at position 106 is Asn, Ala, Pro, Leu, His, Val, or Gln;

Xaa at position 107 is Ala, Ser, Ile, Asn, Pro, Lys, Asp, or Gly;

Xaa at position 108 is Gln, Ser, Met, Trp, Arg, Phe, Pro, His, Ile, Tyr, or Cys;

Xaa at position 109 is Ala, Met, Glu, His, Ser, Pro, Tyr, or Leu;

and which can additionally have Met- or Met-Ala- preceding the amino acid in position 1; and wherein from one to three of the amino acids designated by Xaa are different from the corresponding native amino acids of (1-133) human interleukin-3; or a polypeptide having substantially the same structure and substantially the same biological activity.

Included in the present invention are (15-125) hIL-3 mutant polypeptides of the Formula VI:

Asn Cys Xaa Xaa Xaa Xaa Xaa Glu Xaa Xaa Xaa Xaa Leu Xaa Xaa

[SEQ ID NO:20]

1               5                   10                 15

›DETAILED DESCRIPTION OF THE INVENTION · 7 of 20

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Leu Xaa Xaa Glu Xaa

20                  25                 30

Xaa Xaa Xaa Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Leu Xaa

35                  40                 45

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

50                  55                 60

Xaa Xaa Xaa Leu Xaa Xaa Xaa Xaa Xaa Cys Xaa Pro Xaa Xaa Xaa

65                  70                 75

Xaa Xaa Xaa Xaa Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asp Xaa

80                  85                 90

Xaa Xaa Phe Xaa Xaa Lys Leu Xaa Phe Xaa Xaa Xaa Xaa Leu Xaa

95                 100                105

Xaa Xaa Xaa Xaa Gln Gln

110

wherein

Xaa at position 3 is Ser, Gly, Asp, Met, or Gln;

Xaa at position 4 is Asn, His, Leu, Ile, Phe, Arg, or Gln;

Xaa at position 5 is Met, Phe, Ile, Arg, or Ala;

Xaa at position 6 is Ile or Pro;

Xaa at position 7 is Asp, or Glu;

Xaa at position 9 is Ile, Val, Ala, Leu, or Gly;

Xaa at position 10 is Ile, Val, Phe, or Leu;

Xaa at position 11 is Thr, His, Gly, Gln, Arg, Pro, or Ala;

Xaa at position 12 is His, Phe, Gly, Arg, or Ala;

Xaa at position 14 is Lys, Leu, Gln, Gly, Pro, or Val;

Xaa at position 15 is Gln, Asn, Leu, Arg, or Val;

Xaa at position 16 is Pro, His, Thr, Gly, or Gln;

Xaa at position 17 is Pro, Asp, Gly, Ala, Arg, Leu, or Gln;

Xaa at position 18 is Leu, Arg, Gln, Asn, Gly, Ala, or Glu;

Xaa at position 19 is Pro, Leu, Gln, Ala, or Glu;

Xaa at position 20 is Leu, Val, Gly, Ser, Lys, Ala, Arg, Gln, Glu, Ile, Phe, Thr or Met;

Xaa at position 21 is Leu, Ala, Asn, Pro, Gln, or Val;

Xaa at position 22 is Asp or Leu;

Xaa at position 23 is Phe, Ser, Pro, Trp, or Ile;

Xaa at position 24 is Asn or Ala;

Xaa at position 27 is Asn, Cys, Arg, His, Met, or Pro;

Xaa at position 28 is Gly, Asp, Ser, Cys, Ala, Asn, Ile, Leu, Met, Tyr, or Arg;

Xaa at position 30 is Asp, or Glu:

Xaa at position 31 is Gln, Val, Met, Leu, Thr, Lys, Ala, Asn Glu, Ser or Trp;

Xaa at position 32 is Asp, Phe, Ser, Thr, Cys, Ala, Asn, Gln, Glu, His, Ile, Lys, Tyr, Val or Gly;

Xaa at position 33 is Ile, Val, or His;

Xaa at position 35 is Met, Asn, or Asp;

Xaa at position 36 is Glu, Thr, Ala, Asn, Ser or Asp;

Xaa at position 37 is Asn, Arg, Met, Pro, Ser, Thr, or His;

Xaa at position 38 is Asn or Gly;

Xaa at position 39 is Leu, Met, or Phe;

Xaa at position 40 is Arg, Ala or Ser;

Xaa at position 41 is Arg, Thr, Val, Leu, or Gly;

Xaa at position 42 is Pro, Gly, Cys, Ser, Gln, Ala, Arg, Asn, Glu, His, Leu, Thr, Val or Lys;

Xaa at position 45 is Glu, Tyr, His, Leu, or Arg;

Xaa at position 46 is Ala, Ser, Asn, or Thr;

Xaa at position 47 is Phe or Ser;

Xaa at position 48 is Asn, Val, Pro, Thr, or Ile;

Xaa at position 49 is Arg, Tyr, Lys, Ser, His, or Val;

Xaa at position 50 is Ala or Asn;

Xaa at position 51 is Val, Thr, Leu, or Ser;

Xaa at position 52 is Lys, Ile, Arg, Val, Asn, Glu, or Ser;

Xaa at position 53 is Ser, Phe, Val, Gly, Asn, Ile, or His;

Xaa at position 54 is Leu, Val, Ile, Phe, or His;

Xaa at position 55 is Gln, Ala, Pro, Thr, Glu, Arg, or Gly;

Xaa at position 56 is Asn or Pro;

Xaa at position 57 is Ala, Met, Pro, Arg, Glu, Thr, or Gln;

Xaa at position 58 is Ser, Glu, Met, Ala, His, Asn, Arg, or Asp;

Xaa at position 59 is Ala, Glu, Asp, Leu, Ser, Gly, Thr, Arg, or Pro;

Xaa at position 60 is Ile or Met;

Xaa at position 61 is Glu, Gly, Asp, Ser, or Gln;

Xaa at position 62 is Ser, Val, Ala, Asn, Glu, Pro, Gly, or Asp;

Xaa at position 63 is Ile, Ser, or Leu;

Xaa at position 65 is Lys, Thr, Gly, Asn, Met, Arg, Ile, or Asp;

Xaa at position 66 is Asn, Val, Gly, Thr, Leu, Glu, or Arg;

Xaa at position 67 is Leu, or Val;

Xaa at position 68 is Leu, Gln, Trp, Arg, Asp, Ala, Asn, Glu, His, Met, Phe, Ser, Thr, Tyr or Val;

Xaa at position 69 is Pro, Ala, Thr, Trp, or Met;

Xaa at position 71 is Leu or Val;

Xaa at position 73 is Leu or Ser;

Xaa at position 74 is Ala, Arg, or Trp:

Xaa at position 75 is Thr, Asp, Glu, His, Asn, or Ser;

Xaa at position 76 is Ala, Asp, or Met;

Xaa at position 77 is Ala, Pro, Ser, Thr, Phe, Leu, or Asp;

Xaa at position 78 is Pro or Ser;

Xaa at position 79 is Thr, Asp, Ser, Pro, Ala, Leu, or Arg;

Xaa at position 81 is His, Pro, Arg, Val, Leu, Gly, Asn, Ile, Phe, Ser or Thr;

Xaa at position 82 is Pro or Tyr;

Xaa at position 83 is Ile, Val, or Ala;

Xaa at position 84 is His, Ile, Asn, Leu, Asp, Ala, Thr, Arg, Gln, Glu, Lys, Met, per, Tyr, Val or Pro;

Xaa at position 85 is Ile, Leu, Val, or Phe;

Xaa at position 86 is Lys, Leu, His, Arg, Ile, Gln, Pro or Ser;

Xaa at position 87 is Asp, Pro, Met, Lys, His, Thr, Val, Asn, Ile, Leu or Tyr;

Xaa at position 99 is Gly, Glu, Lys, or Ser;

Xaa at position 90 is Trp, Val, Tyr, Met, or Leu;

Xaa at position 91 is Asn, Pro, Ala, Phe, Ser, Trp, Gln, Tyr, Leu, Lys, Ile, Asp, or His;

Xaa at position 92 is Glu, Ser, Ala, or Gly;

Xaa at position 94 is Arg, Ala, Gln, Ser or Lys;

Xaa at position 95 is Arg, Thr, Glu, Leu, Ser, or Gly;

Xaa at position 98 is Thr, Val, Gln, Glu, His, or Ser;

Xaa at position 100 is Tyr or Trp;

Xaa at position 101 is Leu or Ala;

Xaa at position 102 is Lys, Thr, Met, Val, Trp, Ser, Leu, Ala, Asn, Gln, His, Met, Phe, Tyr or Ile;

Xaa at position 103 is Thr, Ser, or Asn;

Xaa at position 105 is Glu, Ser, Pro, Leu, Thr, or Tyr;

Xaa at position 106 is Asn, Pro, Leu, His, Val, or Gln;

Xaa at position 107 is Ala, Ser, Ile, Asn, Pro, Lys, Asp, or Gly;

Xaa at position 108 is Gln, Ser, Met, Trp, Arg, Phe, Pro, His, Ile, Tyr, or Cys;

Xaa at position 109 is Ala, Met, Glu, His, Ser, Pro, Tyr, or Leu;

and which can additionally have Met- or Met-Ala- preceding the amino acid in position 1; and wherein from one to three of the amino acids designated by Xaa are different from the corresponding amino acids of native (1-133) human interleukin-3; or a polypeptide having substantially the same structure and substantially the same biological activity.

Included in the present invention are (15-125) hIL-3 mutant polypeptides of the Formula VII:

Asn Cys Xaa Xaa Xaa Ile Xaa Glu Xaa Xaa Xaa Xaa Leu Lys Xaa

[SEQ ID NO:21]

1               5                   10                 15

Xaa Xaa Xaa Xaa Xaa Xaa Asp Xaa Xaa Asn Leu Asn Xaa Glu Xaa

20                  25                 30

›DETAILED DESCRIPTION OF THE INVENTION · 8 of 20

Xaa Xaa Ile Leu Met Xaa Xaa Asn Leu Xaa Xaa Xaa Asn Leu Glu

35                  40                 45

Xaa Phe Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Ile

50                  55                 60

Glu Xaa Xaa Leu Xaa Xaa Leu Xaa Xaa Cys Xaa Pro Xaa Xaa Thr

65                  70                 75

Ala Xaa Pro Xaa Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Asp Xaa

80                  85                 90

Xaa Xaa Phe Xaa Xaa Lys Leu Xaa Phe Xaa Xaa Xaa Xaa Leu Glu

95                 100                105

Xaa Xaa Xaa Xaa Gln Gln

110

wherein

Xaa at position 3 is Ser, Gly, Asp, Met, or Gln;

Xaa at position 4 is Asn, His, or Ile;

Xaa at position 5 is Met or Ile;

Xaa at position 7 is Asp or Glu;

Xaa at position 9 is Ile, Ala, Leu, or Gly;

Xaa at position 10 is Ile, Val, or Leu;

Xaa at position 11 is Thr, His, Gln, or Ala;

Xaa at position 12 is His or Ala;

Xaa at position 15 is Gln, Asn, or Val;

Xaa at position 16 is Pro, Gly, or Gln;

Xaa at position 17 is Pro, Asp, Gly, or Gln;

Xaa at position 18 is Leu, Arg, Gln, Asn, Gly, Ala, or Glu;

Xaa at position 19 is Pro or Glu;

Xaa at position 20 is Leu, Val, Gly, Ser, Lys, Ala, Arg, Gln, Glu, Ile, Phe, Thr or Met;

Xaa at position 21 is Leu, Ala, Asn, Pro, Gln, or Val;

Xaa at position 23 is Phe, Ser, Pro, or Trp;

Xaa at position 24 is Asn or Ala;

Xaa at position 28 is Gly, Asp, Ser, Cys, Ala, Asn, Ile, Leu, Met Tyr or Arg;

Xaa at position 30 is Asp or Glu;

Xaa at position 31 is Gln, Val, Met, Leu, Thr, Ala, Asn, Glu, Ser or Lys;

Xaa at position 32 is Asp, Phe, Ser, Thr, Ala, Asn, Gln, Glu, His, Ile, Lys, Tyr, Val or Cys;

Xaa at position 36 is Glu, Ala, Asn, Ser or Asp;

Xaa at position 37 is Asn, Arg, Met, Pro, Ser, Thr, or His;

Xaa at position 40 is Arg or Ala;

Xaa at position 41 is Arg, Thr, Val, Leu, or Gly;

Xaa at position 42 is Pro, Gly, Ser, Gln, Ala, Arg, Asn, Glu, Leu, Thr, Val or Lys;

Xaa at position 46 is Ala or Ser;

Xaa at position 48 is Asn, Pro, Thr, or ale;

Xaa at position 49 is Arg or Lys;

Xaa at position 50 is Ala or Asn;

Xaa at position 51 is Val or Thr;

Xaa at position 52 is Lys or Arg;

Xaa at position 53 is Ser, Phe, or His;

Xaa at position 54 is Leu, Ile, Phe, or His;

Xaa at position 55 is Gln, Ala, Pro, Thr, Glu, Arg, or Gly;

Xaa at position 57 is Ala, Pro, or Arg;

Xaa at position 58 is Ser, Glu, Arg, or Asp;

Xaa at position 59 is Ala or Leu;

Xaa at position 62 is Ser, Val, Ala, Asn, Glu, Pro, or Gly;

Xaa at position 63 is Ile or Leu;

Xaa at position 65 is Lys, Thr, Asn, Met, Arg, Ile, Gly, or Asp;

Xaa at position 66 is Asn, Gly, Glu, or Arg;

Xaa at position 68 is Leu, Gln, Trp, Arg, Asp, Ala, Asn, Glu, His, Ile, Met, Phe, Ser, Thr, Tyr or Val;

Xaa at position 69 is Pro or Thr;

Xaa at position 71 is Leu or Val;

Xaa at position 73 is Leu or Ser;

Xaa at position 74 is Ala or Trp;

Xaa at position 77 is Ala or Pro;

Xaa at position 79 is Thr, Asp, Ser, Pro, Ala, Leu, or Arg;

Xaa at position 81 is His, Pro, Arg, Val, Leu, Gly, Asn, Phe, Ser or Thr;

Xaa at position 82 is Pro or Tyr;

Xaa at position 83 is Ile or Val;

Xaa at position 84 is His, Ile, Asn, Ala, Thr, Leu, Arg, Gln, Lys, Met, Ser, Tyr, Val or Pro;

Xaa at position 85 is Ile, Leu, or Val;

Xaa at position 86 is Lys, Arg, Ile, Gln, Pro, or Ser;

Xaa at position 87 is Asp, Pro, Met, Lys, His, Thr, Asn, Ile, Leu or Tyr;

Xaa at position 90 is Trp or Leu;

Xaa at position 91 is Asn, Pro, Ala, Ser, Trp, Gln, Tyr, Leu, Lys, Ile, Asp, or His;

Xaa at position 92 is Glu, or Gly;

Xaa at position 94 is Arg, Ala, or Ser;

Xaa at position 95 iS Arg, Thr, Glu, Leu, or Ser;

Xaa at position 98 is Thr, Val, or Gln;

Xaa at position 100 is Tyr or Trp;

Xaa at position 101 is Leu or Ala;

Xaa at position 102 is Lys, Thr, Val, Trp, Ser, Ala, His, Met, Phe, Tyr or Ile;

Xaa at position 103 is Thr or Ser;

Xaa at position 106 is Asn, Pro, Leu, His, Val, or Gln;

Xaa at position 107 is Ala, Ser, Ile, Asn, Pro, Asp, or Gly;

Xaa at position 108 is Gln, Ser, Met, Trp, Arg, Phe, Pro, His, Ile, Tyr, or Cys;

Xaa at position 109 is Ala, Met, Glu, His, Ser, Pro, Tyr, or Leu;

which can additionally have Met- or Met-Ala- preceding the amino acid in position 1; and wherein from one to three of the amino acids designated by Xaa are different from the corresponding amino acids of native (15-125) human interleukin-3; or a polypeptide having substantially the same structure and substantially the same biological activity.

Included in the present invention are (15-125) hIL-3 mutant polypeptides of the Formula VIII:

Asn Cys Xaa Xaa Met Ile Asp Glu Xaa Ile Xaa Xaa Leu Lys Xaa

[SEQ ID NO:22]

1               5                   10                 15

Xaa Pro Xaa Pro Xaa Xaa Asp Phe Xaa Asn Leu Asn Xaa Glu Asp

20                  25                 30

Xaa Xaa Ile Leu Met Xaa Xaa Asn Leu Arg Xaa Xaa Asn Leu Glu

35                  40                 45

Ala Phe Xaa Arg Xaa Xaa Lys Xaa Xaa Xaa Asn Ala Ser Ala Ile

50                  55                 60

Glu Xaa Xaa Leu Xaa Xaa Leu Xaa Pro Cys Leu Pro Xaa Xaa Thr

65                  70                 75

Ala Xaa Pro Xaa Arg Xaa Pro Ile Xaa Xaa Xaa Xaa Gly Asp Trp

80                  85                 90

Xaa Glu Phe Xaa Xaa Lys Leu Xaa Phe Tyr Leu Xaa Xaa Leu Glu

95                 100                 105

Xaa Xaa Xaa Xaa Gln Gln

110

wherein

Xaa at position 3 is Ser, Gly, Asp, or Gln;

Xaa at position 4 is Asn, His, or Ile;

Xaa at position 9 is Ile, Ala, Leu, or Gly;

Xaa at position 11 is Thr, His, or Gln;

Xaa at position 12 is His or Ala;

Xaa at position 15 is Gln or Asn;

Xaa at position 16 is Pro or Gly;

Xaa at position 18 is Leu, Arg, Asn, or Ala;

Xaa at position 20 is Leu, Val, Ser, Ala, Arg, Gln, Glu, Ile, Phe, Thr or Met;

Xaa at position 21 is Leu, Ala, Asn, or Pro;

Xaa at position 24 is Asn or Ala:

Xaa at position 28 is Gly, Asp, Ser, Ala, Asn, Ile, Leu, Met, Tyr or Arg;

Xaa at position 31 is Gln, Val, Met, Leu, Ala, Asn, Glu or Lys;

Xaa at position 32 is Asp, Phe, Ser, Ala, Gln, Glu, His, Val or Thr;

Xaa at position 36 is Glu, Asn, Ser or Asp;

Xaa at position 37 is Asn, Arg, Pro, Thr, or His;

Xaa at position 41 is Arg, Leu, or Gly;

Xaa at position 42 is Pro, Gly, Ser, Ala, Asn, Val, Leu or Gln;

Xaa at position 48 is Asn, Pro, or Thr;

›DETAILED DESCRIPTION OF THE INVENTION · 9 of 20

Xaa at position 50 is Ala or Asn;

Xaa at position 51 is Val or Thr;

Xaa at position 53 is Ser or Phe;

Xaa at position 54 is Leu or Phe;

Xaa at position 55 is Gln, Ala, Glu, or Arg;

Xaa at position 62 is Ser, Val, Asn, Pro, or Gly;

Xaa at position 63 is Ile or Leu;

Xaa at position 65 is Lys, Asn, Met, Arg, Ile, or Gly;

Xaa at position 66 is Asn, Gly, Glu, or Arg;

Xaa at position 68 is Leu, Gln, Trp, Arg, Asp, Asn, Glu, His, Met, Phe, Ser, Thr, Tyr or Val;

Xaa at position 73 is Leu or Ser;

Xaa at position 74 is Ala or Trp;

Xaa at position 77 is Ala or Pro;

Xaa at position 79 is Thr, Asp, or Ala;

Xaa at position 81 is His, Pro, Arg, Val, Gly, Asn, Ser or Thr;

Xaa at position 84 is His, Ile, Asn, Ala, Thr, Arg, Gln, Glu, Lys, Met, Ser, Tyr, Val or Leu;

Xaa at position 85 is Ile or Leu;

Xaa at position 86 is Lys or Arg;

Xaa at position 87 is Asp, Pro, Met, Lys, His, Pro, Asn, Ile, Leu or Tyr;

Xaa at position 91 is Asn, Pro, Ser, Ile or Asp;

Xaa at position 94 is Arg, Ala, or Ser;

Xaa at position 95 is Arg, Thr, Glu, Leu, or Ser;

Xaa at position 98 is Thr or Gln;

Xaa at position 102 is Lys, Val, Trp, or Ile;

Xaa at position 103 is Thr, Ala, His, Phe, Tyr or Ser;

Xaa at position 106 is Asn, Pro, Leu, His, Val, or Gln;

Xaa at position 107 is Ala, Ser, Ile, Pro, or Asp;

Xaa at position 108 is Gln, Met, Trp, Phe, Pro, His, Ile, or Tyr;

Xaa at position 109 is Ala, Met, Glu, Ser, or Leu;

and which can additionally have Met- or Met-Ala- preceding the amino acid in position 1; and wherein from one to three of the amino acids designated by Xaa are different from the corresponding amino acids of native (1-133)human interleukin-3; or a polypeptide having substantially the same structure and substantially the same biological activity.

In Formulas V, VI, VII and VIII the Asn in position 1 corresponds to the Asn in position 15 of native hIL-3 and positions 1 to 111 correspond to positions 15 to 125 in the native hIL-3 sequence shown in FIG. 1 .

Also included in the present invention are polypeptides of the following formula (IX):

1               5                  10

[SEQ ID NO:129]

(Met) m -Ala Pro Met Thr Gln Thr Thr Ser Leu Lys Thr

15                   20

Ser Trp Val Asn Cys Ser Xaa Met Ile Asp Glu Ile Ile

25                  30                   35

Xaa His Leu Lys Xaa Pro Pro Xaa Pro Leu Leu Asp Xaa

40                  45                   50

Asn Asn Leu Asn Xaa Glu Asp Xaa Asp Ile Leu Met Glu

55                   60

Xaa Asn Leu Arg Xaa Pro Asn Leu Xaa Xaa Phe Xaa Arg

65                  70                  75

Ala Val Lys Xaa Leu Xaa Asn Ala Ser Xaa Ile Glu Xaa

80                   85

Ile Leu Xaa Asn Leu Xaa Pro Cys Leu Pro Xaa Ala Thr

90                   95                 100

Ala Ala Pro Xaa Arg His Pro Ile Xaa Ile Lys Xaa Gly

105                 110                 115

Asp Trp Xaa Glu Phe Arg Xaa Lys Leu Thr Phe Tyr Leu

120                 125

Xaa Thr Leu Glu Xaa Ala Gln Xaa Gln Gln Thr Thr Leu

130

Ser Leu Ala Ile Phe

wherein m is 0 or 1; Xaa at position 18 is Asn or Ile; Xaa at position 25 is Thr or His; Xaa at position 29 is Gln, Arg, or Val; Xaa at position 32 is Leu, Ala, or Asn; Xaa at position 37 is Phe, Pro, or Ser; Xaa at position 42 is Glu, Ala, or Ser; Xaa at position 45 is Gln, Val, or Met; Xaa at position 51 is Asn or Arg; Xaa at position 55 is Arg, Leu, or Thr; Xaa at position 59 is Glu or Leu; Xaa at position 60 is Ala or Ser; Xaa at position 62 is Asn or Val; Xaa at position 67 is Ser, Asn, or His; Xaa at position 69 is Gln or Glu; Xaa at position 73 is Ala or Gly; Xaa at position 76 is Ser or Ala; Xaa at position 79 is Lys or Arg; Xaa at position 82 is Leu, Glu, or Val; Xaa at position 87 is Leu or Ser; Xaa at position 93 is Pro or Ser; Xaa at position 98 is His, Ile, or Thr; Xaa at position 101 is Asp or Ala; Xaa at position 105 is Asn or Glu; Xaa at position 109 is Arg or Glu; Xaa at position 116 is Lys or Val; Xaa at position 120 is Asn, Gln, or His; Xaa at position 123 is Ala or Glu; wherein from one to three of the amino acids designated by Xaa are different from the corresponding amino acids of native human interleukin-3; or a polypeptide having substantially the same structure and substantially the same biological activity.

Polypeptides of the present invention include those (15-125) hIL-3 muteins of the following formula (X):

1                5                  10

[SEQ ID NO:130]

(Met m -Ala n )p-Asn Cys Ser Xaa Met Ile Asp Glu Ile Ile

15                   20

Xaa His Leu Lys Xaa Pro Pro Xaa Pro Leu Leu Asp Xaa

25                   30                   35

Asn Asn Leu Asn Xaa Glu Asp Xaa Asp Ile Leu Met Glu

40                   45

Xaa Asn Leu Arg Xaa Pro Asn Leu Xaa Xaa Phe Xaa Arg

50                 55                   60

Ala Val Lys Xaa Leu Xaa Asn Ala Ser Xaa Ile Glu Xaa

65                   70                  75

Ile Leu Xaa Asn Leu Xaa Pro Cys Leu Pro Xaa Ala Thr

80                   85

Ala Ala Pro Xaa Arg His Pro Ile Xaa Ile Lys Xaa Gly

90                  95                  100

Asp Trp Xaa Glu Phe Arg Xaa Lys Leu Thr Phe Tyr Leu

105                  110

Xaa Thr Leu Glu Xaa Ala Gln Xaa Gln Gln

wherein m is 0 or 1; n is 0 or 1; p is 0 or 1; Xaa at position 4 is Asn or Ile; Xaa at position 11 is Thr or His; Xaa at position 15 is Gln, Arg, or Val; Xaa at position 18 is Leu, Ala, or Asn; Xaa at position 23 is Phe, Pro, or Ser; Xaa at position 28 is Glu, Ala, or Ser; Xaa at position 31 is Gln, Val, or Met; Xaa at position 37 is Asn or Arg; Xaa at position 41 is Arg, Leu, or Thr; Xaa at position 45 is Glu or Leu; Xaa at position 46 is Ala or Ser; Xaa at position 48 is Asn or Val; Xaa at position 53 is Ser, Asn, or His; Xaa at position 55 is Gln or Glu; Xaa at position 59 is Ala or Gly; Xaa at position 62 is Ser or Ala; Xaa at position 65 is Lys or Arg; Xaa at position 68 is Leu, Glu, or Val; Xaa at position 73 is Leu or Ser; Xaa at position 79 is Pro or Ser; Xaa at position 84 is His, Ile, or Thr; Xaa at position 87 is Asp or Ala; Xaa at position 91 is Asn or Glu; Xaa at position 95 is Arg or Glu; Xaa at position 102 is Lys or Val,; Xaa at position 106 is Asn, Gln, or His; Xaa at position 109 is Ala or Glu;

›DETAILED DESCRIPTION OF THE INVENTION · 10 of 20

wherein from one to three of the amino acids designated by Xaa are different from the corresponding amino acids of native (15-125)human interleukin-3; or a polypeptide having substantially the same structure and substantially the same biological activity.

The present invention includes polypeptides of Formula IX and Formula X above wherein from one to three of the amino acids designated by Xaa are different from the corresponding amino acids of native human interleukin-3 or native (15-125) human interleukin-3; or a polypeptide having substantially the same structure and substantially the same biological activity.

“Mutant amino acid sequence,” “mutant protein” or “mutant polypeptide” refers to a polypeptide having an amino acid sequence which varies from a native sequence or is encoded by a nucleotide sequence intentionally made variant from a native sequence. “Mutant protein,” “variant protein” or “mutein” means a protein comprising a mutant amino acid sequence and includes polypeptides which differ from the amino acid sequence of native hIL-3 due to amino acid deletions, substitutions, or both. “Native sequence” refers to an amino acid or nucleic acid sequence which is identical to a wild-type or native form of a gene or protein.

Human IL-3 can be characterized by its ability to stimulate colony formation by human hematopoietic progenitor cells. The colonies formed include erythroid, granulocyte, megakaryocyte, granulocytic macrophages and mixtures thereof. Human IL-3 has demonstrated an ability to restore bone marrow function and peripheral blood cell populations to therapeutically beneficial levels in studies performed initially in primates and subsequently in humans (Gillio, A. P., et al. (1990); Ganser, A., et al. (1990); Falk, S., et al. (1991). Additional activities of hIL-3 include the ability to stimulate leukocyte migration and chemotaxis; the ability to prime human leukocytes to produce high levels of inflammatory mediators like leukotrienes and histamine; the ability to induce cell surface expression of molecules needed for leukocyte adhesion; and the ability to trigger dermal inflammatory responses and fever. Many or all of these biological activities of hIL-3 involve signal transduction and high affinity receptor binding. Mutant polypeptides of the present invention may exhibit useful properties such as having similar or greater biological activity when compared to native hIL-3 or by having improved half-life or decreased adverse side effects, or a combination of these properties. They may also be useful as antagonists. hIL-3 mutant polypeptides which have little or no activity when compared to native hIL-3 may still be useful as antagonists, as antigens for the production of antibodies for use in immunology or immunotherapy, as genetic probes or as intermediates used to construct other useful hIL-3 muteins. Since hIL-3 functions by binding to its receptor(s) and triggering second messages resulting in competent signal transduction, hIL-3 muteins of this invention may be useful in helping to determine which specific amino acid sequences are responsible for these activities.

The novel hIL-3 mutant polypeptides of the present invention will preferably have at least one biological property of human IL-3 or of an IL-3-like growth factor and may have more than one IL-3-like biological property, or an improved property, or a reduction in an undesirable biological property of human IL-3. Some mutant polypeptides of the present invention may also exhibit an improved side effect profile. For example, they may exhibit a decrease in leukotriene release or histamine release when compared to native hIL-3 or (15-125) hIL-3. Such hIL-3 or hIL-3-like biological properties may include one or more of the following biological characteristics and in vivo and in vitro activities.

One such property is the support of the growth and differentiation of progenitor cells committed to erythroid, lymphoid, and myeloid lineages. For example, in a standard human bone marrow assay, an IL-3-like biological property is the stimulation of granulocytic type colonies, megakaryocytic type colonies, monocyte/macrophage type colonies, and erythroid bursts. Other IL-3-like properties are the interaction with early multipotential stem cells, the sustaining of the growth of pluripotent precursor cells, the ability to stimulate chronic myelogenous leukemia (CML) cell proliferation, the stimulation of proliferation of mast cells, the ability to support the growth of various factor-dependent cell lines, and the ability to trigger immature bone marrow cell progenitors. Other biological properties of IL-3 have been disclosed in the art. Human IL-3 also has some biological activities which may in. some cases be undesirable, for example the ability to stimulate leukotriene release and the ability to stimulate increased histamine synthesis in spleen and bone marrow cultures and in vivo.

Biological activity of hIL-3 and hIL-3 mutant proteins of the present invention is determined by DNA synthesis by human acute myelogenous leukemia cells (AML). The factor-dependent cell line AML 193 was adapted for use in testing biological activity.

One object of the present invention is to provide hIL-3 muteins and hIL-3 deletion muteins with one or more amino acid substitutions in the polypeptide sequence which have similar of improved biological activity in relation to native hIL-3 or native (15-125) hIL-3.

The present invention includes mutant polypeptides comprising minimally amino acid residues 15 to 118 of hIL-3 with or without additional amino acid extensions to the N-terminus and/or C-terminus which further contain from one to three or more amino acid substitutions in the amino acid sequence of the polypeptide. It has been found that the (15-125) hIL-3 mutant is more soluble than is hIL-3 when expressed in the cytoplasm of E. coli , and the protein is secreted to the periplasm in E. coli at higher levels compared to native hIL-3.

When expressed in the E. coli cytoplasm, the above-mentioned mutant hIL-3 polypeptides of the present invention may also be constructed with Met-Ala- at the N-terminus so that upon expression the Met is cleaved off leaving Ala at the N-terminus. These mutant hIL-3 polypeptides may also be expressed in E. coli by fusing a signal peptide to the N-terminus. This signal peptide is cleaved from the polypeptide as part of the secretion process. Secretion in E. coli can be used to obtain the correct amino acid at the N-terminus (e.g., Asn 15 in the (15-125) hIL-3 polypeptide) due to the precise nature of the signal peptidase. This is in contrast to the heterogeneity often observed at the N-terminus of proteins expressed in the cytoplasm in E. coli.

›DETAILED DESCRIPTION OF THE INVENTION · 11 of 20

The hIL-3 mutant polypeptides of the present invention may have hIL-3 or hIL-3-like activity. For example, they may possess one or more of the biological activities of native hIL-3 and may be useful in stimulating the production of hematopoietic cells by human or primate progenitor cells. The hIL-3 muteins of the present invention and pharmaceutical compositions containing them may be useful in the treatment of conditions in which hematopoietic cell populations have been reduced or destroyed due to disease or to treatments such as radiation or chemotherapy.

hIL-3 muteins of the present invention may also be useful as antagonists which block the hIL-3 receptor by binding specifically to it and preventing binding of the agonist.

One potential advantage of the (15-125) hIL-3 muteins of the present invention, particularly those which retain activity similar to or better than that of native hIL-3, is that it may be possible to use a smaller amount of the biologically active mutein to produce the desired therapeutic effect. This may make it possible to reduce the number of treatments necessary to produce the desired therapeutic effect. The use of smaller amounts may also reduce the possibility of any potential antigenic effects or other possible undesirable side effects. For example, if a desired therapeutic effect can be achieved with a smaller amount of polypeptide it may be possible to reduce or eliminate side effects associated with the administration of native IL-3 such as the stimulation of leukotriene and/or histamine release. The hIL-3 muteins of the present invention may also be useful in the activation of stem cells or progenitors which have low receptor numbers. Pharmaceutical compositions containing hIL-3 muteins of the present invention can be administered parenterally, intravenously, or subcutaneously.

In variants which contain an additional cysteine the presence of the cysteine permits the labeling of the protein with ricin which permits targeting ricin and other toxins or tracers using a sulfhydryl linkage to the hIL-3 receptor.

As another aspect of the present invention, there is provided a novel method for producing the novel family of human IL-3 muteins. The method of the present invention involves culturing a suitable cell or cell line( which has been transformed with a vector containing a DNA sequence coding for expression of a novel hIL-3 mutant polypeptide. Suitable cells or cell lines may be bacterial cells. For example, the various strains of E. coli are well-known as host cells in the field of biotechnology. Examples of such strains include E. coli strains JM101 [Yanish-Perron, et al. (1985)] and MON105 [Obukowicz, et al. (1992)]. Various strains of B subtilis may also be employed in this method. Many strains of yeast cells known to those skilled in the art are also available as host cells for expression of the polypeptides of the present invention.

Also suitable for use in the present invention are mammalian cells, such as Chinese hamster ovary cells (CHO). General methods for expression of foreign genes in mammalian cells are reviewed in; Kaufman, R. J. (1987) High level production of proteins-in mammalian cells, in Genetic Engineering, Principles and Methods , Vol. 9, J. K. Setlow, editor, Plenum Press, New York. An expression vector is constructed in which a strong promoter capable of functioning in mammalian cells drives transcription of a eukaryotic secretion signal peptide coding region, which is translationally fused to the coding region for the hIL-3 variant. For example, plasmids such as pcDNA I/Neo, pRc/RSV, and pRc/CMV (obtained from Invitrogen Corp., San Diego, Calif.) can be used. The eukaryotic secretion signal peptide coding region can be from the hIL-3 gene itself or it can be from another secreted mammalian protein (Bayne, M. L. et al. (1987) Proc. Natl. Acad. Sci. USA 84, 2638-2642). After construction of the vector containing the hIL-3 variant gene, the vector DNA is transfected into mammalian cells. Such cells can be, for example, the COS7, HeLa, BHK, CHO, or mouse L lines. The cells can be cultured, for example, in DMEM media (JRH Scientific). The hIL-3 variant secreted into the media can be recovered by standard biochemical approaches following transient expression 24-72 hours after transfection of the cells or after establishment of stable cell lines following selection for neomycin resistance. The selection of suitable mammalian host cells and methods for transformation, culture, amplification, screening and product production and purification are known in the art. See, e.g., Gething and Sambrook, Nature, 2:620-625 (1981), or alternatively, Kaufman et al, Mol. Cell. Biol. , 5(7):1750-1759 (1985) or Howley et al., U.S. Pat. No. 4,419,446. Another suitable mammalian cell line is the monkey COS-1 cell line. A similarly useful mammalian cell line is the CV-1 cell line.

Where desired, insect cells may be utilized as host cells in the method of the present invention. See, e.g. Miller et al, Genetic Engineering, 8:277-298 (Plenum Press 1986) and references cited therein. In addition, general methods for expression of-foreign genes in insect cells using Baculovirus vectors are described in: Summers, M. D. and Smith, G. E. (1987)—A manual of methods for Baculovirus vectors and insect cell culture procedures, Texas Agricultural Experiment Station Bulletin No. 1555. An expression vector is constructed comprising a Baculovirus transfer vector, in which a strong Baculovirus promoter (such as the polyhedron promoter) drives transcription of a eukaryotic secretion signal peptide coding region, which is translationally fused to the coding region for the hIL-3 variant polypeptide. For example, the plasmid pVL1392 (obtained from Invitrogen Corp., San Diego, Calif.) can be used. After construction of the vector carrying the hIL-3 variant gene, two micrograms of this DNA is cotransfected with one microgram of Baculovirus DNA (see Summers & Smith, 1987) into insect cells, strain SF9. Pure recombinant Baculovirus carrying the hIL-3 variant is used to infect cells cultured, for example, in Excell 401 serum-free medium (in Biosciences, Lenexa, Kans.). The hIL-3 variant secreted into the medium can be recovered by standard biochemical approaches.

›DETAILED DESCRIPTION OF THE INVENTION · 12 of 20

Another aspect of the present invention provides plasmid DNA vectors for use in the method of expression of these novel hIL-3 muteins. These vectors contain the novel DNA sequences described above which code for the novel polypeptides of the invention. Appropriate vectors which can transform microorganisms capable of expressing the hIL-3 muteins include expression vectors comprising nucleotide sequences coding for the hIL-3 muteins joined to transcriptional and translational regulatory sequences which are selected according to the host cells used.

Vectors incorporating modified sequences as described above are included in the present invention and are useful in the production of the hIL-3 mutant polypeptides. The vector employed in the method also contains selected regulatory sequences in operative association with the DNA coding sequences of the invention and capable of directing the replication and expression thereof in selected host cells.

The present invention also includes the construction and expression of (15-125)human interleukin-3 muteins having one or more amino acid substitutions in secretion vectors that optimize accumulation of correctly folded, active polypeptide. While many heterologous proteins have been secreted in E. coil there is still a great deal of unpredictability and limited success (Stader and Silhavy 1990). Full-length hIL-3 is such a protein, where attempts to secrete the protein in E. coli resulted in low levels of secretion. Secretion of the variant (15-125) hIL-3 mutant polypeptides of the present invention as a fusion with a signal peptide such as lamB results in correctly folded protein that can be removed from the periplasm of E. coli by osmotic shock fractionation. This property of the variant (15-125) hIL-3 muteins allows for the direct and rapid screening for bioactivity of the secreted material in the crude osmotic shock fraction, which is a significant advantage. Furthermore, it provides a means of using the (15-125) hIL-3 muteins to conduct structure activity relationship (SAR) studies of the hIL-3 molecule. A further advantage of secretion of (15-125) hIL-3 muteins fused to the lamb signal peptide is that the secreted polypeptide has the correct N-terminal amino acid (Asn) due to the precise nature of the cleavage of the signal peptide by signal peptidase, as part of the secretion process.

The (15-125) hIL-3 muteins of the present invention may include hIL-3 polypeptides having Met-, Ala- or Met-Ala- attached to the N-terminus. When the muteins are expressed in E. coli , polypeptides with and without Met attached to the N-terminus are obtained. The methlonine can in some cases be removed by methionine aminopeptidase.

Amino terminal sequences of some of the hIL-3 muteins made in E. coli were determined using the method described by Hunkapillar et al., (1983). It was found that hIL-3 proteins made in E. coli from genes encoding Met-(15-125) hIL-3 were isolated as Met-(15-125) hIL-3. Proteins produced from genes encoding Met-Ala-(15-125) hIL-3 were produced as Ala-(15-125) hIL-3. The N-termini of proteins made in the cytoplasm of E. coli are affected by posttranslational processing by methionine aminopeptidase (Ben-Bassat et al., 1987) and possibly by other peptidases.

One method of creating the preferred hIL-3 (15-125) mutant genes is cassette mutagenesis [Wells, et al. (1985)] in which a portion of the coding sequence of hIL-3 in a plasmid is replaced with synthetic oligonucleotides that encode the desired amino acid substitutions in a portion of the gene between two restriction sites. In a similar manner amino acid substitutions could be made in the full-length hIL-3 gene, or genes encoding variants of hIL-3 in which from 1 to 14 amino acids have been deleted from the N-terminus and/or from 1 to 15 amino acids have been deleted from the C-terminus. When properly assembled these oligonucleotides would encode hIL-3 variants with the desired amino acid substitutions and/or deletions from the N-terminus and/or C-terminus. These and other mutations could be created by those skilled in the art by other mutagenesis methods including; oligonucleotide-directed mutagenesis [Zoller and Smith (1982, 1983, 1984), Smith (1985), Kunkel (1985), Taylor, et al. (1985), Deng and Nickoloff (1992)] or polymerase chain reaction (PCR) techniques [Saiki, (1985)].

Pairs of complementary synthetic oligonucleotides encoding portions of the amino terminus of the hIL-3 gene can be made and annealed to each other. Such pairs would have protruding ends compatible with ligation to NcoI at one end. The NcoI site would include the codon for the initiator methionine. At the other end of oligonucleotide pairs, the protruding (or blunt) ends would be compatible with a restriction site that occurs within the coding sequence of the hIL-3 gene. The DNA sequence of the oligonucleotide would encode sequence for amino acids of hIL-3 with the exception of those substituted and/or deleted from the sequence.

The NcoI enzyme and the other restriction enzymes chosen should have recognition sites that occur only once in the DNA of the plasmid chosen. Plasmid DNA can be treated with the chosen restriction endonucleases then ligated to the annealed oligonucleotides. The ligated mixtures can be used to transform competent JM101 cells to resistance to an appropriate antibiotic. Single colonies can be picked and the plasmid DNA examined by restriction analysis and/or DNA sequencing to identify plasmids with mutant hIL-3 genes.

One example of a restriction enzyme which cleaves within the coding sequence of the hIL-3 gene is ClaI whose recognition site is at codons 20 and 21. The use of ClaI to cleave the sequence of hIL-3 requires that the plasmid DNA be isolated from an E. coli strain that fails to methylate adenines in the DNA at GATC recognition sites. This is because the recognition site for ClaI, ATCGAT, occurs within the sequence GATCGAT which occurs at codons 19, 20 and 21 in the hIL-3 gene. The A in the GATC sequence is methylated in most E. coli host cells. This methylation prevents ClaI from cleaving at that particular sequence. An example of a strain that does not methylate adenines is GM48.

›DETAILED DESCRIPTION OF THE INVENTION · 13 of 20

Interpretation of Activity of Single Amino Acid Mutants in IL-3 (15-125)

As illustrated in Tables 6 and 9, there are certain positions in the IL-3 (15-125) molecule which are intolerant of substitutions, in that most or all substitutions at these positions resulted in a considerable decrease in bioactivity. There are two likely classes of such “down-mutations”: mutations that affect overall protein structure, and mutations that interfere directly with the interaction between the IL-3 molecule and its receptor. Mutations affecting the three-dimensional structure of the protein will generally lie in the interior of the protein, while mutations affecting receptor binding will generally lie on the surface of the protein. Although the three-dimensional structure of IL-3 is unknown, there are simple algorithms which can aid in the prediction of the structure. One such algorithm is the use of “helical wheels” (Kaiser, E. T. & Kezdy, F. J., Science, 223:249-255 (1984)). In this method, the presence of alpha helical protein structures can be predicted by virtue of their amphipathic nature. Helices in globular proteins commonly have an exposed hydrophilic side and a buried hydrophobic side. As a broad generalization, in globular proteins, hydrophobic residues are present in the interior of the protein, and hydrophilic residues are present on the surface. By displaying the amino acid sequence of a protein on such a “helical wheel” it is possible to derive a model for which amino acids in alpha helices are exposed and which are buried in the core of the protein. Such an analysis of the IL-3 (15-125) molecule predicts that the following helical residues are buried in the core:

M19, I20, I23, I24, L27, L58, F61, A64, L68, A71, I74, I77, L78, L81, W104, F107, L111, Y114, L115, L118.

In addition, cysteine residues at positions 16 and 84 are linked by a disulfide bond, which is important for the overall structure or “folding” of the protein. Finally, mutations which result in a major disruption of the protein structure may be expressed at low level in the secretion system used in our study, for a variety of reasons: either because the mis-folded protein is poorly recognized by the secretion machinery of the cell; because mis-folding of the protein results in aggregation, and hence the protein cannot be readily extracted from the cells; or because the mis-folded protein is more susceptible to degradation by cellular proteases. Hence, a block in secretion may indicate which positions in the IL-3 molecule which are important for maintenance of correct protein structure.

In order to retain the activity of a variant of IL-3, it is necessary to retain both the structural integrity of the protein, and retain the specific residues important for receptor contact. Hence it is possible to define specific amino acid residues in IL-3 (15-125) which must be retained in order to preserve biological activity.

Residues predicted to be important for interaction with the receptor: D21, E22, E43, D44, L48, R54, R94, D103, K110, F113.

Residues predicted to be structurally important: C16, L58, F61, A64, I74, L78, L81, C84, P86, P92, P96, F107, L111, L115, L118.

The hIL-3 muteins of the present invention may be useful in the treatment of diseases characterized by a decreased levels of either myeloid, erythroid, lymphoid, or megakaryocyte cells of the hematopoietic system or combinations thereof. In addition, they may be used to activate mature myeloid and/or lymphoid cells. Among conditions susceptible to treatment with the polypeptides of the present invention is leukopenia, a reduction in the number of circulating leukocytes (white cells) in the peripheral blood. Leukopenia may be induced by exposure to certain viruses or to radiation. It is often a side effect of various forms of cancer therapy, e.g., exposure to chemotherapeutic drugs and of infection or hemorrhage. Therapeutic treatment of leukopenia with these hIL-3 mutant polypeptides of the present invention may avoid undesirable side effects caused by treatment with presently available drugs.

The hIL-3 muteins of the present invention may be useful in the treatment of neutropenia and, for example, in the treatment of such conditions as aplastic anemia, cyclic neutropenia, idiopathic neutropenia, Chdiak-Higashi syndrome, systemic lupus erythematosus (SLE), leukemia, myelodysplastic syndrome and myelofibrosis.

Many drugs may cause bone marrow suppression or hematopoietic deficiencies. Examples of such drugs are AZT, DDI, alkylating agents and anti-metabolites used in chemotherapy, antibiotics such as chloramphenicol, penicillin and sulfa drugs, phenothiazones, tranquilizers such as meprobamate, and diuretics. The hIL-3 muteins of the present invention may be useful in preventing or treating the bone marrow Suppression or hematopojetic deficiencies which often occur in patients treated with these drugs.

Hematopoietic deficiencies may also occur as a result of viral, microbial or parasitic infections and as a result of treatment for renal disease or renal failure, e.g., dialysis. The hIL-3 muteins of the present invention may be useful in treating such hematopoietic deficiency.

The treatment of hematopoietic deficiency may include administration of the hIL-3 mutein of a pharmaceutical composition containing the hIL-3 mutein to a patient. The hIL-3 muteins of the present invention may also be useful for the activation and amplification of hematopoietic precursor cells by treating these cells in vitro with the muteins of the present invention prior to injecting the cells into a patient.

Various immunodeficiencies e.g., in T and/or B lymphocytes, or immune disorders, e.g., rheumatoid arthritis, may also be beneficially affected by treatment with the hIL-3 mutant polypeptides of the present invention. Immunodeficiencies may be the result of viral infections e.g. HTLVI, HTLVII, HTLVIII, severe exposure to radiation, cancer therapy or the result of other medical treatment. The hIL-3 mutant polypeptides of the present invention may also be employed, alone or in combination with other hematopoietins, in the treatment of other blood cell deficiencies, including thrombocytopenia (platelet deficiency), or anemia. Other uses for these novel polypeptides are in the treatment of patients recovering from bone marrow transplants in vivo and ex vivo, and in the development of monoclonal and polyclonal antibodies generated by standard methods for diagnostic or therapeutic use.

›DETAILED DESCRIPTION OF THE INVENTION · 14 of 20

Other aspects of the present invention are methods and therapeutic compositions for treating the conditions referred to above. Such compositions comprise a therapeutically effective amount of one or more of the hIL-3 muteins of the present invention in a mixture with a pharmaceutically acceptable carrier. This composition can be administered either parenterally, intravenously or subcutaneously. When administered, the therapeutic composition for use in this invention is preferably in the form of a pyrogen-free, parenterally acceptable aqueous solution. The preparation of such a parenterally acceptable protein solution, having due regard to pH, isotonicity, stability and the like, is within the skill of the art.

The dosage regimen involved in a method for treating the above-described conditions will be determined by the attending physician considering various factors which modify the action of drugs, e.g. the condition, body weight, sex and diet of the patient, the severity of any infection, time of administration and other clinical factors. Generally, a daily regimen may be in the range of 0.2-150 μg/kg of non-glycosylated IL-3 protein per kilogram of body weight. This dosage regimen is referenced to a standard level of biological activity which recognizes that native IL-3 generally possesses an EC 50 at or about 10 picoMolar to 100 picoMolar in the AML proliferation assay described herein. Therefore, dosages would be adjusted relative to the activity of a given mutein vs. the activity of native (reference) IL-3 and it would not be unreasonable to note that dosage regimens may include doses as low as 0.1 microgram and as high as 1 milligram per kilogram of body weight per day. In addition, there may exist specific circumstances where dosages of IL-3 mutein would be adjusted higher or lower than the range of 10-200 micrograms per kilogram of body weight. These include co-administration with other CSF or growth factors; co-administration with chemotherapeutic drugs and/or radiation; the use of glycosylated IL-3 mutein; and various patient-related issues mentioned earlier in this section. As indicated above, the therapeutic method and compositions may also include co-administration with other human factors. A non-exclusive list of other appropriate hematopoietins, CSFs and interleukins for simultaneous or serial co-administration with the polypeptides of the present invention includes GM-CSF, CSF-1, G-CSF, Meg-CSF, M-CSF, erythropoietin (EPO), IL-1, IL-4, IL-2, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, LIF, B-cell growth factor, B-cell differentiation factor and eosinophil differentiation factor, stem cell factor (SCF) also known as steel factor or c-kit ligand, or combinations thereof. The dosage recited above would be adjusted to compensate for such additional components in the therapeutic composition. Progress of the treated patient can be monitored by periodic assessment of the hematological profile, e.g., differential cell count and the like.

Materials and Methods for hTL-1 Mutein Expression in E. coli

Unless noted otherwise, all specialty chemicals were obtained from Sigma Co., (St. Louis, Mo.). Restriction endonucleases, T4 poly-nucleotides kinase, E. coli DNA polymerase I large fragment (Klenow) and T4 DNA ligase were obtained from New England Biolabs (Beverly, Mass.) or Boehringer Mannheim (Indianapolis, Ind.). All chemicals and enzymes were used according to manufacturer's directions.

Escherichia coli Strains

Strain JM101: delta (pro lac), supE, thi, F′ (traD36, proAB, lacI-Q, lacZdeltaM15) (Messing, 1979). This strain can be obtained from the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, Md. 20852, accession number 33876. MON 105 (W3110 rpoH358) (Obukowicz, et al., 1992) is a derivative of W3110 (Bachmann, 1972) and has been assigned ATCC accession number 55204. Strain GM48: dam-3, dcm-6, gal, ara, lac, thr, leu, tonA, tsx (Marinus, 1973) was used to make plasmid DNA that is not methylated at the sequence GATC.

Genes and Plasmids

The gene used for hIL-3 production in E. coli was obtained from British Biotechnology Incorporated, Cambridge, England, catalogue number BBG14. This gene is carried on a pUC based plasmid designated pP0518. The human IL-3 gene sequence is from Yang, et al. (1986).

The plasmids used for production of hIL-3 in E. coli contain genetic elements whose use has been described (Olins et al., 1988; Olins and Rangwala, 1990). The replicon used is that of pBR327 [(Bolivar et al. (1977); Soberon et al., 1980] which is maintained at a copy number of about 50 in the cell (Covarrubias, et al., (1981)). A gene encoding the beta-lactamase protein is present on the plasmids. This protein confers ampicillin resistance on the cell. This resistance serves as a selectable phenotype for the presence of the plasmid in the cell.

Intracellular Expression Plasmids

For cytoplasmic (intracellular) expression vectors the transcription promoter was derived from the recA gene of E. coli (Sancar et al., 1980). This promoter, designated precA, is contained on 72 base pairs (bp) BglII, BamHI fragment which includes the RNA polymerase binding site and the lexA repressor binding site (the operator). This segment of DNA provides high level transcription that is regulated even when the recA promoter is on a plasmid with the pBR327 origin of replication (Olins et al., 1988) incorporated herein by reference.

Secretion Expression Plasmids

In secretion expression plasmids the transcription promoter was derived from the ara B, A. and D genes of E. coli (Greenfield et al., 1978). This promoter is designated pAraBAD and is contained on a 323 base pair SacrII, BglII restriction fragment. The lamB secretion leader (Wong et al., 1988, Clement et al., 1981) was fused to the N-terminus of the hIL-3 gene at the recognition sequence for the enzyme NcoI (5′CCATGG3′). The hIL-3 genes used were engineered to have a HindIII recognition site (5′AAGCTT3′) following the coding sequence of the gene. Downstream of the gene is a 550 bp fragment containing the origin of replication of the single stranded phage f1 [Olins and Rangwala (1989)].

›DETAILED DESCRIPTION OF THE INVENTION · 15 of 20

These hIL-3 variants were expressed as a fusion with the lamB signal peptide operatively joined to the araBAD promoter (Greenfield, 1978) and the g10-L ribosome binding site (Olins et al. 1988). The signal peptide is removed as part of the secretion process. The processed form was selectively released from the periplasm by osmotic shock as a correctly folded and fully active molecule. Secretion of (15-125) hIL-3 was further optimized by using low inducer (arabinose) concentration and by growth at 30° C. These conditions resulted in lower accumulation levels of unprocessed lamB signal peptide (15-125) hIL-3 fusion, maximal accumulation levels of processed (15-125) hIL-3 and selective release of (15-125) hIL-3 by osmotic shock fractionation. The use of a tightly regulated promoter such as araBAD from which the transcription level and hence the expression level can be modulated allowed for the optimization of secretion of (15-125) hIL-3.

The ribosome binding site (RBS) used is that from gene 10 of phage T7 (Olins et al., 1988). This is encoded in a 100 base pair (bp) fragment placed adjacent to precA. In the plasmids used herein, the recognition sequence for the enzyme NcoI (5′CCATGG3′) follows the g10-L RBS. It is at this NcoI site that the hIL-3 genes are joined to the plasmid. It is expected that the nucleotide sequence at this junction will be recognized in mRNA as a functional start site for translation (Olins et al., 1988). The hIL-3 genes used were engineered to have a HindIII recognition site (5′AAGCTT3′) following the coding sequence of the gene. Downstream of the gene is a 550 base pair fragment containing the origin of replication of the single stranded phage f1 (Dente et al., 1983; Olins, et al., 1990) both incorporated herein by reference. A plasmid containing these elements is pMON2341. Another plasmid containing these elements is pMON5847 which has been deposited at the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Md. 20852 under the accession number ATCC 68912.

Synthesis of Oligonucleotides

oligonucleotides were synthesized by the cyanoethyl method (Addam et al. 1983, McBride, et al. 1983, Sinba et al., 1984) on Nucleotide Synthesizer model 380A or 380B from Applied Biosystems, Inc. (Foster City, Calif.). Some oligonucleotides were purchased from Genosys Biotechnologies Inc. (The Woodlands, Tex.) or Midland Certified Reagent Co. (Midland, Tex.). The degenerate oligonucleotides were synthesized by machine mixing an equal molar ratio of the desired nucleosides in the condensation reaction at degenerate positions. Oligonucleotides were purified by polyacrylamide gel electrophoresis at concentrations from 12-20% (19:1 crosslinked) in 0.5×Tris borate (TBE) buffer (0.045 M Tris, 0.045 M boric acid, 1.25 mM EDTA) as described by Atkinson (1984) . The Oligonucleotides were desalted by passage through a Nensorb 20 column obtained from DuPont/New England Nuclear (Boston, Mass.) using a PREP Automated Sample Processor obtained from DuPont, Co. (Wilmington, Del.).

Quantitation of Synthetic Oligonucleotides

Synthetic oligonucleotides were resuspended in water (100 μl) and quantitated by reading the absorbance at 260 nm on a Beckman DU40 Spectrophotometer (Irvine, Calif.) using a one centimeter by one millimeter quartz cuvette (Maniatis, 1982). The concentration was determined using an extinction coefficient of 1×10 4 (Voet et al., 1963; Mahler and Cordes, 1966). The oligonucleotide was then diluted to the desired concentration.

Quantitation of synthetic DNA fragments can also be achieved by adding 10 to 100 picomoles of DNA to a solution containing kinase buffer (25 mM Tris pH 8.0, 10 mM MgCl 2 , 10 mM DTT and 2 mM spermidine). To the reaction mix is added ATP to 20 micromolar, ATP radiolabeled at the gamma phosphate (5000-10,0000 dpm/pmol) and 5 units of T4 polynucleotide kinase. Radiolabelled material is obtained from New England Nuclear (Boston, Mass.). The 10 microliter mixture is incubated at 37° C. for one hour. A 1 microliter aliquot of the mixture is chromatographed on DEAE paper (DE81 from Whatman) in 0.35 M ammonium bicarbonate. The counts that remain at the origin are used to determine the concentration of the synthetic DNA.

Recombinant DNA Methods

Isolation of plasmid DNA from E. coli cultures was performed as described (Birnboim and Doly, 1979). Some DNAs were purified by Magic™ miniprep columns, available from Promega (Madison, Wis.).

Purified plasmid DNA was treated with restriction endonucleases according to manufacturer's instructions. Analysis of the DNA fragments produced by treatment with restriction enzymes was done by agarose or polyacrylamide gel electrophoresis. Agarose (DNA grade from Fisher, Pittsburgh Pa.) was used at a concentration of 1.0% in a Tris-acetate running buffer (0.04 M Tris-acetate, 0.001M EDTA). Polyacrylamide (BioRad, Richmond Calif.) was used at a concentration of 6% (19:1 crosslinked) in 0.5×Tris-borate buffer (0.045 M Tris, 0.045 M boric acid, 1.25 mM EDTA), hereafter referred to as PAGE.

DNA polymerase I, large fragment, Klenow enzyme was used according to manufacturer's instructions to catalyze the addition of mononucleotides from 5′ to 3′ of DNA fragments which had been treated with restriction enzymes that leave protruding ends. The reactions were incubated at 65° C. for 10 minutes to heat inactivate the Klenow enzyme.

The synthetic oligonucleotides were made without 5′ or 3′ terminal phosphates. In cases where such oligonucleotides were ligated end to end, the oligonucleotides were treated at a concentration of 10 picomoles per microliter with T4 polynucleotide kinase in the following buffer: 25 mM Tris, pH 8.0, 10 mM MgCl 2 , 10 mM dithiothreitol, 2 mM spermidine, 1 mM rATP. After incubation for 30 minutes at 37° C., the samples were incubated at 65° C. for five minutes to heat inactivate the kinase.

Synthetic Gene Assembly

The (15-125) hIL-3 gene was divided into four regions separated by five convenient restriction sites. In each of the four regions synthetic oligonucleotides were designed so that they would anneal in complementary pairs, with protruding single stranded ends “or blunt ends” and when the pairs were properly assembled would result in a DNA sequence that encoded a portion of the hIL-3 gene. Amino acid substitutions in the hIL-3 gene were made by designing the oligonucleotides to encode the desired substitutions. The complementary oligonucleotides were annealed at concentration of 1 picomole per microliter in ligation buffer plus 50 mM NaCl. The samples were heated in a 100 ml beaker of boiling water and permitted to cool slowly to room temperature. One picomole of each of the annealed pairs of oligonucleotides were ligated with approximately 0.2 picomoles of plasmid DNA, digested with the appropriate restriction enzymes, in ligation buffer (25 mM Tris pH 8.0, 10 mM MgCl 2 , 10 mM dithiothreitol, 1 mM ATP, 2 mM spermidine) with T4 DNA ligase obtained from New England Biolabs (Beverly, Mass.) in a total volume of 20 μl at room temperature overnight.

›DETAILED DESCRIPTION OF THE INVENTION · 16 of 20

DNA fragments were isolated from agarose gels by intercepting the restriction fragments on DEAE membranes from Schleicher and Schuell (Keene, N.H.) and eluting the DNA in 10 mM Tris, 1 mM EDTA, 1 M NaCl at 55° C. for 1 hour, according to manufacturer's directions. The solutions containing the DNA fragment were concentrated and desalted by using Centricon 30 concentrators from Amicon (W. R. Grace, Beverly Mass.) according to the manufacturer's directions. Ligations were performed at 15° C. overnight, except as noted, in ligation buffer (66 mM Tris pH 7.5, 6.6 mM MgCl 2 , 1 mM dithiothreitol, 0.4 mM ATP) with T 4 ligase obtained from New England Biolabs (Beverly, Mass.).

Polymerase Chain Reaction

Polymerase Chain Reaction (hereafter referred to as PCR) techniques (Saiki, 1985) used the reagent kit and thermal cycler from Perkin-Elmer Cetus (Norwalk, Conn.). PCR is based on a thermostable DNA polymerase from Thermus aquaticus . The PCR technique is a DNA amplification method that mimics the natural DNA replication process in that the number of DNA molecules doubles after each cycle, in a way similar to in vivo replication. The DNA polymerase mediated extension is in a 5′→3′ direction. The term “primer” as used herein refers to an oligonucleotide sequence that provides an end to which the DNA polymerase can add nucleotides that are complementary to a nucleotide sequence. The latter nucleotide sequence is referred to as the “template”, to which the primers are annealed. The amplified PCR product is defined as the region comprised between the 5′ ends of the extension primers. Since the primers have defined sequences, the product will have discrete ends, corresponding to the primer sequenCes. The primer extension reaction was carried out using 20 picomoles (pmoles) of each of the oligonucleotides and 1 picogram of template plasmid DNA for 35 cycles (1 cycle is defined as 94° C. for one minute, 50° C. for two minutes and 72° C. for three minutes). The reaction mixture was extracted with an equal volume of phenol/chloroform (50% phenol and 50% chloroform, volume to volume) to remove proteins. The aqueous phase, containing the amplified DNA, and solvent phase were separated by centrifugation for 5 minutes in a microcentrifuge (Model 5414 Eppendorf Inc, Fremont Calif.). To precipitate the amplified DNA the aqueous phase was removed and transferred to a fresh tube to which was added 1/10 volume of 3M NaOAc (pH 5.2) and 2.5 volumes of ethanol (100% stored at minus 20° C.). The solution was mixed and placed on dry ice for 20 minutes. The DNA was pelleted by centrifugation for 10 minutes in a microcentrifuge and the solution was removed from the pellet. The DNA pellet was washed with 70% ethanol, ethanol removed and dried in a speedvac concentrator (Savant, Farmingdale, N.Y.). The pellet was resuspended in 25 microliters of TE (20 mM Tris-HCl pH 7.9, 1 mM EDTA). Alternatively the DNA was precipitated by adding equal volume of 4M NH 4 OAc and one volume of isopropanol [Treco, (1989)]. The solution was mixed and incubated at room temperature for 10 minutes and centrifuged. These conditions selectively precipitate DNA fragments larger than ˜20 bases and were used to remove oligonucleotide primers. One quarter of the reaction was digested with restriction enzymes [Higuchi, (1989)] and on completion heated to 70° C. to inactivate the enzymes.

Two Step Site-directed PCR Mutagenesis

Single amino acid substitution variants were created at positions 17-123 of hIL-3 in two site-directed mutagenesis steps by PCR (Bauer et al. manuscript in preparation).

The single amino acid substitution variants at positions 94-105 of hIL-3 were created as described below. In the first mutagenesis step plasmid DNA, containing the hIL-3 gene (amino acids 15-125), was the template in the PCR reaction. The DNA sequence of one of the oligonucleotide primers was designed to replace 12 base in the hIL-3 gene (15-125) with 12 bases encoding two translation stop codons (5′TAATAA3′), followed. by the recognition sequence (5′GTCGAC3′) restriction enzyme SalI. This 12 base sequence was substituted in the hIL-3 gene following the codon for amino acids 93, 97 and 101. Plasmids containing these mutagenized genes served as the templates for the second mutagenesis step.

In the second mutagenesis step, the 12 base substitution introduced in the first mutagenesis step, was replaced using a 32 fold degenerate oligonucleotide. The degenerate oligonucleotides were synthesized by machine mixing an equal molar ratio of the desired nucleosides in the condensation reaction at degenerate positions. The degenerate oligonucleotides have G, A, T or C in the first and second positions and G or C in the third position of a single codon. The other bases in the oligonucleotides corresponded to the hIL-3 sequence. The degenerate oligonucleotides theoretically contain 32 different codons, encoding all 20 amino acids and one translation stop codon, at a single position. At the other 9 bases the DNA sequence was restored to encode the native hIL-3 protein sequence. This pool of single amino acid substitutions at a single position is referred to as a “library”. This two step PCR site-directed mutagenesis approach was used to facilitate the identification of single amino acid substitution variants by differential DNA hybridization.

The single amino acid substitution variants at positions 17-93 and 106-123 of hIL-3 (15-125) were created as described below. In the first mutagenesis step plasmid DNA, containing the hIL-3 gene (15-125), was the template in the PCR reaction. The DNA sequence of one of the oligonucleotide primers was designed to delete 18 bases in the hIL-3 gene that encode the following amino acids; 17-22, 23-28, 29-34, 35-40, 41-46, 47-52, 53-58, 59-64, 65-70, 71-76, 77-82, 83-88, 88-93, 106-111, 112-117 and 118-123. Plasmids containing these deletion genes served as the templates for the second mutagenesis step.

In the second mutagenesis step the 18 base deletion, created in the first mutagenesis step, was restored using a 32 fold degenerate oligonucleotide. The degenerate oligonucleotides have G, A, T or C in the first and second positions and G or C in the third position of a single codon. The other bases in the oligonucleotides corresponded to the hIL-3 sequence. The degenerate oligonucleotides theoretically contain 32 different codons, encoding all 20 amino acids and one translation stop codon, at a single position. At the other 9 bases the DNA sequence was restored to encode the native hIL-3 protein sequence. This pool of single amino acid substitutions at a single position is referred to as a “library”. This two step PCR site-directed mutagenesis approach was used to facilitate the identification of single amino acid substitution variants by differential DNA hybridization.

›DETAILED DESCRIPTION OF THE INVENTION · 17 of 20

Recovery of Recombinant Plasmids from Ligation Mixes and Transformation of E. coli Cells with Recombinant Plasmid DNA

E. coli JM101 cells were made competent to take up DNA. Typically, 20 to 100 ml of cells were grown in LB medium to a density of approximately 150 Klett units and then collected by centrifugation. The cells were resuspended in one half culture volume of 50 mM CaCl 2 and held at 4° C. for one hour. The cells were again collected by centrifugation and resuspended in one tenth culture volume of 50 mM CaCl 2 . DNA was added to a 150 microliter volume of these cells, and the samples were held at 4° C. for 30 minutes. The samples were shifted to 42° C. for one minute, one milliliter of LB was added, and the samples were shaken at 37° C. for one hour. Cells from these samples were spread on plates containing ampicillin to select for transformants. The plates were incubated overnight at 37° C. Single colonies were picked and grown in LB supplemented with ampicillin overnight at 37° C. with shaking. From these cultures DNA was isolated for restriction analysis.

Typically plasmids were constructed, using methods described herein or by references cited herein, as follows except as noted in examples included herein. DNA fragments were purified from agarose or polyacrylamide gels. Purified DNA fragments were ligated and the ligation reaction mixture was used to transform E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin containing plates. Plasmid DNA was isolated from a single colony grown in LB Broth and screened by restriction analysis for the desired construct and sequenced to determine that the DNA sequence was correct.

Culture Media

LB medium (Maniatis et al., 1982) was used for growth of cells for DNA isolation. M9 minimal medium supplemented with 1.0% casamino acids, acid hydrolyzed casein, Difco (Detroit, Mich.) was used for cultures in which recombinant hIL-3 was produced. The ingredients in the M9 medium were as follows: 3g/liter KH 2 PO 4 , 6 g/l Na 2 HPO 4 , 0.5 g/l NaCl, 1 g/l NH 4 Cl, 1.2 mM MgSO 4 , 0.025 mM CaCl 2 , 0.2% glucose (0.2% glycerol with the AraBAD promoter), 1% casamino acids, 0.1 ml/l trace minerals (per liter 108 g FeCl 3 . 6H 2 O, 4.0 g ZnSO 4 .7H 2 O, 7.0 CoCl 2 .2H 2 O, 7.0 g Na 2 MoO 4 .2H 2 O, 8.0 g CuSO 4 .5H 2 O, 2.0 g H 3 BO 3 , 5.0 g MnSO 4 .H 2 O, 100 ml concentrated HCl). Bacto agar from Difco was used for solid media and ampicillin (Polycillin-N from Bristol-Meyers, Evansville, Ind.) was added to both liquid and solid LB media at 200 micrograms per milliliter.

DNA Sequence Analysis

The nucleotide sequencing of plasmid DNA was performed using a Genesis 2000 sequencer obtained from DuPont (Wilmington, Del.) according to the methods of Prober et al. (1987) and Sanger et al. (1977). Some DNA sequences were determined using Sequenase™ polymerase according to the protocol of its supplier, U.S. Biochemicals (Cleveland, Ohio).

Production of Recombinant hIL-3 Muteins in E. coli with Vectors Employing the recA Promoter

E. coli strains harboring the plasmids of interest were grown at 37° C. in M9 plus casamino acids medium with shaking in a Gyrotory water bath Model G76 from New Brunswick Scientific (Edison, N.J.). Growth was monitored with a Klett Summerson meter (green 54 filter), Klett Mfg. Co. (New York, N.Y.). At a Klett value of approximately 150, an aliquot of the culture (usually one milliliter) was removed for protein analysis. To the remaining culture, nalidixic acid (10 mg/ml) in 0.1 N NaOH was added to a final concentration of 50 μg/ml. The cultures were shaken at 37° C. for three to four hours after addition of nalidixic acid. A high degree of aeration was maintained throughout the bacterial growth in order to achieve maximal production of the desired gene product. The cells were examined under a light microscope for the presence of retractile bodies (RBs). One milliliter aliquots of the culture were removed for analysis of protein content.

Production of Recombinant hITL-3 Proteins from the AraBAD Promoter in E. coli

E. coli strains harboring the plasmids of interest were grown at 30° C. with shaking in M9 medium plus casamino acids and glycerol. Growth was monitored with a Klett Summerson calorimeter, using a green 54 filter. At a Klett value of about 150, an aliquot of the culture (usually one milliliter) was removed for protein analysis. To the remaining culture, 20% arabinose was added to a final concentration of 0.05%. The cultures were shaken at 30° C. for three to four hours after addition of arabinose. A high degree of aeration was maintained throughout the bacterial growth in order to achieve maximal production of the desired gene product. One milliliter aliquots of the culture were removed for analysis of protein content.

Secretion and Osmotic Shock

Three hour post induction samples were fractionated by osmotic shock [Neu and Heppel (1965)]. The Klett value of the cultures was determined and 1 ml of cells were centrifuged in a Signa mierocentrifuge (West Germany) model 202MK in 1.5 mls snap top microcentrifuge tubes for 5 minutes at 10,000 rpm. The cell pellet was resuspended very gently by pipeting in a room temperature sucrose solution (20% sucrose w/v, 30 mM Tris-Hcl pH7.5, 1 mM EDTA), using 1 μl/1 Klett unit. Following a 10 minute incubation at room temperature, the cells were centrifuged for 5 minutes at 10,000 rpm. The sucrose fraction was carefully removed from the cell pellet. The cell pellet was then resuspended very gently by pipeting in ice cold distilled water, using 1 μl/1 Klett unit. Following a 10 minute incubation on ice, the cells were centrifuged for 5 minutes at 12,000 rpm. The water fraction was carefully removed. Equal volumes of the sucrose and water fractions were pooled and aliquoted to provide samples for ELISA and biological activity screening.

Analysis of Protein Content of E. coli Cultures Producing hTL-3 Mutant Polypeptides

Bacterial cells from cultures treated as described above were collected from the medium by centrifugation. Aliquots of these cells were resuspended in SDS loading. buffer (4×: 6 g SDS, 10 ml beta-mercaptoethanol, 25 ml upper Tris gel stock (0.5 M Tris HCl pH 6.8, 0.4% SDS) brought to 50 ml with glycerol, 0.2% bromophenol blue was added) at a concentration of one microliter per Klett unit. These samples were incubated at 85° C. for five minutes and vortexed. Five or ten microliter aliquots of these samples were loaded on 15% polyacrylamide gels prepared according to the method of Laemmli (1970). Protein bands were visualized by staining the gels with a solution of acetic acid, methanol and water at 5:1:5 (volume to volume) ratio to which Coomassie blue had been added to a final concentration of 1%. After staining, the gels were washed in the same solution without the Coomassie blue and then washed with a solution of 7% acetic acid, 5% methanol. Gels were dried on a gel drier Model SE1160 obtained from Hoeffer (San Francisco, Calif.). The amount of stained protein was measured using a densitometer obtained from Joyce-Loebl (Gateshead, England). The values obtained were a measure of the amount of the stained hIL-3 protein compared to the total of the stained protein of the bacterial cells.

›DETAILED DESCRIPTION OF THE INVENTION · 18 of 20

Western Blot Analysis of hTL-3 Muteins Made in E. coli

In some E. coli cultures producing hIL-3, the level of accumulation of the hIL-3 protein is lower than 5% of total bacterial protein. To detect hIL-3 produced at this level, Western blot analysis was used. Proteins from cultures induced with nalidixic acid or arabinose. were run on polyacrylamide gels as described above except that volumes of sample loaded were adjusted to produce appropriate signals. After electrophoresis, the proteins were electroblotted to APT paper, Transa-bind, Schleicher and Schuell (Keene, N.H.) according to the method of Renart et al. (1979). Antisera used to probe these blots had been raised in rabbits, using peptides of the sequence of amino acids 20 to 41 and 94 to 118 of hIL-3 as the immunogens. The presence of bound antibody was detected with Staphylococcal protein A radiolabeled with 125 I, obtained from New England Nuclear (Boston, Mass.).

Fractionation of E. coli Cells Producing hIL-3 Proteins in the Cytoplasm

Cells from E. coli cultures harboring plasmids that produce hIL-3 muteins were induced with nalidixic acid. After three hours, the hIL-3 muteins accumulated in refractile bodies. The first step in purification of the hIL-3 muteins was to sonivate cells. Aliquots of the culture were resuspended from cell pellets in sonication buffer: 10 mM Tris, pH 8.0, 1 mM EDTA, 50 mM NaCl and 0.1 mM PMSF. These resuspended cells were subjected to several repeated sonication bursts using the microtip from a Sonicator cell disrupter, Model W-375 obtained from Heat Systems-Ultrasonics Inc. (Farmingdale, N.Y.). The extent of sonication was monitored by examining the homogenates under a light microscope. When nearly all of the cells had been broken, the homogenates were fractionated by centrifugation. The pellets, which contain most of the refractile bodies, are highly enriched for hIL-3 muteins.

Methods: Extraction, Refolding and Purification of Interleukin-3 (IL-3) Muteins Expressed as Refractile Bodies in E. coli.

Extraction of refractile bodies (RB's):

For each gram of RB's (and typically one gram is obtained from a 300 ml E. coli culture), 5 ml of a solution containing 6M guanidine hydrochloride (GnHCl), 50 mM 2-N-cyclohexylaminoethanesulfonic acid (CHES) pH 9.5 and 20 mM dithiothreitol (DTT) was added. The RB's were extracted with a Bio-Homogenizer for 15-30 seconds and gently rocked for 2 hours at 5 degrees centigrade (5° C.) to allow the protein to completely reduce and denature.

Refolding of the IL-3 Muteins

The protein solution was transferred to dialysis tubing (1000 molecular weight cut-off) and dialyzed against at least 100 volumes of 4M GnHCl-50 mM CHES pH 8.0. The dialysis was continued overnight at 5° C. while gently stirring. Subsequently dialysis was continued against at least 100 volumes of 2M GnHCl-50 mM CHES pH 8.0 and dialyzed overnight at 5° C. while gently stirring.

Purification of the IL-3 Muteins

The protein solution was removed from the dialysis tubing and acidified by the addition of 40% acetonitrile (CH 3 CN)-0.2% trifluoroacetic acid (TFA) to a final concentration of 20% CH 3 CN-0.1% TFA. This was centrifuged (16,000×g for 5 minutes) to clarify and the supernatant was loaded onto a Vydac C-18 reversed phase column (10×250 mm) available from Vydac (Hesperia, Calif.) previously equilibrated in 20% CH 3 CN-0.1% TFA. The column was eluted with a linear gradient (0.2% CH 3 CN/minute) between 40-50% CH 3 CN-0.1% TFA at a flow rate of 3 ml/minute while collecting 1.5 ml fractions. The fractions were analyzed by polyacrylamide gel electrophoresis (SDS-PAGE) and the appropriate fractions pooled. The pooled material was dried by lyophilization or in a Speed Vac concentrator. The dry powder was reconstituted with 10 mM ammonium bicarbonate pH 7.5, centrifuged (16,000×g for 5 minutes) to clarify and assayed for protein concentration by the method of Bradford (1976) with bovine serum albumin as the standard. Such protein can be further analyzed by additional techniques such as, SDS-PAGE, electrospray mass spectrometry, reverse phase HPLC, capillary zone electrophoresis, amino acid composition analysis, and ELISA (enzyme-linked immunosorbent assay).

hIL-3 Sandwich ELISA

IL-3 protein concentrations were determined using a sandwich ELISA based on an affinity purified polyclonal goat anti-rhIL-3. Microtiter plates (Dynatech Immulon II) were coated with 150 μl goat-anti-rhIL-3 at a concentration of approximately 1 μg/ml in 100 mM NaHCO3, pH 8.2. Plates were incubated overnight at room temperature in a chamber maintaining 100% humidity. Wells were emptied and the remaining reactive sites on the plate were blocked with 200 μl of solution containing 10 mM PBS, 3% BSA and 0.05% Tween 20, pH 7.4 for 1 hour at 37° C. and 100% humidity. Wells were emptied and washed 4× with 150 mM NaCl containing 0.05% Tween 20 (wash buffer). Each well then received 150 μl of dilution buffer (10 mM PBS containing 0.1% BSA, 0.01% Tween 20, pH 7.4), containing rhIL-3 standard, control, sample or dilution buffer alone. A standard curve was prepared with concentrations ranging from 0.125 ng/ml to 5 ng/ml using a stock solution of rhIL-3 (concentration determined by amino acid composition analysis). Plates were incubated 2,5 hours at 37° C. and 100% humidity. Wells were emptied and each plate was washed 4× with wash buffer. Each well then received 150 μl of an optimal dilution (as determined in a checkerboard assay format) of goat anti-rhIL-3 conjugated to horseradish peroxidase. Plates were incubated 1.5 hours at 37° C. and 100% humidity. Wells were emptied and each plate was washed 4× with wash buffer. Each well then received 150 ul of ABTS substrate solution (Kirkegaard and Perry). Plates were incubated at room temperature until the color of the standard wells containing 5 ng/ml rhIL-3 had developed enough to yield an absorbance between 0.5-1.0 when read at a test wavelength of 410 nm and a reference wavelength of 570 nm on a Dynatech microtiter plate reader. Concentrations of immunoreactive rhIL-3 in unknown samples were calculated from the standard curve using software supplied with the plate reader.

›DETAILED DESCRIPTION OF THE INVENTION · 19 of 20

AML Prolifpraton Assay for Bioactive Human Interleukkin-3

The factor-dependent cell line AML 193 was obtained from the American Type Culture Collection (ATCC, Rockville, Md.). This cell line, established from a patient with acute myelogenous leukemia, is a growth factor dependent cell line which displayed enhanced growth in GM/CSF supplemented medium (Lange, B., et al., (1987); Valtieri, M., et al., (1987). The ability of AML 193 cells to proliferate in the presence of human IL-3 has also been documented. (Santoli, D., et al., (1987)). A cell line variant was used, AML 193 1.3, which was adapted for long term growth In IL-3 by washing out the growth factors and starving the cytokine dependent AML 193 cells for growth factors for 24 hours. The cells were then replated at 1×10 5 cells/well in a 24 well plate in media containing 100 U/ml IL-3. It took approximately 2 months for the cells to grow rapidly in IL-3. These cells were maintained as AML 193 1.3 thereafter by supplementing tissue culture medium (see below) with human IL-3.

AML 193 1.3 cells were washed 6 times in cold Hanks balanced salt solution (HBSS, Gibco, Grand Island, N.Y.) by centrifuging cell suspensions at 250×g for 10 minutes followed by decantation of supernatant. Pelleted cells were resuspended in HBSS and the procedure was repeated until six wash cycles were completed. Cells washed six times by this procedure were resuspended in tissue culture medium at a density ranging from 2×10 5 to 5×10 5 viable cells/ml. This medium was prepared by supplementing Iscove's modified Dulbeccols Medium (IMDM, Hazleton, Lenexa, Kans.) with albumin, transferrin, lipids and 2-mercaptoethanol. Bovine albumin (Boehringer-Mannheim, Indianapolis, Ind.) was added at 500 μg/ml; human transferrin (Boehringer-Mannheim, Indianapolis, Ind.) was added at 100 μg/ml; soybean lipid (Boehringer-Mannheim, Indianapolis, Ind.) was added at 50 μg/ml; and 2-mercaptoethanol (Sigma, St. Louis, Mo.) was added at 5×10 −5 M.

Serial dilutions of human interleukin-3 or human interleukin-3 variant protein (hIL-3 mutein) were made in triplicate series in tissue culture medium supplemented as stated above in 96 well Costar 3596 tissue culture plates. Each well contained 50 gl of medium containing interleukin-3 or interleukin-3 variant protein once serial dilutions were completed. Control wells contained tissue culture medium alone (negative control). AMM 193 1.3 cell suspensions prepared as above were added to each well by pipetting 50 μl (2.5×10 4 cells) into each well. Tissue culture plates were incubated at 37° C. with 5% CO 2 in humidified air for 3 days. On day 3, 0.5 μCi 3 H-thymidine (2 Ci/mM, New England Nuclear, Boston, Mass.) was added in 50 μl of tissue culture medium. Cultures were incubated at 37° C. with 5% CO 2 in humidified air for 18-24 hours. Cellular DNA was harvested onto glass filter mats (Pharmacia LKB, Gaithersburg, Md.) using a TOMTEC cell harvester (TOMTEC, Orange, Conn.) which utilized a water wash cycle followed by a 70% ethanol wash cycle. Filter mats were allowed to air dry and then placed into sample bags to which scintillation fluid (Scintiverse II, Fisher Scientific, St. Louis, Mo. or BetaPlate Scintillation Fluid, Pharmacia LKB, Gaithersburg, Md.) was added. Beta emissions of samples from individual tissue culture wells were counted in a LKB Betaplate model 1205 scintillation counter (Pharmacia LKB, Gaithersburg, Md.) and data was expressed as counts per minute of 3 H-thymidine incorporated into cells from each tissue culture well. Activity of each human interleukin-3 preparation or human interleukin-3 variant preparation was quantitated by measuring cell proliferation ( 3 H-thymidine incorporation) induced by graded concentrations of interleukin-3 or interleukin-3 variant. Typically, concentration ranges from 0.05 pM-10 5 pM are quantitated in these assays. Activity is determined by measuring the dose of interleukin-3 or interleukin-3 variant which provides 50% of maximal proliferation [EC 50 =0.5× (maximum average counts per minute of 3 H-thymidine incorporated per well among triplicate cultures of all concentrations of interleukin-3 tested - background proliferation measured by 3 H-thymidine incorporation observed in triplicate cultures lacking interleukin-3]. This EC 50 value is also equivalent to 1 unit of bioactivity. Every assay was performed with native interleukin-3 as a reference standard so that relative activity levels could be assigned.

Relative biological activities of some IL-3 muteins of the present invention are shown in Table 1. The Relative Biological Activity of IL-3 mutants is calculated by dividing the EC 50 of (1-133) hIL-3 by the EC 50 of the mutant. The Relative Biological Activity may represent the average of replicate assays.

The following assay is used to measure IL-3 mediated sulfidoleukotriene release from human mononuclear cells.

IL-3 Mediated Sulfidoleukotriene Release from Human Mononuclear Cells

Heparin-containing human blood was collected and layered onto an equal volume of Ficoll-Paque (Pharmacia #17-0840-02) ready to use medium (density 1.077 g/ml.). The Ficoll was warmed to room temperature prior to use and clear 50 ml polystyrene tubes were utilized. The Ficoll gradient was spun at 300× g for 30 minutes at room temperature using a H1000B rotor in a Sorvall RT6000B refrigerated centrifuge. The band containing the mononuclear cells was carefully removed, the volume adjusted to 50 mls with Dulbecco's phosphate-buffered saline (Gibco Laboratories cat. #310-4040PK), spun at 400×g for 10 minutes at 40° C. and the supernatant was carefully removed. The cell pellet was washed twice with HA Buffer [20 mM Hepes (Sigma # H-3375), 125 mM NaCl (Fisher # S271-500), 5 mM KCl (sigma # P-9541), 0.5 mM glucose (Sigma # G-5000), 0.025% Human Serum Albumin (Calbiochem #126654) and spun at 300×g, 10 min., 4° C. The cells were resuspended in HACM Buffer (HA buffer supplemented with 1 mM CaC12 (Fisher # C79-500) and 1 mM MgC12 (Fisher # M-33) at a concentration of 1×106 cells/ml and 180 μl were transferred into each well of 96 well tissue culture plates. The cells were allowed to acclimate at 37° C. for 15 minutes. The cells were primed by adding 10 μls of a 20× stock of various concentrations of cytokine to each well (typically 100000, 20000, 4000, 800, 160, 32, 6.4, 1.28, 0 fM IL3). The cells were incubated for 15 minutes at 37° C. Sulfidoleukotriene release was activated by the addition of 10 μl of 20×(1000 nM) fmet-leu-phe (Calbiochem #344252) final concentration 50 nM FMLP and incubated for 10 minutes at 37° C. The plates were spun at 350×g at 4° C. for 20 minutes. The supernatants were removed and assayed for sulfidoleukotrienes using Cayman's Leukotriene C4 EIA kit (Cat. #420211) according to manufacturers' directions. Native (15-125) hIL-3 was run as a standard control in each assay.

›DETAILED DESCRIPTION OF THE INVENTION · 20 of 20

Native hIL-3 possesses Considerable inflammatory activity and has been shown to stimulate synthesis of the arachidonic acid metabolites LTC 4 , LTD 4 , and LTE 4 ; histamine synthesis and histamine release. Human clinical trials with native hIL-3 have documented inflammatory responses (Biesma, et al., BLOOD, 80:1141-1148 (1992) and Postmus, et al., J. CLIN. ONCOL., 0:1131-1140 (1992)). A recent study indicates that leukotrienes are involved in IL-3 actions in vivo and may contribute significantly to the biological effects of IL-3 treatment (Denzlinger, C., et al., BLOOD, 81:2466-2470 (1993))

Some muteins of the present invention may have an improved therapeutic profile as compared to native hIL-3 or (15-125) hIL-3. For example, some muteins of the present invention may have a similar or more potent growth factor activity relative to native hIL-3 or (15-125) hIL-3 without having a similar or corresponding increase in the stimulation of leukotriene or histamine. These muteins would be expected to have a more favorable therapeutic profile since the amount of polypeptide which needs to be given to achieve the desired growth factor activity (e. g. cell proliferation) would have a lesser leukotriene or histamine stimulating effect. In studies with native hIL-3, the stimulation of inflammatory factors has been an undesirable side effect of the treatment, Reduction or elimination of the stimulation of mediators of inflammation would provide an advantage over the use of native hIL-3.

Some muteins of the present invention may have antigenic profiles which differ from that of native hIL-3. For example, in a competition ELISA with an affinity purified polyclonal goat anti-hIL-3 antibody, native hIL-3 significantly blocked the binding of labeled hIL-3 to polyclonal anti-hIL-3 antibody. Some polypeptides of the present invention, particularly those with several amino acids differing from those of native hIL-3, fail to block the binding of hIL-3 to anti-hIL-3 antibody.

Table 2 lists the sequences of some oligonucleotides used in making the muteins of the present invention.

Table 3 lists the amino acid sequence of native (15-125) hIL-3 (Peptide #1) and the amino acid sequences of some mutant polypeptides of the present invention. The sequences are shown with the amino acid numbering corresponding to that of native hIL-3 [FIG. 1 ].

Polypeptides corresponding to SEQ ID NOS. 15, 16, 17, 18 and 129 comprising (1-133) hIL-3 containing one or more amino acid substitutions can be made using the procedures described above and in the following examples by starting with the appropriate oligonuctiotides and then constructing the DNA encoding the polypeptide and expressing it in an appropriate host cell. In a similar manner polypeptides which correspond to SEQ ID NOS. 19, 20, 21, 22 and 130 and contain one or more amino acid substitutions and wherein from 1 to 14 amino acids have been sequentially deleted from the N-terminus, or from 1 to 15 amino acids have been deleted from the C-terminus or deletions of amino acids have been made from both the N-terminus and the C-terminus can also be made by following the procedures described above and in the following examples, beginning with the appropriate starting materials.

Additional details may be found in U.S. patent application Ser. No. 07/981,044 filed Nov. 24, 1992, now abandoned which is hereby incorporated by reference in its entirety.

Additional details may be found in co filed U.S. patent application Ser. No. 08/411,795 which is hereby incorporated by reference in its entirety.

All references, patents or applications cited herein are incorporated by reference in their entirety.

Further details known to those skilled in the art may be found in T. Maniatis, et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory (1982) and references cited therein, incorporated herein by reference in its entirety; and in J. Sambrook, et al., Molecular Cloning, A Laboratory Manual, 2nd edition, Cold Spring Harbor Laboratory (1989) and references cited therein, incorporated herein by reference in its entirety.

The following examples will illustrate the invention in greater detail although it will be understood that the invention is not limited to these specific examples.

Amino acids are shown herein by standard one letter or three letter abbreviations as follows:

Various other examples will be apparent to the person skilled in the art after reading the present disclosure without departing from the spirit and scope of the invention. It is intended that all such other examples be included within the scope of the appended claims.

›REFERENCES · 1 of 2

Adams, S. P., Kavka, K. S., Wykes, E. J., Holder, S. B. and Galluppi, G. R. Hindered Dialkyamino Nucleoside Phosphate reagents in the synthesis of two DNA 51-mers. J. Am. Chem. Soc., 105, 661-663 (1983).

Atkinson, T. and Smith, M., in Gait, M. J., Oligonucleotide Sythesis (1984) (IRL Press, Oxford England).

Bachmann, B., Pedigrees of some mutant strains of Escherichia coli K-12, Bacteriological Reviews, 3:525-557 (1972).

Bayne, M. L., Expression of a synthetic gene encoding human insulin-like growth factor I in cultured mouse fibroblasts. Proc. Natl. Acad. Sci. USA 84, 2638-2642 (1987).

Ben-Bassat, A., K. Bauer, S-Y. Chang, K. Myambo, A. Boosman and S. Ching. Processing of the initiating methionine from proteins: properties of the Escherichia coli methionine aminopeptidase and its gene structure. J. Bacteriol., 169: 751-757 (1987).

Biesma, B. et al., Effects of interleukin-3 after chemotherapy for advanced ovarian cancer. Blood, 80:1141-1148 (1992).

Birnboim, H. C. and J. Doly. A rapid alkaline extraction method for screening recombinant plasmid DNA. Nucleic Acids Research, 7(6): 1513-1523 (1979).

Bradford, M. M., A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding, Analytical Biochemistry, 72: 248-254 (1976).

Clark-Lewis, I., L. E. Hood and S. B. H. Kent. Role of disulfide bridges in determining the biological activity of interleukin 3, Proc. Natl. Acad. Sci.,USA, 85: 7897-7901 (1988).

Clement, J. M. and Hofnung, M. Gene sequence of the receptor, an outer membrane protein of E. coli K12. Cell, 27: 507-514 (1981).

Covarrubias, L., L. Cervantes, A. Covarrubias, X. Soberon, I. Vichido, A. Blanco, Y. M. Kupersztoch-Portnoy and F. Bolivar. Construction and characterization of new cloning vehicles. V. Mobilization and coding properties of pBR322 and several deletion derivates including pBR327 and pBR328. Gene 13: 25-35 (1981).

Deng, W. P. & Nickoloff, J. A. Site-directed mutagenesis of virtually any plasmid by eliminating a unique site. Anal. Biochem. 200:81 (1992).

Dente, L., G. Cesareni and R. Cortese, pEMBL: A new family of single stranded plasmids, Nucleic Acids Research, 11: 1645-1655 (1983).

Dunn, J. J. and Studier, F. W., Complete nucleotide sequence of bacteriophage T7 DNA and the locations of T7 genetic elements. J. Mol. Biol. 166:477-535 (1983).

Falk, S., G. Seipelt, A. Ganser, O. G. Ottmann, D. Hoelzer, H. J. Stutte and K. Hubner. Hematopathology 95: 355 (1991).

Fling, M. E., et al. Nucleotide sequence of the transposon Tn7 gene encoding an aminoglycoside-modifying enzyme, 3″(9)-O-nucleotidyltransferase. Nucl. Acids Res. 13:7095-7106 (1985).

Ganser, A., A. Lindemann, G. Seipelt, O. G. Ottmann, F. Herrmann, M. Eder, J. Frisch, G. Schulz, R. Mertelsmann and D. Hoelzer. Effects of Recombinant Human Interleukin-3 in Patients With Normal Hematopoiesis and in Patients with Bone Marrow Failure, Blood 76: 666 (1990).

Gething and Sambrook, Cell-surface expression of influenza haemagglutinin from a cloned DNA copy of the RNA gene, Nature, 293: 620-625 (1981).

Gillio, A. P., C. Gasparetto, J. Laver, M. Abboud, M. A. Bonilla, M. B. Garnick and R. J. O'Reilly. J. Clin. Invest. 85: 1560 (1990).

Gouy, M. and G. Gautier, Codon usage in bacteria: Correlation with gene expressivity, Nucleic Acids Research, 10: 7055-7074 (1982).

Greenfield, L., T. Boone, and G. Wilcox. DNA sequence of the araBAD promoter in Escherichia coli B/r. Proc. Natl. Acad. Sci. USA, 75: 4724-4728 (1978).

Higuchi, R, (1989) in PCR Technology, H. A. Erlich ed., Stockton Press, N.Y. chapter 2-6.

Hunkapiller, M. W., R. W. Hewick, R. J. Dreyer and L. E. Hood. High sensitivity sequencing with a gas-phase sequenator. Methods in Enzymology 153: 399-413 (1983).

Kaufman, et al., Coamplification and Coexpression of Human Tissue-Type Plasminogen Activator and Murine Dihydrofolate Reductase Sequences in Chinese Hamster Ovary Cells, Mol. Cell. Biol., 5(7): 1750-1759 (1985).

Kaufman, R. J. High level production of proteins in mammalian cells, in Genetic Engineering, Principles and Methods, Vol. 9, J. K. Setlow, editor, Plenum Press, New York (1987).

Kunkel, T. A. Rapid and efficient site-specific mutagenesis without phenotypic selection. Proc. Natl. Acad. Sci. USA, 82: 488-492 (1985).

Laemmli, U. K., Cleavage of structural proteins during assembly of the head of bacteriophage T4, Nature, 227:680-685 (1970).

Lange, B., M. Valtieri, D. Santoli, D. Caracciolo, F. Mavilio, I. Gemperlein, C. Griffin, B. Emanuel, J. Finan, P. Nowell, and G. Rovera. Growth factor requirements of childhood acute leukemia: establishment of GM-CSF-defendent cell lines. Blood 70: 192 (1987).

Mahler, H. R. and E. H. Cordes, in Biological Chemistry, p. 128, New York, Harper and Row (1966).

Maniatis, T., E. F. Fritsch and J. Sambrook, Molecular Cloning, A Laboratory Manual. Cold Spring Harbor Laboratory (1982).

Marinus, M. G. Location of DNA methylation genes on the Escherichia coli K-12 genetic map. Molec. Gen. Genet. 127: 47-55 (1973).

McBride, L. J. and Caruthers, M. H. An investigation of several deoxynucleoside phosphoramidites. Tetrahedron Lett., 24, 245-248 (1983).

Messing, J., A multipurpose cloning system based on the single-stranded DNA bacteriophage M13. Recombinant DNA Technical Bulletin, NIH Publication No. 79-99, Vol. 2, No. 2, pp. 43-48 (1979).

Neu, H. C. and L. A. Heppel. The release of enzymes from Escherichia coli by osmotic shock and during the formation of spheroplasts. J. Biol. Chem., 240: 3685-3692 (1965).

Obukowicz, M. G., Staten, N. R. and Krivi, G. G., Enhanced Heterologous Gene Expression in Novel rpoH Mutants of Escherichia coli. Applied and Environmental Microbology 58, No. 5, p. 1511-1523 (1992).

Olins, P. O., C. S. Devine, S. H. Rangwala and K. S. Kavka, The T7 phage gene 10 leader RNA, a ribosome-binding site that dramatically enhances the expression of foreign genes in Escherichia coli, Gene, 73:227-235 (1988).

Olins, P. O. and S. H. Rangwala, Vector for enhanced translation of foreign genes in Escherichia coli, Methods in Enzymology, 18: 115-119 (1990).

›REFERENCES · 2 of 2

Postmus, et al., Effects of recombinant human interleukin-3 in patients with relapsed small-cell lung cancer treated with chemotherapy: a dose-finding study. J. Clin. Oncol., 10:1131-1140 (1992).

Prober, J. M., G. L. Trainor, R. J. Dam, F. W. Hobbst C. W. Robertson, R. J. Zagursky, A. J. Cocuzza, M. A. Jensen and K. Baumeister. A system for rapid DNA sequencing with fluorescent chain-terminating dideoxynucleotides. Science 283: 336-341 (1987).

Renart J., J. Reiser and G. R. Stark, Transfer of proteins from gels to diazobenzyloxymethyl-paper and detection with anti-sera: a method for studying antibody specificity and antigen structure, Proc. Natl. Acad. Sci. USA, 76:3116-3120 (1979).

Saiki, R. K., Schorf, S., Faloona, F., Mullis, K. B., Horn, G. T., Erlich, H. A. and Arnheim, N., Enzymatic Amplification of β-Globin Genomic Sequences and Restriction Site Analysis for Diagnosis of Sickle Cell Anemia, Science, 230: 1350-1354 (1985).

Sambrook, J., et al., Molecular Cloning, A Laboratory Manual, 2nd edition, Cold Spring Harbor Laboratory (1989).

Sancar, A., C. Stachelek, W. Konigsberg and W. D. Rupp, Sequences of the recA gene and protein, Proc. Natl. Acad. Sci., 77: 2611-2615 (1980).

Sanger, F., S. Nicklen and A. R. Coulson. DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. U. S. A. 74: 5463-5467 (1977).

Santoli, D., Y. Yang, S. C. Clark, B. L. Kreider, D. Caracciolo, and G. Rovera. Synergistic and antagonistic effects of recombinant human interleukin (IL-3), IL-1α, granulocyte and macrophage colony-stimulating factors (G-CSF and M-CSF) on the growth of GM-CSF-dependent leukemic cell lines. J. Immunol. 139:348 (1987).

Smith, M. In vitro mutagenesis. Ann. Rev. Genet., 19:423-462 (1985).

Soberon, X., L. Covarrublas and F. Bolivar, Construction and characterization of new cloning vehicles. IV. Deletion derivatives of pBR322 and pBR325, Gene, 9: 211-223 (1980).

Stader, J. A. and T. J. Sulhavy. Engineering Escherichia coli to secrete heterologous gene products, Methods in Enzymology, 185: 166-87 (1990).

Summers, M. D. and G. E. Smith. A manual of methods for Baculovirus vectors and insect cell culture procedures. Texas Agricultural Experiment Station Bulletin No. 1555 (1987).

Taylor, J. W., Ott, J. and Eckstein, F.. The rapid generation of oligonucleotide-directed mutants at high frequency using phosphorothioate modified DNA. Nucl. Acids Res., 13:8764-8785 (1985).

Treco, D. A., in Current protocols in Molecular Biology, Seidman et al., eds. J Wiley N.Y., unit 2.1. (1989)

Valtieri, M., D. Santoli, D. Caracciolo, B. L. Kreider, S. W. Altmann, D. J. Tweardy, I. Gemperlein, F. Mavilio, B. J. Lange and G. Rovera. Establishment and characterization of an undifferentiated human T leukemia cell line which requires granulocyte-macrophage colony stimulating factor for growth. J. Immunol. 138:4042 (1987).

Voet, D., W. B. Gatzer, R. A. Cox, P. Doty. Absorption spectra of the common bases. Biopolymers 1: 193 (1963).

Wells, J. A., Vasser, M., and Powers, D. B. Cassette mutagenesis: an effective method for generation of multiple mutants at defined sites. Gene, 34:315-323 (1985).

Wong, E. Y., R. Seetharam, C. Kotts, R. A. Heeren, B. K. Klein, S. B. Braford, K. J. Mathis, B. F. Bishop, N. R. Siegel, C. E. Smith and W. C. Tacon. Expression of secreted IGF-1 in Escherichia coli. Gene, 68: 193-203 (1988).

Yang, Y., A. B. Clarletta, P. A. Temple, M. P. Chung, S., Koviacic, J. S. Witek-Giannotti, A. C. Leary, R. Kriz, R. E. Donahue, G. G. Wong and S. C. Clark. Human IL-3 (Multi-CSF): Identification by expression cloning of a novel hematopoietic growth factor related to murine IL-3. Cell 47: 3-10 (1985).

Yanisch-Perron, C., J. Viera and J. Messing. Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors. Gene 33: 103-119 (1985).

Zoller, M. J. and Smith, M. Oligonucleotide-directed mutagenesis using M13-derived vectors: an efficient and general procedure for the production of point mutations in any fragment of DNA. Nucleic Acid Research, 10: 6487-6500 (1982).

Zoller, M. J. and Smith, M. Oligonucleotide-directed mutagenesis of DNA fragments cloned into M13 vectors. Methods in Enzymology, 100:468-500 (1983).

Zoller, M. J. and Smith, M. Oligonucleotide-directed Mutagenesis: A simple method using two oligonucleotide primers and a single-stranded DNA template. DNA, 3: 479 (1984).

›Examples72
›EXAMPLE 1

Construction of pMON 5846 (FIG. 4) which Encodes [Met-(1-133) hIL-3 (Arg129)]

A plasmid containing the gene for the cDNA of hIL-3 cloned into pUC18 on an EcoRI to HindIII fragment was obtained from British Biotechnology Limited (Cambridge, England). This plasmid was designated pPO518. The purified plasmid DNA was cleaved by the restriction endonucleases NheI and BamHI. Approximately 0.5 micrograms of cleaved plasmid DNA was ligated to 1.0 picomoles of a pair of annealed oligonucleotides with the following sequence:

5′-CTAGCGATCTTTTAATAAGCTTG-3′ [SEQ ID NO: 1]

3′-GCTAGAAAATTATTCGAACCTAG-5′ [SEQ ID NO: 2]

The ligation mixture was used to transform competent JM101 cells to ampicillin resistance. Colonies were picked, and plasmid DNA was purified and subjected to restriction enzyme analysis. An isolate was identified in which the above oligonucleotide sequence had replaced the portion of the gene that encodes the extreme C-terminus. Within the new sequence was a new stop codon, TAA, and a recognition site for the enzyme HindIII. The new plasmid was designated pMON5846.

›EXAMPLE 2

(a) Construction of Expression Vector Plasmid pMON2341

The plasmid pMON2341 was used to supply the particular replicon and expression elements used for construction of many of the plasmids used to produce hIL-3 and hIL-3 muteins in E. coli. These expression elements are described in the materials and methods section. pMON2341 is derived from pMON5515 (Olins et al., 1988) and from pMON2429. pMON2429 consists of the phage mp18 (Yanisch-Perron et al., 1985) with a BclI fragment carrying the chloramphenicol acetyl transferase (cat) gene from pBR328 (Covarrubias et al., 1981) inserted into the BamHI site. The cat gene in pMON2429 has been altered from that in pBR328 by site directed mutagenesis (Kunkel, 1985). The recognition sites for NcoI and EcoRI which occur in the native gene were altered so that these two restriction enzymes no longer recognize these sites. The changes did not alter the protein specified by the gene. Also, an NcoI site was introduced at the N-terminus of the coding sequence so that it overlaps the codon for initiator methionine.

The steps involved in construction of pMON2341 are listed below:

(1) The DNAs of pMON5515 and pMON2429 were treated with NcoI and HindIII. The fragments were ligated and used to transform competent E. coli to ampicillin resistance. From these colonies, some were identified that were chloramphenicol resistant. From one of these colonies, plasmid DNA was isolated in which the rat atriopeptigen gene of pMON5515 had been replaced by the NcoI to HindIII fragment containing the cat gene from pMON2429. This fragment contains the recognition sites for several restriction enzymes in the portion derived, from the multilinker region of mp18. The new plasmid was designated pMON2412.

(2) pMON2412 was treated with the enzyme ClaI which cleaves at one location in the pBR327 derived portion of the DNA. The protruding ends were rendered blunt by treatment with Klenow in the presence of nucleotide precursors. This DNA was mixed with an isolated 514 bp RsaI fragment derived from pEMBL8 (Dente et al., 1983). This RsaI fragment contains the origin of replication of phage f1. This ligation mixture was used to transform competent E. coli cells to ampicillin resistance. Among the plasmid DNAs isolated from these cells was pMON5578. This plasmid has the structure of pMON2412 with the f1 origin region inserted into the ClaI site. This in illustrated in the Figures and in Olins and Rangwala (1990).

(3) The DNA of pMON5578 was treated with restriction enzymes HindIII and MstII. The DNA was then treated with Klenow enzyme in the presence of nucleotide precursors to render the ends blunt. This treated DNA was ligated and used to transform competent E. coli to ampicillin resistance. From the ampicillin resistant colonies, one plasmid was recovered from which the portion between HindIII and MstII was absent. This deletion resulted in the removal of sequences from the plasmid which are recognized by a number of restriction endonuclease sites. The new plasmid was designated pMON5582.

(4) The DNA of pMON5582 was treated with SstII and BclI and ligated in the presence of annealed oligonucleotides with the sequences shown below.

5′-GGCAACAATTTCTACAAAACACTTGATACTGTATGAGCAT-3′-CGCCGTTGTTAAAGATGTTTTGTGAACTATGACATACTCGTAACAGTATAATTGCTTCAACAGAACAGATC-3′ [SEQ ID NO:3]

TGTCATATTAACGAAGTTGTCTTGT-5′ [SEQ ID NO:4]

This sequence encodes the essential elements of the recA promoter of E. coli including the transcription start site and the lexA repressor binding site (the operator) (Sancar et al., 1980). The plasmid recovered from the ligation mixes contained this recA promoter in place of the one In pMON5582 (and in pMON5515). The functionality of the recA promoter was illustrated by Olins and Rangwala (1990). The new plasmid was designated pMON5594.

(5) To eliminate the single EcoRI site in pMON5594, the DNA was treated with EcoRI, then with Klenow in the presence of nucleotide precursors to render the ends blunt and then the DNA was ligated. From this ligation mix a plasmid was recovered whose DNA was not cleaved with EcoRI. This plasmid was designated pMON5630.

(6) To alter the single recognition site for PstI, plasmid pMON5630 was subjected to site directed mutagenesis (Kunkel, 1985). The oligonucleotide used in this procedure has the sequence shown below.

5′-CCATTGCTGCCGGCATCGTGGTC-3′ [SEQ ID NO:5]

The result of the procedure was to construct pMON2341 which differs from pMON5630 in that the PstI site in the beta-lactamase gene was altered so that PstI no longer recognizes the site. The single nucleotide change does not alter the amino acid sequence of the beta-lactamase protein.

(b) Construction of pMON5847 (FIG. 5) which Encodes [Met-(1-133) hIL-3(Arg 129 )]

Plasmid pMON2341 was used to supply the replicon, promotor, ribosome binding site, transcription terminator and antibiotic resistance marker for the plasmids used to produce hIL-3 in E. coli from cDNA derived hIL-3 genes.

Plasmid pMON2341 was treated with restriction enzymes NcoI and HindIII. The restriction fragment containing the replication origin was purified. The DNA of plasmid pMON5846 was treated with NcoI and HindIII. The restriction fragment containing the hIL-3 gene was gel purified. These purified restriction fragments were mixed and ligated. The ligation mixture was used to transform competent JM101 cells to ampicillin resistance. Colonies were picked, and plasmid DNA was purified and analyzed using restriction enzymes. pMON5847 was identified as a plasmid with the replicon of pMON2341 and the hIL-3 gene in place of the chloramphenicol acetyl transferase gene. JM101 cells harboring this plasmid were cultured in M9 medium and treated with nalidixic acid as described above. Samples of the culture were examined for protein content. It was found that this hIL-3 mutein was produced at about 6% of total cell protein as measured on Coomassie stained polyacrylamide gels.

›EXAMPLE 3

Construction of pMON5854 (FIG. 7) which Encodes [Met-(1-133) hIL-3(Arg 129 )]

To increase the accumulation of hIL-3 in E. coli, the coding sequence of the amino terminal portion of the protein was altered to more closely reflect the codon bias found in E. coli genes that produce high levels of proteins (Gouy and Gautier, 1982). To change the coding sequence for the amino terminal portion of the gene, a pair of synthetic oligonucleotides were inserted between the NcoI and HpaI sites within the coding sequence. About 0.5 micrograms of DNA of the plasmid pMON5847 (Example 2) was treated with NcoI and HpaI. This DNA was mixed with an annealed pair of oligonucleotides with the following sequence:

5′-CATGGCTCCAATGACTCAGACTACTTCTCTTAAGACT-3′-CGAGGTTACTGAGTCTGATGAAGAGAATTCTGATCTTGGGTT-3′ [SEQ ID NO:6]

AGAACCCAA-5′ [SEQ ID NO:7]

The fragments were ligated. The ligation mixture was used to transform competent JM101 to ampicillin resistance. Colonies were picked into broth. From the cultures plasmid DNA was made and examined for the presence of a DdeI site (CTNAG) which occurs in the synthetic sequence but not between the NcoI and HpaI sites in the sequence of pMON5847. The new recombinant plasmid was designated pMON5854. The nucleotide sequence of the DNA in the coding sequence of the amino terminal portion of the hIL-3 gene in pMON5854 was determined by DNA sequencing and found to be the same as that of the synthetic oligonucleotide used in ligation. Cultures of JM101 cells harboring this plasmid were grown and treated with nalidixic acid to induce production of the hIL-3 mutant protein. Analysis of the proteins on Coomassie gels showed that the accumulation of hIL-3 mutein was about 25% of total cell protein in cultures harboring pMON5854, significantly higher than it was in cultures harboring pMON5847.

›EXAMPLE 4

Construction of pMON5887 (FIG. 12) which Encodes [Met-(1-125) hIL-3]

The plasmid DNA of pMON5854 (Example 3) was treated with EcoRI and HindIII and the larger fragment was gel purified. About 0.5 mitrogram of this DNA was ligated to 1 picomole of an annealed pair of oligonucleotides which encode amino acids 107 through 125 of hIL-3. The sequences of these oligonucleotides are shown below. EcoRI to HindIII

5′-AATTCCGTCOTAAMCTGACCTTCTATCTGAAAA-3′-GGCAGCATTTGACTGGAAGATAGACTTTTCCTTGGAGAACGCGCAGGCTCAACAGTAATA-3′ [SEQ ID NO;8]

GGAACCTCTTGCGCGTCCGAGTTGTCATTATTCGA-5′ [SEQ ID NO:9]

After ligation, the DNA was used to transform competent JM101 cells to ampicillin resistance. Colonies were picked into broth and plasmid DNA was isolated from each culture. Restriction analysis of the plasmid DNA showed the presence of an EcoRI to HindIII fragment smaller than that of pMON5854. The nucleotide sequence of the portion of the coding sequence between the EcoRI and HindIII sites was determined to confirm the accuracy of the replaced sequence. The new plasmid was designated pMON5887 encoding Met-(1-125) hIL-3 which has the following amino acid sequence:

[SEQ ID NO:10]

Met Ala Pro Met Thr Gln Thr Thr Ser Leu Lys Thr

Ser Trp Val Asn Cys Ser Asn Met Ile Asp Glu Ile

Ile Thr His Leu Lys Gln Pro Pro Leu Pro Leu Leu

Asp Phe Asn Asn Leu Asn Gly Glu Asp Gln Asp Ile

Leu Met Glu Asn Asn Leu Arg Arg Pro Asn Leu Glu

Ala Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala

Ser Ala Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro

Cys Leu Pro Leu Ala Thr Ala Ala Pro Thr Arg His

Pro Ile His Ile Lys Asp Gly Asp Trp Asn Glu Phe

Arg Arg Lys Leu Thr Phe Tyr Leu Lys Thr Leu Glu

Asn Ala Gln Ala Gln Gln

›EXAMPLE 5

Construction of pMON5967 which Encodes [Met-Ala-(15-125) hIL-3]

Plasmid DNA of pMON5887 isolated from E. coli GM48 (dam-) was cleaved with NcoI and ClaI and ligated to 1 picomole of an annealed pair of oligonucleotides, Nco I and ClaI, encoding amino acids [Met Ala (15-20) hIL-3]. The sequence of these oligonucleotides is shown below.

5′-CATGGCTAACTGCTCTAACATGAT-3′[SEQ ID NO:11]

3′-CGATTGACGAGATTGTACTAGC-5′[SEQ ID NO:12]

The resulting ligation mix was used to transform competent E. coli JM101 cells to ampicillin resistant colonies. Plasmid DNA was isolated from these cells and the size of the inserted fragment was determined to be smaller than that of pMON5887 by restriction analysis using NcoI and NsiI. The nucleotide sequence of the region between NcoI and ClaI was determined and found to be that of the synthetic oligonucleotides. The new plasmid was designated pMON5967 and cells containing it were induced for protein production. Sonicated cell pellets and supernatants were used for protein purification and bio-assay.

›EXAMPLE 6

Construction of pMON5978 which Encodes [Met-Ala-(15-125) hIL-3]

Plasmid DNA of pMON5967 isolated from E. coli GM48(dam-) was cleaved with ClaI and NsiI and ligated to 1 picomole of an annealed assembly of six oligonucleotides encoding hIL-3 amino acids 20-70 (FIG. 2 ). This synthetic fragment encodes three unique restriction sites, EcoRV, XhoI and PstI. The sequence of these oligonucleotides is shown in FIG. 2 .

The resulting ligation mix was used to transform competent E. coli JM101 cells to ampicillin resistant colonies. Plasmid DNA was isolated and screened with XbaI and EcoRV for the presence of the new restriction site EcoRV. The DNA sequence of the region between ClaI and NsiI was determined and found to be the same as that of the synthetic oligonucleotides. The new plasmid was designated pMON5978, and cells containing it were induced for protein production. Sonicated cell pellets and supernatants were used for protein purification and bioassay.

Plasmid pMON5978 encodes [Met-Ala-(15-125) hIL-3] which has the following amino acid sequence:

[SEQ ID NO:13]

Met Ala Asn Cys Ser Asn Met Ile Asp Glu Ile Ile

Thr His Leu Lys Gln Pro Pro Leu Pro Leu Leu Asp

Phe Asn Asn Leu Asn Gly Glu Asp Gln Asp Ile Leu

Met Glu Asn Asn Leu Arg Arg Pro Asn Leu Glu Ala

Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser

Ala Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro Cys

Leu Pro Leu Ala Thr Ala Ala Pro Thr Arg His Pro

Ile His Ile Lys Asp Gly Asp Trp Asn Glu Phe Arg

Arg Lys Leu Thr Phe Tyr Leu Lys Thr Leu Glu Asn

Ala Gln Ala Gln Gln

›EXAMPLE 7

Construction of pMON5898

Plasmid pMON5851 DNA was digested with restriction enzymes HindIII and NcoI resulting in a 3695 base pair NcoI,HindIII fragment. The genetic elements derived from pMON5851 are the beta-lactamase gene (AMP), pBR327 origin of replication, phage f1 origin of replication as the transcription terminator, AraBAD promoter, g10L ribosome binding site and the lamB secretion leader. The AraBAD promoter is identical to that described in plasmid pMON6235 and the lamB signal peptide sequence used is that shown in FIG. 8 fused to hIL-3 at the NcoI recognition site. Plasmid pMON5873 DNA was digested with restriction enzymes HindIII and NcoI resulting in a 408 base pair NcoI,HindIII fragment. The genetic element derived from pMON5873 is the hIL-3 gene (1-133). Clones containing the hIL-3 (1-133) gene contained a 408 base pair NcoI, HindIII restriction fragment. This construct was designated pMON5898.

›EXAMPLE 8

Construction of pMON5987

Plasmid pMON6458 DNA was digested with restriction enzymes NcoI and HindIII, resulting in a 3940 base pair NcoI, HindIII fragment. The genetic elements derived from pMON6458 are the beta-lactamase gene (AMP), pBR327 origin of replication, phage f1 origin of replication as the transcription terminator, AraBAD promoter, g10L ribosome binding site and lamB secretion leader. Plasmid pMON5978 DNA was digested with NcoI and NsiI. The resulting 170 base pair NcoI, NsiI fragment encodes amino acids 15-71 of (15-125) hIL-3. Plasmid pMON5976 DNA was digested with NsiI and HindIII. The resulting 175 base pair NsiI, HindIII fragment encodes amino acids 72-125 of (15-125) hIL-3. The restriction fragments were ligated, and the ligation reaction mixture was used to transform E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and screened for the restriction sites EcoRV and NheI and DNA sequenced to confirm the correct insert.

›EXAMPLE 9

Construction of pMON5988

The plasmid DNA of pMON5987 was digested with NheI and EcoRI, resulting in a 3903 base pair NheI, EcoRI fragment. The 3903 base pair NheI, EcoRI fragment was ligated to 1.0 picomoles of the following annealed oligonucleotides (oligo #3 and Oligo #4):

5′-CTAGCCACGGCCGCACCCACGCGACATCCAATCCATATCAA-3′-GGTGCCGGCGTGGGTGCGCTGTAGGTTAGGTATAGTTGGACGGTGACTGGAATG-3′ [SEQ ID NO:131]

CCTGCCACTGACCTTACAATT-5′ [SEQ ID NO:132]

The ligation reaction mixture was used to transform E. coli K-12 strain JM101 and transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm positive clones.

This plasmid was constructed to change alanine 101 to aspartic acid in the hIL-3 gene (15-125). The Ala 101 to Asp 101 change was confirmed by DNA sequencing. This plasmid was designated pMON5988 and encodes Peptide #1 [SEQ ID NO:65].

›EXAMPLE 10

Construction of pMON5873 which encodes [Met-(1-133) hIL-3]

The gene obtained from British Biotechnology, Ltd. specified arginine at codon position 129. The amino acid specified in the native hIL-3 cDNA is serine. To produce a protein with the native sequence at this position, the portion of the coding sequence between the EcoRI site at codons 106 and 107 and the NheI site at codons 129 and 130 was replaced. Plasmid DNA of pMON5854 (Example 3) and pMON5853 (Example 64) were treated with EcoRI and NheI. The larger fragments of each were gel purified. These were ligated to a pair of an annealed oligonucleotides with the following sequences:

5′-AATTCCGTCGTAAACTGACCTTCTATCTGAAAACC-3′-GGCAGCATTTGACTGGAAGATAGACTTTTGGTTGGAGAACGCGCAGGCTCAACAGACCACTCTGTCG-3′ [SEQ ID NO: 136]

AACCTCTTGCGCGTCCGAGTTGTCTGGTGAGACAGCGATC-5′ [SEQ ID NO:137]

The ligation reaction mixtures were used to transform competent JM101 cells to ampicillin resistance. Colonies were picked into broth and grown. Plasmid DNA was isolated and screened for the presence of a new StyI recognition site present in the synthetic DNA and not in pMON5854 and pMON5853. The nucleotide sequence of the gene in the region between EcoRI and NheI was determined and found to be that of the synthetic oligonucleotides. The new plasmids were designated pMON5873 encoding [Met-(1-133) hIL-3] and pMON5872 encoding [Met-(15-133) hIL-3].

The plasmid, pMON5873, encodes Met-(1-133) hIL-3 which has the following amino acid sequence:

[SEQ ID NO:128]

Met Ala Pro Met Thr Gln Thr Thr Ser Leu Lys Thr

Ser Trp Val Asn Cys Ser Asn Met Ile Asp Glu Ile

Ile Thr His Leu Lys Gln Pro Pro Leu Pro Leu Leu

Asp Phe Asn Asn Leu Asn Gly Glu Asp Gln Asp Ile

Leu Met Glu Asn Asn Leu Arg Arg Pro Asn Leu Glu

Ala Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala

Ser Ala Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro

Cys Leu Pro Leu Ala Thr Ala Ala Pro Thr Arg His

Pro Ile His Ile Lys Asp Gly Asp Trp Asn Glu Phe

Arg Arg Lys Leu Thr Phe Tyr Leu Lys Thr Leu Glu

Asn Ala Gln Ala Gln Gln Thr Thr Leu Ser Leu Ala

Ile Phe

›EXAMPLE 11

Construction of pMON6458

Plasmid pMON6525 DNA was digested with restriction enzymes HindIII and SalI and the resulting 3172 base pair fragment was isolated from a 1% agarose gel by interception onto DEAE membrane. The genetic elements derived from pMON6525 are the beta-lactamase gene (AMP), pBR327 origin of replication, and phage f1 origin of replication as the transcription terminator. (The genetic elements derived from plasmid pMON6525 are identical to those in plasmid pMON2341 which could also be used to construct pMON6458.) Plasmid pMON6457 was, digested with restriction enzymes HindIII and SalI and the resulting 1117 base pair fragment was isolated by PAGE and crush and soak elution. The genetic elements derived from pMON6457 are the pAraBAD promoter, g10L ribosome binding site, lamB secretion leader and the (15-125) hIL-3 gene. The restriction fragments were ligated and the ligation reaction mixture was used to transform E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and the size of the inserted fragment was determined by restriction analysis employing restriction enzymes NcoI and HindIII in double digest. Clones containing the hIL-3 gene (encoding amino acids 15-125) contained a 345 base pair NcoI, HindIII restriction fragment. This construct was designated pMON6458. This plasmid was constructed to eliminate an EcoRI restriction site outside the hIL-3 gene coding region in plasmid pMON6457.

›EXAMPLE 12

Construction of pMON6455

Plasmid pMON5905 DNA was digested with restriction enzymes HindIII and NcoI resulting in a 3936 base pair fragment. The genetic elements derived from pMON5905 are the beta-lactamase gene (AMP), pBR327 origin of replication, pAraBAD promoter, g10L ribosome binding site, lamB secretion leader and phage f1 origin of replication as the transcription terminator. The following genetic elements; beta-lactamase gene (AMP), pBR327 origin of replication, g10L ribosome binding site and phage f1 origin of replication as the transcription terminator, derived from plasmid pMON5905 are identical to those in plasmid pMON5594 which could also be used to construct pMON6455. The AraBAD promoter is identical to that described in pMON6235. The lamB signal peptide sequence used in pMON6455 is that shown in FIG. 8 fused to hIL-3 (15-125) at the NcoI site. Plasmid pMON5887 DNA was digested with restriction enzymes HindIII and NcoI, resulting in a 384 base pair NcoI, HindIII fragment. The restriction fragments were ligated, and the ligation reaction mixture was used to transform into E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and the size of the inserted fragment was determined by restriction analysis employing restriction enzymes NcoI and HindIII in double digest. Positive clones containing the hIL-3 gene (encoding amino acids 1-125) contained a 384 base pair NcoI, HindIII restriction fragment. This construct was designated pMON6455.

›EXAMPLE 13

Construction of pMON6456

Plasmid pMON5905 DNA was digested with restriction enzymes HindIII and NcoI resulting in a 3936 base pair fragment. The genetic elements derived from pMONS905 are the beta-lactamase gene (AMP), pBR327 origin of replication, phage f1 origin of replication as the transcription terminator, pAraBAD promoter, g10L ribosome binding site and the lamB secretion leader. Plasmid pMON5871 was digested with restriction enzymes HindIII and NcoI, resulting in a 330base pair NcoI, HindIII fragment. The genetic element derived from pMON5871 encompassed the bases encoding the (1-107) hIL-3 gene. The restriction fragments were ligated, and the ligation reaction mixture was used to transform E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and the size of the inserted fragment was determined by restriction analysis employing restriction enzymes NcoI and HindIII in double digest. Clones containing the hIL-3 gene (encoding amino acids 1-107) contained a 330 base pair NcoI, HindIII restriction fragment. This construct was designated pMON6456.

›EXAMPLE 14

Construction of pMON6457

Plasmid pMON6455 DNA grown in E. coli strain GM48 (dam-)was digested with restriction enzymes NcoI and ClaI, resulting in a 4293 base pair NcoI, ClaI fragment. The restriction fragment was ligated to 1.0 picomoles of annealed oligonucleotides (Oligo #5 and Oligo #6) with the following sequence coding for Met Ala 14-20 hIL-3:

5′-CATGGCTAACTGCTCTAACATGAT-3′[SEQ ID NO:151]

3′-CGATTGACCAGATTGTACTAGC-5′[SEQ ID NO:152]

The resulting DNA was transformed into E. coli K-12 strain JM101 and transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and the size of the inserted fragment was determined by restriction analysis employing restriction enzymes XbaI and EcoRI in double digest. Positive clones containing the hIL-3 gene (encoding aa 15-125 of hIL-3) contained a 433 base pair XbaI, EcoRI restriction fragment and were DNA sequenced. This construct was designated pMON6457. This plasmid was constructed to delete the first 14 amino acids of hIL-3. The coding sequence of the resulting gene begins as follows:

The first two amino acids (Methionine, Alanine) create an NcoI restriction site and a signal peptidase cleavage site between the lamB signal peptide and (15-125) hIL-3. Plasmid pMON6457 encodes (15-125) hIL-3 which has the amino acid sequence designated SEQ ID NO 65.

›EXAMPLE 15

Construction of pMON6235

One of the DNA fragments used to create this plasmid was generated by site-directed mutagenesis employing PCR techniques described previously using the following oligonucleotides, Oligo #51(A) [SEQ ID NO:155] and Oligo #52(A) [SEQ ID NO:156], were used as primers in this procedure. The template for the PCR reaction was E. coli strain W3110 chromosomal DNA, prepared as described in Maniatis (1982). The oligonucleotide primers were designed to amplify the AraBAD promoter (Greenfield et al., 1978). The resulting DNA product was digested with the restriction enzymes SacII and BglII. The reaction mixture was purified as described previously. Plasmid, pMON5594, DNA was digested with SacII and BglII, resulting in a 4416 base pair SacII,BglII restriction fragment which contains the following genetic elements; beta-lactamase gene (AMP), pBR327 origin of replication, G10L ribosome binding site, phage f1 origin of replication as the transcription terminator and the chloramphenicol acetyl transferase (cat) gene. The 4416 base pair SacII,BglII restriction fragment from pMON5594 was ligated to the PCR-generated SacII, BglII DNA fragment. The ligation mixture was used to transform E. coli K-12 strain JM101. Positive clones contained a 323 base pair SacII,BglII fragment and were DNA sequenced to confirm that the SacII,BglII fragment was the AraBAD promoter. This construct was designated pMON6235.

›EXAMPLE 16

Construction of pMON6460

One of the DNA fragments to construct this plasmid was generated by site-directed mutagenesis employing PCR techniques described previously using the oligonucleotides, Oligo #7 [SEQ ID NO: 26] and Oligo #8 [SEQ ID NO: 27] as primers. The template for the PCR reaction was plasmid pMON6458 DNA. The resulting DNA product was digested with the restriction enzymes NcoI and EcoRI. Upon completion, the digest was heated at 70° C. for 15 minutes to inactivate the enzymes. The restriction fragment was purified by phenol/chloroform extraction and precipitation with equal volume isopropanol in the presence of 2M NH 4 OAc. The oligonucleotide, Oligo #8, introduces two stop codons (TAA) after amino acid 93 of hIL-3 and Creates a SalI restriction endonuclease recognition sequence. The NcoI, EcoRI restriction fragment from pMON6458 was ligated to the PCR-generated NcoI, EcoRI restriction fragment. Positive clones containing the above mentioned changes released a 1023 base pair SalI fragment. This construct was designated pMON6460. This plasmid was constructed to serve as the template for the creation of single amino acid substitution variants at positions 94, 95, 96 and 97 of hIL-3.

›EXAMPLE 17

Construction of pMON6461

One of the DNA fragments to create this plasmid was generated by site-directed mutagenesis employing PCR techniques described previously using the following oligonucleotide, Oligo #7 [SEQ. ID NO: 26] and Oligo #9 [SEQ. ID NO: 28], as primers. The template for the PCR reaction was plasmid pMON6458 DNA. The resulting DNA product was digested with the restriction enzymes NcoI and EcoRI. The oligonucleotide, Oligo #9, introduces two stop codons (TAA) after amino acid 97 of hIL-3 and creates a SalI restriction endonuclease recognition sequence. The NcoI, EcoRI restriction fragment from pMON5458 was ligated to the PCR-generated NcoI, EcoRI DNA fragment. Positive clones containing the above mentioned changes released a 1035 base pair SalI fragment. This construct was designated pMON6461. This plasmid was constructed to serve as the template for the creation of single amino acid substitution variants at positions 98, 99, 100 and 101 of hIL-3.

›EXAMPLE 18

Construction of pMON6462

One of the DNA fragments to create this plasmid was generated by site-directed mutagenesis employing PCR techniques described previously using the following oligonucleotide, Oligo #7 [SEQ. ID NO: 26] and Oligo #10 [SEQ. ID NO: 31], as primers. The template for the PCR reaction was plasmid pMON6458 DNA. The resulting DNA product was digested with the restriction enzymes NcoI and EcoRI. The oligonucleotide, Oligo #10 [SEQ. ID NO: 31] introduces two stop codons (TAA) after amino acid 101 of hIL-3 and creates a SalI restriction endonuclease recognition sequence. The NcoI, EcoRI restriction fragment from pMON5458 was ligated to the PCR-generated NcoI, EcoRI DNA fragment. Positive clones containing the above mentioned changes released a 1047 base pair SalI fragment. This construct was designated pMON6462. This plasmid was constructed to serve as the template for the creation of single amino acid substitution variants at positions 102, 103, 104 and 105 of hIL-3.

›EXAMPLE 19

Construction of Single Amino Acid Substitution Libraries at Positions 94, 95, 96 and 97

One of the DNA fragments used to construct the plasmids containing single amino acid substitution at positions 94, 95, 96 and 97 was generated by site-directed mutagenesis employing PCR techniques described previously. In the PCR reaction plasmid pMON6460 DNA was the template and the oligonucleotide, Oligo #7 [SEQ. ID NO: 26], was used as the primer at the N-terminus, The degenerate oligonucleotides, Oligo #11 [SEQ. ID NO: 32], Oligo #12 [SEQ. ID NO: 33], Oligo #13 [SEQ. ID NO: 34] and Oligo #14 [SEQ. ID NO: 35], were the primers at the C-terminus. These oligonucleotides are 32-fold degenerate, with G, A, T or C in the first and second positions and G or C in the third position of a single codon at amino acid positions 94, 95, 96 and 97 of hIL-3 respectively. These degenerate oligonucleotide primers theoretically contain 32 different codons encoding all 20 amino acid substitutions and one translational stop codon at a single position. The degenerate oligonucleotides (Oligo #11 [SEQ. ID NO: 32], Oligo #12 [SEQ. ID NO: 33], Oligo #13 [SEQ. ID NO: 34] and Oligo #14 [SEQ. ID NO: 35]) replace the twelve bases introduced into pMON6460, that encode the two stop codons (TAA) after amino acid 93 of hIL-3 and the SalI recognition sequence. At the other 9 bases the DNA sequence was restored to encode the native hIL-3 protein sequence. The resulting PCR-generated DNA products were digested with the restriction enzymes NcoI and EcoRI. The 4008 bp NcoI, EcoRI restriction fragment from pMON6460 was ligated to the PCR-generated NcoI, EcoRI DNA fragments. Plasmid DNA from individual colonies was isolated as described previously and screened by DNA dot blot differential hybridization using the oligonucleotide, Oligo #15 [SEQ. ID NO: 36], as the probe which had been labeled with P 32 . Clones shown to be positive by hybridization were selected, plasmid DNA isolated and DNA sequenced to determine the amino acid substitution.

›EXAMPLE 20

Construction of Single Amino Acid Substitution Libraries at Positions 98. 99, 100 and 101

Single amino acid substitutions variants were constructed at position 98, 99, 100 and 101 as described previously, with the following changes. In the PCR reaction the template was plasmid pMON6461 DNA and the oligonucleotide, Oligo #7 [SEQ. ID NO: 26], was used as the primer at the N-terminus. The degenerate oligonucleotides, Oligo #16 [SEQ. ID NO: 37], Oligo #17 [SEQ. ID NO: 38], Oligo #18 [SEQ. ID NO: 39] and Oligo #19 [SEQ. ID NO: 40], were used as primers at the C-terminus. The resulting PCR-generated DNA products were purified and digested with restriction enzymes NcoI and EcoRI. The 4008 bp NcoI, EcoRI restriction fragment from pMON6461 was ligated to the PCR-generated DNA NcoI, EcoRI restriction fragment. Single colonies were screened by DNA dot blot differential hybridization using the oligonucleotide, Oligo #20 [SEQ. ID NO: 41], as the probe. Clones shown to be positive by hybridization were selected, plasmid DNA isolated and DNA sequenced to determine the amino acid substitution.

›EXAMPLE 21

Construction of Single Amino Acid Substitution Libraries at Positions 102, 103, 104 and 105

Single amino acid substitutions variants were constructed at position 102, 103, 104 and 105 as described previously, with the following changes. The template was pMON6462 and the oligonucleotide, Oligo #7 [SEQ. ID NO: 26], was used as the primer at the N-terminus. The degenerate oligonucleotides, Oligo #21 [SEQ. ID NO: 42], Oligo #22 [SEQ. ID NO: 43], Oligo #23 [SEQ. ID NO: 44] and Oligo #24 [SEQ. ID NO: 45] were used as primers at the C-terminus. The resulting PCR-generated DNA products were purified and digested with restriction enzymes, NcoI and EcoRI. The 4008 bp NcoI, EcoRI restriction fragment from pMON6462 was ligated to the PCR-generated NcoI, EcoRI restriction fragment. Single colonies were screened by DNA dot blot differential hybridization using the oligonucleotide, Oligo #25 [SEQ. ID NO: 46], as the probe. Clones shown to be positive by hybridization were selected, plasmid DNA isolated and DNA sequenced to determine the amino acid substitution.

›EXAMPLE 22

Construction of Plasmid pMON6464

Amino acids 17-22 of hIL-3 were deleted using site-directed PCR mutagenesis methods described previously. Plasmid pMON6458 DNA was the template in the PCR reaction using the oligonucleotides, Oligo #26 and Oligo #27 as primers. The resulting PCR-generated DNA products were purified and digested with NcoI and EcoRI. The 4008 bp NcoI, EcoRI restriction fragment from pMON6458 was ligated to the PCR-generated NcoI, EcoRI restriction fragment. Positive clones contained a 263 base pair NcoI, EcoRI restriction fragment in which the bases encoding amino acids 17-22 of hIL-3 have been deleted. pMON6464 was made to serve as the template for the creation of single amino acid substitution variants at positions 17, 18, 19, 20, 21 and 22 of hIL-3.

›EXAMPLE 23

Construction of Plasmid pMON6465

Amino acids 23-28 of hIL-3 were deleted using site-directed PCR mutagenesis methods described previously. Plasmid pMON6458 DNA was the template in the reaction using the oligonucleotides, Oligo # 26 and Oligo #28, as primers. The resulting PCR-generated DNA product was purified and digested with NcoI and EcoRI. The 4008 bp NcoI, EcoRI restriction fragment from pMON6458 was ligated to the PCR-generated NcoI, EcoRI restriction fragment. Positive clones contained a 263 base pair NcoI, EcoRI restriction fragment in which the bases encoding amino acids 23-28 of hIL-3 have been deleted. pMON6465 was made to serve as the template for the creation of single amino acid substitution variants at positions 23, 24, 25, 26, 27 and 28 of hIL-3.

›EXAMPLE 24

Construction of Plasmid pMON6466

Amino acids 29-34 of hIL-3 were deleted using site-directed PCR mutagenesis methods described previously. Plasmid pMON6458 DNA was the template in the reaction using the oligonucleotides, Oligo #26 and Oligo #29 as the primers. The resulting PCR-generated DNA product was purified and digested with NcoI and EcoRI. The 4008 bp NcoI, EcoRI restriction fragment from pMON6458 was ligated to the PCR-generated NcoI, EcoRI restriction fragment. Positive clones contained a 263 base pair NcoI, EcoRI restriction fragment in which the bases encoding amino acids 29-34 of hIL-3 have been deleted. pMON6466 was made to serve as the template for the creation of single amino acid substitution variants at positions 29, 30, 31, 32, 33 and 34 of hIL-3.

›EXAMPLE 25

Construction of Plasmid pMON6467

Amino acids 35-40 of hIL-3 were deleted using site-directed PCR mutagenesis methods described previously. Plasmid pMON5988 DNA was the template in the reaction using the oligonucleotides, Oligo #7 and Oligo #30, as primers. The resulting PCR-generated DNA product was purified and digested with NcoI and EcoRV. The NcoI, EcoRV restriction fragment from pMON5988 was ligated to the PCR-generated NcoI, EcoRV restriction fragment. Positive clones contained a 81 base pair NcoI, EcoRV restriction fragment in which the bases encoding amino acids 35-40 of hIL-3 have been deleted. pMON6467 was made to serve as the template for the creation of single amino acid substitution variants at positions 35, 36, 37, 38, 39 and 40 of hIL-3.

›EXAMPLE 26

Construction of Plasmid pMON6468

Amino acids 41-46 of hIL-3 were deleted using site-directed PCR mutagenesis methods described previously. Plasmid pMON5988 DNA was the template in the reaction using the oligonucleotides, Oligo #7 and Oligo #31, as the primers. The resulting PCR-generated DNA product was purified and digested with NcoI and XhoI. The NcoI, XhoI restriction fragment from pMON5988 was ligated to the PCR-generated NcoI, XhoI restriction fragment. Positive clones contained a 119 base pair NcoI, XhoI restriction fragment in which the bases encoding amino acids 41-46 of hIL-3 have been deleted. pMON6468 was made to serve as the template for the creation of single amino acid substitution variants at positions 41, 42, 43, 44, 45 and 46 of hIL-3.

›EXAMPLE 27

Construction of Plasmid pMON6469

Amino acids 47-52 of hIL-3 were deleted using site-directed PCR mutagenesis methods described previously. Plasmid pMON5988 DNA was the template in the reaction using the oligonucleotides, Oligo #7 and Oligo #32, as the primers. The resulting PCR-generated DNA product was purified and digested with NcoI and XhoI. The NcoI, XhoI restriction fragment from pMON5988 was ligated to the PCR-generated NcoI, XhoI restriction fragment. Positive clones contained a 119 base pair NcoI, XhoI restriction fragment in which the bases encoding amino acids 47-52 of hIL-3 have been deleted. pMON6469 was made to serve as the template for the creation of single amino acid substitution variants at positions 47, 48, 49, 50, 51 and 52 of hIL-3.

›EXAMPLE 28

Construction of Plasmid pMON6470

Amino acids 53-58 of hIL-3 were deleted using site-directed PCR mutagenesis methods described previously. Plasmid, pMON5988, DNA was the template in the reaction using the oligonucleotides, Oligo #7 and Oligo #33, as primers. The resulting PCR-generated DNA product was purified and digested with NcoI and NsiI. The NcoI, NsiI restriction fragment from pMON5988 was ligated to the PCR-generated NcoI, NsiI restriction fragment. Positive clones contained a 152 base pair NcoI, NsiI restriction fragment in which the bases encoding amino acids 53-58 of hIL-3 have been deleted. pMON6470 was made to serve as the template for the creation of single amino acid substitution variants at positions 53, 54, 55, 56, 57 and 58 of hIL-3.

›EXAMPLE 29

Construction of Plasmid pMON6471

Amino acids 59-64 of hIL-3 were deleted using site-directed PCR mutagenesis methods described previously. Plasmid pMON5988 DNA was the template in the reaction using the oligonucleotides, Oligo #7 and Oligo #34, as the primers. The resulting PCR-generated DNA product was purified and digested with NcoI and NsiI. The NcoI, NsiI restriction fragment from pMON5988 was ligated to the PCR-generated NcoI, NsiI restriction fragment. Positive clones contained a 152 base pair NcoI, NsiI restriction fragment in which the bases encoding amino acids 59-64 of hIL-3 have been deleted. pMON6471 was made to serve as the template for the creation of single amino acid substitution variants at positions 59, 60, 61, 62, 63 and 64 of hIL-3.

›EXAMPLE 30

Construction of Plasmid pMON6472

Amino acids 65-70 of hIL-3 were deleted using site-directed PCR mutagenesis methods described previously. Plasmid pMON5988 DNA was the template in the reaction using the oligonucleotides, Oligo #26 and Oligo #35, as primers. The resulting PCR-generated DNA product was purified and digested with EcoRI and XhoI. The EcoRI, XhoI restriction fragment from pMON5988 was ligated to the PCR-generated EcoRI, XhoI restriction fragment. Positive clones contained a 126 base pair EcoRI, XhoI restriction fragment in which the bases encoding amino acids 65-70 of hIL-2 have been deleted. pMON6472 was made to serve as the template for the creation of single amino acid substitution variants at positions 65, 66, 67, 68, 69 and 70 of hIL-3.

›EXAMPLE 31

Construction of Plasmid pMON6473

Amino acids 71-76 of hIL-3 were deleted using site-directed PCR mutagenesis methods described previously. Plasmid, pMON5988, DNA was the template in the reaction using the oligonucleotides, Oligo #26 and Oligo #36, as primers. The resulting PCR-generated DNA product was and digested with PstI and EcoRI. The PstI, EcoRI restriction fragment from pMON5988 was ligated to the PCR-generated PstI, EcoRI restriction fragment. Restriction analysis was with NcoI, NsiI and EcoRI in a triple digest. Positive clones contained a 263 base pair NcoI, EcoRI restriction fragment, in which the bases encoding amino acids 71-76 of hIL-3 have been deleted, and lost the NsiI restriction site. pMON6473 was made to serve as the template for the creation of single amino acid substitution variants at positions 71, 72, 73, 74, 75 and 76 of hIL-3.

›EXAMPLE 32

Construction of Plasmid pMON6474

Amino acids 77-82 of hIL-3 were deleted using site-directed PCR mutagenesis methods described previously. Plasmid pMON5988 DNA was the template in the reaction using the oligonucleotides, Oligo #26 and Oligo #37, as primers. The resulting PCR-generated DNA product was purified and digested with PstI and EcoRI. The PstI, EcoRI restriction fragment from pMON5988 was ligated to the PCR-generated PstI, EcoRI restriction fragment. Restriction analysis was with NcoI, NsiI and EcoRI in a triple digest. Positive clones contained a 170 base pair NcoI, NsiI restriction fragment and a 93 base pair NsiI, EcoRI restriction fragment in which the bases encoding amino acids 77-82 of hIL-3 have been deleted. pMON6474 was made to serve as the template for the creation of single amino acid substitution variants at positions 77, 78, 79, 80, 81 and 82 of hIL-3.

›EXAMPLE 33

Construction of Plasmid pMON6475

Amino acids 83-88 of hIL-3 were deleted using site-directed PCR mutagenesis methods described previously. Plasmid pMON5988 DNA was the template in the reaction using the oligonucleotides, Oligo #26 and Oligo #38, as primers. The resulting PCR-generated DNA product was digested with PstI and EcoRI. The PstI, EcoRI restriction fragment from pMON5988 was ligated to the PCR-generated PstI, EcoRI restriction fragment. Restriction analysis was with NcoI, NsiI and EcoRI in a triple digest. Positive clones contained a 170 base pair NcoI, NsiI restriction fragment and a 93 base pair NsiI, EcoRI restriction fragment in which the bases encoding amino acids 83-88 of hIL-3 have been deleted. pMON6475 was made to serve as the template for the creation of single amino acid substitution variants at positions 83, 84, 85, 86, 87 and 88 of hIL-3.

›EXAMPLE 34

Construction of Plasmid pMON6476

Amino acids 88-93 of hIL-3 were deleted using site-directed PCR mutagenesis methods described previously. Plasmid pMON6458 DNA was the template in the reaction using the oligonucleotides, Oligo #7 and Oligo #39, as primers. The resulting PCR-generated DNA product was purified and digested with NcoI and EcoRI. The NcoI, EcoRI restriction fragment from pMON6458 was ligated to the PCR-generated NcoI, EcoRI restriction fragment. Positive clones contained a 263 base pair NcoI, EcoRI restriction fragment in which the-bases encoding amino acids 88-93 of hIL-3 have been deleted. pMON6476 was made to serve as the template for the creation of single amino acid substitution variants at positions 88, 89, 90, 91, 92 and 93 of hIL-3.

›EXAMPLE 35

Construction of Plasmid pMON6477

Amino acids 106-111 of hIL-3 were deleted using site-directed PCR mutagenesis methods described previously. Plasmid pMON6458 DNA was the template in the reaction using the oligonucleotides, Oligo #7 and Oligo #40, as primers. The resulting PCR-generated DNA fragment was purified and digested with NcoI and HindIII. The NcoI, HindIII restriction fragment from pMON6458 was ligated to the PCR-generated NcoI, HindIII restriction fragment. Positive clones contained a 327 base pair NcoI, HindIII restriction fragment in which the bases encoding amino acids 106-111 of hIL-3 have been deleted. pMON6477 was made to serve as the template for the creation of single amino acid substitution variants at positions 106, 107, 108, 109, 110 and 111 of hIL-3.

›EXAMPLE 36

Construction of Plasmid pMON6478

Amino acids 112-117 of hIL-3 were deleted using site-directed PCR mutagenesis methods described previously. Plasmid pMON6458 DNA was the template in the reaction using the oligonucleotides, Oligo #7 and Oligo #41, as primers. The resulting PCR-generated DNA product was purified and digested with NcoI and HindIII. The 4008 bp NcoI, HindIII restriction fragment from pMON6458 was ligated to the PCR-generated NcoI, HindIII restriction fragment. Positive clones contained a 327 base pair NcoI, HindIII restriction fragment in which the bases encoding amino acids 112-117 of hIL-3 have been deleted. pMON6478 was made to serve as the template for the creation of single amino acid substitution variants at positions 112, 113, 114, 115, 116 and 117 of hIL-3.

›EXAMPLE 37

Construction of Plasmid pMON6479

Amino acids 118-123 of hIL-3 were deleted using site-directed PCR mutagenesis methods described previously. Plasmid pMON6458 DNA was the template in the reaction using the oligonucleotides, oligo #7 and Oligo #42, as primers. The resulting PCR-generated DNA product was purified and digested with NcoI and HindIII. The NcoI, HindIII restriction fragment from pMON6458 was ligated to the PCR-generated NcoI, HindIII restriction fragment. Positive clones contained a 327 base pair NcoI, HindIII restriction fragment in which the bases encoding amino acids 118-123 of hIL-3 have been deleted. pMON6479 was made to serve as the template for the creation of single amino acid substitution variants at positions 118, 119, 120, 121, 122 and 123 of hIL-3.

›EXAMPLE 38

Construction of Single Amino Acid Substitution Libraries at Positions 17, 18, 19, 20, 21 and 22

One of the DNA fragments used to construct the plasmids containing single amino acid substitutions at positions 17, 18, 19, 20, 21 and 22 of hIL-3 was generated by site-directed mutagenesis employing PCR techniques described previously. In the PCR reaction the plasmid pMON6464 DNA was the template and the following 32 fold degenerate oligonucleotides, Oligo #43, Oligo #44, Oligo #45, Oligo #46, Oligo #47 and Oligo #48 were the primers at the C-terminus. The oligonucleotide, Oligo #26, was used as the primer at the N-terminus. The degenerate oligonucleotides replace the eighteen bases, encoding six amino acids, deleted in pMON6464. The degenerate oligonucleotides have G, A, T or C in the first and second positions and G or C in the third position of a single codon at amino acid positions 17, 18, 19, 20, 21 and 22 of hIL-3 respectively. These degenerate oligonucleotide primers result in libraries which theoretically contain 32 different codons encoding all 20 amino acid substitutions and one translational stop codon at one position. At the other five amino acid positions the native hIL-3 DNA sequence was restored. The resulting PCR-generated DNA product was digested with NcoI and EcoRV. Plasmid pMON6464 DNA was digested with restriction enzymes NcoI and EcoRV resulting in a 4190 base pair fragment which was ligated to the PCR-generated NcoI, EcoRV restriction fragments. Plasmid DNA was isolated and screened by DNA dot blot differential hybridization using the oligonucleotide probe, Oligo #139, which had been labeled with P 32 . Clones shown to be positive by colony hybridization were selected, plasmid DNA isolated and DNA sequenced to determine the amino acid substitution.

›EXAMPLE 39

Construction of Single Amino Acid Substitution Libraries at Positions 23, 24, 25, 26, 27 and 28

One of the DNA fragments used to construct the plasmids containing single amino acid substitutions at positions 23, 24, 25, 26, 27 and 28 of hIL-3 was generated by site-directed mutagenesis employing PCR techniques described previously. In the PCR reaction the plasmid pMON6465 DNA was the template and the following 32 fold degenerate oligonucleotides, Oligo #49, Oligo #50, Oligo #51, Oligo #52, Oligo #53 and Oligo #54 were the primers at the C-terminus. The oligonucleotide, Oligo #26, was used as the primer at the N-terminus. The degenerate oligonucleotides replace the eighteen bases, encoding six amino acids, deleted in pMON6465. The degenerate oligonucleotides have G, A, T or C in the first and second positions and G or C in the third position of a single codon at amino acid positions 23, 24, 25, 26, 27 and 28 of hIL-3 respectively. These degenerate oligonucleotide primers result in libraries which theoretically contain 32 different codons encoding all 20 amino acid substitutions and one translational stop codon at one position. At the other five amino acid positions the native hIL-3 DNA sequence was restored. The resulting PCR-generated DNA products were purified and digested with restriction enzymes NcoI and EcoRV. Plasmid pMON6465 DNA was digested with restriction enzymes NcoI and EcoRV and the resulting 4190 base pair fragment was ligated to the PCR-generated NcoI, EcoRV DNA fragments. Transformant bacteria were screened by DNA dot blot differential hybridization using the oligonucleotide probe, Oligo #140, which had been labeled with P 32 . Clones shown to be positive by colony hybridization were selected, plasmid DNA isolated and DNA sequenced to determine the amino acid substitution.

›EXAMPLE 40

Construction of Single Amino Acid Substitution Libraries at Positions 29, 30, 31, 32, 33 and 34

One of the DNA fragments used to construct the plasmids containing single amino acid substitutions at positions 29, 30, 31, 32, 33 and 34 of hIL-3 was generated by site-directed mutagenesis employing PCR techniques described previously. In the PCR reaction the plasmid pMON6466 DNA was the template and the following 32 fold degenerate oligonucleotides, Oligo #55, Oligo #56, Oligo #57, Oligo #58, Oligo #59 and Oligo #60 were the primers at the C-terminus. The oligonucleotide Oligo #26 was used as the primer at the N-terminus. The degenerate oligonucleotides replace the eighteen bases, encoding six amino acids, deleted in pMON6466. The degenerate oligonucleotides have G, A, T or C in the first and second positions and G or C in the third position of a single codon at amino acid positions 29, 30, 31, 32, 33 and 34 of hIL-3 respectively. These degenerate oligonucleotide primers result in libraries which theoretically contain 32 different codons encoding all 20 amino acid substitutions and one translational stop codon at one position. At the other five amino acid positions the native hIL-3 DNA sequence was restored. The resulting PCR-generated DNA products were purified and digested with the restriction enzymes NcoI and EcoRV. Plasmid pMON6466 DNA was digested with restriction enzymes NcoI and EcoRV and the resulting 4190 base pair fragment was ligated to the PCR-generated NcoI, EcoRV DNA fragments. Transformant bacteria were screened by DNA dot blot differential hybridization using the oligonucleotide probe, Oligo #141, which had been labeled with P 32 . Clones shown to be positive by colony hybridization were selected, plasmid DNA isolated and DNA sequenced to determine the amino acid substitution.

›EXAMPLE 41

Construction of Single Amino Acid Substitution Libraries at Positions 35, 36, 37, 38, 39 and 40

One of the DNA fragments used to construct the plasmids containing single amino acid substitutions at positions 35, 36, 37, 38, 39 and 40 of hIL-3 were generated by site-directed mutagenesis employing PCR techniques described previously. In the PCR reaction the plasmid pMON6467 DNA was the template and the following 32 fold degenerate oligonucleotides, Oligo #61, Oligo #62, Oligo #63, Oligo #64, Oligo #65 and Oligo #66 were the primers at the C-terminus. The oligonucleotide, Oligo #7, was used as the primer at the N-terminus. The degenerate oligonucleotides replace the eighteen bases, encoding six amino acids, deleted in pMON6467. The degenerate oligonucleotides have G, A, T or C in the first and second positions and G or C in the third position of a single codon at amino acid positions 35, 36, 37, 38, 39 and 40 of hIL-3 respectively. These degenerate oligonucleotide primers result in libraries which theoretically contain 32 different codons encoding all 20 amino acid substitutions and one translational stop codon at one position. At the other five amino acid positions the native hIL-3 DNA sequence was restored and at the other position, 32 different codons substitutions were created at positions independently. The resulting PCR-generated DNA products were purified and digested with the restriction enzymes NcoI and EcoRV. Plasmid pMON6467 DNA was digested with restriction enzymes NcoI and EcoRV and the resulting 4190 base pair fragment was ligated to the PCR-generated NcoI, EcoRV DNA fragments.

Transformant bacteria were screened by DNA dot blot differential hybridization using the oligonucleotide probe, Oligo #142, which had been labeled with p32. Clones shown to be positive by colony hybridization were selected, plasmid DNA isolated and DNA sequenced to determine the amino acid substitution.

›EXAMPLE 42

Construction of Single Amino Acid Substitution Libraries at Positions 41, 42, 43, 44, 45 and 46

One of the DNA fragments used to construct the plasmids containing single amino acid substitutions at positions 41, 42, 43, 44, 45 and 46 of hIL-3 was generated by site-directed mutagenesis employing PCR techniques described previously. In the PCR reaction the plasmid pMON6468 DNA was the template and the following 32 fold degenerate oligonucleotides, Oligo #67, Oligo #68, Oligo #69, Oligo #70, Oligo #71 and Oligo #72 were the primers at the C-terminus. The oligonucleotide, Oligo #7, was used as the primer at the N-terminus. The degenerate oligonucleotides replace the eighteen bases, encoding six amino acids, deleted in pMON6468. The degenerate oligonucleotides have G, A, T or C in the first and second positions and G or C in the third position of a single codon at amino acid positions 41, 42, 43, 44, 45 and 46 of hIL-3 respectively. These degenerate oligonucleotide primers result in libraries which theoretically contain 32 different codons encoding all 20 amino acid substitutions and one translational stop codon at one position. At the other five amino acid positions the native hIL-3 DNA sequence was restored. The resulting PCR-generated DNA products were purified and digested with the restriction enzymes NcoI and XhoI. Plasmid pMON6468 DNA was digested with restriction enzymes NcoI and XhoI and the resulting 4152 base pair fragment was ligated to the PCR-generated NcoI, XhoI DNA fragments. Transformant bacteria were screened by DNA dot blot differential hybridization using the oligonucleotide probe, Oligo #143, which had been labeled with P 32 . Clones shown to be positive by colony hybridization were selected, plasmid DNA isolated and DNA sequenced to determine the amino acid substitution.

›EXAMPLE 43

Construction of Single Amino Acid Substitution Libraries at Positions 47, 48, 49, 50, 51 and 52

One of the DNA fragments used to construct the plasmids containing single amino acid substitutions at positions 47, 48, 49, 50, 51 and 52 of hIL-3 was generated by site-directed mutagenesis employing PCR techniques described previously. In the PCR reaction the plasmid pMON6469 DNA was the template and the following 32 fold degenerate oligonucleotides, Oligo #73, Oligo #74, Oligo #75, Oligo #76, Oligo #77 and Oligo #78 , were the primers at the C-terminus. The oligonucleotide, Oligo #7, was used as the primer at the N-terminus. The degenerate oligonucleotides replace the eighteen bases, encoding six amino acids, deleted in pMON6469. The degenerate oligonucleotides have G, A, T or C in the first and second positions and G or C in the third position of a single codon at amino acid positions 47, 48, 49, 50, 51 and 52 of hIL-3 respectively. These degenerate oligonucleotide primers result in libraries which theoretically contain 32 different codons encoding all 20 amino acid substitutions and one translational stop codon at one position. At the other five amino acid positions the native hIL-3 DNA sequence was restored. The resulting PCR-generated DNA products were purified and digested with the restriction enzymes NcoI and XhoI. Plasmid pMON6469 DNA was digested with restriction enzymes NcoI and XhoI and the resulting 4152 base pair fragment was ligated to the PCR-generated NcoI, XhoI DNA fragments. Transformant bacteria were screened by DNA dot blot differential hybridization using the oligonucleotide probe, Oligo #143, which had been labeled with P 32 . Clones shown to be positive by colony hybridization were selected, plasmid DNA isolated and DNA sequenced to determine the amino acid substitution.

›EXAMPLE 44

Construction of Single Amino Acid Substitution Libraries at Positions 53, 54, 55, 56, 57 and 58

One of the DNA fragments used to construct the plasmids containing single amino acid substitutions at positions 53, 54, 55, 56, 57 and 58 of hIL-3 was generated by site-directed mutagenesis employing PCR techniques described previously. In the PCR reaction the plasmid pMON6470 DNA was the template and the following 32 fold degenerate oligonucleotides, Oligo #79, Oligo #80, Oligo #81, Oligo #82, Oligo #83 and Oligo #84 , were the primers at the C-terminus. The oligonucleotide, Oligo #7, was used as the primer at the N-terminus. The degenerate oligonucleotides replace the eighteen bases, encoding six amino acids, deleted in pMON6470. The degenerate oligonucleotides have G, A, T or C in the first and second positions and G or C in the third position of a single codon at amino acid positions 53, 54, 55, 56, 57 and 58 of hIL-3 respectively. These degenerate oligonucleotide primers result in libraries which theoretically contain 32 different codons encoding all 20 amino acid substitutions and one translational stop codon at one position. At the other five amino acid positions the native hIL-3 DNA sequence was restored. The resulting PCR-generated DNA products were purified and digested with the restriction enzymes NcoI and NsiI. Plasmid pMON6470 DNA was digested with restriction enzymes NcoI and NsiI and the resulting 4119 base pair fragment was ligated to the PCR-generated NcoI, NsiI DNA fragments. Transformant bacteria were screened by DNA dot blot differential hybridization using the oligonucleotide probe, Oligo #145, which had been labeled with P 32 . Clones shown to be positive by colony hybridization were selected, plasmid DNA isolated and DNA sequenced to determine the amino acid substitution.

›EXAMPLE 45

Construction of Single Amino Acid Substitution Libraries at Positions 59, 60, 61, 62, 63 and 64

One of the DNA fragments used to construct the plasmids containing single amino acid substitutions at positions 59, 60, 61, 62, 63 and 64 of hIL-3 was generated by site-directed mutagenesis employing PCR techniques described previously. In the PCR reaction the plasmid pMON6471 DNA was the template and the following 32 fold degenerate oligonucleotides, Oligo #85, Oligo #86, Oligo #87, Oligo #88, Oligo #89 and Oligo #90 , were the primers at the C-terminus. The oligonucleotide, Oligo #7, was used as the primer at the N-terminus. The degenerate oligonucleotides replace the eighteen bases, encoding six amino acids, deleted in pMON6471. The degenerate oligonucleotides have G, A, T or C in the first and second positions and G or C in the third position of a single codon at amino acid positions 59, 60, 61, 62, 63 and 64 of hIL-3 respectively, These degenerate oligonucleotide primers result in libraries which theoretically contain 32 different codons encoding all 20 amino acid substitutions and one translational stop codon at one position. At the other five amino acid positions the native hIL-3 DNA sequence was restored. The resulting PCR-generated DNA products were purified and digested with the restriction enzymes NcoI and NsiI. Plasmid pMON6471 DNA was digested with restriction enzymes NcoI and NsiI and the resulting 4119 base pair fragment was ligated to the PCR-generated NcoI, NsiI DNA fragments. Transformant bacteria were screened by DNA dot blot differential hybridization using the oligonucleotide probe, Oligo #146, which had been labeled with P 32 . Clones shown to be positive by colony hybridization were selected, plasmid DNA isolated and DNA sequenced to determine the amino acid substitution.

›EXAMPLE 46

Construction of Single Amino Acid Substitution Libraries at Positions 65, 66, 67, 68, 69 and 70

One of the DNA fragments used to construct the plasmids containing single amino acid substitutions at positions 65, 66, 67, 68, 69 and 70 of hIL-3 was generated by site-directed mutagenesis employing PCR techniques described previously. In the PCR reaction the plasmid pMON6472 DNA was the template and the following 32 fold degenerate oligonucleotides, Oligo #91, Oligo #92, Oligo #93, Oligo #94, Oligo #95 and Oligo #96 , were the primers at the N-terminus. The oligonucleotide, Oligo 26, was used as the primer at the C-terminus. The degenerate oligonucleotides replace the eighteen bases, encoding six amino acids, deleted in pMON6472. The degenerate oligonucleotides have G, A, T or C in the first and second positions and G or C in the third position of a single codon at amino acid positions 65, 66, 67, 68, 69 and 70 of hIL-3 respectively. These degenerate oligonucleotide primers result in libraries which theoretically contain 32 different codons encoding all 20 amino acid substitutions and one translational stop codon at one position. At the other five amino acid positions the native hIL-3 DNA sequence was restored. The resulting PCR-generated DNA products were purified and digested with the restriction enzymes EcoRI and XhoI. Plasmid pMON6472 DNA was digested with restriction enzymes EcoRI and XhoI and the resulting 4145 base pair fragment was ligated to the PCR-generated EcoRI, XhoI DNA fragments. Transformant bacteria were screened by DNA dot blot differential hybridization using the oligonucleotide probe, Oligo #147, which had been labeled with P 32 . Clones shown to be positive by colony hybridization were selected, plasmid DNA isolated and DNA sequenced to determine the amino acid substitution.

›EXAMPLE 47

Construction of Single Amino Acid Substitution Libraries at Positions 71, 72, 73, 74, 75 and 76

One of the DNA fragments used to construct the plasmids containing single amino acid substitutions at positions 71, 72, 73, 74, 75 and 76 of hIL-3 was generated by site-directed mutagenesis employing PCR techniques described previously. In the PCR reaction the plasmid pMON6473 DNA was the template and the following 32 fold degenerate oligonucleotides, Oligo #97, Oligo #98, Oligo #99, Oligo #100, Oligo #101 and Oligo #102 , were the primers at the N-terminus. The oligonucleotide, Oligo #26, was used as the primer at the C-terminus. The degenerate oligonucleotides replace the eighteen bases, encoding six amino acids, deleted in pMON6473. The degenerate oligonucleotides have G, A, T or C in the first and second positions and G or C in the third position of a single codon at amino acid positions 71, 72, 73, 74, 75 and 76 of hIL-3 respectively. These degenerate oligonucleotide primers result in libraries which theoretically contain 32 different codons encoding all 20 amino acid substitutions and one translational stop codon at one position. At the other five amino acid positions the native hIL-3 DNA sequence was restored. The resulting PCR-generated DNA fragments were purified and digested with the restriction enzymes EcoRI and PstI. Plasmid pMON6473 DNA was digested with restriction enzymes EcoRI and PstI and the resulting 4171 base pair fragment was ligated to the PCR-generated EcoRI, PstI DNA fragments. Transformant bacteria were screened by DNA dot blot differential hybridization using the oligonucleotide probe, Oligo #148, which had been labeled with P 32 . Clones shown to be positive by colony hybridization were selected, plasmid DNA isolated and DNA sequenced to determine the amino acid substitution.

›EXAMPLE 48

Construction of Single Amino Acid Substitution Libraries at Positions 77, 78, 79, 80, 81 and 82

One of the DNA fragments used to construct the plasmids containing single amino acid substitutions at positions 77, 78, 79, 80, 81 and 82 of hIL-3 was generated by site-directed mutagenesis employing PCR techniques described previously. In the reaction the plasmid pMON6474 DNA was the template and the following 32 fold degenerate oligonucleotides, Oligo #103, Oligo #104, Oligo #105, Oligo #106, Oligo #107 and Oligo #108, were the primers at the N-terminus. The oligonucleotide, Oligo #26, was used as the primer at the C-terminus. The degenerate oligonucleotides replace the eighteen bases, encoding six amino acids, deleted in pMON6474. The degenerate oligonucleotides have G, A, T or C in the first and second positions and G or C in the third position of a single codon at amino acid positions 77, 78, 79, 80, 81 and 82 of hIL-3 respectively. These degenerate oligonucleotide primers result in libraries which theoretically contain 32 different codons encoding all 20 amino acid substitutions and one translational stop codon at one position. At the other five amino acid positions the native hIL-3 DNA sequence was restored. The resulting PCR-generated DNA products were purified and digested with the restriction enzymes EcoRI and PstI as described previosly. Plasmid pMON6474 DNA was digested with restriction enzymes EcoRI and PstI and the resulting 4171 base pair fragment was ligated to the PCR-generated EcoRI, PstI DNA fragments. Transformant bacteria were screened by DNA dot blot differential hybridization using the oligonucleotide probe, Oligo #149, which had been labeled with P 32 . Clones shown to be positive by colony hybridization were selected, plasmid DNA isolated and DNA sequenced to determine the amino acid substitution.

›EXAMPLE 49

Construction of Single Amino Acid Substitution Libraries at Positions 83, 84, 85, 86, 87 and 88

One of the DNA fragments used to construct the plasmids containing single amino acid substitutions at positions 83, 84, 85, 86, 87 and 88 of hIL-3 was generated by site-directed mutagenesis employing PCR techniques described previously. In the PCR reaction the plasmid pMON6475 DNA was the template and the following 32 fold degenerate oligonucleotides, Oligo #109, Oligo #110, Oligo #111, Oligo #112, Oligo #113 and Oligo #114, were the primers at the N-terminus. The oligonucleotide, Oligo #26, was used an the primer at the C-terminus. The degenerate oligonucleotides replace the eighteen bases, encoding six amino acids, deleted in pMON6475. The degenerate oligonucleotides have G, A, T or C in the first and second positions and G or C in the third position of a single codon at amino acid positions 83, 84, 85, 86, 87 and 88 of hIL-3 respectively. These degenerate oligonucleotide primers result in libraries which theoretically contain 32 different codons encoding all 20 amino acid substitutions and one translational stop codon at one position. At the other five amino acid positions the native hIL-3 DNA sequence was restored. The resulting PCR-generated DNA producs were purified and digested with the restriction enzymes EcoRI and PstI. Plasmid pMON6475 DNA was digested with restriction enzymes EcoRI and PstI and the resulting 4171 base pair fragment was ligated to the PCR-generated EcoRI, PstI DNA fragments. Transformant bacteria were screened by DNA dot blot differential hybridization using the oligonucleotide probe, Oligo #150, which had been labeled with P 32 . Clones shown to be positive by colony hybridization were selected, plasmid DNA isolated and DNA sequenced to determine the amino acid substitution.

›EXAMPLE 50

Construction of Single Amino Acid Substitution Libraries at Positions 88, 89, 90, 91, 92 and 93

One of the DNA fragments used to construct the plasmids containing single amino acid substitutions at positions 88, 89, 90, 91, 92 and 93 of hIL-3 was generated by site-directed mutagenesis employing PCR techniques described previously. In the PCR reaction the plasmid pMON6476 DNA was the template and the following degenerate oligonucleotides, Oligo #114, Oligo #115, Oligo #116, Oligo #117, Oligo #118 and Oligo #119, were the primers at the C-terminus. The oligonucleotide, Oligo #7, was used as the primer at the N-terminus. The degenerate oligonucleotides replace the eighteen bases, encoding six amino acids, deleted in pMON6476. The degenerate oligonucleotides have G, A, T or C in the first and second positions and G or C in the third position of a single codon at amino acid positions 88, 89, 90, 91, 92 and 93 of hIL-3 respectively. These degenerate oligonucleotide primers result in libraries which theoretically contain 32 different codons encoding all 20 amino acid substitutions and one translational stop codon at one position. At the other five amino acid positions the native hIL-3 DNA sequence was restored. The resulting PCR-generated DNA products were purified and digested with the restriction enzymes EcoRI and NcoI. Plasmid pMON6476 DNA was digested with restriction enzymes EcoRI and NcoI and the resulting 4008 base pair fragment was ligated to the PCR-generated EcoRI, NcoI DNA fragments. Transformant bacteria were screened by DNA dot blot differential hybridization using the oligonucleotide probe, Oligo #151, which had been labeled with P 32 . Clones shown to be positive by colony hybridization were selected, plasmid DNA isolated and DNA sequenced to determine the amino acid substitution.

›EXAMPLE 51

Construction of Single Amino Acid Substitution Libraries at Positions 106, 107, 108, 109, 110 and 111

One of the DNA fragments used to construct the plasmids containing the single amino acid substitutions at positions 106, 107, 108, 109, 110 and 111 of hIL-3 was generated by site-directed mutagenesis employing PCR techniques described previously in two sequential PCR reactions. In the first PCR reaction, plasmid pMON6477 DNA was the template and the following 32 fold degenerate oligonucleotides, Oligo #120, Oligo #121, Oligo #122, Oligo #123, Oligo #124 and Oligo #125 were the primers at the C-terminus. The oligonucleotide, Oligo #7 was the primer at the N-terminus. The degenerate oligonucleotides replace the eighteen bases, encoding six amino acids, deleted in pMON9477. The degenerate oligonucleotides have G, A, T or C in the first and second positions and G or C in the third position of a single codon at amino acid positions 106, 107, 108, 109, 110 and 111 of hIL-3 respectively. These degenerate oligonucleotide primers result in libraries which theoretically contain 32 different codons encoding all 20 amino acid substitutions and one translational stop codon at one position. At the other five amino acid positions the native hIL-3 DNA sequence was restored. The DNA generated in this PCR reaction was purified by phenol/chloroform extraction and precipitation with equal volume isopropanol in the presence of 2M NH 4 OAc to remove any primer that was not extended. This DNA was then used as a primer in the second PCR reaction.

In the second PCR reaction plasmid pMON6477 DNA was the template, the DNA product generated in the first PCR reaction (described above) was the primer at the N-terminus and the oligonucleotide, Oligo #126 (DNA sequence shown in Table 1), was the primer at the C-terminus. The resulting PCR-generated DNA products were purified and digested with the restriction enzymes HindIII and NcoI. Plasmid pMON6477 was digested with restriction enzymes HindIII and NcoI and the resulting 3944 base pair fragment was ligated to the PCR-generated HindIII, NcoI DNA fragments. Transformant bacteria were screened by DNA dot blot differential hybridization using the oligonucleotide probe, Oligo #152, which had been labeled with P 32 . Clones shown to be positive by colony hybridization were selected, plasmid DNA isolated and DNA sequenced to determine the amino acid substitution.

›EXAMPLE 52

Construction of Single Amino Acid Substitution Libraries at Positions 112, 113, 114, 115, 116 and 117

One of the DNA fragments used to construct the plasmids containing single amino acid substitutions at positions 112, 113, 114, 115, 116 and 117 of hIL-3 was generated by site-directed mutagenesis employing PCR techniques described previously. In the PCR reaction the plasmid pMON6478 DNA was the template and the following 32 fold degenerate oligonucleotides, Oligo #127, Oligo #128, Oligo #129, Oligo #130, Oligo #131 and Oligo #132, were the primers at the C-terminus. The oligonucleotide, Oligo #7, was used as the primer at the N-terminus, The degenerate oligonucleotides replace the eighteen bases, encoding six amino acids, deleted in pMON6478. The degenerate oligonucleotides have G, A, T or C in the first and second positions and G or C in the third position of a single codon at amino acid positions 112, 113, 114, 115, 116 and 117 of hIL-3 respectively. These degenerate oligonucleotide primers result in libraries which theoretically contain 32 different codons encoding all 20 amino acid substitutions and one translational stop codon at one position. At the other five amino acid positions the native hIL-3 DNA sequence was restored. The resulting PCR-generated DNA products were purified and digested with the restriction enzymes HindIII and NcoI. Plasmid pMON6478 was digested with restriction enzymes HindIII and NcoI and the resulting 3944 base pair fragment was ligated to the PCR-generated HindIII, NcoI DNA fragments. Transformant bacteria were screened by DNA dot blot differential hybridization using the oligonucleotide probe, Oligo #153, which had been labeled with P 32 . Clones shown to be positive by colony hybridization were selected, plasmid DNA isolated and DNA sequenced to determine the amino acid substitution.

›EXAMPLE 53

Construction of Single Amino Acid Substitution Libraries at Positions 118, 119, 120, 121, 122 and 123

One of the DNA fragments used to construct the plasmids containing single amino acid substitutions at positions 118, 119, 120, 121, 122 and 123 of hIL-3 was generated by site-directed mutagenesis employing PCR techniques described previously. In the PCR reaction the plasmid pMON6479 DNA was the template and the following 32 fold degenerate oligonucleotides, Oligo #133, Oligo #134, Oligo #135, oligo #136, Oligo #137 and Oligo #138, were the primers at the C-terminus. The oligonucleotide, Oligo #7, was used as the primer at the N-terminus. The degenerate oligonucleotides replace the eighteen bases, encoding six amino acids, deleted in pMON6479. The degenerate oligonucleotides have G, A, T or C in the first and second positions and G or C in the third position of a single codon at amino acid positions 118, 119, 120, 121, 122 and 123 of hIL-3 respectively. These degenerate oligonucleotide primers result in libraries which theoretically contain 32 different codons encoding all 20 amino acid substitutions and one translational stop codon at one position. At the other five amino acid positions the native hIL-3 DNA sequence was restored. The resulting PCR-generated DNA products were purified and digested with the restriction enzymes HindIII and NcoI. Plasmid pMON6479 DNA was digested with restriction enzymes HindIII and NcoI and the resulting 3944 base pair fragment was ligated to the PCR-generated HindIII, NcoI DNA fragments. Transformant bacteria were screened by DNA dot blot differential hybridization using the oligonucleotide probe, Oligo #154, which had been labeled with P 32 . Clones shown to be positive by colony hybridization were selected, plasmid DNA isolated and DNA sequenced to determine the amino acid substitution.

›EXAMPLE 54

Construction of pMON13358

Plasmid pMON5978 DNA (Example 6) was digested with restriction enzymes NsiI and EcoRI and the resulting 3853 base pair NsiI,EcoRI fragment contains the following genetic elements; beta-lactamase gene (AMP), pBR327 origin of replication, phage f1 origin of replication as the transcription terminator, recA promoter, g10L ribosome binding site and the bases encoding amino acids 15-71 and 106-125 of (15-125) hIL-3. The 3853 base pair NsiI,EcoRI restriction fragment from pMON5978 was ligated to the following annealed complementary oligonucleotides.

Oligo #15(A) [SEQ ID NO: 29]

Oligo #16(A) [SEQ ID NO: 30]

In the resulting plasmid the 111 bases between the NsiI and EcoRI restriction sites in the (15-125) hIL-3 gene are replaced with 24 bases from the above mentioned oligonucleotides. This linker also creates a NdeI recognition sequence.

›EXAMPLE 55

Construction of pMON13304

Plasmid pMON13358 DNA is digested with restriction enzymes PstI and EcoRI and the resulting 3846 base pair PstI,EcoRI fragment contains the following genetic elements; beta-lactamase gene (AMP), pBR327 origin of replication, phage f1 origin of replication as the transcription terminator, recA promoter, g10L ribosome binding site and the bases encoding amino acids 15-69 and 106-125 of (15-125) hIL-3. The 3846 base pair NsiI,EcoRI restriction fragment from pMON13358 is ligated to the following annealed complementary oligonucleotides.

When assembled, the oligonucleotides create PstI and EcoRI restriction ends and the DNA sequence that encodes amino acids 70-105 of (15-125) hIL-3 with the following amino acid substitutions; 98I and 100R. The codons encoding amino acids 70-105 of (15-125) hIL-3 are those found in the hIL-3 cDNA sequence except at those positions where amino acid substitutions were made. The plasmid, pMON13304, encodes the (15-125) hIL-3 variant with the following amino acid sequence:

Peptide #A1 [SEQ ID NO:66]

›EXAMPLE 56

Construction of pMON13305

Plasmid pMON13358 DNA is digested with restriction enzymes PstI and EcoRI and the resulting 3846 base pair PstI, EcoRI fragment contains the following genetic elements; beta-lactamase gene (AMP), pBR327 origin of replication, phage f1 origin of replication as the transcription terminator, recA promoter, g10L ribosome binding site and the bases encoding amino acids 15-69 and 106-125 of (15-125) hIL-3. The 3846 base pair NsiI,EcoRI restriction fragment from pMON13358 is ligated to the following annealed complementary oligonucleotides.

When assembled, the oligonucleotides create PstI and EcoRI restriction ends and the DNA sequence that encodes amino acids 70-105 of (15-125) hIL-3 with the following amino acid substitutions; 95R, 98I and 100R. The codons encoding amino acids 70-105 of (15-125) hIL-3 are those found in the hIL-3 cDNA sequence except at those positions where amino acid substitutions were made. The plasmid, pMON13305, encodes the (15-125) hIL-3 variant with the following amino acid sequence:

Peptide #A2 [SEQ ID NO:67]

›EXAMPLE 57

Construction of pMON13286

Plasmid pMON5978 DNA was digested with restriction enzymes NcoI and EcoRV and the resulting 3865 base pair NcoI,EcoRV fragment contains the following genetic elements; beta-lactamase gene (AMP), pBR327 origin of replication, phage f1 origin of replication as the transcription terminator, precA promoter, g10L ribosome binding site and the bases encoding amino acids 47-125 of (1-125) hIL-3. The 3865 base pair NcoI,EcoRV restriction fragment from pMON5978 was ligated to the following annealed complementary oligonucleotides.

When assembled, the oligonucleotides create NcoI and EcoRV restriction ends and the DNA sequence that encodes amino acids 15-46 of (15-125) hIL-3 with the following amino acid substitutions; 42D, 45M and 46S. The codons encoding amino acids 15-46 of (15-125) hIL-3 are those found in the hIL-3 cDNA sequence except at those positions where amino acid substitutions were made. The plasmid, pMON13286, encodes the (15-125) hIL-3 variant with the following amino acid sequence:

›EXAMPLE 58

Construction of pMON5853 (FIG. 6) which Encodes [Met-(15-133) hIL-3 (Arg129)]

Plasmid DNA of pMON5847 (Example 2) was treated with NcoI. The restriction enzyme was inactivated by heat treatment (65° C. for 10 minutes). The DNA was then treated with large fragment of DNA polymerase I (Klenow) in the presence of all four nucleotide precursors. This produces DNA termini with non-overlapping ends. After 5 minutes at 37° C., the polymerase was inactivated by heat treatment at 65° C. for 10 minutes. The DNA was then treated with HpaI, an enzyme which produces non-overlapping termini. The DNA was ethanol precipitated and ligated. The ligation reaction mixture was used to transform competent JM101 cells to ampicillin resistance. Colonies were picked and plasmid DNA was analyzed by restriction analysis. A plasmid designated pMON5853 was identified as one containing a deletion of the amino terminal 14 codons of the hIL-3 gene. The DNA sequence for the junction of the ribosome binding site to the (15-133) hIL-3 gene was determined to be the following:

The lower line contains the one-letter code for the amino acids specified by the coding sequence of the amino terminus of the 15-133 hIL-3 gene. These are methionine, asparagine, cysteine, serine and asparagine.

When cultures of JM101 cells harboring this plasmid were induced with nalidixic acid, it was found that hIL-3 (15-133) accumulated at levels higher than hIL-3 (pMON5847).

The plasmid, pMON5853, encodes Met-(15-133) hIL-3 (Arg 129 ) which has the following amino acid sequence:

Met Asn Cys Ser Asn Met Ile Asp Glu Ile Ile

Ile Thr His Leu Lys Gln Pro Pro Leu Pro Leu Leu

Asp Phe Asn Asn Leu Asn Gly Glu Asp Gln Asp Ile

Leu Met Glu Asn Asn Leu Arg Arg Pro Asn Leu Glu

Ala Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala

Ser Ala Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro

Cys Leu Pro Leu Ala Thr Ala Ala Pro Thr Arg His

Pro Ile His Ile Lys Asp Gly Asp Trp Asn Glu Phe

Arg Arg Lys Leu Thr Phe Tyr Leu Lys Thr Leu Glu

Asn Ala Gln Ala Gln Gln Thr Thr Leu Arg Leu Ala

Ile Phe [SEQ ID NO:135]

Formula XI shown below is a representation of a [(15-125) hIL-3 mutein] with numbers in bold type added above the amino acids to represent the position at which the amino acid below the bolded number appears in native (1-133) hIL-3 [e.g. the amino acid at position 1 of Formula XI corresponds to the Asn which appears at position 15 in native (1-133) hIL-3]. The number shown in bold indicates the amino acids that correspond to the native IL-3(1-133). The non-bold members below the amino acids sequences are for Seq Id reference numbers. When the muteins are expressed the initial amino acid may be preceded by Met- or Met-Ala-.

Table 6 shows (15-125) hIL-3 muteins of the present invention which have one (and in some cases two) amino acid substitutions in the (15-125) hIL-3 polypeptide and which were constructed as described in the Examples. The mutants in Table 6 were secreted into the periplasmic space in E. coli. The periplasmic content was released by osmotic shock and the material in the crude osmotic shock fraction was screened for growth promoting activity. Biological activity is the growth promoting activity of AML cells relative to (15-125) hIL-3 (pMON6458 or pMMON5988). The numbers in parentheses indicate the number of repeat assays. When a variant was assayed more than once the standard deviation is indicated. An “-” indicates that the hIL3 variant protein level was less than 1.0 μg/ml and was not screened for growth promoting activity.

The mutants in Table 6 were made as described in the Examples, particularly Examples 19, 20, 21 and 38 to 53.

It will be apparent to those skilled in the art that other codons besides those shown in Table 6 can also code for the substituted amino acids in the hIL-3 muteins. The present invention includes the DNAs encoding the mutant hIL-3 polypeptides of the invention including the various codons which can code for the parental and substituted amino acids of the hIL-3 muteins of the invention due to the degeneracy of the genetic code.

hIL-3 (15-125) variant genes encoding the variants listed in Table 6 can also be expressed from intracellular expression vectors to produce large quantities of the variant protein which can be purified and assayed for biological activity. The hIL-3 variant genes, from Table 6, can be excised from the secretion expression vector, as a 345 base pair NcoI/HindIII fragment and ligated into an appropriate intracellular expression vector, such as pMON2341 digested with NcoI and HindIII. Examples of variants transferred to pMON2341 in this manner are shown in Table 7. Two examples of such a transfer are described. in the construction of pMON13215 (EXAMPLE 64) and pMON13252 (EXAMPLE 65).

›EXAMPLE 64

Construction of pMON13215

Plasmid, pMON2341, DNA was digested with restriction enzymes NcoI and HindIII resulting in a 3619 base pair NcoI/HindIII fragment. The genetic elements derived from pMON2341 are the beta-lactamase gene (AMP), pBR327 origin of replication, F1 phage origin of replication as the transcription terminator, precA, g10L ribosome binding site. The plasmid encoding the hIL-3 (15-125) Trp (116) variant, from Table 6 wag digested with NcoT and HindIII resulting in a 345 base pair NcoI/HindIII fragment. The 345 Base pair NcoI/HindIII fragment was ligated with the 3619 base pair fragment from pMON2341 and the ligation reaction mixture was used to transform E.coli K-12 strain JM101. Plasmid DNA was isolated and screened by restriction anaylsis using NcoI and HindIII. Positive clones contained a 345 base pair NcoI/HindIII. This construct was designated PMON132I5. The plasmid, pMON13215, encodes the (15-125) hIL-3 variant with the following amino acid sequence:

PEPTIDE A9; (15-125)HIL-3 TRP (116) PMON13215

›EXAMPLE 65

Construction of pMON13252

Plasmid, pMON2341, DNA was digested with restriction enzymes NcoI and HindIII resulting in a 3619 base pair NcoI/HindIII fragment. The genetic elements derived from pMON2341 are the beta-lactamase gene (AMP), pBR327 origin of replication F1 phage origin of replication as the transcription terminator, precA, g10L ribosome binding site. The plasmid encoding the hIL-3 (15-125) Asp ( 50) variant, from Table 6, was digested with NcoI and HindIII resulting in a 345 base pair NcoI/HindIII fragment. This 345 Base pair NcoI/HindIII fragment was ligated with the 3619 base pair fragment from pMON2341 and the ligation reaction mixture was used to transform E. coli K-12 strain JM101. Plasmid DNA was isolated and screened by restriction analysis using NcoI and HindIII. Positive clones contained a 345 base pair NcoI/HindIII. This construct was designated pMON13252. The plasmid, pMON13252, encodes the (15-125) hIL-3 variant with the following amino acid sequence:

PEPTIDE A10; (15-125)HIL-3 ASP (50) pMON13252

Table 7 shows the biological activity of (15-125) hIL-3 mutant polypeptides of the present invention expressed from Intracellular expression vectors. Upon expression these muteins may have Met- or Met-Ala-preceding the initial (15-125) hIL-3 amino acid. The relative biological activity of IL-3 mutants is calculated by dividing the EC 50 (1-133) hIL-3 by the EC 50 of the mutant.

›EXAMPLE 66 · 1 of 12

The variants in Table 8 were constructed by cassette mutagenesis using methods described in the Materials and Methods and the Examples contained herein, particularly Examples 54-57. Parental plasmid DNA (Table 8), digested with the appropriate restriction enzymes (Table 8), was ligated with the indicated annealed pairs of complementary oligonucleotides (Table 8). The assembled oligonucleotides create appropriate restriction ends and a portion of the (15-125) hIL-3 gene sequence Individual isolates were screened by restriction analysis and DNA sequenced to confirm that the desired changes in the (15-125) hIL-3 variant gene were made. The oligonucleotides create change(s) in the (15-125) hIL-3 gene which enclode the corresponding amino acid substitution in the variant polypeptide (Table 8). The amino acids substitutions in polypeptide #1 (SEQ ID NO:65) are indicated in Table 8.

It will be apparent to those skilled in the art that other codons besides those shown in Table 8 can also code for the substituted amino acids in the hIL-3 muteins. The present invention includes the DNAs encoding the mutant hIL-3 polypeptides of the invention including the various codons which can code for the parental and substituted amino acids of the hIL-3 muteins of the invention due to the degeneracy of the genetic code.

hIL-3 (15-125) variant genes encoding the variants listed in Table 8 can also be expressed from intracellular expression vectors to produce large quantities of the variant protein which can be purified and assayed for biological activity. The hIL-3 variant genes, from Table 8, can be excised from the secretion expression vector, as a 345 base pair NcoI/HindIII fragment and ligated into an appropriate intrecellular expression vector, such as pMON2341 digested with NcoI and HindIII.

Table 9 shows the biological activity of (15-125) hIL-3 muteins of the present invention which have one amino acid substitutions in the (15-125) hIL-3 polypeptide and which were constructed as described in Example 66. The mutants in Table 9 were secreted into the periplasmic space in E. coli. The periplasmic content was released by osmotic shock and the material in the crude osmotic shock fraction was screened for growth promoting activity. Biological activity is the growth promoting activity of AML cells relative to (1-125) hIL-3 (pMON6458 or pMMON5988). The relative biological activity of IL-3 mutants is calculated by dividing the EC 50 (1-133) hIL-3 by the EC 50 of the mutant. The numbers in parentheses indicate the number of repeat assays. When a variant was assayed more than once the standard deviation is indicated. An “*” 0 indicates that the hIL3 variant protein level was less than 1.0 μg/ml and was not screened for growth promoting activity.

CTAGCGATCT TTTAATAAGC TTG 23

23 base pairs

nucleic acid

single

linear

DNA (synthetic)

2

GATCCAAGCT TATTAAAAGA TCG 23

69 base pairs

nucleic acid

single

linear

DNA (synthetic)

3

GGCAACAATT TCTACAAAAC ACTTGATACT GTATGAGCAT ACAGTATAAT TGCTTCAACA 60

GAACAGATC 69

67 base pairs

nucleic acid

single

linear

DNA (synthetic)

4

TGTTCTGTTG AAGCAATTAT ACTGTATGCT CATACAGTAT CAAGTGTTTT GTAGAAATTG 60

TTGCCGC 67

23 base pairs

nucleic acid

single

linear

DNA (synthetic)

5

CCATTGCTGC CGGCATCGTG GTC 23

46 base pairs

nucleic acid

single

linear

DNA (synthetic)

6

CATGGCTCCA ATGACTCAGA CTACTTCTCT TAAGACTTCT TGGGTT 46

42 base pairs

nucleic acid

single

linear

DNA (synthetic)

7

AACCCAAGAA GTCTTAAGAG AAGTAGTCTG AGTCATTGGA GC 42

64 base pairs

nucleic acid

single

linear

DNA (synthetic)

8

AATTCCGTCG TAAACTGACC TTCTATCTGA AAACCTTGGA GAACGCGCAG GCTCAACAGT 60

AATA 64

64 base pairs

nucleic acid

single

linear

DNA (synthetic)

9

AGCTTATTAC TGTTGAGCCT GCGCGTTCTC CAAGGTTTTC AGATAGAAGG TCAGTTTACG 60

ACGG 64

126 amino acids

amino acid

linear

peptide

10

Met Ala Pro Met Thr Gln Thr Thr Ser Leu Lys Thr Ser Trp Val Asn

1 5 10 15

Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu Lys Gln Pro Pro

20 25 30

Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly Glu Asp Gln Asp Ile

35 40 45

Leu Met Glu Asn Asn Leu Arg Arg Pro Asn Leu Glu Ala Phe Asn Arg

50 55 60

Ala Val Lys Ser Leu Gln Asn Ala Ser Ala Ile Glu Ser Ile Leu Lys

65 70 75 80

Asn Leu Leu Pro Cys Leu Pro Leu Ala Thr Ala Ala Pro Thr Arg His

85 90 95

Pro Ile His Ile Lys Asp Gly Asp Trp Asn Glu Phe Arg Arg Lys Leu

100 105 110

Thr Phe Tyr Leu Lys Thr Leu Glu Asn Ala Gln Ala Gln Gln

115 120 125

24 base pairs

nucleic acid

single

linear

DNA (synthetic)

11

CATGGCTAAC TGCTCTAACA TGAT 24

22 base pairs

nucleic acid

single

linear

DNA (synthetic)

12

CGATCATGTT AGAGCAGTTA GC 22

113 amino acids

amino acid

linear

peptide

13

Met Ala Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu Lys

1 5 10 15

Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly Glu Asp

20 25 30

Gln Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn Leu Glu Ala

35 40 45

Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser Ala Ile Glu Ser

50 55 60

Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu Ala Thr Ala Ala Pro

65 70 75 80

Thr Arg His Pro Ile His Ile Lys Asp Gly Asp Trp Asn Glu Phe Arg

85 90 95

Arg Lys Leu Thr Phe Tyr Leu Lys Thr Leu Glu Asn Ala Gln Ala Gln

100 105 110

Gln

27 amino acids

amino acid

linear

peptide

14

Met Met Ile Thr Leu Arg Lys Leu Pro Leu Ala Val Ala Val Ala Ala

1 5 10 15

Gly Val Met Ser Ala Gln Ala Met Ala Asn Cys

20 25

Ala Pro Met Thr Gln Thr Thr Ser Leu Lys Thr Ser Trp Val Asn Cys

1 5 10 15

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

20 25 30

Xaa Xaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

35 40 45

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

50 55 60

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

65 70 75 80

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

85 90 95

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Phe Xaa Xaa Xaa Xaa Xaa

100 105 110

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gln Gln Thr Thr Leu

115 120 125

Ser Leu Ala Ile Phe

130

Ala Pro Met Thr Gln Thr Thr Ser Leu Lys Thr Ser Trp Val Asn Cys

1 5 10 15

Xaa Xaa Xaa Xaa Xaa Glu Xaa Xaa Xaa Xaa Leu Xaa Xaa Xaa Xaa Xaa

20 25 30

Xaa Xaa Xaa Xaa Xaa Xaa Asn Leu Xaa Xaa Glu Xaa Xaa Xaa Xaa Leu

35 40 45

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Leu Xaa Xaa Xaa Xaa Xaa Xaa

›EXAMPLE 66 · 2 of 12

50 55 60

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Leu Xaa Xaa

65 70 75 80

Xaa Xaa Xaa Cys Xaa Pro Xaa Xaa Xaa Xaa Xaa Xaa Xaa Arg Xaa Xaa

85 90 95

Xaa Xaa Xaa Xaa Xaa Xaa Asp Xaa Xaa Xaa Phe Xaa Xaa Lys Leu Xaa

100 105 110

Phe Xaa Xaa Xaa Xaa Leu Xaa Xaa Xaa Xaa Xaa Gln Gln Thr Thr Leu

115 120 125

Ser Leu Ala Ile Phe

130

Ala Pro Met Thr Gln Thr Thr Ser Leu Lys Thr Ser Trp Val Asn Cys

1 5 10 15

Xaa Xaa Xaa Ile Xaa Glu Xaa Xaa Xaa Xaa Leu Lys Xaa Xaa Xaa Xaa

20 25 30

Xaa Xaa Xaa Asp Xaa Xaa Asn Leu Asn Xaa Glu Xaa Xaa Xaa Ile Leu

35 40 45

Met Xaa Xaa Asn Leu Xaa Xaa Xaa Asn Leu Glu Xaa Phe Xaa Xaa Xaa

50 55 60

Xaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Ile Glu Xaa Xaa Leu Xaa Xaa

65 70 75 80

Leu Xaa Xaa Cys Xaa Pro Xaa Xaa Thr Ala Xaa Pro Xaa Arg Xaa Xaa

85 90 95

Xaa Xaa Xaa Xaa Xaa Gly Asp Xaa Xaa Xaa Phe Xaa Xaa Lys Leu Xaa

100 105 110

Phe Xaa Xaa Xaa Xaa Leu Glu Xaa Xaa Xaa Xaa Gln Gln Thr Thr Leu

115 120 125

Ser Leu Ala Ile Phe

130

Ala Pro Met Thr Gln Thr Thr Ser Leu Lys Thr Ser Trp Val Asn Cys

1 5 10 15

Xaa Xaa Met Ile Asp Glu Xaa Ile Xaa Xaa Leu Lys Xaa Xaa Pro Xaa

20 25 30

Pro Xaa Xaa Asp Phe Xaa Asn Leu Asn Xaa Glu Asp Xaa Xaa Ile Leu

35 40 45

Met Xaa Xaa Asn Leu Arg Xaa Xaa Asn Leu Glu Ala Phe Xaa Arg Xaa

50 55 60

Xaa Lys Xaa Xaa Xaa Asn Ala Ser Ala Ile Glu Xaa Xaa Leu Xaa Xaa

65 70 75 80

Leu Xaa Pro Cys Leu Pro Xaa Xaa Thr Ala Xaa Pro Xaa Arg Xaa Pro

85 90 95

Ile Xaa Xaa Xaa Xaa Gly Asp Trp Xaa Glu Phe Xaa Xaa Lys Leu Xaa

100 105 110

Phe Tyr Leu Xaa Xaa Leu Glu Xaa Xaa Xaa Xaa Gln Gln Thr Thr Leu

115 120 125

Ser Leu Ala Ile Phe

130

Asn Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

1 5 10 15

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Xaa Xaa Xaa Xaa

20 25 30

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

35 40 45

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

50 55 60

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

65 70 75 80

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Phe Xaa Xaa Xaa

85 90 95

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gln Gln

100 105 110

Asn Cys Xaa Xaa Xaa Xaa Xaa Glu Xaa Xaa Xaa Xaa Leu Xaa Xaa Xaa

1 5 10 15

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Leu Xaa Xaa Glu Xaa Xaa Xaa

20 25 30

Xaa Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Leu Xaa Xaa Xaa Xaa

35 40 45

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Leu

50 55 60

Xaa Xaa Xaa Xaa Xaa Cys Xaa Pro Xaa Xaa Xaa Xaa Xaa Xaa Xaa Arg

65 70 75 80

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asp Xaa Xaa Xaa Phe Xaa Xaa Lys

85 90 95

Leu Xaa Phe Xaa Xaa Xaa Xaa Leu Xaa Xaa Xaa Xaa Xaa Gln Gln

100 105 110

Asn Cys Xaa Xaa Xaa Ile Xaa Glu Xaa Xaa Xaa Xaa Leu Lys Xaa Xaa

1 5 10 15

Xaa Xaa Xaa Xaa Xaa Asp Xaa Xaa Asn Leu Asn Xaa Glu Xaa Xaa Xaa

20 25 30

Ile Leu Met Xaa Xaa Asn Leu Xaa Xaa Xaa Asn Leu Glu Xaa Phe Xaa

35 40 45

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Ile Glu Xaa Xaa Leu

50 55 60

Xaa Xaa Leu Xaa Xaa Cys Xaa Pro Xaa Xaa Thr Ala Xaa Pro Xaa Arg

65 70 75 80

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Asp Xaa Xaa Xaa Phe Xaa Xaa Lys

85 90 95

Leu Xaa Phe Xaa Xaa Xaa Xaa Leu Glu Xaa Xaa Xaa Xaa Gln Gln

100 105 110

Asn Cys Xaa Xaa Met Ile Asp Glu Xaa Ile Xaa Xaa Leu Lys Xaa Xaa

1 5 10 15

Pro Xaa Pro Xaa Xaa Asp Phe Xaa Asn Leu Asn Xaa Glu Asp Xaa Xaa

20 25 30

Ile Leu Met Xaa Xaa Asn Leu Arg Xaa Xaa Asn Leu Glu Ala Phe Xaa

35 40 45

Arg Xaa Xaa Lys Xaa Xaa Xaa Asn Ala Ser Ala Ile Glu Xaa Xaa Leu

50 55 60

Xaa Xaa Leu Xaa Pro Cys Leu Pro Xaa Xaa Thr Ala Xaa Pro Xaa Arg

65 70 75 80

Xaa Pro Ile Xaa Xaa Xaa Xaa Gly Asp Trp Xaa Glu Phe Xaa Xaa Lys

85 90 95

Leu Xaa Phe Tyr Leu Xaa Xaa Leu Glu Xaa Xaa Xaa Xaa Gln Gln

100 105 110

Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu Lys Gln Pro

1 5 10 15

Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly Glu Asp Gln Asp

20 25 30

Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn Leu Glu Ala Phe Asn

35 40 45

Arg Ala Val Lys Ser Leu Gln Asn Ala Ser Ala Ile Glu Ser Ile Leu

50 55 60

Lys Asn Leu Leu Pro Cys Leu Pro Leu Ala Thr Ala Ala Pro Thr Arg

65 70 75 80

His Pro Ile His Ile Lys Asp Gly Asp Trp Asn Glu Phe Arg Arg Lys

85 90 95

Leu Thr Phe Tyr Leu Lys Thr Leu Glu Asn Ala Gln Ala Gln Gln

100 105 110

58 base pairs

nucleic acid

single

linear

DNA (synthetic)

24

CTAGCCACGG CCGCACCCAC GCGACATCCA ATCCATATCA AGGACGGTGA CTGGAATG 58

58 base pairs

nucleic acid

single

linear

DNA (synthetic)

25

TTAACATTCC AGTCACCGTC CTTGATATGG ATTGGATGTC GCGTGGGTGC GGCCGTGG 58

20 base pairs

nucleic acid

single

linear

DNA (synthetic)

26

TGTCTGCTCA GGCCATGGCT 20

67 base pairs

nucleic acid

single

linear

DNA (synthetic)

27

GCGCGAATTC ATTCCAGTCA CCGTCCTTGA TATGGTCGAC TTATTACGTG GGTGCGGCCG 60

TGGCTAG 67

55 base pairs

nucleic acid

single

linear

DNA (synthetic)

28

GCGCGAATTC ATTCCAGTCA CCGTCGACTT ATTAGATTGG ATGTCGCGTG GGTGC 55

16 base pairs

nucleic acid

single

linear

DNA (synthetic)

29

TGAACCATAT GTCAGG 16

24 base pairs

nucleic acid

single

linear

DNA (synthetic)

30

AATTCCTGAC ATATGGTTCA TGCA 24

43 base pairs

nucleic acid

single

linear

DNA (synthetic)

31

GCGCGAATTC GTCGACTTAT TAGTCCTTGA TATGGATTGG ATG 43

67 base pairs

nucleic acid

single

linear

DNA (synthetic)

32

GCGCGAATTC ATTCCAGTCA CCGTCCTTGA TATGGATTGG ATGSNNCGTG GGTGCGGCCG 60

TGGCTAG 67

64 base pairs

nucleic acid

single

linear

DNA (synthetic)

33

GCGCGAATTC ATTCCAGTCA CCGTCCTTGA TATGGATTGG SNNTCGCGTG GGTGCGGCCG 60

TGGC 64

61 base pairs

nucleic acid

single

linear

DNA (synthetic)

34

GCGCGAATTC ATTCCAGTCA CCGTCCTTGA TATGGATSNN ATGTCGCGTG GGTGCGGCCG 60

T 61

58 base pairs

nucleic acid

single

linear

DNA (synthetic)

35

GCGCGAATTC ATTCCAGTCA CCGTCCTTGA TATGSNNTGG ATGTCGCGTG GGTGCGGC 58

24 base pairs

nucleic acid

single

linear

DNA (synthetic)

36

GATATGGATT GGATGTCGCG TGGG 24

55 base pairs

nucleic acid

single

linear

DNA (synthetic)

37

GCGCGAATTC ATTCCAGTCA CCGTCCTTGA TSNNGATTGG ATGTCGCGTG GGTGC 55

52 base pairs

nucleic acid

single

linear

DNA (synthetic)

38

GCGCGAATTC ATTCCAGTCA CCGTCCTTSN NATGGATTGG ATGTCGCGTG GG 52

49 base pairs

nucleic acid

single

linear

DNA (synthetic)

39

GCGCGAATTC ATTCCAGTCA CCGTCSNNGA TATGGATTGG ATGTCGCGT 49

46 base pairs

nucleic acid

single

linear

DNA (synthetic)

40

GCGCGAATTC ATTCCAGTCA CCSNNCTTGA TATGGATTGG ATGTCG 46

24 base pairs

nucleic acid

single

linear

DNA (synthetic)

41

GTCACCGTCC TTGATATGGA TTGG 24

43 base pairs

nucleic acid

single

›EXAMPLE 66 · 3 of 12

linear

DNA (synthetic)

42

GCGCGAATTC ATTCCAGTCS NNGTCCTTGA TATGGATTGG ATG 43

40 base pairs

nucleic acid

single

linear

DNA (synthetic)

43

GCGCGAATTC ATTCCASNNA CCGTCCTTGA TATGGATTGG 40

37 base pairs

nucleic acid

single

linear

DNA (synthetic)

44

GCGCGAATTC ATTSNNGTCA CCGTCCTTGA TATGGAT 37

34 base pairs

nucleic acid

single

linear

DNA (synthetic)

45

GCGCGAATTC SNNCCAGTCA CCGTCCTTGA TATG 34

25 base pairs

nucleic acid

single

linear

DNA (synthetic)

46

GAATTCATTC CAGTCACCGT TCCTT 25

26 base pairs

nucleic acid

single

linear

DNA (synthetic)

47

CGCGCGGAAT TCATTCCAGT CACCGT 26

42 base pairs

nucleic acid

single

linear

DNA (synthetic)

48

CGCGCGCCAT GGCTAACTGC ATTATAACAC ACACTTAAAG CA 42

58 base pairs

nucleic acid

single

linear

DNA (synthetic)

49

CGCGCGCCAT GGCTAACTGC TCTAACATGA TCGATGAACA GCCACCTTTG CCTTTGCT 58

76 base pairs

nucleic acid

single

linear

DNA (synthetic)

50

CGCGCGCCAT GGCTAACTGC TCTAACATGA TCGATGAAAT TATAACACAC TTAAAGCTGG 60

ACTTCAACAA CCTCAA 76

50 base pairs

nucleic acid

single

linear

DNA (synthetic)

51

GCGCGCGATA TCTTGGTCTT CTTCACCATT CAGCGGCAGC GGTGGCTGCT 50

65 base pairs

nucleic acid

single

linear

DNA (synthetic)

52

GCGCGCCTCG AGGTTTGGAC GACGAAGGTT ATTTTCCATC AGGATGAGGT TGTTGAAGTC 60

CAGCA 65

47 base pairs

nucleic acid

single

linear

DNA (synthetic)

53

GCGCGCCTCG AGGTTTGGAC GACGAAGATC TTGGTCTTCA CCATTGA 47

68 base pairs

nucleic acid

single

linear

DNA (synthetic)

54

GCGCGCTGAT GCATTCTGCA GAGACTTGAC AGCACGGTTG AATGCCTCGT TATTTTCCAT 60

CAGGATAT 68

50 base pairs

nucleic acid

single

linear

DNA (synthetic)

55

GCGCGCTGAT GCATTCTGCA GAGACTTGAC GAGGTTTGGA CGACGAAGGT 50

47 base pairs

nucleic acid

single

linear

DNA (synthetic)

56

GCGCGCCTCG AGGCATTCAA CCGTGCTGCA TCAGCAATTG AGAGCAT 47

35 base pairs

nucleic acid

single

linear

DNA (synthetic)

57

GCGCGCCTGC AGAATATTCT TAAAAATCTC CTGCC 35

53 base pairs

nucleic acid

single

linear

DNA (synthetic)

58

GCGCGCCTGC AGAATGCATC AGCAATTGAG AGCCCATGTC TGCCGCTAGC CAC 53

71 base pairs

nucleic acid

single

linear

DNA (synthetic)

59

GCGCGCCTGC AGAATGCATC AGCAATTGAG AGCATTCTTA AAAATCTCCT GACGGCCGCA 60

CCCACGCGAC A 71

67 base pairs

nucleic acid

single

linear

DNA (synthetic)

60

CGCGCGGAAT TCATTCCAGT CACCGTCCTT GATATGGATT GGATGTCGCA GGGCAGACAT 60

GGCAGGA 67

78 base pairs

nucleic acid

single

linear

DNA (synthetic)

61

CGCGCGAAGC TTATTACTGT TGAGCCTGCG CGTTCTCCAA GGTTTTCAGA TAGAAGGTAT 60

TCCAGTCACC GTCCTTGA 78

60 base pairs

nucleic acid

single

linear

DNA (synthetic)

62

CGCGCGAAGC TTATTACTGT TGAGCCTGCG CGTTCTCCAA CAGTTTACGA CGGAATTCAT 60

42 base pairs

nucleic acid

single

linear

DNA (synthetic)

63

CGCGCGAAGC TTATTACTGT TGGGTTTTCA GATAGAAGGT CA 42

58 base pairs

nucleic acid

single

linear

DNA (synthetic)

64

CGCGCGCCAT GGCTAACTGC NNSAACATGA TCGATGAAAT TATAACACAC TTAAAGCA 58

111 amino acids

amino acid

linear

peptide

65

Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu Lys Gln Pro

1 5 10 15

Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly Glu Asp Gln Asp

20 25 30

Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn Leu Glu Ala Phe Asn

35 40 45

Arg Ala Val Lys Ser Leu Gln Asn Ala Ser Ala Ile Glu Ser Ile Leu

50 55 60

Lys Asn Leu Leu Pro Cys Leu Pro Leu Ala Thr Ala Ala Pro Thr Arg

65 70 75 80

His Pro Ile His Ile Lys Asp Gly Asp Trp Asn Glu Phe Arg Arg Lys

85 90 95

Leu Thr Phe Tyr Leu Lys Thr Leu Glu Asn Ala Gln Ala Gln Gln

100 105 110

113 amino acids

amino acid

linear

peptide

66

Met Ala Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu Lys

1 5 10 15

Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly Glu Asp

20 25 30

Gln Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn Leu Glu Ala

35 40 45

Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser Ala Ile Glu Ser

50 55 60

Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu Ala Thr Ala Ala Pro

65 70 75 80

Thr Arg His Pro Ile Ile Ile Arg Asp Gly Asp Trp Asn Glu Phe Arg

85 90 95

Arg Lys Leu Thr Phe Tyr Leu Lys Thr Leu Glu Asn Ala Gln Ala Gln

100 105 110

Gln

113 amino acids

amino acid

linear

peptide

67

Met Ala Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu Lys

1 5 10 15

Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly Glu Asp

20 25 30

Gln Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn Leu Glu Ala

35 40 45

Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser Ala Ile Glu Ser

50 55 60

Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu Ala Thr Ala Ala Pro

65 70 75 80

Thr Arg Arg Pro Ile Ile Ile Arg Asp Gly Asp Trp Asn Glu Phe Arg

85 90 95

Arg Lys Leu Thr Phe Tyr Leu Lys Thr Leu Glu Asn Ala Gln Ala Gln

100 105 110

Gln

339 base pairs

nucleic acid

double

linear

DNA (genomic)

68

ATGGCTAACT GCTCTAACAT GATCGATGAA ATCATCACCC ACCTGAAGCA GCCACCGCTG 60

CCGCTGCTGG ACTTCAACAA CCTCAATGAC GAAGACATGT CTATCCTGAT GGAAAATAAC 120

CTTCGTCGTC CAAACCTCGA GGCATTCAAC CGTGCTGTCA AGTCTCTGCA GAATGCATCA 180

GCAATTGAGA GCATTCTTAA AAATCTCCTG CCATGTCTGC CCCTGGCCAC GGCCGCACCC 240

ACGCGACATC CAATCCATAT CAAGGACGGT GACTGGAATG AATTCCGTCG TAAACTGACC 300

TTCTATCTGA AAACCTTGGA GAACGCGCAG GCTCAACAG 339

113 amino acids

amino acid

linear

peptide

69

Met Ala Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu Lys

1 5 10 15

Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Asp Glu Asp

20 25 30

Met Ser Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn Leu Glu Ala

35 40 45

Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser Ala Ile Glu Ser

50 55 60

Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu Ala Thr Ala Ala Pro

65 70 75 80

Thr Arg His Pro Ile His Ile Lys Asp Gly Asp Trp Asn Glu Phe Arg

85 90 95

Arg Lys Leu Thr Phe Tyr Leu Lys Thr Leu Glu Asn Ala Gln Ala Gln

100 105 110

Gln

45 base pairs

nucleic acid

single

linear

DNA (synthetic)

70

CTTTAAGTGT GTTATAATTT CGTTGATCAT GTTAGAGCAG TTAGC 45

40 base pairs

nucleic acid

single

linear

DNA (synthetic)

71

CATGGCTAAC TGCTCTAACA TGATCCAAGA AATTATAACA 40

45 base pairs

nucleic acid

single

linear

DNA (synthetic)

72

CTTTAAGTGT GTTATAATTT CTTGGATCAT GTTAGAGCAG TTAGC 45

40 base pairs

nucleic acid

single

linear

DNA (synthetic)

73

CATGGCTAAC TGCTCTAACA TGATCGAAGA AATTATAACA 40

76 base pairs

nucleic acid

single

linear

DNA (synthetic)

74

CGCGCGCCAT GGCTAACTGC TCTAACATGA TCGATGAAAT TATAACANNS TTAAAGCAGC 60

CACCTTTGCC TTTGCT 76

76 base pairs

nucleic acid

single

linear

DNA (synthetic)

75

CGCGCGCCAT GGCTAACTGC TCTAACATGA TCGATGAAAT TATAACACAC NNSAAGCAGC 60

CACCTTTGCC TTTGCT 76

76 base pairs

nucleic acid

single

linear

DNA (synthetic)

76

CGCGCGCCAT GGCTAACTGC TCTAACATGA TCGATGAAAT TATAACACAC TTANNSCAGC 60

›EXAMPLE 66 · 4 of 12

CACCTTTGCC TTTGCT 76

94 base pairs

nucleic acid

single

linear

DNA (synthetic)

77

CGCGCGCCAT GGCTAACTGC TCTAACATGA TCGATGAAAT TATAACACAC TTAAAGNNSC 60

CACCTTTGCC TTTGCTGGAC TTCAACAACC TCAA 94

94 base pairs

nucleic acid

single

linear

DNA (synthetic)

78

CGCGCGCCAT GGCTAACTGC TCTAACATGA TCGATGAAAT TATAACACAC TTAAAGCAGN 60

NSCCTTTGCC TTTGCTGGAC TTCAACAACC TCAA 94

94 base pairs

nucleic acid

single

linear

DNA (synthetic)

79

CGCGCGCCAT GGCTAACTGC TCTAACATGA TCGATGAAAT TATAACACAC TTAAAGCAGC 60

CANNSTTGCC TTTGCTGGAC TTCAACAACC TCAA 94

94 base pairs

nucleic acid

single

linear

DNA (synthetic)

80

CGCGCGCCAT GGCTAACTGC TCTAACATGA TCGATGAAAT TATAACACAC TTAAAGCAGC 60

CACCTNNSCC TTTGCTGGAC TTCAACAACC TCAA 94

94 base pairs

nucleic acid

single

linear

DNA (synthetic)

81

CGCGCGCCAT GGCTAACTGC TCTAACATGA TCGATGAAAT TATAACACAC TTAAAGCAGC 60

CACCTTTGNN STTGCTGGAC TTCAACAACC TCAA 94

94 base pairs

nucleic acid

single

linear

DNA (synthetic)

82

CGCGCGCCAT GGCTAACTGC TCTAACATGA TCGATGAAAT TATAACACAC TTAAAGCAGC 60

CACCTTTGCC TNNSCTGGAC TTCAACAACC TCAA 94

65 base pairs

nucleic acid

single

linear

DNA (synthetic)

83

GCGCGCGATA TCTTGGTCTT CACCATTGAG GTTGTTGAAG TCSNNCAGCG GCAGCGGTGG 60

CTGCT 65

65 base pairs

nucleic acid

single

linear

DNA (synthetic)

84

GCGCGCGATA TCTTGGTCTT CACCATTGAG GTTGTTGAAS NNCAGCAGCG GCAGCGGTGG 60

CTGCT 65

65 base pairs

nucleic acid

single

linear

DNA (synthetic)

85

GCGCGCGATA TCTTGGTCTT CACCATTGAG GTTGTTSNNG TCCAGCAGCG GCAGCGGTGG 60

CTGCT 65

65 base pairs

nucleic acid

single

linear

DNA (synthetic)

86

GCGCGCGATA TCTTGGTCTT CACCATTGAG GTTSNNGAAG TCCAGCAGCG GCAGCGGTGG 60

CTGCT 65

65 base pairs

nucleic acid

single

linear

DNA (synthetic)

87

GCGCGCGATA TCTTGGTCTT CACCATTGAG SNNGTTGAAG TCCAGCAGCG GCAGCGGTGG 60

CTGCT 65

65 base pairs

nucleic acid

single

linear

DNA (synthetic)

88

GCGCGCGATA TCTTGGTCTT CACCATTSNN GTTGTTGAAG TCCAGCAGCG GCAGCGGTGG 60

CTGCT 65

83 base pairs

nucleic acid

single

linear

DNA (synthetic)

89

GCGCGCCTCG AGGTTTGGAC GACGAAGGTT ATTTTCCATC AGGATATCTT GGTCTTCACC 60

SNNGAGGTTG TTGAAGTCCA GCA 83

83 base pairs

nucleic acid

single

linear

DNA (synthetic)

90

GCGCGCCTCG AGGTTTGGAC GACGAAGGTT ATTTTCCATC AGGATATCTT GGTCTTCSNN 60

ATTGAGGTTG TTGAAGTCCA GCA 83

83 base pairs

nucleic acid

single

linear

DNA (synthetic)

91

GCGCGCCTCG AGGTTTGGAC GACGAAGGTT ATTTTCCATC AGGATATCTT GGTCSNNACC 60

ATTGAGGTTG TTGAAGTCCA GCA 83

83 base pairs

nucleic acid

single

linear

DNA (synthetic)

92

GCGCGCCTCG AGGTTTGGAC GACGAAGGTT ATTTTCCATC AGGATATCTT GSNNTTCACC 60

ATTGAGGTTG TTGAAGTCCA GCA 83

83 base pairs

nucleic acid

single

linear

DNA (synthetic)

93

GCGCGCCTCG AGGTTTGGAC GACGAAGGTT ATTTTCCATC AGGATATCSN NGTCTTCACC 60

ATTGAGGTTG TTGAAGTCCA GCA 83

83 base pairs

nucleic acid

single

linear

DNA (synthetic)

94

GCGCGCCTCG AGGTTTGGAC GACGAAGGTT ATTTTCCATC AGGATSNNTT GGTCTTCACC 60

ATTGAGGTTG TTGAAGTCCA GCA 83

65 base pairs

nucleic acid

single

linear

DNA (synthetic)

95

GCGCGCCTCG AGGTTTGGAC GACGAAGGTT ATTTTCCATC AGSNNATCTT GGTCTTCACC 60

ATTGA 65

65 base pairs

nucleic acid

single

linear

DNA (synthetic)

96

GCGCGCCTCG AGGTTTGGAC GACGAAGGTT ATTTTCCATS NNGATATCTT GGTCTTCACC 60

ATTGA 65

65 base pairs

nucleic acid

single

linear

DNA (synthetic)

97

GCGCGCCTCG AGGTTTGGAC GACGAAGGTT ATTTTCSNNC AGGATATCTT GGTCTTCACC 60

ATTGA 65

65 base pairs

nucleic acid

single

linear

DNA (synthetic)

98

GCGCGCCTCG AGGTTTGGAC GACGAAGGTT ATTSNNCATC AGGATATCTT GGTCTTCACC 60

ATTGA 65

65 base pairs

nucleic acid

single

linear

DNA (synthetic)

99

GCGCGCCTCG AGGTTTGGAC GACGAAGGTT SNNTTCCATC AGGATATCTT GGTCTTCACC 60

ATTGA 65

65 base pairs

nucleic acid

single

linear

DNA (synthetic)

100

GCGCGCCTCG AGGTTTGGAC GACGAAGSNN ATTTTCCATC AGGATATCTT GGTCTTCACC 60

ATTGA 65

86 base pairs

nucleic acid

single

linear

DNA (synthetic)

101

GCGCGCTGAT GCATTCTGCA GAGACTTGAC AGCACGGTTG AATGCCTCGA GGTTTGGACG 60

ACGSNNGTTA TTTTCCATCA GGATAT 86

86 base pairs

nucleic acid

single

linear

DNA (synthetic)

102

GCGCGCTGAT GCATTCTGCA GAGACTTGAC AGCACGGTTG AATGCCTCGA GGTTTGGACG 60

SNNAAGGTTA TTTTCCATCA GGATAT 86

86 base pairs

nucleic acid

single

linear

DNA (synthetic)

103

GCGCGCTGAT GCATTCTGCA GAGACTTGAC AGCACGGTTG AATGCCTCGA GGTTTGGSNN 60

ACGAAGGTTA TTTTCCATCA GGATAT 86

86 base pairs

nucleic acid

single

linear

DNA (synthetic)

104

GCGCGCTGAT GCATTCTGCA GAGACTTGAC AGCACGGTTG AATGCCTCGA GGTTSNNACG 60

ACGAAGGTTA TTTTCCATCA GGATAT 86

86 base pairs

nucleic acid

single

linear

DNA (synthetic)

105

GCGCGCTGAT GCATTCTGCA GAGACTTGAC AGCACGGTTG AATGCCTCGA GSNNTGGACG 60

ACGAAGGTTA TTTTCCATCA GGATAT 86

86 base pairs

nucleic acid

single

linear

DNA (synthetic)

106

GCGCGCTGAT GCATTCTGCA GAGACTTGAC AGCACGGTTG AATGCCTCSN NGTTTGGACG 60

ACGAAGGTTA TTTTCCATCA GGATAT 86

68 base pairs

nucleic acid

single

linear

DNA (synthetic)

107

GCGCGCTGAT GCATTCTGCA GAGACTTGAC AGCACGGTTG AATGCSNNGA GGTTTGGACG 60

ACGAAGGT 68

68 base pairs

nucleic acid

single

linear

DNA (synthetic)

108

GCGCGCTGAT GCATTCTGCA GAGACTTGAC AGCACGGTTG AASNNCTCGA GGTTTGGACG 60

ACGAAGGT 68

68 base pairs

nucleic acid

single

linear

DNA (synthetic)

109

GCGCGCTGAT GCATTCTGCA GAGACTTGAC AGCACGGTTS NNTGCCTCGA GGTTTGGACG 60

ACGAAGGT 68

68 base pairs

nucleic acid

single

linear

DNA (synthetic)

110

GCGCGCTGAT GCATTCTGCA GAGACTTGAC AGCACGSNNG AATGCCTCGA GGTTTGGACG 60

ACGAAGGT 68

68 base pairs

nucleic acid

single

linear

DNA (synthetic)

111

GCGCGCTGAT GCATTCTGCA GAGACTTGAC AGCSNNGTTG AATGCCTCGA GGTTTGGACG 60

ACGAAGGT 68

68 base pairs

nucleic acid

single

linear

DNA (synthetic)

112

GCGCGCTGAT GCATTCTGCA GAGACTTGAC SNNACGGTTG AATGCCTCGA GGTTTGGACG 60

ACGAAGGT 68

65 base pairs

nucleic acid

single

linear

DNA (synthetic)

113

GCGCGCCTCG AGGCATTCAA CCGTGCTNNS AAGTCTCTGC AGAATGCATC AGCAATTGAG 60

AGCAT 65

65 base pairs

nucleic acid

single

linear

DNA (synthetic)

114

GCGCGCCTCG AGGCATTCAA CCGTGCTGTC NNSTCTCTGC AGAATGCATC AGCAATTGAG 60

AGCAT 65

65 base pairs

nucleic acid

single

linear

DNA (synthetic)

115

GCGCGCCTCG AGGCATTCAA CCGTGCTGTC AAGNNSCTGC AGAATGCATC AGCAATTGAG 60

AGCAT 65

65 base pairs

nucleic acid

single

linear

DNA (synthetic)

116

GCGCGCCTCG AGGCATTCAA CCGTGCTGTC AAGTCTNNSC AGAATGCATC AGCAATTGAG 60

AGCAT 65

65 base pairs

nucleic acid

single

linear

DNA (synthetic)

117

GCGCGCCTCG AGGCATTCAA CCGTGCTGTC AAGTCTCTGN NSAATGCATC AGCAATTGAG 60

AGCAT 65

65 base pairs

nucleic acid

single

linear

DNA (synthetic)

118

GCGCGCCTCG AGGCATTCAA CCGTGCTGTC AAGTCTCTGC AGNNSGCATC AGCAATTGAG 60

AGCAT 65

53 base pairs

nucleic acid

single

linear

›EXAMPLE 66 · 5 of 12

DNA (synthetic)

119

GCGCGCCTGC AGAATNNSTC AGCAATTGAG AGCATTCTTA AAAATCTCCT GCC 53

53 base pairs

nucleic acid

single

linear

DNA (synthetic)

120

GCGCGCCTGC AGAATGCANN SGCAATTGAG AGCATTCTTA AAAATCTCCT GCC 53

53 base pairs

nucleic acid

single

linear

DNA (synthetic)

121

GCGCGCCTGC AGAATGCATC ANNSATTGAG AGCATTCTTA AAAATCTCCT GCC 53

53 base pairs

nucleic acid

single

linear

DNA (synthetic)

122

GCGCGCCTGC AGAATGCATC AGCANNSGAG AGCATTCTTA AAAATCTCCT GCC 53

53 base pairs

nucleic acid

single

linear

DNA (synthetic)

123

GCGCGCCTGC AGAATGCATC AGCAATTNNS AGCATTCTTA AAAATCTCCT GCC 53

53 base pairs

nucleic acid

single

linear

DNA (synthetic)

124

GCGCGCCTGC AGAATGCATC AGCAATTGAG NNSATTCTTA AAAATCTCCT GCC 53

71 base pairs

nucleic acid

single

linear

DNA (synthetic)

125

GCGCGCCTGC AGAATGCATC AGCAATTGAG AGCNNSCTTA AAAATCTCCT GCCATGTCTG 60

CCGCTAGCCA C 71

71 base pairs

nucleic acid

single

linear

DNA (synthetic)

126

GCGCGCCTGC AGAATGCATC AGCAATTGAG AGCATTNNSA AAAATCTCCT GCCATGTCTG 60

CCGCTAGCCA C 71

71 base pairs

nucleic acid

single

linear

DNA (synthetic)

127

GCGCGCCTGC AGAATGCATC AGCAATTGAG AGCATTCTTN NSAATCTCCT GCCATGTCTG 60

CCGCTAGCCA C 71

134 amino acids

amino acid

linear

peptide

128

Met Ala Pro Met Thr Gln Thr Thr Ser Leu Lys Thr Ser Trp Val Asn

1 5 10 15

Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu Lys Gln Pro Pro

20 25 30

Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly Glu Asp Gln Asp Ile

35 40 45

Leu Met Glu Asn Asn Leu Arg Arg Pro Asn Leu Glu Ala Phe Asn Arg

50 55 60

Ala Val Lys Ser Leu Gln Asn Ala Ser Ala Ile Glu Ser Ile Leu Lys

65 70 75 80

Asn Leu Leu Pro Cys Leu Pro Leu Ala Thr Ala Ala Pro Thr Arg His

85 90 95

Pro Ile His Ile Lys Asp Gly Asp Trp Asn Glu Phe Arg Arg Lys Leu

100 105 110

Thr Phe Tyr Leu Lys Thr Leu Glu Asn Ala Gln Ala Gln Gln Thr Thr

115 120 125

Leu Ser Leu Ala Ile Phe

130

Ala Pro Met Thr Gln Thr Thr Ser Leu Lys Thr Ser Trp Val Asn Cys

1 5 10 15

Ser Xaa Met Ile Asp Glu Ile Ile Xaa His Leu Lys Xaa Pro Pro Xaa

20 25 30

Pro Leu Leu Asp Xaa Asn Asn Leu Asn Xaa Glu Asp Xaa Asp Ile Leu

35 40 45

Met Glu Xaa Asn Leu Arg Xaa Pro Asn Leu Xaa Xaa Phe Xaa Arg Ala

50 55 60

Val Lys Xaa Leu Xaa Asn Ala Ser Xaa Ile Glu Xaa Ile Leu Xaa Asn

65 70 75 80

Leu Xaa Pro Cys Leu Pro Xaa Ala Thr Ala Ala Pro Xaa Arg His Pro

85 90 95

Ile Xaa Ile Lys Xaa Gly Asp Trp Xaa Glu Phe Arg Xaa Lys Leu Thr

100 105 110

Phe Tyr Leu Xaa Thr Leu Glu Xaa Ala Gln Xaa Gln Gln Thr Thr Leu

115 120 125

Ser Leu Ala Ile Phe

130

Asn Cys Ser Xaa Met Ile Asp Glu Ile Ile Xaa His Leu Lys Xaa Pro

1 5 10 15

Pro Xaa Pro Leu Leu Asp Xaa Asn Asn Leu Asn Xaa Glu Asp Xaa Asp

20 25 30

Ile Leu Met Glu Xaa Asn Leu Arg Xaa Pro Asn Leu Xaa Xaa Phe Xaa

35 40 45

Arg Ala Val Lys Xaa Leu Xaa Asn Ala Ser Xaa Ile Glu Xaa Ile Leu

50 55 60

Xaa Asn Leu Xaa Pro Cys Leu Pro Xaa Ala Thr Ala Ala Pro Xaa Arg

65 70 75 80

His Pro Ile Xaa Ile Lys Xaa Gly Asp Trp Xaa Glu Phe Arg Xaa Lys

85 90 95

Leu Thr Phe Tyr Leu Xaa Thr Leu Glu Xaa Ala Gln Xaa Gln Gln

100 105 110

58 base pairs

nucleic acid

single

linear

DNA (synthetic)

131

CTAGCCACGG CCGCACCCAC GCGACATCCA ATCCATATCA AGGACGGTGA CTGGAATG 58

58 base pairs

nucleic acid

single

linear

DNA (synthetic)

132

TTAACATTCC AGTCACCGTC CTTGATATGG ATTGGATGTC GCGTGGGTGC GGCCGTGG 58

29 base pairs

nucleic acid

double

linear

DNA (genomic)

133

AAGGAGATAT ATCCATGAAC TGCTCTAAC 29

5 amino acids

amino acid

linear

peptide

134

Met Asn Cys Ser Asn

1 5

120 amino acids

amino acid

linear

peptide

135

Met Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu Lys Gln

1 5 10 15

Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly Glu Asp Gln

20 25 30

Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn Leu Glu Ala Phe

35 40 45

Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser Ala Ile Glu Ser Ile

50 55 60

Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu Ala Thr Ala Ala Pro Thr

65 70 75 80

Arg His Pro Ile His Ile Lys Asp Gly Asp Trp Asn Glu Phe Arg Arg

85 90 95

Lys Leu Thr Phe Tyr Leu Lys Thr Leu Glu Asn Ala Gln Ala Gln Gln

100 105 110

Thr Thr Leu Arg Leu Ala Ile Phe

115 120

71 base pairs

nucleic acid

single

linear

DNA (synthetic)

136

AATTCCGTCG TAAACTGACC TTCTATCTGA AAACCTTGGA GAACGCGCAG GCTCAACAGA 60

CCACTCTGTC G 71

71 base pairs

nucleic acid

single

linear

DNA (synthetic)

137

CTAGCGACAG AGTGGTCTGT TGAGCCTGCG CGTTCTCCAA GGTTTTCAGA TAGAAGGTCA 60

GTTTACGACG G 71

71 base pairs

nucleic acid

single

linear

DNA (synthetic)

138

GCGCGCCTGC AGAATGCATC AGCAATTGAG AGCATTCTTA AANNSCTCCT GCCATGTCTG 60

CCGCTAGCCA C 71

71 base pairs

nucleic acid

single

linear

DNA (synthetic)

139

GCGCGCCTGC AGAATGCATC AGCAATTGAG AGCATTCTTA AAAATNNSCT GCCATGTCTG 60

CCGCTAGCCA C 71

71 base pairs

nucleic acid

single

linear

DNA (synthetic)

140

GCGCGCCTGC AGAATGCATC AGCAATTGAG AGCATTCTTA AAAATCTCNN SCCATGTCTG 60

CCGCTAGCCA C 71

89 base pairs

nucleic acid

single

linear

DNA (synthetic)

141

GCGCGCCTGC AGAATGCATC AGCAATTGAG AGCATTCTTA AAAATCTCCT GNNSTGTCTG 60

CCGCTAGCCA CGGCCGCACC CACGCGACA 89

89 base pairs

nucleic acid

single

linear

DNA (synthetic)

142

GCGCGCCTGC AGAATGCATC AGCAATTGAG AGCATTCTTA AAAATCTCCT GCCANNSCTG 60

CCGCTAGCCA CGGCCGCACC CACGCGACA 89

89 base pairs

nucleic acid

single

linear

DNA (synthetic)

143

GCGCGCCTGC AGAATGCATC AGCAATTGAG AGCATTCTTA AAAATCTCCT GCCATGTNNS 60

CCGCTAGCCA CGGCCGCACC CACGCGACA 89

408 base pairs

nucleic acid

double

linear

DNA (genomic)

144

ATGGCTCCAA TGACTCAGAC TACTTCTCTT AAGACTTCTT GGGTTAACTG CTCTAACATG 60

ATCGATGAAA TTATAACACA CTTAAAGCAG CCACCTTTGC CTTTGCTGGA CTTCAACAAC 120

CTCAATGGGG AAGACCAAGA CATTCTGATG GAAAATAACC TTCGAAGGCC AAACCTGGAG 180

GCATTCAACA GGGCTGTCAA GAGTTTACAG AATGCATCAG CAATTGAGAG CATTCTTAAA 240

AATCTCCTGC CATGTCTGCC CCTGGCCACG GCCGCACCCA CGCGACATCC AATCCATATC 300

AAGGACGGTG ACTGGAATGA ATTCCGTCGT AAACTGACCT TCTATCTGAA AACCTTGGAG 360

AACGCGCAGG CTCAACAGAC CACTCTGTCG CTAGCGATCT TTTAATAA 408

ATC GAT GAA ATC ATC ACC CAC CTG AAG CAG CCA CCG CTG CCG CTG CTG 48

Ile Asp Glu Ile Ile Thr His Leu Lys Gln Pro Pro Leu Pro Leu Leu

1 5 10 15

GAC TTC AAC AAC CTC AAT GGT GAA GAC CAA GAT ATC CTG ATG GAA AAT 96

Asp Phe Asn Asn Leu Asn Gly Glu Asp Gln Asp Ile Leu Met Glu Asn

20 25 30

AAC CTT CGT CGT CCA AAC CTC GAG GCA TTC AAC CGT GCT GTC AAG TCT 144

Asn Leu Arg Arg Pro Asn Leu Glu Ala Phe Asn Arg Ala Val Lys Ser

35 40 45

CTG CAG AAT GCA T 157

Leu Gln Asn Ala

50

52 amino acids

amino acid

linear

protein

146

Ile Asp Glu Ile Ile Thr His Leu Lys Gln Pro Pro Leu Pro Leu Leu

›EXAMPLE 66 · 6 of 12

1 5 10 15

Asp Phe Asn Asn Leu Asn Gly Glu Asp Gln Asp Ile Leu Met Glu Asn

20 25 30

Asn Leu Arg Arg Pro Asn Leu Glu Ala Phe Asn Arg Ala Val Lys Ser

35 40 45

Leu Gln Asn Ala

50

414 base pairs

nucleic acid

double

linear

DNA (genomic)

147

CCATGGCTCC AATGACTCAG ACTACTTCTC TTAAGACTTC TTGGGTTAAC TGCTCTAACA 60

TGATCGATGA AATTATAACA CACTTAAAGC AGCCACCTTT GCCTTTGCTG GACTTCAACA 120

ACCTCAATGG GGAAGACCAA GACATTCTGA TGGAAAATAA CCTTCGAAGG CCAAACCTGG 180

AGGCATTCAA CAGGGCTGTC AAGAGTTTAC AGAATGCATC AGCAATTGAG AGCATTCTTA 240

AAAATCTCCT GCCATGTCTG CCCCTGGCCA CGGCCGCACC CACGCGACAT CCAATCCATA 300

TCAAGGACGG TGACTGGAAT GAATTCCGTC GTAAACTGAC CTTCTATCTG AAAACCTTGG 360

AGAACGCGCA GGCTCAACAG ACCACTCTGT CGCTAGCGAT CTTTTAATAA GCTT 414

414 base pairs

nucleic acid

double

linear

DNA (genomic)

148

AAGCTTATTA AAAGATCGCT AGCGACAGAG TGGTCTGTTG AGCCTGCGCG TTCTCCAAGG 60

TTTTCAGATA GAAGGTCAGT TTACGACGGA ATTCATTCCA GTCACCGTCC TTGATATGGA 120

TTGGATGTCG CGTGGGTGCG GCCGTGGCCA GGGGCAGACA TGGCAGGAGA TTTTTAAGAA 180

TGCTCTCAAT TGCTGATGCA TTCTGTAAAC TCTTGACAGC CCTGTTGAAT GCCTCCAGGT 240

TTGGCCTTCG AAGGTTATTT TCCATCAGAA TGTCTTGGTC TTCCCCATTG AGGTTGTTGA 300

AGTCCAGCAA AGGCAAAGGT GGCTGCTTTA AGTGTGTTAT AATTTCATCG ATCATGTTAG 360

AGCAGTTAAC CCAAGAAGTC TTAAGAGAAG TAGTCTGAGT CATTGGAGCC ATGG 414

81 base pairs

nucleic acid

double

linear

DNA (genomic)

149

ATGATGATTA CTCTGCGCAA ACTTCCTCTG GCGGTTGCCG TCGCAGCGGG CGTAATGTCT 60

GCTCAGGCCA TGGCTAACTG C 81

81 base pairs

nucleic acid

double

linear

DNA (genomic)

150

GCAGTTAGCC ATGGCCTGAG CAGACATTAC GCCCGCTGCG ACGGCAACCG CCAGAGGAAG 60

TTTGCGCAGA GTAATCATCA T 81

24 base pairs

nucleic acid

single

linear

DNA (synthetic)

151

CATGGCTAAC TGCTCTAACA TGAT 24

22 base pairs

nucleic acid

single

linear

DNA (synthetic)

152

CGATCATGTT AGAGCAGTTA GC 22

12 base pairs

nucleic acid

double

linear

DNA (genomic)

153

ATGGCTAACT GC 12

4 amino acids

amino acid

linear

peptide

154

Met Ala Asn Cys

1

34 base pairs

nucleic acid

single

linear

DNA (synthetic)

155

GCCGATACCG CGGCATACTC CCACCATTCA GAGA 34

33 base pairs

nucleic acid

single

linear

DNA (synthetic)

156

GCCGATAAGA TCTAAAACGG GTATGGAGAA ACA 33

89 base pairs

nucleic acid

single

linear

DNA (synthetic)

157

GCGCGCCTGC AGAATGCATC AGCAATTGAG AGCATTCTTA AAAATCTCCT GCCATGTCTG 60

NNSCTAGCCA CGGCCGCACC CACGCGACA 89

89 base pairs

nucleic acid

single

linear

DNA (synthetic)

158

GCGCGCCTGC AGAATGCATC AGCAATTGAG AGCATTCTTA AAAATCTCCT GCCATGTCTG 60

CCGNNSGCCA CGGCCGCACC CACGCGACA 89

89 base pairs

nucleic acid

single

linear

DNA (synthetic)

159

GCGCGCCTGC AGAATGCATC AGCAATTGAG AGCATTCTTA AAAATCTCCT GCCATGTCTG 60

CCGCTANNSA CGGCCGCACC CACGCGACA 89

86 base pairs

nucleic acid

single

linear

DNA (synthetic)

160

CGCGCGGAAT TCATTCCAGT CACCGTCCTT GATATGGATT GGATGTCGCG TGGGTGCGGC 60

SNNGGCCAGG GGCAGACATG GCAGGA 86

86 base pairs

nucleic acid

single

linear

DNA (synthetic)

161

CGCGCGGAAT TCATTCCAGT CACCGTCCTT GATATGGATT GGATGTCGCG TGGGTGCSNN 60

CGTGGCCAGG GGCAGACATG GCAGGA 86

86 base pairs

nucleic acid

single

linear

DNA (synthetic)

162

CGCGCGGAAT TCATTCCAGT CACCGTCCTT GATATGGATT GGATGTCGCG TGGGSNNGGC 60

CGTGGCCAGG GGCAGACATG GCAGGA 86

86 base pairs

nucleic acid

single

linear

DNA (synthetic)

163

CGCGCGGAAT TCATTCCAGT CACCGTCCTT GATATGGATT GGATGTCGCG TSNNTGCGGC 60

CGTGGCCAGG GGCAGACATG GCAGGA 86

86 base pairs

nucleic acid

single

linear

DNA (synthetic)

164

CGCGCGGAAT TCATTCCAGT CACCGTCCTT GATATGGATT GGATGTCGSN NGGGTGCGGC 60

CGTGGCCAGG GGCAGACATG GCAGGA 86

48 base pairs

nucleic acid

single

linear

DNA (synthetic)

165

TTTCAGATAG AAGGTCAGTT TACGACGGAA SNNATTCCAG TCACCGTC 48

48 base pairs

nucleic acid

single

linear

DNA (synthetic)

166

TTTCAGATAG AAGGTCAGTT TACGACGSNN TTCATTCCAG TCACCGTC 48

48 base pairs

nucleic acid

single

linear

DNA (synthetic)

167

TTTCAGATAG AAGGTCAGTT TACGSNNGAA TTCATTCCAG TCACCGTC 48

48 base pairs

nucleic acid

single

linear

DNA (synthetic)

168

TTTCAGATAG AAGGTCAGTT TSNNACGGAA TTCATTCCAG TCACCGTC 48

48 base pairs

nucleic acid

single

linear

DNA (synthetic)

169

TTTCAGATAG AAGGTCAGSN NACGACGGAA TTCATTCCAG TCACCGTC 48

48 base pairs

nucleic acid

single

linear

DNA (synthetic)

170

TTTCAGATAG AAGGTSNNTT TACGACGGAA TTCATTCCAG TCACCGTC 48

23 base pairs

nucleic acid

single

linear

DNA (synthetic)

171

CGCGCGAAGC TTATTACTGT TGA 23

78 base pairs

nucleic acid

single

linear

DNA (synthetic)

172

CGCGCGAAGC TTATTACTGT TGAGCCTGCG CGTTCTCCAA GGTTTTCAGA TAGAASNNCA 60

GTTTACGACG GAATTCAT 78

78 base pairs

nucleic acid

single

linear

DNA (synthetic)

173

CGCGCGAAGC TTATTACTGT TGAGCCTGCG CGTTCTCCAA GGTTTTCAGA TASNNGGTCA 60

GTTTACGACG GAATTCAT 78

78 base pairs

nucleic acid

single

linear

DNA (synthetic)

174

CGCGCGAAGC TTATTACTGT TGAGCCTGCG CGTTCTCCAA GGTTTTCAGS NNGAAGGTCA 60

GTTTACGACG GAATTCAT 78

78 base pairs

nucleic acid

single

linear

DNA (synthetic)

175

CGCGCGAAGC TTATTACTGT TGAGCCTGCG CGTTCTCCAA GGTTTTSNNA TAGAAGGTCA 60

GTTTACGACG GAATTCAT 78

78 base pairs

nucleic acid

single

linear

DNA (synthetic)

176

CGCGCGAAGC TTATTACTGT TGAGCCTGCG CGTTCTCCAA GGTSNNCAGA TAGAAGGTCA 60

GTTTACGACG GAATTCAT 78

78 base pairs

nucleic acid

single

linear

DNA (synthetic)

177

CGCGCGAAGC TTATTACTGT TGAGCCTGCG CGTTCTCCAA SNNTTTCAGA TAGAAGGTCA 60

GTTTACGACG GAATTCAT 78

60 base pairs

nucleic acid

single

linear

DNA (synthetic)

178

CGCGCGAAGC TTATTACTGT TGAGCCTGCG CGTTCTCSNN GGTTTTCAGA TAGAAGGTCA 60

60 base pairs

nucleic acid

single

linear

DNA (synthetic)

179

CGCGCGAAGC TTATTACTGT TGAGCCTGCG CGTTSNNCAA GGTTTTCAGA TAGAAGGTCA 60

60 base pairs

nucleic acid

single

linear

DNA (synthetic)

180

CGCGCGAAGC TTATTACTGT TGAGCCTGCG CSNNCTCCAA GGTTTTCAGA TAGAAGGTCA 60

60 base pairs

nucleic acid

single

linear

DNA (synthetic)

181

CGCGCGAAGC TTATTACTGT TGAGCCTGSN NGTTCTCCAA GGTTTTCAGA TAGAAGGTCA 60

60 base pairs

nucleic acid

single

linear

DNA (synthetic)

182

CGCGCGAAGC TTATTACTGT TGAGCSNNCG CGTTCTCCAA GGTTTTCAGA TAGAAGGTCA 60

60 base pairs

nucleic acid

single

linear

DNA (synthetic)

183

CGCGCGAAGC TTATTACTGT TGSNNCTGCG CGTTCTCCAA GGTTTTCAGA TAGAAGGTCA 60

24 base pairs

nucleic acid

single

linear

DNA (synthetic)

184

TGCTCTAACA TGATCGATGA AATT 24

24 base pairs

nucleic acid

single

linear

DNA (synthetic)

185

GAAATTATAA CACACTTAAA GCAG 24

24 base pairs

nucleic acid

single

linear

DNA (synthetic)

186

AAGCAGCCAC CTTTGCCTTT GCTG 24

24 base pairs

nucleic acid

single

linear

DNA (synthetic)

187

AAGCAGCCAC CGCTGCCGCT GCTG 24

24 base pairs

nucleic acid

single

linear

DNA (synthetic)

188

CTCAATGGTG AAGACCAAGA TATC 24

›EXAMPLE 66 · 7 of 12

24 base pairs

nucleic acid

single

linear

DNA (synthetic)

189

GATATCCTGA TGGAAAATAA CCTT 24

24 base pairs

nucleic acid

single

linear

DNA (synthetic)

190

AACCTTCGTC GTCCAAACCT CGAG 24

24 base pairs

nucleic acid

single

linear

DNA (synthetic)

191

CTCGAGGCAT TCAACCGTGC TGTC 24

24 base pairs

nucleic acid

single

linear

DNA (synthetic)

192

GCTGTCAAGT CTCTGCAGAA TGCA 24

24 base pairs

nucleic acid

single

linear

DNA (synthetic)

193

AATGCATCAG CAATTGAGAG CATT 24

24 base pairs

nucleic acid

single

linear

DNA (synthetic)

194

AGCATTCTTA AAAATCTCCT GCCA 24

24 base pairs

nucleic acid

single

linear

DNA (synthetic)

195

CTGCCATGTC TGCCCCTGGC CACG 24

24 base pairs

nucleic acid

single

linear

DNA (synthetic)

196

CTGGCCACGG CCGCACCCAC GCGA 24

24 base pairs

nucleic acid

single

linear

DNA (synthetic)

197

AATGAATTCC GTCGTAAACT GACC 24

24 base pairs

nucleic acid

single

linear

DNA (synthetic)

198

CTGACCTTCT ATCTGAAAAC CTTG 24

24 base pairs

nucleic acid

single

linear

DNA (synthetic)

199

ACCTTGGAGA ACGCGCAGGC TCAA 24

22 base pairs

nucleic acid

single

linear

DNA (synthetic)

200

GAATGCATCA GCAATTGAGA GC 22

20 base pairs

nucleic acid

single

linear

DNA (synthetic)

201

AATTGCTGAT GCATTCTGCA 20

24 base pairs

nucleic acid

single

linear

DNA (synthetic)

202

ATTCTTAAAA ATCTCCTGCC ATGT 24

24 base pairs

nucleic acid

single

linear

DNA (synthetic)

203

CAGGAGATTT TTAAGAATGC TCTC 24

30 base pairs

nucleic acid

single

linear

DNA (synthetic)

204

CTGCCCCTGG CCACGGCCGC ACCCACGCGA 30

30 base pairs

nucleic acid

single

linear

DNA (synthetic)

205

GGGTGCGGCC GTGGCCAGGG GCAGACATGG 30

34 base pairs

nucleic acid

single

linear

DNA (synthetic)

206

CATCCAATCA TCATCCGTGA CGGTGACTGG AATG 34

44 base pairs

nucleic acid

single

linear

DNA (synthetic)

207

AATTCATTCC AGTCACCGTC ACGGATGATG ATTGGATGTC GCGT 44

34 base pairs

nucleic acid

single

linear

DNA (synthetic)

208

CGCCCAATCA TCATCCGTGA CGGTGACTGG AATG 34

44 base pairs

nucleic acid

single

linear

DNA (synthetic)

209

AATTCATTCC AGTCACCGTC ACGGATGATG ATTGGGCGTC GCGT 44

40 base pairs

nucleic acid

single

linear

DNA (synthetic)

210

CATGGCTAAC TGCTCTAACA TGATCGATGA AATTATAACA 40

45 base pairs

nucleic acid

single

linear

DNA (synthetic)

211

CTTTAAGTGT GTTATAATTT CATCGATCAT GTTAGAGCAG TTAGC 45

36 base pairs

nucleic acid

single

linear

DNA (synthetic)

212

CACTTAAAGC AGCCACCTTT GCCTTTGCTG GACTTC 36

36 base pairs

nucleic acid

single

linear

DNA (synthetic)

213

GAGGTTGTTG AAGTCCAGCA AAGGCAAAGG TGGCTG 36

27 base pairs

nucleic acid

single

linear

DNA (synthetic)

214

AACAACCTCA ATGACGAAGA CATGTCT 27

18 base pairs

nucleic acid

single

linear

DNA (synthetic)

215

AGACATGTCT TCGTCATT 18

339 base pairs

nucleic acid

double

linear

DNA (genomic)

216

ATGGCTAACT GCTCTAACAT GATCGATGAA ATCATCACCC ACCTGAAGCA GCCACCGCTG 60

CCGCTGCTGG ACTTCAACAA CCTCAATGGT GAAGACCAAG ATATCCTGAT GGAAAATAAC 120

CTTCGTCGTC CAAACCTCGA GGCATTCAAC CGTGCTGTCA ACTCTCTGCA GAATGCATCA 180

GCAATTGAGA GCATTCTTAA AAATCTCCTG CCATGTCTGC CCCTGGCCAC GGCCGCACCC 240

ACGCGACATC CAATCCATAT CAAGGACGGT GACTGGAATG AATTCCGTCG TAAACTGACC 300

TTCTATCTGA AAACCTTGGA GAACGCGCAG GCTCAACAG 339

111 amino acids

amino acid

linear

peptide

217

Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu Lys Gln Pro

1 5 10 15

Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly Glu Asp Gln Asp

20 25 30

Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn Leu Glu Ala Phe Asn

35 40 45

Arg Ala Val Lys Ser Leu Gln Asn Ala Ser Ala Ile Glu Ser Ile Leu

50 55 60

Lys Asn Leu Leu Pro Cys Leu Pro Leu Ala Thr Ala Ala Pro Thr Arg

65 70 75 80

His Pro Ile His Ile Lys Asp Gly Asp Trp Asn Glu Phe Arg Arg Lys

85 90 95

Leu Thr Phe Tyr Leu Trp Thr Leu Glu Asn Ala Gln Ala Gln Gln

100 105 110

111 amino acids

amino acid

linear

peptide

218

Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu Lys Gln Pro

1 5 10 15

Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly Glu Asp Gln Asp

20 25 30

Ile Leu Met Asp Asn Asn Leu Arg Arg Pro Asn Leu Glu Ala Phe Asn

35 40 45

Arg Ala Val Lys Ser Leu Gln Asn Ala Ser Ala Ile Glu Ser Ile Leu

50 55 60

Lys Asn Leu Leu Pro Cys Leu Pro Leu Ala Thr Ala Ala Pro Thr Arg

65 70 75 80

His Pro Ile His Ile Lys Asp Gly Asp Trp Asn Glu Phe Arg Arg Lys

85 90 95

Leu Thr Phe Tyr Leu Lys Thr Leu Glu Asn Ala Gln Ala Gln Gln

100 105 110

45 base pairs

nucleic acid

single

linear

DNA (synthetic)

219

CTTTAAGTGT GTTATAATTT CTTCGATCAT GTTAGAGCAG TTAGC 45

339 base pairs

nucleic acid

double

linear

DNA (genomic)

220

ATGGCTAACT GCTCTAACAT GATCGATGAA ATCATCACCC ACCTGAAGCA GCCACCGCTG 60

CCGCTGCTGG ACTTCAACAA CCTCAATGGT GAAGACCAAG ATATCCTGAT GGAAAATAAC 120

CTTCGTCGTC CAAACCTCGA GGCATTCAAC CGTGCTGTCA ACTCTCTGCA GAATGCATCA 180

GCAATTGAGA GCATTCTTAA AAATCTCCTG CCATGTCTGC CCCTGGCCAC GGCCGCACCC 240

ACGCGACATC CAATCCATAT CAAGGACGGT GACTGGAATG AATTCCGTCG TAAACTGACC 300

TTCTATCTGT GGACCTTGGA GAACGCGCAG GCTCAACAG 339

40 base pairs

nucleic acid

single

linear

DNA (synthetic)

221

CATGGCTAAC TGCTCTAACA TGATCAACGA AATTATAACA 40

58 base pairs

nucleic acid

single

linear

DNA (synthetic)

222

CGCGCGCCAT GGCTAACTGC TCTNNSATGA TCGATGAAAT TATAACACAC TTAAAGCA 58

58 base pairs

nucleic acid

single

linear

DNA (synthetic)

223

CGCGCGCCAT GGCTAACTGC TCTAACNNSA TCGATGAAAT TATAACACAC TTAAAGCA 58

58 base pairs

nucleic acid

single

linear

DNA (synthetic)

224

CGCGCGCCAT GGCTAACTGC TCTAACATGN NSGATGAAAT TATAACACAC TTAAAGCA 58

58 base pairs

nucleic acid

single

linear

DNA (synthetic)

225

CGCGCGCCAT GGCTAACTGC TCTAACATGA TCNNSGAAAT TATAACACAC TTAAAGCA 58

58 base pairs

nucleic acid

single

linear

DNA (synthetic)

226

CGCGCGCCAT GGCTAACTGC TCTAACATGA TCGATNNSAT TATAACACAC TTAAAGCA 58

76 base pairs

nucleic acid

single

linear

DNA (synthetic)

227

CGCGCGCCAT GGCTAACTGC TCTAACATGA TCGATGAANN SATAACACAC TTAAAGCAGC 60

CACCTTTGCC TTTGCT 76

76 base pairs

nucleic acid

single

linear

DNA (synthetic)

228

CGCGCGCCAT GGCTAACTGC TCTAACATGA TCGATGAAAT TNNSACACAC TTAAAGCAGC 60

CACCTTTGCC TTTGCT 76

76 base pairs

nucleic acid

single

linear

DNA (synthetic)

229

CGCGCGCCAT GGCTAACTGC TCTAACATGA TCGATGAAAT TATANNSCAC TTAAAGCAGC 60

CACCTTTGCC TTTGCT 76

40 base pairs

nucleic acid

single

linear

DNA (synthetic)

230

CATGGCTAAC TGCTCTAACA TGATCAGCGA AATTATAACA 40

45 base pairs

nucleic acid

single

linear

DNA (synthetic)

231

CTTTAAGTGT GTTATAATTT CGCTGATCAT GTTAGAGCAG TTAGC 45

40 base pairs

nucleic acid

single

linear

DNA (synthetic)

232

CATGGCTAAC TGCTCTAACA TGATCACCGA AATTATAACA 40

45 base pairs

nucleic acid

single

linear

DNA (synthetic)

233

CTTTAAGTGT GTTATAATTT CCGTGATCAT GTTAGAGCAG TTAGC 45

›EXAMPLE 66 · 8 of 12

40 base pairs

nucleic acid

single

linear

DNA (synthetic)

234

CATGGCTAAC TGCTCTAACA TGATCGATAA CATTATAACA 40

45 base pairs

nucleic acid

single

linear

DNA (synthetic)

235

CTTTAAGTGT GTTATAATGT TATCGATCAT GTTAGAGCAG TTAGC 45

40 base pairs

nucleic acid

single

linear

DNA (synthetic)

236

CATGGCTAAC TGCTCTAACA TGATCGATGA CATTATAACA 40

45 base pairs

nucleic acid

single

linear

DNA (synthetic)

237

CTTTAAGTGT GTTATAATGT CATCGATCAT GTTAGAGCAG TTAGC 45

40 base pairs

nucleic acid

single

linear

DNA (synthetic)

238

CATGGCTAAC TGCTCTAACA TGATCGATCA GATTATAACA 40

45 base pairs

nucleic acid

single

linear

DNA (synthetic)

239

CTTTAAGTGT GTTATAATCT GATCGATCAT GTTAGAGCAG TTAGC 45

40 base pairs

nucleic acid

single

linear

DNA (synthetic)

240

CATGGCTAAC TGCTCTAACA TGATCGATCT GATTATAACA 40

45 base pairs

nucleic acid

single

linear

DNA (synthetic)

241

CTTTAAGTGT GTTATAATCA GATCGATCAT GTTAGAGCAG TTAGC 45

40 base pairs

nucleic acid

single

linear

DNA (synthetic)

242

CATGGCTAAC TGCTCTAACA TGATCGATGT TATTATAACA 40

45 base pairs

nucleic acid

single

linear

DNA (synthetic)

243

CTTTAAGTGT GTTATAATAA CATCGATCAT GTTAGAGCAG TTAGC 45

36 base pairs

nucleic acid

single

linear

DNA (synthetic)

244

CACTTAAAGC AGCCACCTTT GCCTGCTCTG GACTTC 36

36 base pairs

nucleic acid

single

linear

DNA (synthetic)

245

GAGGTTGTTG AAGTCCAGAG CAGGCAAAGG TGGCTG 36

36 base pairs

nucleic acid

single

linear

DNA (synthetic)

246

CACTTAAAGC AGCCACCTTT GCCTCGTCTG GACTTC 36

36 base pairs

nucleic acid

single

linear

DNA (synthetic)

247

GAGGTTGTTG AAGTCCAGAC GAGGCAAAGG TGGCTG 36

36 base pairs

nucleic acid

single

linear

DNA (synthetic)

248

CACTTAAAGC AGCCACCTTT GCCTCAGCTG GACTTC 36

36 base pairs

nucleic acid

single

linear

DNA (synthetic)

249

GAGGTTGTTG AAGTCCAGCT GAGGCAAAGG TGGCTG 36

36 base pairs

nucleic acid

single

linear

DNA (synthetic)

250

CACTTAAAGC AGCCACCTTT GCCTGAACTG GACTTC 36

36 base pairs

nucleic acid

single

linear

DNA (synthetic)

251

GAGGTTGTTG AAGTCCAGCT CAGGCAAAGG TGGCTG 36

36 base pairs

nucleic acid

single

linear

DNA (synthetic)

252

CACTTAAAGC AGCCACCTTT GCCTATCCTG GACTTC 36

36 base pairs

nucleic acid

single

linear

DNA (synthetic)

253

GAGGTTGTTG AAGTCCAGGA TAGGCAAAGG TGGCTG 36

36 base pairs

nucleic acid

single

linear

DNA (synthetic)

254

CACTTAAAGC AGCCACCTTT CCCTTTCCTG GACTTC 36

36 base pairs

nucleic acid

single

linear

DNA (synthetic)

255

GAGGTTGTTG AAGTCCAGGA AAGGCAAAGG TGGCTG 36

36 base pairs

nucleic acid

single

linear

DNA (synthetic)

256

CACTTAAAGC AGCCACCTTT GCCTACCCTG GACTTC 36

36 base pairs

nucleic acid

single

linear

DNA (synthetic)

257

GAGGTTGTTG AAGTCCAGGG TAGGCAAAGG TGGCTG 36

27 base pairs

nucleic acid

single

linear

DNA (synthetic)

258

AACAACCTCA ATCGTGAAGA CCAAGAT 27

18 base pairs

nucleic acid

single

linear

DNA (synthetic)

259

ATCTTGGTCT TCACGATT 18

27 base pairs

nucleic acid

single

linear

DNA (synthetic)

260

AACAACCTCA ATAACGAAGA CCAAGAT 27

18 base pairs

nucleic acid

single

linear

DNA (synthetic)

261

ATCTTGGTCT TCGTTATT 18

27 base pairs

nucleic acid

single

linear

DNA (synthetic)

262

AACAACCTCA ATGAAGAAGA CCAAGAT 27

18 base pairs

nucleic acid

single

linear

DNA (synthetic)

263

ATCTTGGTCT TCTTCATT 18

27 base pairs

nucleic acid

single

linear

DNA (synthetic)

264

AACAACCTCA ATATCGAAGA CCAAGAT 27

18 base pairs

nucleic acid

single

linear

DNA (synthetic)

265

ATCTTGGTCT TCGATATT 18

27 base pairs

nucleic acid

single

linear

DNA (synthetic)

266

AACAACCTCA ATCTGGAAGA CCAAGAT 27

18 base pairs

nucleic acid

single

linear

DNA (synthetic)

267

ATCTTGGTCT TCCAGATT 18

27 base pairs

nucleic acid

single

linear

DNA (synthetic)

268

AACAACCTCA ATAAAGAAGA CCAAGAT 27

18 base pairs

nucleic acid

single

linear

DNA (synthetic)

269

ATCTTGGTCT TCTTTATT 18

27 base pairs

nucleic acid

single

linear

DNA (synthetic)

270

AACAACCTCA ATATGGAAGA CCAAGAT 27

18 base pairs

nucleic acid

single

linear

DNA (synthetic)

271

ATCTTGGTCT TCCATATT 18

27 base pairs

nucleic acid

single

linear

DNA (synthetic)

272

AACAACCTCA ATTTCGAAGA CCAAGAT 27

18 base pairs

nucleic acid

single

linear

DNA (synthetic)

273

ATCTTGGTCT TCGAAATT 18

27 base pairs

nucleic acid

single

linear

DNA (synthetic)

274

AACAACCTCA ATACCGAAGA CCAAGAT 27

18 base pairs

nucleic acid

single

linear

DNA (synthetic)

275

ATCTTGGTCT TCGGTATT 18

27 base pairs

nucleic acid

single

linear

DNA (synthetic)

276

AACAACCTCA ATTACGAAGA CCAAGAT 27

18 base pairs

nucleic acid

single

linear

DNA (synthetic)

277

ATCTTGGTCT TCGTAATT 18

27 base pairs

nucleic acid

single

linear

DNA (synthetic)

278

AACAACCTCA ATGTTGAAGA CCAAGAT 27

18 base pairs

nucleic acid

single

linear

DNA (synthetic)

279

ATCTTGGTCT TCAACATT 18

27 base pairs

nucleic acid

single

linear

DNA (synthetic)

280

AACAACCTCA ATGGGCGTGA CCAAGAT 27

18 base pairs

nucleic acid

single

linear

DNA (synthetic)

281

ATCTTGGTCT CGCCCATT 18

27 base pairs

nucleic acid

single

linear

DNA (synthetic)

282

AACAACCTCA ATGGGCAGGA CCAAGAT 27

18 base pairs

nucleic acid

single

linear

DNA (synthetic)

283

ATCTTGGTCC TGCCCATT 18

27 base pairs

nucleic acid

single

linear

DNA (synthetic)

284

AACAACCTCA ATGGGGGTGA CCAAGAT 27

18 base pairs

nucleic acid

single

linear

DNA (synthetic)

285

ATCTTGGTCA CCCCCATT 18

27 base pairs

nucleic acid

single

linear

DNA (synthetic)

286

AACAACCTCA ATGGGACCGA CCAAGAT 27

18 base pairs

nucleic acid

single

linear

DNA (synthetic)

287

ATCTTGGTCG GTCCCATT 18

27 base pairs

nucleic acid

single

linear

DNA (synthetic)

288

AACAACCTCA ATGGGGAAGC TCAAGAT 27

18 base pairs

nucleic acid

single

linear

DNA (synthetic)

289

ATCTTGAGCT TCCCCATT 18

27 base pairs

nucleic acid

single

linear

DNA (synthetic)

290

AACAACCTCA ATGGGGAAAA CCAAGAT 27

18 base pairs

nucleic acid

single

linear

DNA (synthetic)

291

ATCTTGGTTT TCCCCATT 18

27 base pairs

nucleic acid

single

linear

DNA (synthetic)

292

AACAACCTCA ATGGGGAACA GCAAGAT 27

18 base pairs

nucleic acid

single

linear

DNA (synthetic)

293

ATCTTGCTGT TCCCCATT 18

27 base pairs

nucleic acid

single

linear

DNA (synthetic)

294

AACAACCTCA ATGGGGAAGA ACAAGAT 27

18 base pairs

nucleic acid

single

linear

DNA (synthetic)

295

ATCTTGTTCT TCCCCATT 18

27 base pairs

nucleic acid

single

linear

DNA (synthetic)

296

AACAACCTCA ATGGGGAAGA CGCTGAT 27

18 base pairs

nucleic acid

single

linear

DNA (synthetic)

297

ATCAGCGTCT TCCCCATT 18

27 base pairs

nucleic acid

single

linear

DNA (synthetic)

298

AACAACCTCA ATGGGGAAGA CCGTGAT 27

18 base pairs

nucleic acid

single

linear

DNA (synthetic)

299

ATCACGGTCT TCCCCATT 18

27 base pairs

nucleic acid

single

linear

DNA (synthetic)

300

AACAACCTCA ATGGGGAAGA CAACGAT 27

18 base pairs

nucleic acid

single

linear

DNA (synthetic)

301

ATCGTTGTCT TCCCCATT 18

›EXAMPLE 66 · 9 of 12

27 base pairs

nucleic acid

single

linear

DNA (synthetic)

302

AACAACCTCA ATGGGGAAGA CGACGAT 27

18 base pairs

nucleic acid

single

linear

DNA (synthetic)

303

ATCGTCGTCT TCCCCATT 18

27 base pairs

nucleic acid

single

linear

DNA (synthetic)

304

AACAACCTCA ATGGTGAAGA CGAAGAT 27

18 base pairs

nucleic acid

single

linear

DNA (synthetic)

305

ATCTTCGTCT TCCCCATT 18

27 base pairs

nucleic acid

single

linear

DNA (synthetic)

306

AACAACCTCA ATGGTGAAGA CCACGAT 27

18 base pairs

nucleic acid

single

linear

DNA (synthetic)

307

ATCGTGGTCT TCCCCATT 18

27 base pairs

nucleic acid

single

linear

DNA (synthetic)

308

AACAACCTCA ATGGGGAAGA CATCGAT 27

18 base pairs

nucleic acid

single

linear

DNA (synthetic)

309

ATCGATGTCT TCCCCATT 18

27 base pairs

nucleic acid

single

linear

DNA (synthetic)

310

AACAACCTCA ATGGGGAAGA CTCCGAT 27

18 base pairs

nucleic acid

single

linear

DNA (synthetic)

311

ATCGGAGTCT TCCCCATT 18

27 base pairs

nucleic acid

single

linear

DNA (synthetic)

312

AACAACCTCA ATGGGGAAGA CCAAGCT 27

18 base pairs

nucleic acid

single

linear

DNA (synthetic)

313

AGCTTGGTCT TCCCCATT 18

27 base pairs

nucleic acid

single

linear

DNA (synthetic)

314

AACAACCTCA ATGGGGAAGA CCAAAAC 27

18 base pairs

nucleic acid

single

linear

DNA (synthetic)

315

GTTTTGGTCT TCCCCATT 18

27 base pairs

nucleic acid

single

linear

DNA (synthetic)

316

AACAACCTCA ATGGGGAAGA CCAACAG 27

18 base pairs

nucleic acid

single

linear

DNA (synthetic)

317

CTGTTGGTCT TCCCCATT 18

27 base pairs

nucleic acid

single

linear

DNA (synthetic)

318

AACAACCTCA ATGGGGAAGA CCAAGAA 27

18 base pairs

nucleic acid

single

linear

DNA (synthetic)

319

TTCTTGGTCT TCCCCATT 18

27 base pairs

nucleic acid

single

linear

DNA (synthetic)

320

AACAACCTCA ATGGGGAAGA CCAACAC 27

18 base pairs

nucleic acid

single

linear

DNA (synthetic)

321

GTGTTGGTCT TCCCCATT 18

27 base pairs

nucleic acid

single

linear

DNA (synthetic)

322

AACAACCTCA ATGGGGAAGA CCAAATC 27

18 base pairs

nucleic acid

single

linear

DNA (synthetic)

323

GATTTGGTCT TCCCCATT 18

27 base pairs

nucleic acid

single

linear

DNA (synthetic)

324

AACAACCTCA ATGGGGAAGA CCAACTG 27

18 base pairs

nucleic acid

single

linear

DNA (synthetic)

325

CAGTTGGTCT TCCCCATT 18

27 base pairs

nucleic acid

single

linear

DNA (synthetic)

326

AACAACCTCA ATGGGGAAGA CCAAAAA 27

18 base pairs

nucleic acid

single

linear

DNA (synthetic)

327

TTTTTGGTCT TCCCCATT 18

27 base pairs

nucleic acid

single

linear

DNA (synthetic)

328

AACAACCTCA ATGGGGAAGA CCAATAC 27

18 base pairs

nucleic acid

single

linear

DNA (synthetic)

329

GTATTGGTCT TCCCCATT 18

27 base pairs

nucleic acid

single

linear

DNA (synthetic)

330

AACAACCTCA ATGGGGAAGA CCAAGTT 27

18 base pairs

nucleic acid

single

linear

DNA (synthetic)

331

AACTTGGTCT TCCCCATT 18

36 base pairs

nucleic acid

single

linear

DNA (synthetic)

332

ATCGCTATGG AAAATAACCT TCGAAGGCCA AACCTG 36

27 base pairs

nucleic acid

single

linear

DNA (synthetic)

333

CCTTCGAAGG TTATTTTCCA TAGCGAT 27

36 base pairs

nucleic acid

single

linear

DNA (synthetic)

334

ATCGAAATGG AAAATAACCT TCGAAGGCCA AACCTG 36

27 base pairs

nucleic acid

single

linear

DNA (synthetic)

335

CCTTCGAAGG TTATTTTCCA TTTCGAT 27

36 base pairs

nucleic acid

single

linear

DNA (synthetic)

336

ATCAAAATGG AAAATAACCT TCGAAGGCCA AACCTG 36

27 base pairs

nucleic acid

single

linear

DNA (synthetic)

337

CCTTCGAAGG TTATTTTCCA TTTTGAT 27

36 base pairs

nucleic acid

single

linear

DNA (synthetic)

338

ATCATGATGG AAAATAACCT TCGAAGGCCA AACCTG 36

27 base pairs

nucleic acid

single

linear

DNA (synthetic)

339

CCTTCGAAGG TTATTTTCCA TCATGAT 27

36 base pairs

nucleic acid

single

linear

DNA (synthetic)

340

ATCACCATGG AAAATAACCT TCGAAGGCCA AACCTG 36

27 base pairs

nucleic acid

single

linear

DNA (synthetic)

341

CCTTCGAAGG TTATTTTCCA TGGTGAT 27

36 base pairs

nucleic acid

single

linear

DNA (synthetic)

342

ATCGTTATGG AAAATAACCT TCGAAGGCCA AACCTG 36

27 base pairs

nucleic acid

single

linear

DNA (synthetic)

343

CCTTCGAAGG TTATTTTCCA TAACGAT 27

36 base pairs

nucleic acid

single

linear

DNA (synthetic)

344

ATCCTGATGC ACAATAACCT TCGAAGGCCA AACCTG 36

27 base pairs

nucleic acid

single

linear

DNA (synthetic)

345

CCTTCGAAGG TTATTGTGCA TCAGGAT 27

36 base pairs

nucleic acid

single

linear

DNA (synthetic)

346

ATCCTGATGA TGAATAACCT TCGAAGGCCA AACCTG 36

27 base pairs

nucleic acid

single

linear

DNA (synthetic)

347

CCTTCGAAGG TTATTCATCA TCAGGAT 27

36 base pairs

nucleic acid

single

linear

DNA (synthetic)

348

ATCCTGATGT TCAATAACCT TCGAAGGCCA AACCTG 36

27 base pairs

nucleic acid

single

linear

DNA (synthetic)

349

CCTTCGAAGG TTATTGAACA TCAGGAT 27

36 base pairs

nucleic acid

single

linear

DNA (synthetic)

350

ATCCTGATGG CTAATAACCT TCGAAGGCCA AACCTG 36

27 base pairs

nucleic acid

single

linear

DNA (synthetic)

351

CCTTCGAAGG TTATTAGCCA TCAGGAT 27

36 base pairs

nucleic acid

single

linear

DNA (synthetic)

352

ATCCTGATGA ACAATAACCT TCGAAGGCCA AACCTG 36

27 base pairs

nucleic acid

single

linear

DNA (synthetic)

353

CCTTCGAAGG TTATTGTTCA TCAGGAT 27

36 base pairs

nucleic acid

single

linear

DNA (synthetic)

354

ATCCTGATGA TCAATAACCT TCGAAGGCCA AACCTG 36

27 base pairs

nucleic acid

single

linear

DNA (synthetic)

355

CCTTCGAAGG TTATTGATCA TCAGGAT 27

36 base pairs

nucleic acid

single

linear

DNA (synthetic)

356

ATCCTGATGA AAAATAACCT TCGAAGGCCA AACCTG 36

27 base pairs

nucleic acid

single

linear

DNA (synthetic)

357

CCTTCGAAGG TTATTTTTCA TCAGGAT 27

36 base pairs

nucleic acid

single

linear

DNA (synthetic)

358

ATCCTGATGT CCAATAACCT TCGAAGGCCA AACCTG 36

27 base pairs

nucleic acid

single

linear

DNA (synthetic)

359

CCTTCGAAGG TTATTGGACA TCAGGAT 27

36 base pairs

nucleic acid

single

linear

DNA (synthetic)

360

ATCCTGATGG TTAATAACCT TCGAAGGCCA AACCTG 36

27 base pairs

nucleic acid

single

linear

DNA (synthetic)

361

CCTTCGAAGG TTATTAACCA TCAGGAT 27

36 base pairs

nucleic acid

single

linear

DNA (synthetic)

362

ATCCTGATGG AAAATAACCT TGCTAGGCCA AACCTG 36

27 base pairs

nucleic acid

single

linear

DNA (synthetic)

363

CCTAGCAAGG TTATTTTCCA TCAGGAT 27

36 base pairs

nucleic acid

single

linear

DNA (synthetic)

364

ATCCTGATGG AAAATAACCT TAACAGGCCA AACCTG 36

27 base pairs

nucleic acid

single

linear

DNA (synthetic)

365

CCTGTTAAGG TTATTTTCCA TCAGGAT 27

36 base pairs

nucleic acid

single

linear

DNA (synthetic)

366

ATCCTGATGG AAAATAACCT TCACAGGCCA AACCTG 36

27 base pairs

nucleic acid

single

linear

DNA (synthetic)

367

CCTGTGAAGG TTATTTTCCA TCAGGAT 27

36 base pairs

nucleic acid

single

linear

DNA (synthetic)

368

ATCCTGATGG AAAATAACCT TAAAAGGCCA AACCTG 36

27 base pairs

nucleic acid

single

linear

DNA (synthetic)

369

CCTTTTAAGG TTATTTTCCA TCAGGAT 27

36 base pairs

nucleic acid

single

linear

DNA (synthetic)

›EXAMPLE 66 · 10 of 12

370

ATCCTGATGG AAAATAACCT TCGAAGGGCT AACCTG 36

24 base pairs

nucleic acid

single

linear

DNA (synthetic)

371

CCTGTTGAAT GCCTCCAGGT TAGC 24

36 base pairs

nucleic acid

single

linear

DNA (synthetic)

372

ATCCTGATGG AAAATAACCT TCGAAGGCGT AACCTG 36

24 base pairs

nucleic acid

single

linear

DNA (synthetic)

373

CCTGTTGAAT GCCTCCAGGT TACG 24

36 base pairs

nucleic acid

single

linear

DNA (synthetic)

374

ATCCTGATGG AAAATAACCT TCGAAGGAAC AACCTG 36

24 base pairs

nucleic acid

single

linear

DNA (synthetic)

375

CCTGTTGAAT GCCTCCAGGT TGTT 24

36 base pairs

nucleic acid

single

linear

DNA (synthetic)

376

ATCCTGATGG AAAATAACCT TCGAAGGGAA AACCTG 36

24 base pairs

nucleic acid

single

linear

DNA (synthetic)

377

CCTGTTGAAT GCCTCCAGGT TTTC 24

36 base pairs

nucleic acid

single

linear

DNA (synthetic)

378

ATCCTGATGG AAAATAACCT TCGAAGGCAC AACCTG 36

24 base pairs

nucleic acid

single

linear

DNA (synthetic)

379

CCTGTTGAAT GCCTCCAGGT TGTG 24

36 base pairs

nucleic acid

single

linear

DNA (synthetic)

380

ATCCTGATGG AAAATAACCT TCGAAGGCTG AACCTG 36

24 base pairs

nucleic acid

single

linear

DNA (synthetic)

381

CCTGTTGAAT GCCTCCAGGT TCAG 24

36 base pairs

nucleic acid

single

linear

DNA (synthetic)

382

ATCCTGATGG AAAATAACCT TCGAAGGTTC AACCTG 36

24 base pairs

nucleic acid

single

linear

DNA (synthetic)

383

CCTGTTGAAT GCCTCCAGGT TGAA 24

36 base pairs

nucleic acid

single

linear

DNA (synthetic)

384

ATCCTGATGG AAAATAACCT TCGAAGGACC AACCTG 36

24 base pairs

nucleic acid

single

linear

DNA (synthetic)

385

CCTGTTGAAT GCCTCCAGGT TGGT 24

36 base pairs

nucleic acid

single

linear

DNA (synthetic)

386

ATCCTGATGG AAAATAACCT TCGAAGGTAC AACCTG 36

24 base pairs

nucleic acid

single

linear

DNA (synthetic)

387

CCTGTTGAAT GCCTCCAGGT TGTA 24

36 base pairs

nucleic acid

single

linear

DNA (synthetic)

388

ATCCTGATGG AAAATAACCT TCGAAGGGTT AACCTG 36

24 base pairs

nucleic acid

single

linear

DNA (synthetic)

389

CCTGTTGAAT GCCTCCAGGT TAAC 24

18 base pairs

nucleic acid

single

linear

DNA (synthetic)

390

AAAAATCTCG CTCCATGT 18

18 base pairs

nucleic acid

single

linear

DNA (synthetic)

391

AGCGAGATTT TTAAGAAT 18

18 base pairs

nucleic acid

single

linear

DNA (synthetic)

392

AAAAATCTCA ACCCATGT 18

18 base pairs

nucleic acid

single

linear

DNA (synthetic)

393

GTTGAGATTT TTAAGAAT 18

18 base pairs

nucleic acid

single

linear

DNA (synthetic)

394

AAAAATCTCG AACCATGT 18

18 base pairs

nucleic acid

single

linear

DNA (synthetic)

395

TTCGAGATTT TTAAGAAT 18

18 base pairs

nucleic acid

single

linear

DNA (synthetic)

396

AAAAATCTCC ACCCATGT 18

18 base pairs

nucleic acid

single

linear

DNA (synthetic)

397

GTGGAGATTT TTAAGAAT 18

18 base pairs

nucleic acid

single

linear

DNA (synthetic)

398

AAAAATCTCA TCCCATGT 18

18 base pairs

nucleic acid

single

linear

DNA (synthetic)

399

GATGAGATTT TTAAGAAT 18

18 base pairs

nucleic acid

single

linear

DNA (synthetic)

400

AAAAATCTCA TGCCATGT 18

18 base pairs

nucleic acid

single

linear

DNA (synthetic)

401

CATGAGATTT TTAAGAAT 18

18 base pairs

nucleic acid

single

linear

DNA (synthetic)

402

AAAAATCTCT TCCCATGT 18

18 base pairs

nucleic acid

single

linear

DNA (synthetic)

403

GAAGAGATTT TTAAGAAT 18

18 base pairs

nucleic acid

single

linear

DNA (synthetic)

404

AAAAATCTCT CCCCATGT 18

18 base pairs

nucleic acid

single

linear

DNA (synthetic)

405

GGAGAGATTT TTAAGAAT 18

18 base pairs

nucleic acid

single

linear

DNA (synthetic)

406

AAAAATCTCA CCCCATGT 18

18 base pairs

nucleic acid

single

linear

DNA (synthetic)

407

GGTGAGATTT TTAAGAAT 18

18 base pairs

nucleic acid

single

linear

DNA (synthetic)

408

AAAAATCTCT ACCCATGT 18

18 base pairs

nucleic acid

single

linear

DNA (synthetic)

409

GTAGAGATTT TTAAGAAT 18

27 base pairs

nucleic acid

single

linear

DNA (synthetic)

410

CTGCCCCTGG CCACGGCCGC AGCTACG 27

24 base pairs

nucleic acid

single

linear

DNA (synthetic)

411

ATGGATTGGA TGTCGCGTAG CTGC 24

27 base pairs

nucleic acid

single

linear

DNA (synthetic)

412

CTGCCCCTGG CCACGGCCGC AGGTACG 27

24 base pairs

nucleic acid

single

linear

DNA (synthetic)

413

ATGGATTGGA TGTCGCGTAC CTGC 24

27 base pairs

nucleic acid

single

linear

DNA (synthetic)

414

CTGCCCCTGG CCACGGCCGC AATCACG 27

24 base pairs

nucleic acid

single

linear

DNA (synthetic)

415

ATGGATTGGA TGTCGCGTGA TTGC 24

21 base pairs

nucleic acid

single

linear

DNA (synthetic)

416

GCTCATCCAA TCCATATCAA G 21

24 base pairs

nucleic acid

single

linear

DNA (synthetic)

417

ATGGATTGGA TGAGCCGTGG GTGC 24

21 base pairs

nucleic acid

single

linear

DNA (synthetic)

418

CAGCATCCAA TCCATATCAA G 21

24 base pairs

nucleic acid

single

linear

DNA (synthetic)

419

ATGGATTGGA TGCTGCGTGG GTGC 24

21 base pairs

nucleic acid

single

linear

DNA (synthetic)

420

CACCATCCAA TCCATATCAA G 21

24 base pairs

nucleic acid

single

linear

DNA (synthetic)

421

ATGGATTGGA TGGTGCGTGG GTGC 24

21 base pairs

nucleic acid

single

linear

DNA (synthetic)

422

AAACATCCAA TCCATATCAA G 21

24 base pairs

nucleic acid

single

linear

DNA (synthetic)

423

ATGGATTGGA TGTTTCGTGG GTGC 24

21 base pairs

nucleic acid

single

linear

DNA (synthetic)

424

CGAGCTCCAA TCCATATCAA G 21

24 base pairs

nucleic acid

single

linear

DNA (synthetic)

425

ATGGATTGGA GCTCGCGTGG GTGC 24

21 base pairs

nucleic acid

single

linear

DNA (synthetic)

426

CGAAACCCAA TCCATATCAA G 21

24 base pairs

nucleic acid

single

linear

DNA (synthetic)

427

ATGGATTGGG TTTCGCGTGG GTGC 24

21 base pairs

nucleic acid

single

linear

DNA (synthetic)

428

CGAGACCCAA TCCATATCAA G 21

24 base pairs

nucleic acid

single

linear

DNA (synthetic)

429

ATGGATTGGG TCTCGCGTGG GTGC 24

21 base pairs

nucleic acid

single

linear

DNA (synthetic)

430

CGAATCCCAA TCCATATCAA G 21

24 base pairs

nucleic acid

single

linear

DNA (synthetic)

431

ATGGATTGGG ATTCGCGTGG GTGC 24

21 base pairs

nucleic acid

single

linear

DNA (synthetic)

432

CGAAAACCAA TCCATATCAA G 21

24 base pairs

nucleic acid

single

linear

DNA (synthetic)

433

ATGGATTGGT TTTCGCGTGG GTGC 24

21 base pairs

nucleic acid

single

linear

DNA (synthetic)

434

CGAATGCCAA TCCATATCAA G 21

24 base pairs

nucleic acid

single

linear

DNA (synthetic)

435

ATGGATTGGC ATTCGCGTGG GTGC 24

21 base pairs

nucleic acid

single

linear

DNA (synthetic)

436

CGATTCCCAA TCCATATCAA G 21

24 base pairs

nucleic acid

single

linear

DNA (synthetic)

437

ATGGATTGGG AATCGCGTGG GTGC 24

21 base pairs

nucleic acid

single

linear

DNA (synthetic)

438

CGATCCCCAA TCCATATCAA G 21

24 base pairs

nucleic acid

single

linear

DNA (synthetic)

439

ATGGATTGGG GATCGCGTGG GTGC 24

21 base pairs

nucleic acid

single

linear

DNA (synthetic)

440

CGATGGCCAA TCCATATCAA G 21

24 base pairs

nucleic acid

single

linear

DNA (synthetic)

441

ATGGATTGGC CATCGCGTGG GTGC 24

21 base pairs

nucleic acid

single

linear

DNA (synthetic)

›EXAMPLE 66 · 11 of 12

442

CGATACCCAA TCCATATCAA G 21

24 base pairs

nucleic acid

single

linear

DNA (synthetic)

443

ATGGATTGGG TATCGCGTGG GTGC 24

34 base pairs

nucleic acid

single

linear

DNA (synthetic)

444

CATCCAATCC AAATCAAGGA CGGTGACTGG AATG 34

44 base pairs

nucleic acid

single

linear

DNA (synthetic)

445

AATTCATTCC AGTCACCGTC CTTGATTTGG ATTGGATGTC GCGT 44

34 base pairs

nucleic acid

single

linear

DNA (synthetic)

446

CATCCAATCG AAATCAAGGA CGGTGACTGG AATG 34

44 base pairs

nucleic acid

single

linear

DNA (synthetic)

447

AATTCATTCC AGTCACCGTC CTTGATTTCG ATTGGATGTC GCGT 44

34 base pairs

nucleic acid

single

linear

DNA (synthetic)

448

CATCCAATCA TGATCAAGGA CGGTGACTGG AATG 34

44 base pairs

nucleic acid

single

linear

DNA (synthetic)

449

AATTCATTCC AGTCACCGTC CTTGATCATG ATTGGATGTC GCGT 44

34 base pairs

nucleic acid

single

linear

DNA (synthetic)

450

CATCCAATCT TCATCAAGGA CGGTGACTGG AATG 34

44 base pairs

nucleic acid

single

linear

DNA (synthetic)

451

AATTCATTCC AGTCACCGTC CTTGATGAAG ATTGGATGTC GCGT 44

34 base pairs

nucleic acid

single

linear

DNA (synthetic)

452

CATCCAATCT CCATCAAGGA CGGTGACTGG AATG 34

44 base pairs

nucleic acid

single

linear

DNA (synthetic)

453

AATTCATTCC AGTCACCGTC CTTGATGGAG ATTGGATGTC GCGT 44

34 base pairs

nucleic acid

single

linear

DNA (synthetic)

454

CATCCAATCG TAATCAAGGA CGGTGACTGG AATG 34

44 base pairs

nucleic acid

single

linear

DNA (synthetic)

455

AATTCATTCC AGTCACCGTC CTTGATTACG ATTGGATGTC GCGT 44

21 base pairs

nucleic acid

single

linear

DNA (synthetic)

456

CGACATCCAA TCCGTATCAA G 21

24 base pairs

nucleic acid

single

linear

DNA (synthetic)

457

ACGGATTGGA TGTCGCGTGG GTGC 24

21 base pairs

nucleic acid

single

linear

DNA (synthetic)

458

CGACATCCAA TCAAAATCAA G 21

24 base pairs

nucleic acid

single

linear

DNA (synthetic)

459

TTTGATTGGA TGTCGCGTGG GTGC 24

21 base pairs

nucleic acid

single

linear

DNA (synthetic)

460

CGACATCCAA TCTACATCAA G 21

24 base pairs

nucleic acid

single

linear

DNA (synthetic)

461

GTAGATTGGA TGTCGCGTGG GTGC 24

16 base pairs

nucleic acid

single

linear

DNA (synthetic)

462

GCTGGTGACT GGAATG 16

26 base pairs

nucleic acid

single

linear

DNA (synthetic)

463

AATTCATTCC AGTCACCAGC CTTGAT 26

16 base pairs

nucleic acid

single

linear

DNA (synthetic)

464

AACGGTGACT GGAATG 16

26 base pairs

nucleic acid

single

linear

DNA (synthetic)

465

AATTCATTCC AGTCACCGTT CTTGAT 26

16 base pairs

nucleic acid

single

linear

DNA (synthetic)

466

GAAGGTGACT GGAATG 16

26 base pairs

nucleic acid

single

linear

DNA (synthetic)

467

AATTCATTCC AGTCACCTTC CTTGAT 26

16 base pairs

nucleic acid

single

linear

DNA (synthetic)

468

GGTGGTGACT GGAATG 16

26 base pairs

nucleic acid

single

linear

DNA (synthetic)

469

AATTCATTCC AGTCACCACC CTTGAT 26

16 base pairs

nucleic acid

single

linear

DNA (synthetic)

470

ATCGGTGACT GGAATG 16

26 base pairs

nucleic acid

single

linear

DNA (synthetic)

471

AATTCATTCC AGTCACCGAT CTTGAT 26

16 base pairs

nucleic acid

single

linear

DNA (synthetic)

472

CTGGGTGACT GGAATG 16

26 base pairs

nucleic acid

single

linear

DNA (synthetic)

473

AATTCATTCC AGTCACCCAG CTTGAT 26

16 base pairs

nucleic acid

single

linear

DNA (synthetic)

474

TTCGGTGACT GGAATG 16

26 base pairs

nucleic acid

single

linear

DNA (synthetic)

475

AATTCATTCC AGTCACCGAA CTTGAT 26

16 base pairs

nucleic acid

single

linear

DNA (synthetic)

476

TCCGGTGACT GGAATG 16

26 base pairs

nucleic acid

single

linear

DNA (synthetic)

477

AATTCATTCC AGTCACCGGA CTTGAT 26

32 base pairs

nucleic acid

single

linear

DNA (synthetic)

478

AATTCGCTAG GAAACTGACG TTCTATCTGA AA 32

37 base pairs

nucleic acid

single

linear

DNA (synthetic)

479

CTCAAGGGTT TTCAGATAGA ACGTCAGTTT CCTAGCG 37

32 base pairs

nucleic acid

single

linear

DNA (synthetic)

480

AATTCCAGAG GAAACTGACG TTCTATCTGA AA 32

37 base pairs

nucleic acid

single

linear

DNA (synthetic)

481

CTCAAGGGTT TTCAGATAGA ACGTCAGTTT CCTCTGG 37

32 base pairs

nucleic acid

single

linear

DNA (synthetic)

482

AATTCCACAG GAAACTGACG TTCTATCTGA AA 32

37 base pairs

nucleic acid

single

linear

DNA (synthetic)

483

CTCAAGGGTT TTCAGATAGA ACGTCAGTTT CCTGTGG 37

32 base pairs

nucleic acid

single

linear

DNA (synthetic)

484

AATTCTCCAG GAAACTGACG TTCTATCTGA AA 32

37 base pairs

nucleic acid

single

linear

DNA (synthetic)

485

CTCAAGGGTT TTCAGATAGA ACGTCAGTTT CCTGGAG 37

32 base pairs

nucleic acid

single

linear

DNA (synthetic)

486

AATTCCGGAG GCGTCTGACG TTCTATCTGA AA 32

37 base pairs

nucleic acid

single

linear

DNA (synthetic)

487

CTCAAGGGTT TTCAGATAGA ACGTCAGACG CCTCCGG 37

32 base pairs

nucleic acid

single

linear

DNA (synthetic)

488

AATTCCGGAG GGAACTGACG TTCTATCTGA AA 32

37 base pairs

nucleic acid

single

linear

DNA (synthetic)

489

CTCAAGGGTT TTCAGATAGA ACGTCAGTTC CCTCCGG 37

32 base pairs

nucleic acid

single

linear

DNA (synthetic)

490

AATTCCGGAG GCACCTGACG TTCTATCTGA AA 32

37 base pairs

nucleic acid

single

linear

DNA (synthetic)

491

CTCAAGGGTT TTCAGATAGA ACGTCAGGTG CCTCCGG 37

32 base pairs

nucleic acid

single

linear

DNA (synthetic)

492

AATTCCGGAG GATCCTGACG TTCTATCTGA AA 32

37 base pairs

nucleic acid

single

linear

DNA (synthetic)

493

CTCAAGGGTT TTCAGATAGA ACGTCAGGAT CCTCCGG 37

32 base pairs

nucleic acid

single

linear

DNA (synthetic)

494

AATTCCGGAG GTCCCTGACG TTCTATCTGA AA 32

37 base pairs

nucleic acid

single

linear

DNA (synthetic)

495

CTCAAGGGTT TTCAGATAGA ACGTCAGGGA CCTCCGG 37

32 base pairs

nucleic acid

single

linear

DNA (synthetic)

496

AATTCCGGAG GAAACTGACG GACTATCTGA AA 32

37 base pairs

nucleic acid

single

linear

DNA (synthetic)

497

CTCAAGGGTT TTCAGATAGT CCGTCAGTTT CCTCCGG 37

32 base pairs

nucleic acid

single

linear

DNA (synthetic)

498

AATTCCGGAG GAAACTGACG ATCTATCTGA AA 32

37 base pairs

nucleic acid

single

linear

DNA (synthetic)

499

CTCAAGGGTT TTCAGATAGA TCGTCAGTTT CCTCCGG 37

32 base pairs

nucleic acid

single

linear

DNA (synthetic)

500

AATTCCGGAG GAAACTGACG CTGTATCTGA AA 32

37 base pairs

nucleic acid

single

linear

DNA (synthetic)

501

CTCAAGGGTT TTCAGATACA GCGTCAGTTT CCTCCGG 37

32 base pairs

nucleic acid

single

linear

DNA (synthetic)

502

AATTCCGGAG GAAACTGACG AAATATCTGA AA 32

37 base pairs

nucleic acid

single

linear

DNA (synthetic)

503

CTCAAGGGTT TTCAGATATT TCGTCAGTTT CCTCCGG 37

32 base pairs

nucleic acid

single

linear

DNA (synthetic)

504

AATTCCGGAG GAAACTGACG GTTTATCTGA AA 32

37 base pairs

nucleic acid

single

linear

DNA (synthetic)

505

CTCAAGGGTT TTCAGATAAA CCGTCAGTTT CCTCCGG 37

32 base pairs

nucleic acid

single

linear

DNA (synthetic)

506

AATTCCGGAG GAAACTGACG TTCTATCTGG CT 32

37 base pairs

nucleic acid

single

linear

DNA (synthetic)

507

CTCAAGGGTA GCCAGATAGA ACGTCAGTTT CCTCCGG 37

32 base pairs

nucleic acid

single

linear

›EXAMPLE 66 · 12 of 12

DNA (synthetic)

508

AATTCCGGAG GAAACTGACG TTCTATCTGC GT 32

37 base pairs

nucleic acid

single

linear

DNA (synthetic)

509

CTCAAGGGTA CGCAGATAGA ACGTCAGTTT CCTCCGG 37

32 base pairs

nucleic acid

single

linear

DNA (synthetic)

510

AATTCCGGAG GAAACTGACG TTCTATCTGA AC 32

37 base pairs

nucleic acid

single

linear

DNA (synthetic)

511

CTCAAGGGTG TTCAGATAGA ACGTCAGTTT CCTCCGG 37

32 base pairs

nucleic acid

single

linear

DNA (synthetic)

512

AATTCCGGAG GAAACTGACG TTCTATCTGC AG 32

37 base pairs

nucleic acid

single

linear

DNA (synthetic)

513

CTCAAGGGTC TGCAGATAGA ACGTCAGTTT CCTCCGG 37

32 base pairs

nucleic acid

single

linear

DNA (synthetic)

514

AATTCCGGAG GAAACTGACG TTCTATCTGC AC 32

37 base pairs

nucleic acid

single

linear

DNA (synthetic)

515

CTCAAGGGTG TGCAGATAGA ACGTCAGTTT CCTCCGG 37

32 base pairs

nucleic acid

single

linear

DNA (synthetic)

516

AATTCCGGAG GAAACTGACG TTCTATCTGA TG 32

37 base pairs

nucleic acid

single

linear

DNA (synthetic)

517

CTCAAGGGTC ATCAGATAGA ACGTCAGTTT CCTCCGG 37

32 base pairs

nucleic acid

single

linear

DNA (synthetic)

518

AATTCCGGAG GAAACTGACG TTCTATCTGT TC 32

37 base pairs

nucleic acid

single

linear

DNA (synthetic)

519

CTCAAGGGTG AACAGATAGA ACGTCAGTTT CCTCCGG 37

32 base pairs

nucleic acid

single

linear

DNA (synthetic)

520

AATTCCGGAG GAAACTGACG TTCTATCTGT AC 32

37 base pairs

nucleic acid

single

linear

DNA (synthetic)

521

CTCAAGGGTG TACAGATAGA ACGTCAGTTT CCTCCGG 37

40 base pairs

nucleic acid

single

linear

DNA (synthetic)

522

CATGGCTAAC TGCTCTAACA TGATCGATGA AATTATAACA 40

36 base pairs

nucleic acid

single

linear

DNA (synthetic)

523

CACTTAAAGC AGCCACCTTT GCCTTTGCTG GACTTC 36

27 base pairs

nucleic acid

single

linear

DNA (synthetic)

524

AACAACCTCA ATGGGGAAGA CCAAGAT 27

45 base pairs

nucleic acid

single

linear

DNA (synthetic)

525

CTTTAAGTGT GTTATAATTT CATCGATCAT GTTAGAGCAG TTAGC 45

36 base pairs

nucleic acid

single

linear

DNA (synthetic)

526

GAGGTTGTTG AAGTCCAGCA AAGGCAAAGG TGGCTG 36

18 base pairs

nucleic acid

single

linear

DNA (synthetic)

527

ATCTTGGTCT TCCCCATT 18

36 base pairs

nucleic acid

single

linear

DNA (synthetic)

528

ATCCTGATGG AAAATAACCT TCGAAGGCCA AACCTG 36

24 base pairs

nucleic acid

single

linear

DNA (synthetic)

529

GAGGCATTCA ACAGGGCTGT CAAG 24

15 base pairs

nucleic acid

single

linear

DNA (synthetic)

530

AGTTTACAGA ATGCA 15

27 base pairs

nucleic acid

single

linear

DNA (synthetic)

531

CCTTCGAAGG TTATTTTCCA TCAGGAT 27

24 base pairs

nucleic acid

single

linear

DNA (synthetic)

532

CCTGTTGAAT GCCTCCAGGT TTGG 24

20 base pairs

nucleic acid

single

linear

DNA (synthetic)

533

TTCTGTAAAC TCTTGACAGC 20

21 base pairs

nucleic acid

single

linear

DNA (synthetic)

534

TCAGCAATTG AGAGCATTCT T 21

18 base pairs

nucleic acid

single

linear

DNA (synthetic)

535

AAAAATCTCC TGCCATGT 18

48 base pairs

nucleic acid

single

linear

DNA (synthetic)

536

CTGCCCCTGG CCACGGCCGC ACCCACGCGA CATCCAATCC ATATCAAG 48

27 base pairs

nucleic acid

single

linear

DNA (synthetic)

537

CTGCCCCTGG CCACGGCCGC ACCCACG 27

21 base pairs

nucleic acid

single

linear

DNA (synthetic)

538

CGACATCCAA TCCATATCAA G 21

16 base pairs

nucleic acid

single

linear

DNA (synthetic)

539

GACGGTGACT GGAATG 16

19 base pairs

nucleic acid

single

linear

DNA (synthetic)

540

GCTCTCAATT GCTGATGCA 19

18 base pairs

nucleic acid

single

linear

DNA (synthetic)

541

CAGGAGATTT TTAAGAAT 18

48 base pairs

nucleic acid

single

linear

DNA (synthetic)

542

ATGGATTGGA TGTCGCGTGG GTGCGGCCGT GGCCAGGGGC AGACATGG 48

24 base pairs

nucleic acid

single

linear

DNA (synthetic)

543

GGCCGTGGCC AGGGGCAGAC ATGG 24

24 base pairs

nucleic acid

single

linear

DNA (synthetic)

544

ATGGATTGGA TGTCGCGTGG GTGC 24

26 base pairs

nucleic acid

single

linear

DNA (synthetic)

545

AATTCATTCC AGTCACCGTC CTTGAT 26

32 base pairs

nucleic acid

single

linear

DNA (synthetic)

546

AATTCCGGAG GAAACTGACG TTCTATCTGA AA 32

32 base pairs

nucleic acid

single

linear

DNA (synthetic)

547

ACCCTTGAGA ATGCGCAGGC TCAACAGTAA TA 32

37 base pairs

nucleic acid

single

linear

DNA (synthetic)

548

CTCAAGGGTT TTCAGATAGA ACGTCAGTTT CCTCCGG 37

27 base pairs

nucleic acid

single

linear

DNA (synthetic)

549

AGCTTATTAC TGTTGAGCCT GCGCATT 27

›Tables in the description — 21
TABLE 1 — BIOLOGICAL ACTIVITY OF IL-3 MUTEINS Relative * The Relative Biological Activity of IL-3 mutants is calculated by dividing the EC 50 of (1-133) hIL-3 by the EC 50 of the mutant.
PlasmidPolypeptideBiological
CodeStructureActivity
Reference(1-133)hIL-31.0
pMON13286[SEO ID NO. 69]8.0
pMON13304[SEO ID NO. 66]3.2
Abbreviated DesignationAmino Acid
AAlaAlanine
CCysCysteine
DAspAspartic acid
EGluGlutamic acid
FPhePhenylalanine
GGlyGlycine
HHisHistidine
IIleIsoleucine
KLysLysine
LLeuLeucine
MMetMethionine
NAsnAsparagine
PProProline
QGlnGlutamine
RArgArginine
SSerSerine
TThrThreonine
VValValine
WTrpTryptophan
YTyrTyrosine
5′ATG GCT AAC TGC . . .3′[SEQ ID NO:153]
Met Ala Asn Cys . . .[SEQ ID NO:154]
15
Oligo #155[SEQ ID NO:200]
Oligo #156[SEQ ID NO:201]
Oligo #157[SEQ ID NO:202]
Oligo #158[SEQ ID NO:203]
Oligo #159[SEQ ID NO:204]
Oligo #160[SEQ ID NO:205]
Oligo #161[SEQ ID NO:206]
Oligo #162[SEQ ID NO:207]
Oligo #155[SEQ ID NO:200]
Oligo #156[SEQ ID NO:201]
Oligo #157[SEQ ID NO:202]
Oligo #158[SEQ ID NO:203]
Oligo #159[SEQ ID NO:204]
Oligo #160[SEQ ID NO:205]
Oligo #163[SEQ ID NO:208]
Oligo #164[SEQ ID NO:209]
Oligo #165[SEQ ID NO:210]
Oligo #166[SEQ ID NO:211]
Oligo #167[SEQ ID NO: 212]
Oligo #168[SEQ ID NO:213]
Oligo #169[SEQ ID NO:214]
Oligo #170[SEQ ID NO:215]
5′-AAGGAGATATATCCATGAACTGCTCTAAC-3′[SEQ ID NO:133]
M N C S N[SEQ ID NO:134]
TABLE 6 — (15-125) HUMAN INTERLEUKIN-3 MUTANTS 2 Double mutant; has PRO at position 35. 3 Double mutant; has THR at position 49. 4 Double mutant; has Gly at position 32. 5 Double mutant; has Leu at position 31. 6 Double mutant; has Gly at position 46. 7 Double mutant; Arg at position 42. 8 Double mutant; Phe at position 53. 9 Double mutant; has Val at position 49. 10 Double mutant; has Pro at position 73. 11 Double mutant; has Thr at position 64. 12 Double mutant; has Pro at position 73. 13 Double mutant; has Met at position 74. 14 Double mutant; has Ser at position 105.
hIL-3 aaPARENTAL(15-125)hIL-3 MUTANT
POSITION 1aaCODONaaSEQ ID NO:CODONBIOL ACTIVITY
17/3 1SERTCTLYS19AAG<0.018 (1)
17/3SERTCTGLY19GGG1.2 ± 1.1 (3)
17/3SERTCTASP19GAC1.0 ± 0.7 (3)
17/3SERTCTMET19ATG0.50 (1)
17/3SERTCTGLN19CAG1.2 ± 0.7 (3)
17/3SERTCTARG19AGG<0.070 (1)
18/4ASNAACHIS19CAC1.2 ± 0.3 (3)
18/4ASNAACLEU19CTC0.45 ± 0.42 (4)
18/4ASNAACILE19ATC1.5 ± 0.2 (2)
18/4ASNAACPHE19TTC0.19 ± 0.26 (2)
18/4ASNAACARG19CGG0.10 (1)
18/4ASNAACGLN19CAA0.37 (1)
19/5METATGPHE19TTC0.25 (1)
19/5METATGILE19ATG0.77 ± 0.70 (9)
19/5METATGARG19AGG0.17 (1)
19/5METATGGLY19GGA0.06 (1)
19/5METATGALA19GCG0.19 (1)
19/5METATGCYS19TGC—
20/6ILEATCCYS19TGC—
20/6ILEATCGLN19CAG—
20/6ILEATCGLU19GAG<0.025 (1)
20/6ILEATCARG19CGC<0.025 (1)
20/6ILEATCPRO19CCG0.29 ± 0.16 (3)
20/6ILEATCALA19GCG0.18 (1)
21/7ASPGATPHE19TTC<0.016 (1)
21/7ASPGATLYS19AAG0.027 ± 0.027 (2)
21/7ASPGATARG19AGG<0.008 (1)
21/7ASPGATALA19GCG0.07 ± 0.06 (3)
21/7ASPGATGLY19GGG0.032 (1)
21/7ASPGATVAL19GTG<0.008 (1)
22/8GLUGAATRP19TGG—
22/8GLUGAAPRO19CCG<0.015 (1)
22/8GLUGAASER19TCG<0.015 (1)
22/8GLUGAAALA19GCC<0.015 (1)
22/8GLUGAAHIS19CAC<0.015 (1)
22/8GLUGAAGLY19GGC<0.008 (1)
23/9ILEATTVAL19GTG0.18 (1)
23/9ILEATTALA 219GCG1.16 ± 0.16 (3)
23/9ILEATTLEU19TTG1.3 (1)
23/9ILEATTGLY 219GGG0.06 (1)
23/9ILEATTTRP19TGG—
23/9ILEATTLYS 219AAG—
23/9ILEATTPHE19TTC—
23/9ILEATTLEU 219TTG3.0 ± 1.1 (3)
23/9ILEATTSER 219AGC<0.005 (1)
23/9ILEATTARG 219CGC—
24/10ILEATAGLY19GGG<0.004 (1)
24/10ILEATAVAL19GTC0.89 ± 0.23 (4)
24/10ILEATAARG 319CGG—
24/10ILEATASER19AGC<0.003 (1)
24/10ILEATAPHE19TTC0.29 ± 0.24 (2)
24/10ILEATALEU19CTG0.52 ± 0.12 (3)
25/11THRACAHIS19CAC1.11 ± 0.2 (3)
25/11THRACAGLY19GGC0.48 ± 0.27 (4)
25/11THRACAGLN19CAG1.0 ± 0.8 (4)
25/11THRACAARG19CGG0.26 ± 0.17 (2)
25/11THRACAPRO19CCG0.36 (1)
31/17PROCCTGLY19GGG0.79 ± 0.61 (2)
31/17PROCCTALA19GCC0.49 (1)
31/17PROCCTARG19CGC0.25 ± 0.20 (2)
31/17PROCCTLEU19CTG0.22 (1)
31/17PROCCTGLN19CAG0.62 ± 0.04 (2)
31/17PROCCTLEU 419CTG0.30 ± 0.20 (3)
32/18LEUTTGVAL 219GTG0.01 (1)
32/18LEUTTGARG19CCC1.5 ± 1.0 (4)
32/18LEUTTGCLN19CAG0.93 ± 0.18 (3)
32/18LEUTTGASN19AAC1.2 ± 0.5 (5)
32/18LEUTTGGLY 519GGC0.84 ± 1.0 (3)
32/18LEUTTGALA19GCG1.4 ± 0.7 (5)
32/18LEUTTGGLU19GAG0.88 ± 0.37 (2)
33/19PROCC(T/C)LEU19CTG0.13 (1)
33/19PROCC(T/C)GLN19CAG0.22 ± 0.20 (2)
33/19PROCC(T/C)ALA19GCG0.30 ± 0.14 (2)
33/19PROCC(T/C)THR19ACC<0.018 (1)
33/19PROCC(T/C)GLU19GAG0.54 ± 0.43 (2)
34/20LEUTTGVAL19GTG1.2 ± 0.6 (3)
34/20LEUTTGGLY19GGG0.64 ± 0.74 (2)
34/20LEUTTGSER19TCG1.5 ± 0.7 (4)
34/20LEUTTGLYS19AAG0.97 ± 0.28 (2)
34/20LEUTTGMET19ATG1.1 ± 0.5 (3)
35/21LEUCTGALA19GCC1.6 ± 0.5 (3)
35/21LEUCTGGLY19GGC<0.006 ± 0.002 (3)
35/21LEUCTGASN19AAC1.1 ± 1.7 (5)
35/21LEUCTGPRO19CCC1.8 ± 2.0 (5)
35/21LEUCTGGLN19CAA0.98 ± 1.1 (5)
35/21LEUCTGVAL19GTG0.76 ± 0.86 (5)
36/22ASPGACLEU19CTC0.20 (1)
25/11THRACAALA19GCC0.86 ± 0.27 (3)
26/12HISCACTHR19ACG0.010 (1)
26/12HISCACPHE19TTC0.26 (1)
26/12HISCACGLY19GGG0.19 (1)
26/12HISCACARG19CGG0.21 (1)
26/12HISCACALA19GCC0.56 ± 0.03 (2)
26/12HISCACTRP19TGG—
27/13LEUTTAGLY19GGG—
27/13LEUTTAARG19AGG—
27/13LEUTTATHR19ATC0.084 (1)
27/13LEUTTASER19TCC—
27/13LEUTTAALA19GCG0.01 (1)
28/14LYSAAGARG19CGG0.42 ± 0.07 (2)
28/14LYSAAGLEU19TTG—
28/14LYSAAGTRP19TGG—
29/14LYSAAGGLN19CAG0.27 (1)
28/14LYSAAGGLY19GGC0.36 ± 0.07 (2)
29/14LYSAAGPRO19CCC0.10 ± 0.04 (2)
28/14LYSAAGVAL19GTG0.19 ± 0.12 (2)
29/15GLNCAGASN19AAC1.62 ± 1.7 (3)
29/15GLNCAGLEU19CTG0.284
29/15GLNCAGPRO19CCG—
29/15ARGCAGARG19AGG0.44 ± 0.16 (4)
29/15GLNCAGVAL19GTG0.62 ± 0.40 (4)
30/16PROCCAHIS19CAC0.26 (1)
30/16PROCCATHR19ACG0.36 (1)
30/16PROCCAGLY19GGG1.2 ± 0.8 (3)
30/16PROCCAASP19GAC—
30/16PROCCAGLN19CAG0.61 ± 0.37 (3)
30/16PROCCASER19TCG—
30/16PROCCALEU19TTC—
30/16PROCCALYS19AAG—
31/17PROCCTASP19GAC0.66 ± 0.71 (3)
36/22ASPGACVAL19GTG—
37/23PHETTCSER19AGC0.62 ± 0.40 (4)
37/23PHETTCPRO19CCG0.65 ± 0.39 (4)
37/23PHETTCTRP19TGG—
37/23PHETTCILE19ATC0.1 (1)
36/24ASNAACALA19GCN1.9 (1)
40/26LEUCTCTRP19TGG—
40/26LEUCTCARG19CGC—
41/27ASNAATCYS19TGC0.18 (1)
41/27ASNAATARG19CGC0.13 ± 0.13 (2)
41/27ASNAATLEU19CTG0.09 ± 0.07 (2)
41/27ASNAATHIS19CAC0.49 ± 0.26 (4)
41/27ASNAATMET19ATG0.30 ± 0.38 (4)
41/27ASNAATPRO19CCG0.12 (1)
42/28GLYGGGASP19GAC5.7 ± 5.7 (6)
42/28GLYGGGSER19AGC4.3 ± 4.8 (7)
42/28GLYGGGCYS19TGC0.53 (1)
42/28GLYGGGALA19GCC5.9 ± 4.1 (7)
43/29GLUGAAASN19AAC0.050 (1)
43/29GLUGAATYR19TAC0.010 (1)
43/29GLUGAALEU19CTC<0.009 (1)
43/29GLUGAAPHE19TTC<0.009 (1)
43/29GLUGAAASP19GAC0.044 (1)
43/29GLUGAAALA19GCC<0.009 (1)
43/29GLUGAACYS19TGC<0.009 (1)
43/29GLUGAASER19AGC<0.009 (1)
44/30ASPGACSER19TCA0.007 (1)
44/30ASPGACLEU19CTG<0.007 (1)
44/30ASPGACARG19AGG<0.007 (1)
44/30ASPGACLYS19AAG<0.007 (1)
44/30ASPGACTHR19ACG—
44/30ASPGACMET19ATG<0.007 (1)
44/30ASPGACTRP19TGG<0.007 (1)
44/30ASPGACPRO19CCC<0.007 (1)
45/31GLNCAAPRO19CCC—
45/31GLNCAAPHE19TTC0.007 (1)
45/31GLNCAAVAL19GTC6.7 ± 6.1 (5)
45/31GLNCAAMET19ATG3.4 ± 1.8 (5)
45/31GLNCAALEU19TTG1.1 ± 1.3 (2)
45/31GLNCAATHR19ACG0.96 ± 1.5 (3)
45/31GLNCAALYS19AAG1.6 ± 2.2 (5)
45/31GLNCAATRP19TGG0.10 (1)
46/32ASPGACPHE19TTC1.2 ± 0.5 (3)
46/32ASPGACSER19TCC7.9 ± 6.4 (4)
46/32ASPGACTHR19ACC1.8 ± 0.2 (2)
46/32ASPGACCYS19TGC0.80 (1)
46/32ASPGACGLY19GGC0.25 (1)
47/33ILEATTGLY19GGC<0.015 (1)
47/33ILEATTVAL19GTG0.38 (1)
47/33ILEATTHIS19CAC0.10 (1)
47/33ILEATTSER19TCC0.03 (1)
47/33ILEATTARG19AGG0.09 (1)
47/33ILEATTPRO19CCG<0.015 (1)
48/34LEUCTGSER19AGC<0.009 (1)
48/34LEUCTGCYS19TCG—
48/34LEUCTGARG19CGC<0.009 (1)
48/34LEUCTGILE19ATC0.036 (1)
48/34LEUCTGHIS19CAC<0.009 (1)
48/34LEUCTGPHE19TTC<0.009 (1)
48/34LEUCTGASN19AAC<0.009 (1)
49/35METATGARG19CGC0.007 (1)
49/35METATGALA19GCC0.091 (1)
49/35METATGGLY19GGC0.036 (1)
49/35METATGPRO19CCC<0.009 (1)
49/35METATGASN19AAC0.23 (1)
49/35METATGHIS19CAC<0.009 (1)
49/35METATGASP19GAC0.28 ± 0.48 (3)
50/36GLUGAALEU19CTC0.01 (1)
50/36GLUGAATHR19ACC0.20 (1)
50/36GLUGAAASP19GAC—
50/36GLUGAATYR19TAC0.09 (1)
50/36GLUGAAGLN19CTG0.02 (1)
51/37ASNAATARG19CGC2.0 ± 0.8 (3)
51/37ASNAATMET19ATG0.75 ± 0.50 (2)
51/37ASNAATPRO19CCG2.77 ± 1.6 (3)
51/37ASNAATSER19TCC0.87 ± 0.44 (3)
51/37ASNAATTHR19ACG2.3 ± 1.6 (3)
51/37ASNAATHIS19CAC1.3 ± 0.9 (5)
52/38ASNAACHIS19CAC0.004 (1)
52/39ASNAACARG19CGC0.004 (1)
52/36ASNAACLEU19TGG0.003 (1)
52/38ASNAACGLY19GGC0.22 (1)
52/38ASNAACSER19AGC0.07 (1)
52/38ASNAACTHR19ACG0.44 ± 0.30 (3)
53/39LEUCTTTHR19ACC<0.005 (1)
53/39LEUCTTALA19GCG—
53/39LEUCTTGLY19GGC<0.005 (1)
53/39LEUCTTGLU19GAG<0.005 (1)
53/39LEUCTTPRO19CCG<0.005 (1)
53/39LEUCTTLYS19AAG<0.005 (1)
53/39LEUCTTSER19AGC0.008 (1)
53/39LEUCTTMET19ATG0.31 (1)
54/40ARGCGAASP19GAC<0.005 (1)
54/40ARGCGAILE19ATC0.05 (1)
54/40ARGCGASER19TCC0.10 (1)
54/40ARGCGAVAL19GTC<0.005 (1)
54/40ARGCGATHR19ACC0.015 (1)
54/40ARGCGAGLN19CAG0.04 (1)
54/40ARGCGALEU19TTG0.03 (1)
55/41ARGAGCTHR19ACC0.65 ± 1.1 (4)
55/41ARGAGGVAL19GTC0.96 ± 0.36 (3)
55/41ARGAGGSER19TCG0.065 (1)
55/41ARGAGGLEU19CTG1.1 ± 1.2 (4)
55/41ARGAGCGLY19GGC1.0 ± 0.6 (4)
56/42PROCCAGLY19GGC1.1 ± 0.8 (3)
56/42PROCCACYS19TGC0.21 (1)
56/42PROCCASER19AGC1.4 ± 0.4 (2)
56/42PROCCAGLN19CAG1.8 (1)
56/42PROCCALYS19AAG0.60 (1)
57/43ASNAACGLY 619GGC—
58/44LEUCTGSER19ACC<0.041 (1)
58/44LEUCTGASP19GAC<0.041 (1)
58/44LEUCTGARG19CGG<0.041 (1)
58/44LEUCTGGLN19CAG<0.041 (1)
58/44LEUCTGVAL19GTC<0.041 (1)
58/44LEUCTGCYS19TGC—
59/45GLUGAGTYR19TAC0.41 ± 0.37 (5)
59/45GLUGAGHIS19CAC0.38 ± 0.31 (2)
59/45GLUGAGLEU19CTC0.46 ± 0.36 (6)
59/45GLUGAGPRO19CCC—
59/45GLUGAGARG19CGC0.15 (1)
60/46ALAGCASER19AGC0.91 ± 0.55 (4)
60/46ALAGCAPRO19CCC—
60/46ALAGCATYR19TAC<0.008 (1)
60/46ALAGCAASN19AAC0.38 (1)
60/46ALAGCATHR19ACG0.21 (1)
61/47PHETTCASN19AAC—
61/47PHETTCGLU19GAG<0.010 (1)
61/47PHETTCPRO19CCC—
61/47PHETTCLYS19AAG<0.010 (1)
61/47PHETTCARG19CGC0.006 (1)
61/47PHETTCSER19TCG0.17 (1)
62/48ASNAACHIS19CAC—
62/48ASNAACVAL19GTG0.37 ± 0.25 (4)
62/48ASNAACARG19AGG—
62/48ASNAACPRO 719CCG1.6 ± 0.4 (3)
62/48ASNAACPRO19CCG2.0 ± 0.3 (3)
62/48ASNAACTHR 819ACG2.3 ± 1.1 (3)
62/45ASNAACASP19GAC—
62/48ASNAACILE19ATC0.56 ± 0.24 (4)
63/49ARGA(G/A)GTYR19TAC0.47 (1)
63/49ARGA(G/A)GTRP19TGG0.09 (1)
63/49ARGA(G/A)GLYS19AGG0.52 (1)
63/49ARGA(G/A)GSER 919TCC0.13 (1)
63/49ARGA(G/A)GHIS19CAC0.42 ± 0.25 (7)
63/49ARGA(G/A)GPRO19CCG<0.014 ± 0.013(2)
63/49ARGA(G/A)GVAL19GTG0.39 ± 0.34 (3)
64/50ALAGCTASN19AAC1.5 ± 2.9 (4)
64/50ALAGCTPRO19CCG<0.023 (1)
64/50ALAGCTSER19AGC<0.023 (1)
64/50ALAGCTLYS19AAG<0.047 (1)
65/51VALGTCTHR19ACC0.71 ± 0.64 (3)
65/51VALGTCPRO19CCG<0.014 (1)
65/51VALGTCHIS19CAC<0.014 (1)
65/51VALGTCLEU19CTC0.42 (1)
65/51VALGTCPHE19TTC0.061 (1)
65/51VALGTCSER19TCC0.34 (1)
66/52LYSAAGILE 1019ATC0.42 (1)
66/52LYSAAGARG19AGG0.79 ± 0.18 (2)
66/52LYSAAGVAL19GTC0.38 ± 0.17 (2)
66/52LYSAAGASN19AAC0.32 (1)
66/52LYSAAGGLU19GAG0.14 (1)
66/52LYSAAGSER19TCG0.31 (1)
66/52LYSAAGVAL 1119GTG0.055 (1)
67/53SERAGTALA19GCG<0.014 (1)
67/53SERAGTPHE19TTC1.2 ± 0.2 (2)
67/53SERAGTVAL19GTG0.24 (1)
67/53SERAGTGLY19GGG0.50 ± 0.29 (4)
67/53SERAGTASN19AAC0.52 ± 0.28 (7)
67/53SERAGTILE19ATC0.29 (1)
67/53SERAGTPRO19CCG0.055 (1)
67/53SERAGTHIS19CAC0.99 ± 0.62 (6)
68/54LEUTTAVAL19GTC0.14 (1)
68/54LEUTTATRP19TGG0.07 (1)
68/54LEUTTASER19AGC<0.003 (1)
68/54LEUTTAILE19ATC0.84 ± 0.47 (3)
68/54LEUTTAPHE19TTC1.7 ± 0.3 (3)
68/54LEUTTATHR19ACG0.011 (1)
68/54LEUTTAHIS19CAC0.82 ± 0.45 (2)
69/55GLNCAGALA19GCG1.2 ± 0.8 (3)
69/55GLNCAGPRO19CCA0.74 0.45 (4)
69/55GLNCAGTHR19ACG0.97 ± 0.46 (4)
69/55GLNCAGTRP19TGG—
69/55GLNCAGGLU19GAG1.4 ± 0.7 (3)
69/55GLNCAGARG19CGG1.4 ± 1.1 (3)
69/55GLNCAGGLY19GGG0.68 ± 0.02 (2)
69/55GLNCAGLEU19CTC—
70/56ASNAA(C/T)LEU19TTG0.032 (1)
70/56ASNAA(C/T)VAL19GTG—
70/56ASNAA(C/T)TRP19TGG—
70/56ASNAA(C/T)PRO 1219CCG0.43 ± 0.29 (2)
70/56ASNAA(C/T)ALA 1319GCC0.03 (1)
71/57ALAGCAMET19ATG0.23 (1)
71/57ALAGCALEU19CTG<0.005 (1)
71/57ALAGCAPRO19CCC0.58 (1)
71/57ALAGCAARG19AGG0.66 (1)
71/57ALAGCAGLU19GAG0.46 ± 0.27
71/57ALAGCATHR19ACC0.34 ± 0.41 (3)
71/57ALAGCAGLN19GGC0.42 ± 0.32 (3)
71/57ALAGCATRP19TGG—
71/57ALAGCAASN19AAC0.09 (1)
72/58SERTCAGLU19GAG0.62 ± 0.27 (3)
72/56SERTCAMET19ATG0.45 ± 0.55 (3)
72/58SERTCAALA19GCC0.48 ± 0.33 (3)
72/58SERTCAHIS19CAC0.10 (1)
72/58SERTCAASN19AAC0.38 ± 0.44 (3)
72/58SERTCAARG19CGG0.81 ± 0.43 (4)
72/58SERTCAASP19GAC0.58 ± 0.39 (3)
73/59ALAGCAGLU19GAG0.49 ± 0.32 (3)
73/59ALAGCAASP19GAC0.27 (1)
73/59ALAGCALEU19CTG0.55 ± 0.45 (4)
73/59ALAGCASER19AGC0.37 ± 0.36 (2)
73/59ALAGCAGLY19CGG0.38 ± 0.32 (3)
73/59ALAGCATHR19ACC0.31 (1)
73/59ALAGCAARG19AGG0.40 ± 0.18 (3)
74/60ILEAT(T/C)MET19ATG<0.16 (1)
74/60ILEAT(T/C)THR19ACG—
74/60ILEAT(T/C)PRO19CCG—
74/60ILEAT(T/C)ARG19AGG—
74/60ILEAT(T/C)GLY19GCG0.006 (1)
74/60ILEAT(T/C)ALA19GCG—
75/61GLUGAGLYS19AAG0.07 ± 0.07 (2)
75/61GLUGAGGLY19GGG0.27 ± 0.20 (2)
75/61GLUGAGASP19GAC0.18 (1)
75/61GLUGAGPRO19CCG—
75/61GLUGAGTRP19TGG—
75/61GLUGAGARG19CGG—
75/61GLUGAGSER19TCG0.27 ± 0.22 (3)
75/61GLUGAGGLN19CAG0.40 ± 0.38 (3)
75/61GLUGAGLEU19TTG—
76/62SERAGCVAL19GTG1.0 ± 0.2 (2)
76/62SERAGCALA19GCG0.94 ± 0.46 (2)
76/62SERAGCASN19AAC1.2 (1)
76/62SERAGCTRP19TGG—
76/62SERAGCGLU19GAG0.90 ± 0.19 (2)
76/62SERAGCPRO19CCG2.1 ± 0.8 (4)
76/62SERAGCGLY19GGC1.3 ± 1.0 (4)
76/62SERAGCASP19GAC0.29 (1)
77/63ILEATTSER19AGC0.48 ± 0.38 (4)
77/63ILEATTARG19CGC0.09 ± 0.04 (2)
77/63ILEATTTHR19ACG<0.008 (1)
77/63ILEATTLEU19TTG2.0 ± 0.1 (3)
78/64LEUCTTALA19GCG—
78/64LEUCTTSER19TCC—
78/64LEUCTTGLU19GAG<0.006 (1)
78/64LEUCTTPHE19TTC—
78/64LEUCTTGLY19GGG—
78/64LEUCTTARG19AGG—
79/65LYSAA(A/G)THR19ACA0.77 ± 0.91 (6)
79/65LYSAA(A/G)GLY19GGG1.1 ± 0.9 (6)
79/65LYSAA(A/G)ASN19AAC1.0 ± 0.6 (6)
79/65LYSAA(A/G)MET19ATG1.6 ± 0.7 (6)
79/65LYSAA(A/G)ARG19CGC1.04 ± 0.7 (7)
79/65LYSAA(A/G)ILE19ATC1.0 ± 0.6 (6)
79/65LYSAA(A/G)GLY19GGG1.2 ± 0.4 (6)
79/65LYSAA(A/G)ASP19GAC0.72 ± 0.38 (7)
80/66ASNAATTRP19TGG—
80/66ASNAATVAL19GTC0.32 (1)
80/66ASNAATGLY19GGC1.5 ± 1.4 (4)
80/66ASNAATTHR19ACG0.13 (1)
80/66ASNAATLEU19CTG0.33 ± 0.14 (2)
80/66ASNAATGLU19GAG1.1 ± 0.8 (4)
80/66ASNAATARG19AGG1.0 ± 0.8 (4)
81/67LEUCTCGLN19CAA—
81/67LEUCTCGLY19GGC<0.023 (1)
81/67LEUCTCALA19GCG<0.047 (1)
81/67LEUCTCTRP19TGG<0.005 (1)
81/67LEUCTCARG19CGG—
81/67LEUCTCVAL19GTG0.16 ± 0.18 (2)
81/67LEUCTCLYS19AAG—
82/68LEUC(TG/CC)GLN19CAG1.8 ± 0.3 (3)
82/68LEUC(TG/CC)LYS19AAG0.05 (1)
82/68LEUC(TG/CC)TRP19TGG2.7 ± 1.3 (4)
82/68LEUC(TG/CC)ARG19AGC1.1 ± 0.2 (3)
82/68LEUC(TG/CC)ASP19GAC2.7 ± 1.3 (4)
82/68LEUC(TG/CC)VAL19GTG1.5 ± 1.1 (5)
83/69PROCCAALA19GCA0.41 (1)
83/69PROCCATHR19ACC0.66 ± 0.12 (3)
83/69PROCCAARG19CGG—
83/69PROCCATRP19TGG0.29 (1)
83/69PROCCAMET19ATG0.43 ± 0.28 (3)
84/70CYSTG(T/C)GLU19GAG<0.014 (1)
84/70CYSTG(T/C)GLY19GGG<0.006 (1)
84/70CYSTG(T/C)ARG19AGG—
84/70CYSTG(T/C)MET19ATG—
84/70CYSTG(T/C)VAL19GTG—
85/71LEUCTGASN19AAC—
85/71LEUCTGVAL19GTG0.52 ± 0.21 (5)
85/71LEUCTGGLN19CAG—
86/72PROCCCCYS19TGC—
86/72PROCCCARG19AGG—
86/72PROCCCALA19GCG—
86/72PROCCCLYS19AAG—
87/73LEU(C/A)TGSER19AGC1.5 ± 0.4 (3)
87/73LEU(C/A)TGTRP19TGG—
87/73LEU(C/A)TGGLY19GGG—
88/74ALAGCCLYS19AAG—
88/74ALAGCCARG19AGG0.11 ± 0.10 (2)
88/74ALAGCCVAL19GTG0.09 ± 0.02 (2)
88/74ALAGCCTRP19TGG1.8 ± 0.2 (2)
89/75THRAC(G/A)ASP19GAC0.24 ± 0.10 (2)
89/75THRAC(G/A)CYS19TGC—
89/75THRAC(G/A)LEU19CTC0.01 (1)
89/75THRAC(G/A)VAL19GTG0.08 (1)
69/75THRAC(G/A)GLU19GAG0.11 (1)
89/75THRAC(G/A)HIS19CAC0.16 ± 0.06 (2)
89/75THRAC(G/A)ASN19AAC0.21 ± 0.04 (2)
89/75THRAC(G/A)SER19TCG0.25 ± 0.07 (2)
90/76ALAGCCPRO19CCC0.03 (1)
90/76ALAGCCSER19TCG—
90/76ALAGCCTHR19ACC0.48 (1)
90/76ALAGCCGLY19GGC<0.006 (1)
90/76ALAGCCASP19GAC0.44 ± 0.29 (4)
90/76ALAGCCILE19ATC—
90/76ALAGCCMET19ATG0.25 ± 0.13 (2)
91/77ALAGCAPRO19CCC1.9 ± 1.2 (3)
91/77ALAGCASER19TCC0.12 ± 0.07 (2)
91/77ALAGCATHR19ACC0.48 ± 0.16 (2)
91/77ALAGCAPHE19TTC0.44 ± 0.50 (3)
91/77ALAGCALEU19CTC0.43 ± 0.27 (S)
91/77ALAGCAASP19GAC0.55 ± 0.09 (2)
91/77ALAGCAHIS19CAC—
92/76PROCCCPHE19TTC—
92/78PROCCCARG19CGG—
92/78PROCCCSER19AGC0.26 (1)
92/78PROCCCLYS19AAG—
92/78PROCCCHIS19CAC—
92/78PROCCCLEU19CTG—
93/79THRACGASP19GAC1.3 ± 0.7 (4)
93/79THRACGSER19TCG0.70 ± 0.56 (4)
93/79THRACGASN19AAC—
93/79THRACGPRO19CCC0.53 ± 0.36 (4)
93/79ThRACGALA19GCG1.13 ± 0.2 (3)
93/79THRACGLEU19CTG0.69 ± 0.42
93/79THRACGARG19CGC0.93 ± 0.96 (4)
94/80ARGCGAILE19ATC<0.020 (1)
94/80ARGCGASER19TCC<0.100 (1)
94/80ARGCGAGLU19GAG<0.020 (1)
94/90ARGCGALEU19CTG<0.020 (1)
94/50ARGCGAVAL19GTG<0.024 (1)
94/80ARGCGAPRO19CCC<0.024 (1)
95/81HISCATGLN19CAG<0.010 (1)
95/81HISCATPRO19CCG1.6 ± 0.8 (3)
95/81HISCATARG19CGC4.7 ± 5.9 (2)
95/81HISCATVAL19GTC1.2 ± 1.7 (2)
95/81HISCATLEU19CTC0.7 (1)
95/81HISCATGLY19GGC1.7 ± 2.4 (5)
95/81HISCATTHR19ACC2.9 ± 4.5 (4)
95/81HISCATTYR19TAC0.07 (1)
96/82PROCCALYS19AAG<0.010 ± 0.001 (2)
96/82PROCCATYR19TAC0.69 (1)
96/82PROCCAGLY19GGG<0.040 (1)
96/82PROCCAILE19ATC<0.040 (1)
96/82PROCCATHR19ACC<0.040 (1)
97/83ILEATCVAL19GTC0.91 ± 1.2 (8)
97/83ILEATCLYS19AAG<0.024
97/83ILEATCALA19GCG0.15 (1)
97/83ILEATCASN19AAT<0.02 (1)
98/84HISCATILE19ATC5.0 ± 4.9 (12)
98/84HISCATASN19AAC1.4 ± 0.4 (2)
98/84HISCATLEU19CTC2.4 ± 1.0 (2)
98/84HISCATASP19GAC0.38 ± 0.49 (5)
98/84HISCATALA19GCC2.0 ± 1.0 (3)
98/84HISCATTHR19ACG1.6 ± 0.3 (2)
98/84HISCATLEU19TTG1.5 (1)
98/84HISCATPRO19CCG0.55 (1)
99/85ILEATCLEU19CTG1.4 ± 1.4 (7)
99/85ILEATCARG19CGC<0.025 (1)
99/85ILEATCASP19GAC<0.025 (1)
99/65ILEATCVAL19GTC0.51 ± 0.59 (3)
99/55ILEATCPRO19CCG<0.025 (1)
99/85ILEATCGLN19CAG<0.018 ± 0.010 (2)
99/85ILEATCGLY19GGG<0.018 ± 0.10 (2)
99/85ILEATCSER19TCG<0.025 (1)
99/85ILEATCPHE19TTC0.45 (1)
99/85ILEATCHIS19CAC<0.025 (1)
100/86LYSAAGTYR19TAC0.03 (1)
100/96LYSAAGLEU19TTG0.33 ± 0.31 (3)
100/96LYSAAGHIS19CAC0.36 ± 0.22 (9)
100/86LYSAAGARG19AGC4.7 ± 5.9 (4)
100/86LYSAAGILE19ATC0.95 (1)
100/86LYSAAGSER19AGC0.95 (1)
100/86LYSAAGGLN19CAG0.78 ± 0.80 (7)
100/86LYSAAGPRO19CCG0.70 (1)
101/87ASPGACPRO19CCC2.3 ± 3.1 (4)
101/87ASPGACMET19ATG1.8 ± 2.5 (6)
101/87ASPGACLYS19AAG1.2 ± 1.7 (3)
101/87ASPGACHIS19CAC2.5 (1)
101/87ASPGACTHR19ACG0.90 ± 0.77 (3)
101/87ASPGACTYR19TAC0.59 (1)
101/87ASPGACVAL19GTC0.42 (1)
101/87ASPGACTYR19TAC1.0 ± 0.02 (2)
101/87ASPGACGLN19CAG0.07 (1)
102/88GLYGGTLEU19CTC<0.015 ± 0.007 (2)
102/88GLYGGTGLU19GAG0.40 ± 0.07 (3)
102/88GLYGGTLYS19AGG0.16 ± 0.14 (2)
102/88GLYGGTSER19TCC0.29 (1)
102/88GLYGGTTYR19TAC0.04 (1)
102/88GLYGGTPRO19CCC<0.011 (1)
103/89ASPGACSER19TCC0.02 (1)
104/90TRPTGGVAL19GTG0.11 ± 0.06 (5)
104/90TRPTGGCYS19AGC0.07 ± 0.03 (5)
104/90TRPTGGTYR19TAC0.34 ± 0.42 (5)
104/90TRPTGGTHR19ACC0.04 ± 0.02 (2)
104/90TRPTGGMET19ATG0.14 (1)
104/90TRPTGGPRO19CCC0.02 ± 0.02 (2)
104/90TRPTGGLEU19TTG0.65 ± 1.0 (3)
104/90TRPTGGGLN19CAG0.008 (1)
104/90TRPTGGLYS19AAG—
104/90TRPTGGGLY19GAG—
104/90TRPTGGALA19GCC—
104/90TRPTGGPHE19TTC—
104/90TRPTGGGLY19GGC—
105/91ASNAATPRO19CCG4.8 ± 8.5 (5)
105/91ASNAATALA19GCC0.65 ± 0.30 (3)
105/91ASNAATPHE19TTC0.13 (1)
105/91ASNAATSER19TCC1.9 ± 2.7 (5)
105/91ASNAATTRP19TGG0.95 (1)
105/91ASNAATGLN19CAA0.57 ± 0.52 (3)
105/91ASNAATTYR19TAC0.66 ± 0.53 (4)
105/91ASNAATLEU19CTC0.87 ± 0.79 (2)
105/91ASNAATLYS19AAG0.70 (1)
105/91ASNAATILE19ATC1.0 (1)
105/91ASNAATASP19GAC1.0 ± 0.9 (4)
105/91ASNAATHIS19CAC0.71 ± 0.48 (2)
106/92GLUGAASER19TCC0.17 ± 0.21 (2)
106/92GLUGAAALA19GCG0.235 ± 0.26 (2)
106/92GLUGAALYS19AAG—
106/92GLUGAATHR19ACC—
106/92GLUGAAILE19ATC—
106/92GLUGAAGLY19GGC0.70 ± 0.76 (4)
106/92GLUGAAPRO19CCC—
108/94ARGCGGLYS19AAG0.11 ± 0.03 (2)
108/94ARGCGGASP19GAC—
108/94ARGCGGLEU19TTG0.01 (1)
108/94ARGCGGTHR19ACG0.08 (1)
108/94ARGCGGILE19ATC<0.01 (1)
108/94ARGCGGPRO19CCC—
109/95ARGAGGTHR19ACC1.1 ± 0.2 (3)
109/95ARGAGGPRO19CCC—
109/95ARGAGGGLU19GAG1.1 ± 0.1 (3)
109/95ARGAGGTYR19TAC<0.006 (1)
109/95ARGAGGLEU19CTC1.2 ± 0.9 (4)
109/95ARGAGGSER19TCG1.7 ± 0.8 (4)
109/95ARGAGGGLY19GGG0.17 (1)
110/96LYSAAAALA19GCC<0.08 (1)
110/96LYSAAAASN19AAC—
110/96LYSAAATHR19ACG—
110/96LYSAAALEU19CTC—
110/96LYSAAAARG19CGG—
110/96LYSAAAGLN19CAG—
110/96LYSAAATRP19TGG—
111/97LEUCTGILE19ATC—
111/97LEUCTGARG19CGG—
111/97LEUCTGASP19GAC—
111/97LEUCTGMET19ATG—
112/98THRACGVAL19GTG0.55 ± 0.44 (3)
112/98THRACGGLN19CAG1.7 ± 1.0 (3)
112/98THRACGTYR19TAC<0.018 (1)
112/98THRACGGLU19GAG0.12 (1)
112/98THRACGHIS19CAC0.25 ± 0.40 (3)
112/99THRACGSER19TCC0.17 ± 0.15 (2)
112/98THRACGPHE19TTC—
113/99PHETTCSER19AGC—
113/99PHETTCCYS19TGC—
113/99PHETTCHIS19CAC<0.009 (1)
113/99PHETTCGLY19GGC—
113/99PHETTCTRP19TGG—
113/99PHETTCTYR19TAC0.07 (1)
113/99PHETTCASN19AAC—
114/100TYRTATCYS19TGC—
114/100TYRTATHIS19CAC—
114/100TYRTATSER19AGC—
114/100TYRTATTRP19TGG0.88 (1)
114/100TYRTATARG19AGG—
114/100TYRTATLEU19CTC<0.018 (1)
115/101LEUCTGASN19AAC<0.004 (1)
115/101LEUCTGVAL19GTG—
115/101LEUCTGPRO19CCC<0.004 (1)
115/101LEUCTGARG19AGG<0.004 (1)
115/101LEUCTGALA19GCG0.50 (1)
115/101LEUCTGHIS19CAC—
115/101LEUCTGTHR19ACC—
115/101LEUCTGTRP19TGG—
115/101LEUCTGMET19ATG<0.008 (1)
116/102LYSAAALEU 1419TTG—
116/102LYSAAAPRO 1419CCG<0.004 (1)
116/102LYSAAATHR 1419ACC0.50 (1)
116/102LYSAAAMET 1419ATG0.13 (1)
116/102LYSAAAASP 1419GAC<0.018 (1)
116/102LYSAAAVAL19GTG2.3 ± 1.2 (5)
116/102LYSAAAGLU19GAG0.06 (1)
116/102LYSAAAARG19CGC0.06 (1)
116/102LYSAAATRP19TGG2.3 ± 1.0 (4)
116/102LYSAAASER19TCG0.69 ± 0.51 (5)
116/102LYSAAALEU19CTC0.14 ± 0.02 (2)
116/102LYSAAAILE19ATC1.3 ± 0.3 (3)
116/102LYSAAATHR19ACG0.84 ± 0.30 (4)
117/103THRACCSER19AGC1.1 ± 0.2 (3)
117/103THRACCASN19AAC0.31 ± 0.39 (3)
117/103THRACCILE19ATC—
117/103THRACCTRP19TGG0.02 (1)
117/103THRACCLYS19AAG<0.005 (1)
117/103THRACCPRO19CCG—
118/104LEUCTTSER19TCA—
118/104LEUCTTPRO19CCC—
118/104LEUCTTALA19GCC—
118/104LEUCTTGLU19GAG—
118/104LEUCTTCYS19TGC—
118/104LEUCTTASP19GAC—
118/104LEUCTTTYR19TAC—
119/105GLUGAGSER19TCC0.26 ± 0.19 (2)
119/105GLUGAGLYS19AAG0.04 (1)
119/105GLUGAGPRO19CCG0.31 ± 0.27 (3)
119/105GLUGAGLEU19CTG0.35 ± 0.35 (3)
119/105GLUGAGTHR19ACC0.25 ± 0.27 (3)
119/105GLUGAGTYR19TAC0.30 ± 0.32 (3)
119/105GLUGAGARG19CGC0.06 (1)
120/106ASNAATALA19GCC<0.009 (1)
120/106ASNAATPRO19CCC1.7 ± 0.7 (3)
120/106ASNAATLEU19TTG1.2 ± 0.3 (3)
120/106ASNAATHIS19CAC1.0 ± 0.3 (2)
120/106ASNAATVAL19GTG1.7 ± 0.3 (3)
120/106ASNAATGLN19CAG0.85 ± 0.16 (2)
121/107ALAGCGSER19AGC1.2 ± 0.2 (3)
121/107ALAGCGILE19ATC2.8 ± 2.5 (2)
121/107ALAGCGASN19AAC0.91 ± 0.77 (5)
121/107ALAGCGPRO19CCG1.3 (1)
121/107ALAGCGLYS19AAG0.26 ± 0.24 (2)
121/107ALAGCGASP19GAC1.8* ± 0.9 (3)
121/107ALAGCGGLY19GGC0.69 (1)
122/108GLNGCGSER19AGC0.9.6 ± 0.41 (3)
122/108GLNCA(G/A)MET19ATG1.7 ± 0.5 (3)
122/108GLNCA(G/A)TRP19TGG1.4 (1)
122/108GLNCA(G/A)ARG19AGG0.78 (1)
122/108GLNCA(G/A)PHE19TTC2.3 ± 1.1 (3)
122/108GLNCA(G/A)PRO19CCG1.0 (1)
122/108GLNCA(G/A)HIS19CAC1.4 (1)
122/108GLNCA(G/A)ILE19ATC2.7 ± 0.8 (3)
122/108GLNCA(G/A)TYR19TAC1.7 ± 0.3 (2)
122/108GLNCA(G/A)CYS19TGC0.58 (1)
123/109ALAGCTMET19ATG2.0 ± 0.2 (3)
123/109ALAGCTGLU19GAG2.1 ± 1.0 (3)
123/109ALAGCTHIS19CAC0.98 ± 0.72 (3)
123/109ALAGCTSER19AGC1.4 ± 0.8 (3)
123/109ALAGCTPRO19CCC0.64 ± 0.16 (2)
123/109ALAGCTTYR19TAC0.51 ± 0.25 (2)
123/109ALAGCTLEU19CTG1.2 ± 0.1 (2)
1 The first position number representes the amino acid position in (1-133)hIL-3 and the second number represents the position in (15-125)hIL-3 in which the Asn at position 15 of native hIL-3 is position 1 in (15-125)hIL-3 (See the numbering for Formula XI)
TABLE 7 — position/
mutantNATIVESUBSTITUTIONRELATIVE
pMON number(15-125) hiL-3amino acidamino acidSEQ ID NO:POTENCY
pMON1320145/31MGlnMet196.3
pMON1320251/37RAsnArg191.58
pMON1320351/37PAsnPro192.5
pMON1320451/37TAsnThr193.16
pMON1320556/42SProSer196.3
pMON1320698/84IHisIle196.3
pMON1320745/31VGlnVal194
pMON1320842/28DGlyAsp196.3
pMON1320942/28SGlySer1912.6
pMON1321042/28AGlyAla192.5
pMON1321146/32SAspSer1916
pMON1321282/68WLeuTrp195
pMON1321382/68DLeuAsp194
pMON13214100/86RLysArg194
pMON13215116/102WLysTrp1931
pMON1321623/9LIleLeu194
pMON1321732/18RLeuArg197.9
pMON1321832/18NLeuAsn192
pMON1321932/18ALeuAla191.58
pMON1322034/20SLeuSer196.3
pMON1322134/20MLeuMet196.3
pMON1322250/36DGluAsp197.9
pMON1322362/48IAsnIle19*
pMON13224166/52RLysArg194
pMON13225176/62PSerPro191.25
pMON1322677/63LIleLeu191.58
pMON1322722/8GGluGly190.008
pMON13228115/101MLeuMet190.04
pMON13229122/108IGlnIle191
pMON1323151/37HAsnHis191.25
pMON1323259/45LGluLeu191.99
pMON1323363/49HArgHis19*
pMON1323464/50NAlaAsn190.03
pMON1323565/51TValThr191.58
pMON1323676/62VSerVal192.5
pMON1323776/62ASerAla195
pMON1323891/77PAlaPro19*
pMON13240100/86QLysGln192.5
pMON13241101/87MAspMet196.3
pMON13242105/91NAsnAsn19*
pMON13243116/102VLysVal1979
pMON13244122/108FGlnPhe196.3
pMON13245123/109EAlaGln191.58
position/
mutantNATIVESUBSTITUTIONRELATVE
pMON number(1-133) hiL-3amino acidamino acidSEQ ID NO:POTENCY
pMON1324642DGlyAsp1520
pMON1324742SGlySer15*
pMON1324842AGlyAla1516
pMON1324945VGlnVal155
pMON1325045MGlnMet15*
pMON1325146SAspSer155
pMON1325250DGluAsp155
pMON13253981HisIle15*
pMON1326497VIleVal154
pMON1326675KGluLys150.25
pMON1326789NThrAsn152.5
TABLE 9 — (15-125) hIL-3 MUTANT
PARENTALBIOL
aa positionAAcodonAASEQ ID NO:codonACTIVITY
21/7ASPGATASN19AAC0.01
21/7ASPGATGLN19CAA0.07
21/7ASPGATGLU19GAA0.5
21/7ASPGATSER19AGC0.1
21/7ASPGATTHR19ACC0.1
22/8GLUGAAASN19AAC*
22/8GLUGAAASP19GAC*
22/8GLUGAAGLN19CAG<0.01
22/8GLUGAALEU19CTG*
22/8GLUGAAVAL19GTT*
34/20LEUTTGALA19GCT2.2
34/20LEUTTGARG19CGT2.2
34/20LEUTTGGLN19CAG1.1
34/20LEUTTGGLU19GAA1.5
34/20LEUTTGILE19ATC1.3
34/20LEUTTGPHE19TTC1.8
34/20LEUTTGTHR19ACC1.1
42/28GLYGGGASN19AAC1.3 (3) 0.28
42/28GLYGGGILE19ATC10
42/28GLYGGGLEU19CTG10.1 (3) 7.57
42/28GLYGGGMET19ATG2.2 (3) 1.14
42/28GLYGGGTYR19TAC11 (2) 8.9
42/28GLYGGGVAL19GTT0.33
43/29GLUGAAARG19CGT*
43/29GLUGAAGLN19CAG<0.004
43/29GLUGAAGLY19GGT*
43/29GLUGAATHR19ACC0.005
44/30ASPGACALA19GCT*
44/30ASPGACASN19AAC*
44/30ASPGACGLN19CAG*
44/30ASPGACGLU19GAA0.66
45/31GLNCAAALA19GCT1
45/31GLNCAAASN19AAC15.8
45/31GLNCAAGLU19GAA2.3
45/31GLNCAAILE19ATC4.9
45/31GLNCAASER19TCC0.7
46/32ASPGACALA19GCT6.3
46/32ASPGACASN19AAC0.66, 1.1
46/32ASPGACGLN19CAG6.3
46/32ASPGACGLU19GAA1.97 (3) 2.14
46/32ASPGACHIS19CAC3.2, 1.4
46/32ASPGACILE19ATC0.5
46/32ASPGACLYS19AAA0.5
46/32ASPGACTYR19TAC0.66
46/32ASPGACVAL19GTT6.3
48/34LEUCTGGLU19GAA*
48/34LEUCTGHIS19*
48/34LEUCTGLYS19AAA*
48/34LEUCTGTHR19ACC*
48/34LEUCTGVAL19CAC*
50/36GLUGAAALA19GCT0.5
50/36GLUGAAASN19AAC1.7
50/36GLUGAAHIS19CAC*
50/36GLUGAALYS19AAA*
50/36GLUGAASER19TCC1.3
50/36GLUGAAVAL19GTT*
54/40ARGCGAALA19GCT0.9
54/40AFGCGAASN19AAC*
54/40ARGCGAHIS19CAC0.01
54/40ARGCGALYS19AAA0.2
56/42PROCAAALA19GCT1.8
56/42PROCAAASN190.6
56/42PROCAAARG19CGT1.2
56/42PROCAAGLU19GAA0.9
56/42PROCAAHIS19CAC0.4
56/42PROCAALEU19CTG1.2
56/42PROCAAPHE19TTC
56/42PROCAATHR19ACC0.6
56/42PROCAAVAL19GTT1.1
82/68LEUCTGALA19GCT0.5
82/68LEUCTGASN19AAC2.9
82/68LEUCTGGLU19GAA4.57 (3) 5.0
82/68LEUCTGHIS19CAC2.2
82/68LEUCTGILE19ATC0.8
82/68LEUCTGMET19ATG1.1
82/68LEUCTGPHE19TTC3.2
82/68LEUCTGSER19TCC2.2
82/68LEUCTGTHR19ACC1.6
82/68LEUCTGTYR19TAC2.7
94/80ARGCGAGLN19CAG0.03
94/80ARGCGAHIS19CAC0.01
94/80ARGCGALYS19AAA*
95/81HISCATASN19AAC2.7 (2) 2.3
95/81HISCATILE19ATC0.33
95/81HISCATLYS19AAA0.9
95/81HISCATMET19ATG1
95/81HISCATPHE19TTC0.66
95/81HISCATSER19TCC4
95/81HISCATTRP19TGG*
98/84HISCATARG19CGT3.2
98/84HISCATGLN19CAA2.2
98/84HISCATGLU19GAA1.55 (2) 0.15
98/84HISCATLYS19AAA4
98/84HISCATMET19ATG2.2
98/84HISCATPHE19TTC1
98/84HISCATSER19TCC4
98/84HISCATTHR192.2
98/84HISCATVAL19GTA2.4 (2) 0.8
101/87ASPGACASN19AAC7
101/87ASPGACGLU19GAA*
101/87ASPGACILE19ATC3.2
101/87ASPGACLEU19CTG3.2
108/94ARGCGGALA19GCT4
108/94ARGCGGGLN19CAG0.4
108/94ARGCGGHIS19CAC*
108/94ARGCGGSER19TCC3.7
110/96LYSAAAGLU19GAA*
110/96LYSAAAHIS19CAC*
110/96LYSAAAILE19ATC*
113/99PHETTCASP19GAC*
113/99PHETTCILE19ATC*
113/99PHETTCLEU19CTG*
113/99PHETTCLYS19AAA*
116/102LYSAAAALA19GCT5
116/102LYSAAAARG19CGT0.03
116/102LYSAAAASN19AAC0.22
116/102LYSAAAGLN19CAG0.33
116/102LYSAAAHIS19CAC3.2
116/102LYSAAAMET19ATG0.9
116/102LYSAAAPHE19TTC2.5
116/102LYSAAATYR19TAC5.4 (2) 0.3
549
23 base pairsnucleic acidsinglelinear
DNA (synthetic)
1
133 amino acidsamino acidlinear
peptide
Modified-site/note= “Met- may or may not precede theamino acid in position 1”
Modified-site17/note= “Xaa at position 17 is Ser,Lys, Gly, Asp, Met, Gln, or Arg”
Modified-site18/note= “Xaa at position 18 is Asn,His, Leu, Ile, Phe, Arg, or Gln”
Modified-site19/note= “Xaa at positiion 19 is Met,Phe, Ile, Arg, Gly, Ala, or Cys”
Modified-site20/note= “Xaa at position 20 is Ile,Cys, Gln, Glu, Arg, Pro, or Ala”
Modified-site21/note= “Xaa at position 21 is Asp,Phe, Lys, Arg, Ala, Gly, Glu, Gln, Asn, Thr, Ser,or Val”
Modified-site22/note= “Xaa at position 22 is Glu,Trp, Pro, Ser, Ala, His, Asp, Asn, Gln, Leu, Val,or Gly”
Modified-site23/note= “Xaa at position 23 is Ile,Val, Ala, Leu, Gly, Trp, Lys, Phe, Leu, Ser, orArg”
Modified-site24/note= “Xaa at position 24 is Ile,Gly, Val, Arg, Ser, Phe, or Leu”
Modified-site25/note= “Xaa at position 25 is Thr,His, Gly, Gln, Arg, Pro, or Ala”
Modified-site26/note= “Xaa at position 26 is His,Thr, Phe, Gly, Arg, Ala, or Trp”
Modified-site27/note= “Xaa at position 27 is Leu,Gly, Arg, Thr, Ser, or Ala”
Modified-site28/note= “Xaa at position 28 is Lys,Arg, Leu, Gln, Gly, Pro, Val, or Trp”
Modified-site29/note= “Xaa at position 29 is Gln,Asn, Leu, Pro, Arg, or Val”
Modified-site30/note= “Xaa at position 30 is Pro,His, Thr, Gly, Asp, Gln, Ser, Leu, or Lys”
Modified-site31/note= “Xaa at position 31 is Pro,Asp, Gly, Ala, Arg, Leu, or Gln”
Modified-site32/note= “Xaa at position 32 is Leu,Val, Arg, Gln, Asn, Gly, Ala, or Glu”
Modified-site33/note= “Xaa at position 33 is Pro,Leu, Gln, Ala, Thr, or Glu”
Modified-site34/note= “Xaa at position 34 is Leu,Val, Gly, Ser, Lys, Glu, Gln, Thr, Arg, Ala, Phe,Ile, or Met”
Modified-site35/note= “Xaa at position 35 is Leu,Ala, Gly, Asn, Pro, Gln, or Val”
Modified-site36/note= “Xaa at position 36 is Asp,Leu, or Val”
Modified-site37/note= “Xaa at position 37 is Phe,Ser, Pro, Trp, or Ile”
Modified-site38/note= “Xaa at position 38 is Asn,or Ala”
Modified-site40/note= “Xaa at position 40 is Leu,Trp, or Arg”
Modified-site41/note= “Xaa at position 41 is Asn,Cys, Arg, Leu, His, Met, or Pro”
Modified-site42/note= “Xaa at position 42 is Gly,Asp, Ser, Cys, Asn, Lys, Thr, Leu, Val, Glu, Phe, Tyr,Ile, Met, or Ala”
Modified-site43/note= “Xaa at position 43 is Glu,Asn, Tyr, Leu, Phe, Asp, Ala, Cys, Gln, Arg, Thr, Gly,or Ser”
Modified-site44/note= “Xaa at position 44 is Asp,Ser, Leu, Arg, Lys, Thr, Met, Trp, Glu, Asn, Gln, Ala,or Pro”
Modified-site45/note= “Xaa at position 45 is Gln,Pro, Phe, Val, Met, Leu, Thr, Lys, Trp, Asp, Asn, Arg,Ser, Ala, Ile, Glu, or His”
Modified-site46/note= “Xaa at position 46 is Asp,Phe, Ser, Thr, Cys, Glu, Asn, Gln, Lys, His, Ala, Tyr,Ile, Val, or Gly”
Modified-site47/note= “Xaa at position 47 is Ile,Gly, Val, Ser, Arg, Pro, or His”
Modified-site48/note= “Xaa at position 48 is Leu,Ser, Cys, Arg, Ile, His, Phe, Glu, Lys, Thr, Ala, Met,Val, or Asn”
Modified-site49/note= “Xaa at position 49 is Met,Arg, Ala, Gly, Pro, Asn, His, or Asp”
Modified-site50/note= “Xaa at position 50 is Glu,Leu, Thr, Asp, Tyr, Lys, Asn, Ser, Ala, Ile, Val, His,Phe, Met, or Gln”
Modified-site51/note= “Xaa at position 51 is Asn,Arg, Met, Pro, Ser, Thr, or His”
Modified-site52/note= “Xaa at position 52 is Asn,His, Arg, Leu, Gly, Ser, or Thr”
Modified-site53/note= “Xaa at position 53 isLeu, Thr, Ala, Gly, Glu, Pro, Lys, Ser, or Met”
Modified-site54/note= “Xaa at position 54 is Arg,Asp, Ile, Ser, Val, Thr, Gln, Asn, Lys, His, Ala,or Leu”
Modified-site55/note= “Xaa at position 55 is Arg,Thr, Val, Ser, Leu, or Gly”
Modified-site56/note= “Xaa at position 56 is Pro,Gly, Cys, Ser, Gln, Glu, Arg, His, Thr, Ala, Tyr,Phe, Leu, Val, or Lys”
Modified-site57/note= “Xaa at position 57 is Asnor Gly”
Modified-site58/note= “Xaa at position 58 is Leu,Ser, Asp, Arg, Gln, Val, or Cys”
Modified-site59/note= “Xaa at position 59 is Glu,Tyr, His, Leu, Pro, or Arg”
Modified-site60/note= “Xaa at position 60 is Ala,Ser, Pro, Tyr, Asn, or Thr”
Modified-site61/note= “Xaa at position 61 is Phe,Asn, Glu, Pro, Lys, Arg, or Ser”
Modified-site62/note= “Xaa at position 62 is Asn,His, Val, Arg, Pro, Thr, Asp, or Ile”
Modified-site63/note= “Xaa at position 63 is Arg,Tyr, Trp, Lys, Ser, His, Pro, or Val”
Modified-site64/note= “Xaa at position 64 is Ala,Asn, Pro, Ser, or Lys”
Modified-site65/note= “Xaa at position 65 is Val,Thr, Pro, His, Leu, Phe, or Ser”
Modified-site66/note= “Xaa at position 66 is Lys,Ile, Arg, Val, Asn, Glu, or Ser”
Modified-site67/note= “Xaa at position 67 is Ser,Ala, Phe, Val, Gly, Asn, Ile, Pro, or His”
Modified-site68/note= “Xaa at position 68 is Leu,Val, Trp, Ser, Ile, Phe, Thr, or His”
Modified-site69/note= “Xaa at position 69 is Gln,Ala, Pro, Thr, Glu, Arg, Trp, Gly, or Leu”
Modified-site70/note= “Xaa at position 70 is Asn,Leu, Val, Trp, Pro, or Ala”
Modified-site71/note= “Xaa at position 71 isAla,Met,Leu,Pro,Arg,Glu,Thr,Gln,Trp,or Asn”
Modified-site72/note= “Xaa at position 72 is Ser,Glu, Met, Ala, His, Asn, Arg, or Asp”
Modified-site73/note= “Xaa at position 73 is Ala,Glu, Asp, Leu, Ser, Gly, Thr, or Arg”
Modified-site74/note= “Xaa at position 74 is Ile,Met, Thr, Pro, Arg, Gly, or Ala”
Modified-site75/note= “Xaa at position 75 isGlu, Lys, Gly, Asp, Pro, Trp, Arg, Ser, Gln,or Leu”
Modified-site76/note= “Xaa at position 76 is Ser,Val, Ala, Asn, Trp, Glu, Pro, Gly, or Asp”
Modified-site77/note= “Xaa at position 77 is Ile,Ser, Arg, Thr, or Leu”
Modified-site78/note= “Xaa at position 78 is Leu,Ala, Ser, Glu, Phe, Gly, or Arg”
Modified-site79/note= “Xaa at position 79 is Lys, Thr,Asn, Met, Arg, Ile, Gly, or Asp”
Modified-site80/note= “Xaa at position 80 is Asn,Trp, Val, Gly, Thr, Leu, Glu, or Arg”
Modified-site81/note= “Xaa at position 81 is Leu,Gln, Gly, Ala, Trp, Arg, Val, or Lys”
Modified-site82/note= “Xaa at position 82 is Leu,Gln, Lys, Trp, Arg, Asp, Glu, Asn, His, Thr, Ser, Ala,Tyr, Phe, Ile, Met, or Val”
Modified-site83/note= “Xaa at position 83 is Pro,Ala, Thr, Trp, Arg, or Met”
Modified-site84/note= “Xaa at position 84 is Cys,Glu, Gly, Arg, Met, or Val”
Modified-site85/note= “Xaa at position 85 is Leu,Asn, Val, or Gln”
Modified-site86/note= “Xaa at position 86 is Pro,Cys, Arg, Ala, or Lys”
Modified-site87/note= “Xaa at position 87 is Leu,Ser, Trp, or Gly”
Modified-site88/note= “Xaa at position 88 is Ala,Lys, Arg, Val, or Trp”
Modified-site89/note= “Xaa at position 89 is Thr,Asp, Cys, Leu, Val, Glu, His, Asn, or Ser”
Modified-site90/note= “Xaa at position 90 is Ala,Pro, Ser, Thr, Gly, Asp, Ile, or Met”
Modified-site91/note= “Xaa at position 91 is Ala,Pro, Ser, Thr, Phe, Leu, Asp, or His”
Modified-site92/note= “Xaa at position 92 is Pro,Phe, Arg, Ser, Lys, His, Ala, Gly, Ile, or Leu”
Modified-site93/note= “Xaa at position 93 is Thr,Asp, Ser, Asn, Pro, Ala, Leu, or Arg”
Modified-site94/note= “Xaa at position 94 is Arg,Ile, Ser, Glu, Leu, Val, Gln, Lys, His, Ala, or Pro”
Modified-site95/note= “Xaa at position 95 is His,Gln, Pro, Arg, Val, Leu, Gly, Thr, Asn, Lys, Ser, Ala,Trp, Phe, Ile, or Tyr”
Modified-site96/note= “Xaa at position 96 is Pro,Lys, Tyr, Gly, Ile, or Thr”
Modified-site97/note= “Xaa at position 97 is Ile,Val, Lys, Ala, or Asn”
Modified-site98/note= “Xaa at position 98 is His,Ile, Asn, Leu, Asp, Ala, Thr, Glu, Gln, Ser, Phe, Met,Val, Lys, Arg, Tyr, or Pro”
Modified-site99/note= “Xaa at position 99 is Ile,Leu, Arg, Asp, Val, Pro, Gln, Gly, Ser, Phe,or His”
Modified-site100/note= “Xaa at position 100 isLys, Tyr, Leu, His, Arg, Ile, Ser, Gln, or Pro”
Modified-site101/note= “Xaa at position 101 isAsp, Pro, Met, Lys, His, Thr, Val, Tyr, Glu, Asn, Ser,Ala, Gly, Ile, Leu, or Gln”
Modified-site102/note= “Xaa at position 102 is Gly,Leu, Glu, Lys, Ser, Tyr, or Pro”
Modified-site103/note= “Xaa at position 103 is Asp,or Ser”
Modified-site104/note= “Xaa at position 104 isTrp, Val, Cys, Tyr, Thr, Met, Pro, Leu, Gln, Lys, Ala,Phe, or Gly”
Modified-site105/note= “Xaa at position 105 isAsn, Pro, Ala, Phe, Ser, Trp, Gln, Tyr, Leu, Lys, Ile,Asp, or His”
Modified-site106/note= “Xaa at position 106 is Glu,Ser, Ala, Lys, Thr, Ile, Gly, or Pro”
Modified-site108/note= “Xaa at position 108 is Arg,Lys, Asp, Leu, Thr, Ile, Gln, His, Ser, Ala, or Pro”
Modified-site109/note= “Xaa at position 109 is Arg,Thr, Pro, Glu, Tyr, Leu, Ser, or Gly”
Modified-site110/note= “Xaa at position 110 is Lys,Ala, Asn, Thr, Leu, Arg, Gln, His, Glu, Ser, Ala,or Trp”
Modified-site111/note= “Xaa at position 111 is Leu,Ile, Arg, Asp, or Met”
Modified-site112/note= “Xaa at position 112 is Thr,Val, Gln, Tyr, Glu, His, Ser, or Phe”
Modified-site113/note= “Xaa at position 113 is Phe,Ser, Cys, His, Gly, Trp, Tyr, Asp, Lys, Leu, Ile, Val,or Asn”
Modified-site114/note= “Xaa at position 114 is Tyr,Cys, His, Ser, Trp, Arg, or Leu”
Modified-site115/note= “Xaa at position 115 isLeu, Asn, Val, Pro, Arg, Ala, His, Thr, Trp, orMet”
Modified-site116/note= “Xaa at position 116 is Lys,Leu, Pro, Thr, Met, Asp, Val, Glu, Arg, Trp, Ser,Asn, His, Ala, Tyr, Phe, Gln, or Ile”
Modified-site117/note= “Xaa at position 117 is Thr,Ser, Asn, Ile, Trp, Lys, or Pro”
Modified-site118/note= “Xaa at position 118 is Leu,Ser, Pro, Ala, Glu, Cys, Asp, or Tyr”
Modified-site119/note= “Xaa at position 119 is Glu,Ser, Lys, Pro, Leu, Thr, Tyr, or Arg”
Modified-site120/note= “Xaa at position 120 is Asn,Ala, Pro, Leu, His, Val, or Gln”
Modified-site121/note= “Xaa at position 121 is Ala,Ser, Ile, Asn, Pro, Lys, Asp, or Gly”
Modified-site122/note= “Xaa at position 122 isGln, Ser, Met, Trp, Arg, Phe, Pro, His, Ile, Tyr,or Cys”
Modified-site123/note= “Xaa at position 123 is Ala,Met, Glu, His, Ser, Pro, Tyr, or Leu”
15
133 amino acidsamino acidlinear
peptide
Modified-site/note= “Met- may or may not precedethe amino acid in position 1”
Modified-site17/note= “Xaa at position 17 is Ser,Gly, Asp, Met, or Gln”
Modified-site18/note= “Xaa at position 18 is Asn,His, Leu, Ile, Phe, Arg, or Gln”
Modified-site19/note= “Xaa at position 19 is Met,Phe, Ile, Arg, or Ala”
Modified-site20/note= “Xaa at position 20 is Ileor Pro”
Modified-site21/note; “Xaa at position 21 is Aspor Glu”
Modified-site23/note= “Xaa at position 23 is Ile,Val, Ala, Leu, or Gly”
Modified-site24/note= “Xaa at position 24 is Ile,Val, Phe, or Leu”
Modified-site25/note= “Xaa at position 25 is Thr,His, Gly, Gln, Arg, Pro, or Ala”
Modified-site26/note= “Xaa at position 26 is His,Phe, Gly, Arg, or Ala”
Modified-site28/note= “Xaa at position 28 is Lys,Leu, Gln, Gly, Pro, or Val”
Modified-site29/note= “Xaa at position 29 is Gln,Asn, Leu, Arg, or Val”
Modified-site30/note= “Xaa at position 30 is Pro,His, Thr, Gly, or Gln”
Modified-site31/note= “Xaa at position 31 is Pro,Asp, Gly, Ala, Arg, Leu, or Gln”
Modified-site32/note= “Xaa at position 32 Leu,Arg, Gln, Asn, Gly, Ala, or Glu”
Modified-site33/note= “Xaa at position 33 is Pro,Leu, Gln, Ala, or Glu”
Modified-site34/note= “Xaa at position 34 is Leu,Val, Gly, Ser, Lys, Ala, Arg, Gln, Glu, Ile, Phe,Thr, or Met”
Modified-site35/note= “Xaa at position 35 is Leu,Ala, Asn, Pro, Gln, or Val”
Modified-site36/note= “Xaa at position 36 is Aspor Leu”
Modified-site37/note= “Xaa at position 37 is Phe,Ser, Pro, Trp, or Ile”
Modified-site38/note= “Xaa at position 38 is Asnor Ala”
Modified-site41/note= “Xaa at position 41 is Asn,Cys, Arg, His, Met, or Pro”
Modified-site42/note= “Xaa at position 42 is Gly,Asp, Ser, Cys, Ala, Asn, Ile, Leu, Met, Tyr, Val,or Arg”
Modified-site44/note=“Xaa at position 44 is Asp orGlu”
Modified-site45/note= “Xaa at position 45 is Gln,Val, Met, Leu, Thr, Lys, Ala, Asn, Glu, Ser, or Trp”
Modified-site46/note= “Xaa at position 46 is Asp,Phe, Ser, Thr, Cys, Ala, Asn, Gln, Glu, His, Ile, Lys,Tyr, Val, or Gly”
Modified-site47/note= “Xaa at position 47 is Ile, Val,or His”
Modified-site49/note= “Xaa at position 49 is Met,Asn, or Asp”
Modified-site50/note= “Xaa at position 50 is Glu,Thr, Ala, Asn, Ser, or Asp”
Modified-site51/note= “Xaa at position 51 is Asn,Arg, Met, Pro, Ser, Thr, or His”
Modified-site52/note= “Xaa at position 52 is Asnor Gly”
Modified-site53/note= “Xaa at position 53 is Leu,Met, or Phe”
Modified-site54/note= “Xaa at position 54 is ArgAla, or Ser”
Modified-site55/note= “Xaa at position 55 is Arg,Thr, Val, Leu, or Gly”
Modified-site56/note= “Xaa at position 56 is Pro,Gly, Cys, Ser, Gln, Ala, Arg, Asn, Glu, His, Leu, Thr,Val, or Lys”
Modified-site59/note= “Xaa at position 59 is Glu,Tyr, His, Leu, or Arg”
Modified-site60/note= “Xaa at position 60 is Ala,Ser, Asn, or Thr”
Modified-site61/note= “Xaa at position 61 is Pheor Ser”
Modified-site62/note= “Xaa at position 62 is Asn,Val, Pro, Thr, or Ile”
Modified-site63/note= “Xaa at position 63 is Arg,Tyr, Lys, Ser, His, or Val”
Modified-site64/note= “Xaa at position 64 is Alaor Asn”
Modified-site65/note= “Xaa at position 65 is Val,Thr, Leu, or Ser”
Modified-site66/note= “Xaa at position 66 is Lys,Ile, Arg, Val, Asn, Glu, or Ser”
Modified-site67/note= “Xaa at position 67 is Ser,Phe, Val, Gly, Asn, Ile, or His”
Modified-site68/note= “Xaa at position 68 is Leu,Val, Ile, Phe, or His”
Modified-site69/note= “Xaa at position 69 is Gln,Ala, Pro, Thr, Glu, Arg, or Gly”
Modified-site70/note= “Xaa at position 70 is Asnor Pro”
Modified-site71/note= “Xaa at position 71 is Ala,Met, Pro, Arg, Glu, Thr, or Gln”
Modified-site72/note= “Xaa at position 72 is Ser,Glu, Met, Ala, His, Asn, Arg, or Asp”
Modified-site73/note= “Xaa at position 73 is Ala,Glu, Asp, Leu, Ser, Gly, Thr, Arg, or Pro”
Modified-site74/note= “Xaa at position 74 is Ileor Met”
Modified-site75/note= “Xaa at position 75 is Glu,Gly, Asp, Ser, or Gln”
Modified-site76/note= “Xaa at position 76 is Ser,Val, Ala, Asn, Glu, Pro, Gly, or Asp”
Modified-site77/note= “Xaa at position 77 is Ile,Ser, or Leu”
Modified-site79/note= “Xaa at position 79 is Lys,Thr, Gly, Asn, Met, Arg, Ile, Gly, or Asp”
Modified-site80/note= “Xaa at position 80 is Asn,Val, Gly, Thr, Leu, Glu, or Arg”
Modified-site81/note= “Xaa at position 81 is Leuor Val”
Modified-site82/note= “Xaa at position 82 is Leu,Gln, Trp, Arg, Asp, Ala, Asn, Glu, His, Met, Phe,Ser, Thr, Tyr, or Val”
Modified-site83/note= “Xaa at position 83 is Pro,Ala, Thr, Trp, or Met”
Modified-site85/note= “Xaa at position 85 is Leuor Val”
Modified-site87/note= “Xaa at position 87 is Leuor Ser”
Modified-site88/note= “Xaa at position 88 is Ala,Arg, or Trp”
Modified-site89/note= “Xaa at position 89 is Thr,Asp, Glu, His, Asn, or Ser”
Modified-site90/note= “Xaa at position 90 is Ala,Asp, or Met”
Modified-site91/note= “Xaa at position 91 is Ala,Pro, Ser, Thr, Phe, Leu, or Asp”
Modified-site92/note= “Xaa at position 92 is Proor Ser”
Modified-site93/note= “Xaa at position 93 is Thr,Asp, Ser, Pro, Ala, Leu, or Arg”
Modified-site95/note= “Xaa at position 95 is His,Pro, Arg, Val, Leu, Gly, Asn, Ile, Phe, Ser,or Thr”
Modified-site96/note= “Xaa at position 96 is Proor Tyr”
Modified-site97/note= “Xaa at position 97 is Ile,Val, or Ala”
Modified-site98/note= “Xaa at position 98 is His,Ile, Asn, Leu, Asp, Ala, Thr, Leu, Arg, Gln, Glu,Lys, Met, Ser, Tyr, Val, or Pro”
Modified-site99/note= “Xaa at position 99 is Ile,Leu, Val, or Phe”
Modified-site100/note= “Xaa at position 100 is Lys,Leu, His, Arg, Ile, Gln, Pro, or Ser”
Modified-site101/note= “Xaa at position 101 is Asp,Pro, Met, Lys, His, Thr, Val, Asn, Ile, Leu, or Tyr”
Modified-site102/note= “Xaa at position 102 is Gly,Glu, Lys, or Ser”
Modified-site104/note= “Xaa at position 104 is Trp,Val, Tyr, Met, or Leu”
Modified-site105/note= “Xaa at position 105 isAsn, Pro, Ala, Phe, Ser, Trp, Gln, Tyr, Leu, Lys,Ile, Asp or His”
Modified-site106/note= “Xaa at position 106 is Glu,Ser, Ala, or Gly”
Modified-site108/note= “Xaa at position 108 is Arg,Ala, Gln, Ser, or Lys”
Modified-site109/note= “Xaa at position 109 is Arg,Thr, Glu, Leu, Ser, or Gly”
Modified-site112/note= “Xaa at position 112 is Thr,Val, Gln, Glu, His, or Ser”
Modified-site114/note= “Xaa at position 114 is Tyror Trp”
Modified-site115/note= “Xaa at position 115 is Leuor Ala”
Modified-site116/note= “Xaa at position 116 is Lys,Thr, Met, Val, Trp, Ser, Leu, Ala, Asn, Gln, His, Met,Phe, Tyr, or Ile”
Modified-site117/note= “Xaa at position 117 is Thr,Ser, or Asn”
Modified-site119/note= “Xaa at position 119 isGlu, Ser, Pro, Leu, Thr, or Tyr”
Modified-site120/note= “Xaa at position 120 is Asn,Pro, Leu, His, Val, or Gln”
Modified-site121/note= “Xaa at position 121 is Ala,Ser, Ile, Asn, Pro, Lys, Asp, or Gly”
Modified-site122/note= “Xaa at position 122 isGln, Ser, Met, Trp, Arg, Phe, Pro, His, Ile, Tyr,or Cys”
Modified-site123/note= “Xaa at position 123 is Ala,Met, Glu, His, Ser, Pro, Tyr, or Leu”
16
133 amino acidsamino acidlinear
peptide
Modified-site/note= “Met- may or may not precedethe amino acid in position 1”
Modified-site17/note= “Xaa at position 17 is Ser,Gly, Asp, Met, or Gln”
Modified-site18/note= “Xaa at position 18 is Asn,His, or Ile”
Modified-site19/note= “Xaa at position 19 is Metor Ile”
Modified-site21/note= “Xaa at position 21 is Aspor Glu”
Modified-site23/note= “Xaa at position 23 is Ile,Ala, Leu, or Gly”
Modified-site24/note= “Xaa at position 24 is Ile,Val, or Leu”
Modified-site25/note= “Xaa at position 25 is Thr,His, Gln, or Ala”
Modified-site26/note= “Xaa at position 26 is Hisor Ala”
Modified-site29/note= “Xaa at position 29 is Gln,Asn, or Val”
Modified-site30/note= “Xaa at position 30 is Pro,Gly, or Gln”
Modified-site31/note= “Xaa at position 31 is Pro,Asp, Gly, or Gln”
Modified-site32/note= “Xaa at position 32 is Leu,Arg, Gln, Asn, Gly, Ala, or Glu”
Modified-site33/note= “Xaa at position 33 is Proor Glu”
Modified-site34/note= “Xaa at position 34 is Leu,Val, Gly, Ser, Lys, Ala, Arg, Gln, Glu, Ile, PheThr, or Met”
Modified-site35/note= “Xaa at position 35 is Leu,Ala, Asn, Pro, Gln, or Val”
Modified-site37/note= “Xaa at position 37 is Phe,Ser, Pro, or Trp”
Modified-site38/note= “Xaa at position 38 is Asnor Ala”
Modified-site42/note= “Xaa at position 42 is Gly,Asp, Ser, Cys, Ala, Asn, Ile, Leu, Met, Tyr, or Arg”
Modified-site45/note= “Xaa at position 45 is Gln,Val, Met, Leu, Thr, Ala, Asn, Glu, Ser, or Lys”
Modified-site46/note= “Xaa at position 46 is Asp,Phe, Ser, Thr, Ala, Asn, Gln, Glu, His, Ile, Lys,Tyr, Val, or Cys”
Modified-site50/note= “Xaa at position 50 is Glu,Ala, Asn, Ser, or Asp”
Modified-site51/note= “Xaa at position 51 is Asn,Arg, Met, Pro, Ser, Thr, or His”
Modified-site54/note= “Xaa at position 54 is Argor Ala”
Modified-site55/note= “Xaa at position 55 is Arg,Thr, Val, Leu, or Gly”
Modified-site56/note= “Xaa at position 56 is Pro,Gly, Ser, Gln, Ala, Arg, Asn, Glu, Leu, Thr, Val,or Lys”
Modified-site60/note= “Xaa at position 60 is Alaor Ser”
Modified-site62/note= “Xaa at position 62 is Asn,Pro, Thr, or Ile”
Modified-site63/note= “Xaa at position 63 is Argor Lys”
Modified-site64/note= “Xaa at position 64 is Alaor Asn”
Modified-site65/note= “Xaa at position 65 is Valor Thr”
Modified-site66/note= “Xaa at position 66 is Lysor Arg”
Modified-site67/note= “Xaa at position 67 is SerPhe or His”
Modified-site68/note= “Xaa at position 68 is Leu,Ile, Phe, or His”
Modified-site69/note= “Xaa at position 69 is Gln,Ala, Pro, Thr, Glu, Arg, or Gly”
Modified-site71/note= “Xaa at position 71 is Ala,Pro, or Arg”
Modified-site72/note= “Xaa at position 72 is Ser,Glu, Arg, or Asp”
Modified-site73/note= “Xaa at position 73 is Alaor Leu”
Modified-site76/note= “Xaa at position 76 is Ser,Val, Ala, Asn, Glu, Pro, or Gly”
Modified-site77/note= “Xaa at position 77 is Ileor Leu”
Modified-site79/note= “Xaa at position 79 isLys, Thr, Gly, Asn, Met, Arg, Ile, Gly, or Asp”
Modified-site80/note= “Xaa at position 80 is Asn,Gly, Glu, or Arg”
Modified-site82/note= “Xaa at position 82 is Leu,Gln, Trp, Arg, Asp, Ala, Asn, Glu, His, Ile, Met,Phe, Ser, Thr, Tyr, or Val”
Modified-site83/note= “Xaa at position 83 is Proor Thr”
Modified-site85/note= “Xaa at position 85 is Leuor Val”
Modified-site87/note= “Xaa at position 87 is Leuor Ser”
Modified-site88/note= “Xaa at position 88 is Alaor Trp”
Modified-site91/note= “Xaa at position 91 is Alaor Pro”
Modified-site93/note= “Xaa at position 93 is Thr,Asp, Ser, Pro, Ala, Leu, or Arg”
Modified-site95/note= “Xaa at position 95 is His,Pro, Arg, Val, Leu, Gly, Asn, Phe, Ser, or Thr”
Modified-site96/note= “Xaa at position 96 is Proor Tyr”
Modified-site97/note= “Xaa at position 97 is Ileor Val”
Modified-site98/note= “Xaa at position 98 is His,Ile, Asn, Leu, Ala, Thr, Leu, Arg, Gln, Leu, Lys,Met, Ser, Tyr, Val, or Pro”
Modified-site99/note= “Xaa at position 99 is Ile,Leu, or Val”
Modified-site100/note= “Xaa at position 100 is Lys,Arg, Ile, Gln, Pro, or Ser”
Modified-site101/note= “Xaa at position 101 is Asp,Pro, Met, Lys, His, Thr, Pro, Asn, Ile, Leu, or Tyr”
Modified-site104/note= “Xaa at position 104 is Trpor Leu”
Modified-site105/note= “Xaa at position 105 isAsn, Pro, Ala, Ser, Trp, Gln, Tyr, Leu, Lys, Ile,Asp, or His”
Modified-site106/note= “Xaa at position 106 is Gluor Gly”
Modified-site109/note= “Xaa at position 109 is Arg,Thr, Glu, Leu, or Ser”
Modified-site112/note= “Xaa at position 112 is Thr,Val, or Gln”
Modified-site114/note= “Xaa at position 114 is Tyror Trp”
Modified-site115/note= “Xaa at position 115 is Leuor Ala”
Modified-site116/note= “Xaa at position 116 is Lys,Thr, Val, Trp, Ser, Ala, His, Met, Phe, Tyr, or Ile”
Modified-site117/note= “Xaa at position 117 is Thror Ser”
Modified-site120/note= “Xaa at position 120 is Asn,Pro, Leu, His, Val, or Gln”
Modified-site121/note= “Xaa at position 121 is Ala,Ser, Ile, Asn, Pro, Asp, or Gly”
Modified-site122/note= “Xaa at position 122 isGln, Ser, Met, Trp, Arg, Phe, Pro, His, Ile, Tyr,or Cys”
Modified-site123/note= “Xaa at position 123 is Ala,Met, Glu, His, Ser, Pro, Tyr, or Leu”
17
133 amino acidsamino acidlinear
peptide
Modified-site/note= “Met- may or may not precedethe amino acid in position 1”
Modified-site17/note= “Xaa at position 17 is Ser,Gly, Asp, or Gln”
Modified-site18/note= “Xaa at position 18 is Asn,His, or Ile”
Modified-site23/note= “Xaa at position 23 is Ile,Ala, Leu, or Gly”
Modified-site25/note= “Xaa at position 25 is Thr,His, or Gln”
Modified-site26/note= “Xaa at position 26 is Hisor Ala”
Modified-site29/note=“Xaa at position 29 is Glnor Asn”
Modified-site30/note= “Xaa at position 30 is Proor Gly”
Modified-site32/note= “Xaa at position 32 is Leu,Arg, Asn, or Ala”
Modified-site34/note= “Xaa at position 34 is Leu,Val, Ser, Ala, Arg, Gln, Glu, Ile, Phe, Thr, or Met”
Modified-site35/note= “Xaa at position 35 is Leu,Ala, Asn, or Pro”
Modified-site38/note= “Xaa at position 38 is Asnor Ala”
Modified-site42/note= “Xaa at position 42 is Gly,Asp, Ser, Ala, Asn, Ile, Leu, Met, Tyr, or Arg”
Modified-site45/note= “Xaa at position 45 is Gln,Val, Met, Leu, Ala, Asn, Glu, or Lys”
Modified-site46/note= “Xaa at position 46 is Asp,Phe, Ser, Ala, Gln, Glu, His, Val, or Thr”
Modified-site50/note= “Xaa at position 50 is Glu,Asn, Ser, or Asp”
Modified-site51/note= “Xaa at position 51 is Asn,Arg, Pro, Thr, or His”
Modified-site55/note= “Xaa at position 55 is Arg,Leu, or Gly”
Modified-site56/note= “Xaa at position 56 is Pro,Gly, Ser, Ala, Asn, Val, Leu, or Gln”
Modified-site62/note= “Xaa at position 62 is Asn,Pro, or Thr”
Modified-site64/note= “Xaa at position 64 is Alaor Asn”
Modified-site65/note= “Xaa at position 65 is Valor Thr”
Modified-site67/note= “Xaa at position 67 is Seror Phe”
Modified-site68/note= “Xaa at position 68 is Leuor Phe”
Modified-site69/note= “Xaa at position 69 is Gln,Ala, Glu, or Arg”
Modified-site76/note= “Xaa at position 76 is Ser,Val, Asn, Pro, or Gly”
Modified-site77/note= “Xaa at position 77 is Ileor Leu”
Modified-site79/note= “Xaa at position 79 is Lys,Gly, Asn, Met, Arg, Ile, or Gly”
Modified-site80/note= “Xaa at position 80 is Asn,Gly, Glu, or Arg”
Modified-site82/note= “Xaa at position 82 is Leu,Gln, Trp, Arg, Asp, Asn, Glu, His, Met, Phe, Ser,Thr, Tyr, or Val”
Modified-site87/note= “Xaa at position 87 is Leuor Ser”
Modified-site88/note= “Xaa at position 88 is Alaor Trp”
Modified-site91/note= “Xaa at position 91 is Alaor Pro”
Modified-site93/note= “Xaa at position 93 is Thr,Asp, or Ala”
Modified-site95/note= “Xaa at position 95 is His,Pro, Arg, Val, Gly, Asn, Ser, or Thr”
Modified-site98/note= “Xaa at position 98 is His,Ile, Asn, Ala, Thr, Arg, Gln, Glu, Lys, Met, Ser,Tyr, Val, or Leu”
Modified-site99/note= “Xaa at position 99 is Ileor Leu”
Modified-site100/note= “Xaa at position 100 is Lysor Arg”
Modified-site101/note= “Xaa at position 101 is Asp,Pro, Met, Lys, Thr, His, Pro, Asn, Ile, Leu, or Tyr”
Modified-site105/note= “Xaa at position 105 is Asn,Pro, Ser, Ile, or Asp”
Modified-site108/note= “Xaa at position 108 is Arg,Ala, or Ser”
Modified-site109/note= “Xaa at position 109 is Arg,Thr, Glu, Leu, or Ser”
Modified-site112/note= “Xaa at position 112 is Thror Gln”
Modified-site116/note= “Xaa at position 116 is Lys,Val, Trp, Ala, His, Phe, Tyr, or Ile”
Modified-site117/note= “Xaa at position 117 is Thror Ser”
Modified-site120/note= “Xaa at position 120 is Asn,Pro, Leu, His, Val, or Gln”
Modified-site121/note= “Xaa at position 121 is Ala,Ser, Ile, Pro, or Asp”
Modified-site122/note= “Xaa at position 122 is Gln,Met, Trp, Phe, Pro, His, Ile, or Tyr”
Modified-site123/note= “Xaa at position 123 is Ala,Met, Glu, Ser, or Leu”
18
111 amino acidsamino acidlinear
peptide
Modified-site/note= “Met- or Met-Ala- may or maynot precede the amino acid in position 1”
Modified-site/note= “Xaa at position 3 is Ser,Lys, Gly, Asp, Met, Gln, or Arg”
Modified-site/note= “Xaa at position 4 is Asn,His, Leu, Ile, Phe, Arg, or Gln”
Modified-site/note= “Xaa at position 5 is Met,Phe, Ile, Arg, Gly, Ala, or Cys”
Modified-site/note= “Xaa at position 6 is Ile,Cys, Gln, Glu, Arg, Pro, or Ala”
Modified-site/note= “Xaa at position 7 is Asp,Phe, Lys, Arg, Ala, Gly, Glu, Gln, Asn, Thr, Ser,or Val”
Modified-site/note= “Xaa at position 8 is Glu,Trp, Pro, Ser, Ala, His, Asp, Asn, Gln, Leu, Val,or Gly”
Modified-site/note= “Xaa at position 9 isIle, Val, Ala, Leu, Gly, Trp, Lys, Phe, Leu, Seror Arg”
Modified-site10/note= “Xaa at position 10 is Ile,Gly, Val, Arg, Ser, Phe, or Leu”
Modified-site11/note= “Xaa at position 11 is Thr,His, Gly, Gln, Arg, Pro, or Ala”
Modified-site12/note= “Xaa at position 12 is His,Thr, Phe, Gly, Arg, Ala, or Trp”
Modified-site13/note= “Xaa at position 13 is Leu,Gly, Arg, Thr, Ser, or Ala”
Modified-site14/note= “Xaa at position 14 is Lys,Arg, Leu, Gln, Gly, Pro, Val, or Trp”
Modified-site15/note= “Xaa at position 15 is Gln,Asn, Leu, Pro, Arg, or Val”
Modified-site16/note= “Xaa at position 16 is Pro,His, Thr, Gly, Asp, Gln, Ser, Leu, or Lys”
Modified-site17/note= “Xaa at position 17 is Pro,Asp, Gly, Ala, Arg, Leu, or Gln”
Modified-site18/note= “Xaa at position 18 is Leu,Val, Arg, Gln, Asn, Gly, Ala, or Glu”
Modified-site19/note= “Xaa at position 19 is Pro,Leu, Gln, Ala, Thr, or Glu”
Modified-site20/note= “Xaa at position 20 is Leu,Val, Gly, Ser, Lys, Glu, Gln, Thr, Arg, Ala, Phe,Ile, or Met”
Modified-site21/note= “Xaa at position 21 is Leu,Ala, Gly, Asn, Pro, Gln, or Val”
Modified-site22/note= “Xaa at position 22 is Asp,Leu, or Val”
Modified-site23/note= “Xaa at position 23 is Phe,Ser, Pro, Trp, or Ile”
Modified-site24/note= “Xaa at position 24 is Asnor Ala”
Modified-site26/note= “Xaa at position 26 is Leu,Trp, or Arg”
Modified-site27/note= “Xaa at position 27 is Asn,Cys, Arg, Leu, His, Met, or Pro”
Modified-site28/note= “Xaa at position 28 is Gly,Asp, Ser, Cys, Ala, Lys, Asn, Thr, Leu, Val, Glu,Phe, Tyr, Ile, or Met”
Modified-site29/note= “Xaa at position 29 is Glu,Asn, Tyr, Leu, Phe, Asp, Ala, Cys, Gln, Arg, Thr,Gly, or Ser”
Modified-site30/note= “Xaa at position 30 is Asp,Ser, Leu, Arg, Lys, Thr, Met, Trp, Glu, Asn, Gln,Ala, or Pro”
Modified-site31/note= “Xaa at position 31 is Gln,Pro, Phe, Val, Met, Leu, Thr, Lys, Asp, Asn, Arg,Ser, Ala, Ile, Glu, His, or Trp”
Modified-site32/note= “Xaa at position 32 is Asp,Phe, Ser, Thr, Cys, Glu, Asn, Gln, Lys, His, Ala,Tyr, Ile, Val, or Gly”
Modified-site33/note= “Xaa at position 33 is Ile,Gly, Val, Ser, Arg, Pro, or His”
Modified-site34/note= “Xaa at position 34 is Leu,Ser, Cys, Arg, Ile, His, Phe, Glu, Lys, Thr, Ala,Met, Val, or Asn”
Modified-site35/note= “Xaa at position 35 is Met,Arg, Ala, Gly, Pro, Asn, His, or Asp”
Modified-site36/note= “Xaa at position 36 is Glu,Leu, Thr, Asp, Tyr, Lys, Asn, Ser, Ala, Ile, Val,His, Phe, Met, or Gln”
Modified-site37/note= “Xaa at position 37 is Asn,Arg, Met, Pro, Ser, Thr, or His”
Modified-site38/note= “Xaa at position 38 is Asn,His, Arg, Leu, Gly, Ser, or Thr”
Modified-site39/note= “Xaa at position 39 isLeu, Thr, Ala, Gly, Glu, Pro, Lys, Ser, or Met”
Modified-site40/note= “Xaa at position 40 is Arg,Asp, Ile, Ser, Val, Thr, Gln, Asn, Lys, His,Ala, or Leu”
Modified-site41/note= “Xaa at position 41 is Arg,Thr, Val, Ser, Leu, or Gly”
Modified-site42/note= “Xaa at position 42 is Pro,Gly, Cys, Ser, Gln, Glu, Arg, His, Thr, Ala, Tyr,Phe, Leu, Val, or Lys”
Modified-site43/note= “Xaa at position 43 is Asnor Gly”
Modified-site44/note= “Xaa at position 44 is Leu,Ser, Asp, Arg, Gln, Val, or Cys”
Modified-site45/note= “Xaa at position 45 is Glu,Tyr, His, Leu, Pro, or Arg”
Modified-site46/note= “Xaa at position 46 is Ala,Ser, Pro, Tyr, Asn, or Thr”
Modified-site47/note= “Xaa at position 47 is Phe,Asn, Glu, Pro, Lys, Arg, or Ser”
Modified-site48/note= “Xaa at position 48 is Asn,His, Val, Arg, Pro, Thr, Asp, or Ile”
Modified-site49/note= “Xaa at position 49 is Arg,Tyr, Trp, Lys, Ser, His, Pro, or Val”
Modified-site50/note= “Xaa at position 50 is Ala,Asn, Pro, Ser, or Lys”
Modified-site51/note= “Xaa at position 51 is Val,Thr, Pro, His, Leu, Phe, or Ser”
Modified-site52/note= “Xaa at position 52 is Lys,Ile, Arg, Val, Asn, Glu, or Ser”
Modified-site53/note= “Xaa at position 53 is Ser,Ala, Phe, Val, Gly, Asn, Ile, Pro, or His”
Modified-site54/note= “Xaa at position 54 is Leu,Val, Trp, Ser, Ile, Phe, Thr, or His”
Modified-site55/note= “Xaa at position 55 is Gln,Ala, Pro, Thr, Glu, Arg, Trp, Gly, or Leu”
Modified-site56/note= “Xaa at position 56 is Asn,Leu, Val, Trp, Pro, or Ala”
Modified-site57/note= “Xaa at position 57 is Ala,Met, Leu, Pro, Arg, Glu, Thr, Gln, Trp, or Asn”
Modified-site58/note= “Xaa at position 58 is Ser,Glu, Met, Ala, His, Asn, Arg, or Asp”
Modified-site59/note= “Xaa at position 59 is Ala,Glu, Asp, Leu, Ser, Gly, Thr, or Arg”
Modified-site60/note= “Xaa at position 60 is Ile,Met, Thr, Pro, Arg, Gly, Ala”
Modified-site61/note= “Xaa at position 61 isGlu, Lys, Gly, Asp, Pro, Trp, Arg, Ser, Gln,or Leu”
Modified-site62/note= “Xaa at position 62 is Ser,Val, Ala, Asn, Trp, Glu, Pro, Gly, or Asp”
Modified-site63/note= “Xaa at position 63 is Ile,Ser, Arg, Thr, or Leu”
Modified-site64/note= “Xaa at position 64 is Leu,Ala, Ser, Glu, Phe, Gly, or Arg”
Modified-site65/note= “Xaa at position 65 is Lys,Thr, Gly, Asn, Met, Arg, Ile, or Asp”
Modified-site66/note= “Xaa at position 66 is Asn,Trp, Val, Gly, Thr, Leu, Glu, or Arg”
Modified-site67/note= “Xaa at position 67 is Leu,Gln, Gly, Ala, Trp, Arg, Val, or Lys”
Modified-site68/note= “Xaa at position 68 is Leu,Gln, Lys, Trp, Arg, Asp, Glu, Asn, His, Thr, Ser, Ala,Tyr, Phe, Ile, Met, or Val”
Modified-site69/note= “Xaa at position 69 is Pro,Ala, Thr, Trp, Arg, or Met”
Modified-site70/note= “Xaa at position 70 is Cys,Glu, Gly, Arg, Met, or Val”
Modified-site71/note= “Xaa at position 71 is Leu,Asn, Val, or Gln”
Modified-site72/note= “Xaa at position 72 is Pro,Cys, Arg, Ala, or Lys”
Modified-site73/note= “Xaa at position 73 is Leu,Ser, Trp, or Gly”
Modified-site74/note= “Xaa at position 74 is Ala,Lys, Arg, Val, or Trp”
Modified-site75/note= “Xaa at position 75 is Thr,Asp, Cys, Leu, Val, Glu, His, Asn, or Ser”
Modified-site76/note= “Xaa at position 76 is Ala,Pro, Ser, Thr, Gly, Asp, Ile, or Met”
Modified-site77/note= “Xaa at position 77 is Ala,Pro, Ser, Thr, Phe, Leu, Asp, or His”
Modified-site78/note= “Xaa at position 78 is Pro,Phe, Arg, Ser, Lys, His, Ala, Gly, Ile, or Leu”
Modified-site79/note= “Xaa at position 79 is Thr,Asp, Ser, Asn, Pro, Ala, Leu, or Arg”
Modified-site80/note= “Xaa at position 80 is Arg,Ile, Ser, Glu, Leu, Val, Gln, Lys, His, Ala, or Pro”
Modified-site81/note= “Xaa at position 81 is His,Gln, Pro, Arg, Val, Leu, Gly, Thr, Asn, Lys, Ser,Ala, Trp, Phe, Ile, or Tyr”
Modified-site82/note= “Xaa at position 82 is Pro,Lys, Tyr, Gly, Ile, or Thr”
Modified-site83/note= “Xaa at position 83 is Ile,Val, Lys, Ala, or Asn”
Modified-site84/note= “Xaa at position 84 is His,Ile, Asn, Leu, Asp, Ala, Thr, Glu, Gln, Ser,Phe, Met, Val, Lys, Arg, Tyr, or Pro”
Modified-site85/note= “Xaa at position 85 isIle, Leu, Arg, Asp, Val, Pro, Gln, Gly, Ser,Phe, or His”
Modified-site86/note= “Xaa at position 86 isLys, Tyr, Leu, His, Arg, Ile, Ser, Gln, or Pro”
Modified-site87/note= “Xaa at position 87 isAsp, Pro, Met, Lys, His, Thr, Val, Tyr, Glu, Asn,Ser, Ala, Gly, Ile, Leu, or Gln”
Modified-site88/note= “Xaa at position 88 Gly,Leu, Glu, Lys, Ser, Tyr, or Pro”
Modified-site89/note= “Xaa at position 89 is Aspor Ser”
Modified-site90/note= “Xaa at position 90 isTrp, Val, Cys, Tyr, Thr, Met, Pro, Leu, Gln, Lys,Ala, Phe, or Gly”
Modified-site91/note= “Xaa at position 91 isAsn, Pro, Ala, Phe, Ser, Trp, Gln, Tyr, Leu, Lys,Ile, Asp, or His”
Modified-site92/note= “Xaa at position 92 is Glu,Ser, Ala, Lys, Thr, Ile, Gly, or Pro”
Modified-site94/note= “Xaa at position 94 is Arg,Lys, Asp, Leu, Thr, Ile, Gln, His, Ser, Ala, or Pro”
Modified-site95/note= “Xaa at position 95 is Arg,Thr, Pro, Glu, Tyr, Leu, Ser, or Gly”
Modified-site96/note= “Xaa at position 96 is Lys,Asn, Thr, Leu, Gln, Arg, His, Glu, Ser, Ala,or Trp”
Modified-site97/note= “Xaa at position 97 is Leu,Ile, Arg, Asp, or Met”
Modified-site98/note= “Xaa at position 98 is Thr,Val, Gln, Tyr, Glu, His, Ser, or Phe”
Modified-site99/note= “Xaa at position 99 is Phe,Ser, Cys, His, Gly, Trp, Tyr, Asp, Lys, Leu, Ile,Val, or Asn”
Modified-site100/note= “Xaa at position 100 is Tyr,Cys, His, Ser, Trp, Arg, or Leu”
Modified-site101/note= “Xaa at position 101 is Leu,Asn, Val, Pro, Arg, Ala, His, Thr, Trp, or Met”
Modified-site102/note= “Xaa at position 102 isLys, Leu, Pro, Thr, Met, Asp, Val, Glu, Arg, Trp,Ser, Asn, His, Ala, Tyr, Phe, Gln, or Ile”
Modified-site103/note= “Xaa at position 103 is Thr,Ser, Asn, Ile, Trp, Lys, or Pro”
Modified-site104/note= “Xaa at position 104 is Leu,Ser, Pro, Ala, Glu, Cys, Asp, or Tyr”
Modified-site105/note= “Xaa at position 105 is Glu,Ser, Lys, Pro, Leu, Thr, Tyr, or Arg”
Modified-site106/note= “Xaa at position 106 is Asn,Ala, Pro, Leu, His, Val or Gln”
Modified-site107/note= “Xaa at position 107 is Ala,Ser, Ile, Asn, Pro, Lys, Asp, or Gly”
Modified-site108/note= “Xaa at position 108 isGln, Ser, Met, Trp, Arg, Phe, Pro, His, Ile, Tyr,or Cys”
Modified-site109/note= “Xaa at position 109 is Ala,Met, Glu, His, Ser, Pro, Tyr, or Leu”
19
111 amino acidsamino acidlinear
peptide
Modified-site/note= “Met- or Met-Ala- may or maynot precede the amino acid in position 1”
Modified-site/note= “Xaa at position 3 is Ser,Gly, Asp, Met, or Gln”
Modified-site/note= “Xaa at position 4 is Asn,His, Leu, Ile, Phe, Arg, or Gln”
Modified-site/note= “Xaa at position 5 is Met,Phe, Ile, Arg, or Ala”
Modified-site/note= “Xaa at position 6 is Ile orPro”
Modified-site/note= “Xaa at position 7 is Asp orGlu”
Modified-site/note= “Xaa at position 9 is Ile,Val, Ala, Leu, or Gly”
Modified-site10/note= “Xaa at position 10 is Ile,Val, Phe, or Leu”
Modified-site11/note= “Xaa at position 11 is Thr,His, Gly, Gln, Arg, Pro, or Ala”
Modified-site12/note= “Xaa at position 12 is His,Phe, Gly, Arg, or Ala”
Modified-site14/note= “Xaa at position 14 is Lys,Leu, Gln, Gly, Pro, or Val”
Modified-site15/note= “Xaa at position 15 is Gln,Asn, Leu, Arg, or Val”
Modified-site16/note= “Xaa at position 16 is Pro,His, Thr, Gly, or Gln”
Modified-site17/note= “Xaa at position 17 is Pro,Asp, Gly, Ala, Arg, Leu, or Gln”
Modified-site18/note= “Xaa at position 18 is Leu,Arg, Gln, Asn, Gly, Ala or Glu”
Modified-site19/note= “Xaa at poisiton 19 is Pro,Leu, Gln, Ala, or Glu”
Modified-site20/note= “Xaa at positon 20 is Leu,Val, Gly, Ser, Lys, Ala, Arg, Gln, Glu, Ile, Phe,Thr, or Met”
Modified-site21/note= “Xaa at position 21 is Leu,Ala, Asn, Pro, Gln, or Val”
Modified-site22/note= “Xaa at position 22 is Aspor Leu”
Modified-site23/note= “Xaa at position 23 is Phe,Ser, Pro, Trp, or Ile”
Modified-site24/note= “Xaa at position 24 is Asnor Ala”
Modified-site27/note= “Xaa at position 27 is Asn,Cys, Arg, His, Met, or Pro”
Modified-site28/note= “Xaa at position 28 is Gly,Asp, Ser, Cys, Ala, Asn, Ile, Leu, Met, Tyr, or Arg”
Modified-site30/note= “Xaa at position 30 is Aspor Glu”
Modified-site31/note= “Xaa at position 31 is Gln,Val, Met, Leu, Thr, Lys, Ala, Asn, Glu, Ser, or Trp”
Modified-site32/note= “Xaa at position 32 is Asp,Phe, Ser, Thr, Cys, Ala, Asn, Gln, Glu, His, Ile,Lys, Tyr, Val, or Gly”
Modified-site33/note= “Xaa at position 33 is Ile,Val, or His”
Modified-site35/note= “Xaa at position 35 is Met,Asn, or Asp”
Modified-site36/note= “Xaa at position 36 is Glu,Thr, Ala, Asn, Ser, or Asp”
Modified-site37/note= “Xaa at position 37 is Asn,Arg, Met, Pro, Ser, Thr, or His”
Modified-site38/note= “Xaa at position 38 is Asnor Gly”
Modified-site39/note= “Xaa at position 39 is Leu,Met, or Phe”
Modified-site40/note= “Xaa at position 40 is Arg,Ala, or Ser”
Modified-site41/note= “Xaa at position 41 is Arg,Thr, Val, Leu, or Gly”
Modified-site42/note= “Xaa at position 42 is Pro,Gly, Cys, Ser, Gln, Ala, Arg, Asn, Glu, His, Leu,Thr, Val, or Lys”
Modified-site45/note= “Xaa at position 45 is Glu,Tyr, His, Leu, or Arg”
Modified-site46/note= “Xaa at position 46 is Ala,Ser, Asn, or Thr”
Modified-site47/note= “Xaa at position 47 is Pheor Ser”
Modified-site48/note= “Xaa at position 48 is Asn,Val, Pro, Thr, or Ile”
Modified-site49/note= “Xaa at position 49 is Arg,Tyr, Lys, Ser, His, or Val”
Modified-site50/note= “Xaa at position 50 is Alaor Asn”
Modified-site51/note= “Xaa at position 51 is Val,Thr, Leu, or Ser”
Modified-site52/note= “Xaa at position 52 is Lys,Ile, Arg, Val, Asn, Glu, or Ser”
Modified-site53/note= “Xaa at position 53 is Ser,Phe, Val, Gly, Asn, Ile, or His”
Modified-site54/note= “Xaa at position 54 is Leu,Val, Ile, Phe, or His”
Modified-site55/note= “Xaa at position 55 is Gln,Ala, Pro, Thr, Glu, Arg, or Gly”
Modified-site56/note= “Xaa at position 56 is Asnor Pro”
Modified-site57/note= “Xaa at position 57 is Ala,Met, Pro, Arg, Glu, Thr, or Gln”
Modified-site58/note= “Xaa at position 58 is Ser,Glu, Met, Ala, His, Asn, Arg, or Asp”
Modified-site59/note= “Xaa at position 59 is Ala,Glu, Asp, Leu, Ser, Gly, Thr, Arg, or Pro”
Modified-site60/note= “Xaa at position 60 is Ileor Met”
Modified-site61/note= “Xaa at position 61 is Glu,Gly, Asp, Ser, or Gln”
Modified-site62/note= “Xaa at position 62 is Ser,Val, Ala, Asn, Glu, Pro, Gly, or Asp”
Modified-site63/note= “Xaa at position 63 is Ile,Ser, or Leu”
Modified-site65/note= “Xaa at position 65 is Lys,Thr, Gly, Asn, Met, Arg, Ile, or Asp”
Modified-site66/note= “Xaa at position 66 is Asn,Val, Gly, Thr, Leu, Glu, or Arg”
Modified-site67/note= “Xaa at position 67 is Leuor Val”
Modified-site68/note= “Xaa at position 68 is Leu,Gln, Trp, Arg, Asp, Ala, Asn, Glu, His, Met, Phe,Ser, Thr, Tyr, or Val”
Modified-site69/note= “Xaa at position 69 is Pro,Ala, Thr, Trp, or Met”
Modified-site71/note= “Xaa at position 71 is Leuor Val”
Modified-site73/note= “Xaa at position 73 is Leuor Ser”
Modified-site74/note= “Xaa at position 74 is Ala,Arg, or Trp”
Modified-site75/note= “Xaa at position 75 is Thr,Asp, Glu, His, Asn, or Ser”
Modified-site76/note= “Xaa at position 76 is Ala,Asp, or Met”
Modified-site77/note= “Xaa at position 77 is Ala,Pro, Ser, Thr, Phe, Leu, or Asp”
Modified-site78/note= “Xaa at position 78 is Proor Ser”
Modified-site79/note= “Xaa at position 79 is Thr,Asp, Ser, Pro, Ala, Leu, or Arg”
Modified-site81/note= “Xaa at position 81 is His,Pro, Arg, Val, Leu, Gly, Asn, Ile, Phe, Ser, or Thr”
Modified-site82/note= “Xaa at position 82 is Proor Tyr”
Modified-site83/note= “Xaa at position 83 is Ile,Val, or Ala”
Modified-site84/note= “Xaa at position 84 is His,Ile, Asn, Leu, Asp, Ala, Thr, Arg, Gln, Glu, Lys,Met, Ser, Tyr, Val, or Pro”
Modified-site85/note= “Xaa at position 85 is Ile,Leu, Val, or Phe”
Modified-site86/note= “Xaa at position 86 is Lys,Leu, His, Arg, Ile, Gln, Pro, or Ser”
Modified-site87/note= “Xaa at position 87 is Asp,Pro, Met, Lys, His, Thr, Val, Asn, Ile, Leu, or Tyr”
Modified-site88/note= “Xaa at position 88 is Gly,Glu, Lys, or Ser”
Modified-site90/note= “Xaa at position 90 is Trp,Val, Tyr, Met, or Leu”
Modified-site91/note=“Xaa at position 91 is Asn, Pro, Ala, Phe, Ser,Trp, Gln, Tyr, Leu, Lys, Ile, Asp, or His”
Modified-site92/note= “Xaa at position 92 is Glu,Ser, Ala, or Gly”
Modified-site94/note= “Xaa at position 94 is Arg,Ala, Gln, Ser, or Lys”
Modified-site95/note= “Xaa at position 95 Arg,Thr, Glu, Leu, Ser, or Gly”
Modified-site98/note= “Xaa at position 98 is Thr,Val, Gln, Glu, His, or Ser”
Modified-site100/note= “Xaa at position 100 is Tyror Trp”
Modified-site101/note= “Xaa at position 101 is Leuor Ala”
Modified-site102/note= “Xaa at position 102 is Lys,Thr, Met, Val, Trp, Ser, Leu, Ala, Asn, Gln, His,Met, Phe, Tyr, or Ile”
Modified-site103/note= “Xaa at position 103 is Thr,Ser, or Asn”
Modified-site105/note= “Xaa at position 105 is Glu,Ser, Pro, Leu, Thr, or Tyr”
Modified-site106/note= “Xaa at position 106 is Asn,Pro, Leu, His, Val, or Gln”
Modified-site107/note= “Xaa at position 107 is Ala,Ser, Ile, Asn, Pro, Lys, Asp, or Gly”
Modified-site108/note=“Xaa at position 108 is Gln, Ser, Met, Trp, Arg, Phe,Pro, His, Ile, Tyr, or Cys”
Modified-site109/note= “Xaa at position 109 is Ala,Met, Glu, His, Ser, Pro, Tyr, or Leu”
20
111 amino acidsamino acidlinear
peptide
Modified-site/note= “Met- or Met-Ala- may or maynot precede the amino acid in position 1”
Modified-site/note= “Xaa at position 3 is Ser,Gly, Asp, Met, or Gln”
Modified-site/note= “Xaa at position 4 is Asn,His, or Ile”
Modified-site/note= “Xaa at position 5 is Metor Ile”
Modified-site/note= “Xaa at position 7 is Asp orGlu”
Modified-site/note= “Xaa at position 9 is Ile,Ala, Leu, or Gly”
Modified-site10/note= “Xaa at position 10 is Ile,Val, or Leu”
Modified-site11/note= “Xaa at position 11 is Thr,His, Gln, or Ala”
Modified-site12/note= “Xaa at position 12 is Hisor Ala”
Modified-site15/note= “Xaa at position 15 is Gln,Asn, or Val”
Modified-site16/note= “Xaa at position 16 is Pro,Gly, or Gln”
Modified-site17/note= “Xaa at position 17 is Pro,Asp, Gly, or Gln”
Modified-site18/note= “Xaa at position 18 is Leu,Arg, Gln, Asn, Gly, Ala, or Glu”
Modified-site19/note= “Xaa at position 19 is Proor Glu”
Modified-site20/note= “Xaa at position 20 is Leu,Val, Gly, Ser, Lys, Ala, Arg, Gln, Glu, Ile, Phe,Thr, or Met”
Modified-site21/note= “Xaa at position 21 is Leu,Ala, Asn, Pro, Gln, or Val”
Modified-site23/note= “Xaa at position 23 is Phe,Ser, Pro, or Trp”
Modified-site24/note= “Xaa at position 24 is Asnor Ala”
Modified-site28/note= “Xaa at position 28 is Gly,Asp, Ser, Cys, Ala, Asn, Ile, Leu, Met, Tyr, or Arg”
Modified-site30/note= “Xaa at position 30 is Aspor Glu”
Modified-site31/note= “Xaa at position 31 is Gln,Val, Met, Leu, Thr, Ala, Asn, Glu, Ser, or Lys”
Modified-site32/note= “Xaa at position 32 is Asp,Phe, Ser, Thr, Ala, Asn, Gln, Glu, His, Ile, Lys,Tyr, Val, or Cys”
Modified-site36/note= “Xaa at position 36 is Glu,Ala, Asn, Ser, or Asp”
Modified-site37/note= “Xaa at position 37 is Asn,Arg, Met, Pro, Ser, Thr, or His”
Modified-site40/note= “Xaa at position 40 is Argor Ala”
Modified-site41/note= “Xaa at position 41 is Arg,Thr, Val, Leu, or Gly”
Modified-site42/note= “Xaa at position 42 is Pro,Gly, Ser, Gln, Ala, Arg, Asn, Glu, Leu, Thr, Val,or Lys”
Modified-site46/note= “Xaa at position 46 is Alaor Ser”
Modified-site48/note= “Xaa at position 48 is Asn,Pro, Thr, or Ile”
Modified-site49/note= “Xaa at position 49 is Argor Lys”
Modified-site50/note= “Xaa at position 50 is Alaor Asn”
Modified-site51/note= “Xaa at position 51 is Valor Thr”
Modified-site52/note= “Xaa at position 52 is Lysor Arg”
Modified-site53/note= “Xaa at position 53 is Ser,Phe, or His”
Modified-site54/note= “Xaa at position 54 is Leu,Ile, Phe, or His”
Modified-site55/note= “Xaa at position 55 is Gln,Ala, Pro, Thr, Glu, Arg, or Gly”
Modified-site57/note= “Xaa at position 57 is Ala,Pro, or Arg”
Modified-site58/note= “Xaa at position 58 is Ser,Glu, Arg, or Asp”
Modified-site59/note= “Xaa at position 59 is Alaor Leu”
Modified-site62/note= “Xaa at position 62 is Ser,Val, Ala, Asn, Glu, Pro, or Gly”
Modified-site63/note= “Xaa at position 63 is Ileor Leu”
Modified-site65/note= “Xaa at position 65 is Lys,Thr, Gly, Asn, Met, Arg, Ile, Gly, or Asp”
Modified-site66/note= “Xaa at position 66 is Asn,Gly, Glu, or Arg”
Modified-site68/note= “Xaa at position 68 is Leu,Gln, Trp, Arg, Asp, Ala, Asn, Glu, His, Ile, Met,Phe, Ser, Thr, Tyr, or Val”
Modified-site69/note= “Xaa at position 69 is Proor Thr”
Modified-site71/note= “Xaa at position 71 is Leuor Val”
Modified-site73/note= “Xaa at position 73 is Leuor Ser”
Modified-site74/note= “Xaa at position 74 is Alaor Trp”
Modified-site77/note= “Xaa at position 77 is Alaor Pro”
Modified-site79/note= “Xaa at position 79 is Thr,Asp, Ser, Pro, Ala, Leu, or Arg”
Modified-site81/note= “Xaa at position 81 is His,Pro, Arg, Val, Leu, Gly, Asn, Phe, Ser, or Thr”
Modified-site82/note= “Xaa at position 82 is Proor Tyr”
Modified-site83/note= “Xaa at position 83 is Ileor Val”
Modified-site84/note= “Xaa at position 84 is His,Ile, Asn, Leu, Ala, Thr, Leu, Arg, Gln, Leu, Lys,Met, Ser, Tyr, Val, or Pro”
Modified-site85/note= “Xaa at position 85 is Ile,Leu, or Val”
Modified-site86/note= “Xaa at position 86 is Lys,Arg, Ile, Gln, Pro, or Ser”
Modified-site87/note= “Xaa at position 87 is Asp,Pro, Met, Lys, His, Thr, Asn, Ile, Leu, or Tyr”
Modified-site90/note= “Xaa at position 90 is Trpor Leu”
Modified-site91/note=“Xaa at position 91 is Asn,Pro, Ala, Ser, Trp, Gln, Tyr, Leu, Lys, Ile, Asp,or His”
Modified-site92/note= “Xaa at position 92 is Gluor Gly”
Modified-site94/note= “Xaa at position 94 is Arg,Ala, or Ser”
Modified-site95/note= “Xaa at position 95 is Arg,Thr, Glu, Leu, or Ser”
Modified-site98/note= “Xaa at position 98 is Thr,Val, or Gln”
Modified-site100/note= “Xaa at position 100 is Tyror Trp”
Modified-site101/note= “Xaa at position 101 is Leuor Ala”
Modified-site102/note= “Xaa at position 102 is Lys,Thr, Val, Trp, Ser, Ala, His, Met, Phe, Tyr, or Ile”
Modified-site103/note= “Xaa at position 103 is Thror Ser”
Modified-site106/note= “Xaa at position 106 is Asn,Pro, Leu, His, Val, or Gln”
Modified-site107/note= “Xaa at position 107 is Ala,Ser, Ile, Asn, Pro, Asp, or Gly”
Modified-site108/note= “Xaa at position 108 is Gln,Ser, Met, Trp, Arg, Phe, Pro, His, Ile, Tyr, or Cys”
Modified-site109/note= “Xaa at position 109 is Ala,Met, Glu, His, Ser, Pro, Tyr, or Leu”
21
111 amino acidsamino acidlinear
peptide
Modified-site/note= “Met- or Met-Ala- may or maynot precede the amino acid in position 1”
Modified-site/note= “Xaa at position 3 is Ser,Gly, Asp, or Gln”
Modified-site/note= “Xaa at position 4 is Asn,His, or Ile”
Modified-site/note= “Xaa at position 9 is Ile,Ala, Leu, or Gly”
Modified-site11/note= “Xaa at position 11 is Thr,His, or Gln”
Modified-site12/note= “Xaa at position 12 is Hisor Ala”
Modified-site15/note= “Xaa at position 15 is Glnor Asn”
Modified-site16/note= “Xaa at position 16 is Proor Gly”
Modified-site18/note= “Xaa at position 18 is Leu,Arg, Asn, or Ala”
Modified-site20/note= “Xaa at position 20 is Leu,Val, Ser, Ala, Arg, Gln, Glu, Ile, Phe, Thr, or Met”
Modified-site21/note= “Xaa at position 21 is Leu,Ala, Asn, or Pro”
Modified-site24/note= “Xaa at position 24 is Asnor Ala”
Modified-site28/note= “Xaa at position 28 is Gly,Asp, Ser, Ala, Asn, Ile, Leu, Met, Tyr, or Arg”
Modified-site31/note= “Xaa at position 31 is Gln,Val, Met, Leu, Ala, Asn, Glu, or Lys”
Modified-site32/note= “Xaa at position 32 is Asp,Phe, Ser, Ala, Gln, Glu, His, Val, or Thr”
Modified-site36/note= “Xaa at position 36 is Glu,Asn, Ser, or Asp”
Modified-site37/note= “Xaa at position 37 is Asn,Arg, Pro, Thr, or His”
Modified-site41/note= “Xaa at position 41 is Arg,Leu, or Gly”
Modified-site42/note= “Xaa at position 42 is Pro,Gly, Ser, Ala, Asn, Val, Leu, or Gln”
Modified-site48/note= “Xaa at position 48 is Asn,Pro, or Thr”
Modified-site50/note= “Xaa at position 50 is Alaor Asn”
Modified-site51/note= “Xaa at position 51 is Valor Thr”
Modified-site53/note= “Xaa at position 53 is Seror Phe”
Modified-site54/note= “Xaa at position 54 is Leuor Phe”
Modified-site55/note= “Xaa at position 55 is Gln,Ala, Glu, or Arg”
Modified-site62/note= “Xaa at position 62 is Ser,Val, Asn, Pro, or Gly”
Modified-site63/note= “Xaa at position 63 is Ileor Leu”
Modified-site65/note= “Xaa at position 65 is Lys,Asn, Met, Arg, Ile, or Gly”
Modified-site66/note= “Xaa at position 66 is Asn,Gly, Glu, or Arg”
Modified-site68/note= “Xaa at position 68 is Leu,Gln, Trp, Arg, Asp, Asn, Glu, His, Met, Phe, Ser,Thr, Tyr, or Val”
Modified-site73/note= “Xaa at position 73 is Leuor Ser”
Modified-site74/note= “Xaa at position 74 is Alaor Trp”
Modified-site77/note= “Xaa at position 77 is Alaor Pro”
Modified-site79/note= “Xaa at position 79 is Thr,Asp, or Ala”
Modified-site81/note= “Xaa at position 81 is His,Pro, Arg, Val, Gly, Asn, Ser, or Thr”
Modified-site84/note= “Xaa at position 84 is His,Ile, Asn, Ala, Thr, Arg, Gln, Glu, Lys, Met,Ser, Tyr, Val, or Leu”
Modified-site85/note= “Xaa at position 85 is Ileor Leu”
Modified-site86/note= “Xaa at position 86 is Lysor Arg”
Modified-site87/note= “Xaa at position 87 is Asp,Pro, Met, Lys, His, Pro, Asn, Ile, Leu, or Tyr”
Modified-site91/note= “Xaa at position 91 is Asn,Pro, Ser, Ile, or Asp”
Modified-site94/note= “Xaa at position 94 is Arg,Ala, or Ser”
Modified-site95/note= “Xaa at position 95 is Arg,Thr, Glu, Leu, or Ser”
Modified-site98/note= “Xaa at position 98 is Thror Gln”
Modified-site102/note= “Xaa at position 102 is Lys,Val, Trp, or Ile”
Modified-site103/note= “Xaa at position 103 is Thr,Ala, His, Phe, Tyr, or Ser”
Modified-site106/note= “Xaa at position 106 is Asn,Pro, Leu, His, Val, or Gln”
Modified-site107/note= “Xaa at position 107 is Ala,Ser, Ile, Pro, or Asp”
Modified-site108/note= “Xaa at position 108 is Gln,Met, Trp, Phe, Pro, His, Ile, or Tyr”
Modified-site109/note= “Xaa at position 109 is Ala,Met, Glu, Ser, or Leu”
22
111 amino acidsamino acidlinear
peptide
Modified-site/note= “Met- or Met-Ala- may or maynot precede the amino acid in position 1”
23
133 amino acidsamino acidlinear
peptide
Modified-site/note= “Met- may or may not precedethe amino acid in position 1”
Modified-site18/note= “Xaa at position 18 is Asnor Ile”
Modified-site25/note= “Xaa at position 25 is Thror His”
Modified-site29/note= “Xaa at position 29 is Gln,Arg, or Val”
Modified-site32/note= “Xaa at position 32 is Leu,Ala, or Asn”
Modified-site37/note= “Xaa at position 37 is Phe,Pro, or Ser”
Modified-site42/note= “Xaa at position 42 is Glu,Ala, or Ser”
Modified-site45/note= “Xaa at position 45 is Gln,Val, or Met”
Modified-site51/note= “Xaa at position 51 is Asnor Arg”
Modified-site55/note= “Xaa at position 55 is Arg,Leu, or Thr”
Modified-site59/note= “Xaa at position 59 is Gluor Leu”
Modified-site60/note= “Xaa at position 60 is Alaor Ser”
Modified-site62/note= “Xaa at position 62 is Asnor Val”
Modified-site67/note= “Xaa at position 67 is Ser,Asn, or His”
Modified-site69/note= “Xaa at position 69 is Glnor Glu”
Modified-site73/note= “Xaa at position 73 is Alaor Gly”
Modified-site76/note= “Xaa at position 76 is Seror Ala”
Modified-site79/note= “Xaa at position 79 is Lysor Arg”
Modified-site82/note= “Xaa at position 82 is Leu,Glu, or Val”
Modified-site87/note= “Xaa at position 87 is Leuor Ser”
Modified-site93/note= “Xaa at position 93 is Proor Ser”
Modified-site98/note= “Xaa at position 98 is His,Ile, or Thr”
Modified-site101/note= “Xaa at position 101 is Aspor Ala”
Modified-site105/note= “Xaa at position 105 is Asnor Glu”
Modified-site109/note= “Xaa at position 109 is Argor Glu”
Modified-site116/note= “Xaa at position 116 is Lysor Val”
Modified-site120/note= “Xaa at position 120 is Asn,Gln, or His”
Modified-site123/note= “Xaa at position 123 is Alaor Glu”
129
111 amino acidsamino acidlinear
peptide
Modified-site/note= “Met- or Met-Ala may or maynot precede the amino acid in position 1”
Modified-site/note= “Xaa at position 4 is Asn orIle”
Modified-site11/note= “Xaa at position 11 is Thror His”
Modified-site15/note= “Xaa at position 15 is Gln,Arg, or Val”
Modified-site18/note= “Xaa at position 18 is Leu,Ala, or Asn”
Modified-site23/note= “Xaa at position 23 is Phe,Pro, or Ser”
Modified-site28/note= “Xaa at position 28 is Glu,Ala, or Ser”
Modified-site31/note= “Xaa at position 31 is Gln,Val, or Met”
Modified-site37/note= “Xaa at position 37 is Asnor Arg”
Modified-site41/note= “Xaa at position 41 is Arg,Leu, or Thr”
Modified-site45/note= “Xaa at position 45 is Gluor Leu”
Modified-site46/note= “Xaa at position 46 is Alaor Ser”
Modified-site48/note= “Xaa at position 48 is Asnor Val”
Modified-site53/note= “Xaa at position 53 is Ser,Asn, or His”
Modified-site55/note= “Xaa at position 55 is Glnor Glu”
Modified-site59/note= “Xaa at position 59 is Alaor Gly”
Modified-site62/note= “Xaa at position 62 is Seror Ala”
Modified-site65/note= “Xaa at position 65 is Lysor Arg”
Modified-site68/note= “Xaa at position 68 is Leu,Glu, or Val”
Modified-site73/note= “Xaa at position 73 is Leuor Ser”
Modified-site79/note= “Xaa at position 79 is Proor Ser”
Modified-site84/note= “Xaa at position 84 is His,Ile, or Thr”
Modified-site87/note= “Xaa at position 87 is Aspor Ala”
Modified-site91/note= “Xaa at position 91 is Asnor Glu”
Modified-site95/note= “Xaa at position 95 is Argor Glu”
Modified-site102/note= “Xaa at position 102 is Lysor Val”
Modified-site106/note= “Xaa at position 106 is Asn,Gln, or His”
Modified-site109/note= “Xaa at position 109 is Alaor Glu”
130
1 of 100 part labels are ours — the grant heads the rest

Claims as granted

22 claims

Log in to read the claims of this application.

Log in to unlock

Classifications

24 codes
IPC · International Patent Classification
Section A — Human necessities
  • A61K45/00
  • A61K38/20
  • A61K38/00
  • A61P43/00
  • A61P7/00
Section C — Chemistry; metallurgy
  • C07K1/00
  • C12P21/04
  • C07K17/00
  • C07K14/00
  • C12N15/24
  • C12P21/02
  • C12N1/19
  • C07K14/54
  • C12R1/19
  • C07H21/04
  • C12N1/21
  • C12N5/10
  • C12N1/15
  • C12N15/09
  • C12N5/08
  • C12N15/61
USPC · US Patent Classification
435/69.52424/85.2435/372

Claim changes

Soon
Coming soonHow the claims changed between publication and grant

See which claims were amended, added or cancelled during examination, with every added and removed word marked.

AmendedAddedCancelledUnchanged

The published claims of this application are not paired with the granted ones in what we hold.

File wrapper

⤢ drag to zoom19961997199819992000200120022003USPTOApplicantNon-final rejectionResponse after non-finalResponse after finalNotice of allowance
USPTOApplicanthover for detail · click to open
Pendency
7.0 y
2,554 days filing → grant
Office actions
2
non-final + final
Responses
3
1 RCE
Interviews
2
examiner interview summaries
Examiner
Gary L. Kunz
art unit 1647 · TC 1600
Citations: 38 back · 1 forward

See the full prosecution history — every USPTO and applicant action on this file, in order.

Log in to unlock

Documents

Log in to open the documents of this file: the application as filed, every office action and response, the notice of allowance.

Log in to unlock

Chain of title

No assignments have been recorded for this application yet.